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Toxoplasma gondii chronically infects ~2 billion people worldwide. This neurotropic 
protozoan is the 2nd leading cause of death due to foodborne illness in the US, and has been 
designated as one of five Neglected Parasitic Infections targeted by the CDC for public health 
action. Currently, there is no efficacious T. gondii therapeutic capable of treating the chronic 
dormant-phase toxoplasmosis infection in the CNS. T. gondii cathepsin L (TgCPL) has been 
implicated as a viable target for treatment of the chronic stage infection.  Confirmation that 
TgCPL inhibition can eliminate neuronal cysts in a mouse with chronic toxoplasmosis is a 
crucial step in demonstrating that TgCPL is a valid target in chronic toxoplasmosis. Initially, a 
series of TgCPL dipeptide nitrile inhibitors was developed, improving potency for the T. gondii 
enzyme from 2 µM to as low as 115 nM. Although we successfully demonstrated that this 
compound class can penetrate the blood brain barrier, it also exhibits rapid clearance in vivo. A 
high throughput screen was then conducted and a triazine nitrile scaffold was selected based on 
literature precedent of this chemotype as inhibitors of human cathepsins and predicted BBB 
penetrant properties. Scaffold hopping to this chemotype resulted in an instantaneous gain of 
potency (TgCPL IC50 = 34 nM), however reduced metabolic stability relative to the 
corresponding dipeptide. Analogs were then synthesized to optimize metabolic stability, CNS 
permeability, and selectivity over human isoforms. Overall, we improved potency against TgCPL 
to as low as 5 nM and identified features that can be exploited to gain selectivity vs HsCPL (10-
fold), and significantly improved metabolic stability (up to t1/2 >60 min in MLM). Importantly, 
we achieved CNS penetrance (up to Brain /Plasma = 1.4) and demonstrated that treatment of 
 xvii 
chronic stage T. gondii bradyzoite cysts with triazine nitrile inhibitors reduces parasite viability 
with efficacy equivalent to a TgCPL genetic knockout. This is the first example of a CNS 
penetrant, reversible TgCPL inhibitor showing efficacy in an in vitro model of the chronic stage 
parasite. Current endeavors are advancing toward in vivo proof-of-concept that pharmacological 
inhibition of TgCPL is an effective method of treating chronic T. gondii infection in the CNS. 
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Chapter 1 Introduction 
 
 
Toxoplasma Gondii: Historical Perspective 
 
Figure 1. Morphology of intracellular Toxoplasma gondii tachyzoites. 
(left) Transmission electron micrograph of the intracellular Toxoplasma gondii tachyzoite stage. (right) Outlines of 
some host and parasite organelles.1 
 
Toxoplasma gondii was first discovered in 1908 by Nicolle and Manceaux in the tissues of 
the North African comb rat, or Gundi (Ctenodactylus gundi). Around the same time in Brazil, 
Splendore also isolated the protozoan from rabbit tissues.2-4 Some historians additionally credit 
two other researchers with the discovery of Toxoplasma.5-6 In 1908, Samuel Taylor Darling 
observed what may have been Toxoplasma in a human muscle biopsy, but incorrectly identified 
it as Sarcosporidia.7 Alphonse Laveran may have also observed toxoplasma prior to Nicolle and 
Manceaux during his work describing Plasmodium sp. and the causative agent of malaria.8-9 As 
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the only member of the genus Toxoplasma, this parasite’s name does not originate from its 
“toxic” or harmful nature. Nicolle and Manceaux conferred this name to the protozoan based on 
the parasites morphology (toxon = bow, plasma = shape) and the original infected host.10-11 It 
wasn’t until 1932 that this parasite was found to be an agent of infectious disease in humans 
when Wolf et al. reported a case of a congenitally infected infant and another case of toxoplasma 
encephalitis.12 Over the course of the next 50 years, Toxoplasma-like infections were described 
in various animal species, including humans, and our understanding of human toxoplasmosis 
increased. It wasn’t until the 1970’s that the complex T. gondii life cycle and various routes of 
transmission were fully understood when Hutchinison et.al. reported the discovery of parasite 
oocysts in cat feces.13-16 Toxoplasma gondii became recognized as a severe and life-threatening 
organism after several cases of toxoplasmic encephalitis were reported around the same time.  In 
the 1980s, once immunodeficiency syndrome (AIDS) became epidemic, T. gondii became 
widely recognized as a cause of morbidity and mortality in immunodeficient patients. This 
parasite continues to be a relevant disease in the modern era, especially in the case of 
immunodeficient patients and pregnant women. With an estimated two billion people chronically 











Figure 2. Phylogenetic tree of parasitic alveolates in the Apicomplexa phylum 
 
Toxoplasma gondii is an obligate intracellular protozoan parasite that belongs to the 
Apicomplexa phylum, Conoidasida class, Eucoccidiorida order, Sarcocystidae family, 
Toxoplasmatinae subfamily, and is the only member of the genus Toxoplasma that has been 
described (Figure 2).19 All Apicomplexa are intracellular parasites that cause a variety of 
diseases in humans and animals. All the Apicomplexa (over 5000) are characterized by a 
complex organelle structure at the anterior region called the apical complex. This unique 
structure is used in host cell invasion and is what gives the phylum its name. 20 Toxoplasma is 
often used as a model system for Apicomplexa for its amenability to genetic manipulation, high 
efficiency of transfection, availability of cell markers, and the relative ease with which the 
parasite can be studied using microscopic techniques due to its size.21-22 
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Parasite Life Cycle 
 
Figure 3. Toxoplasma gondii infection cycle 
Image derived from Hunter and Sibley (2012)23 
 
As is common for Apicomplexa, T. gondii exhibits a complex life cycle. The protozoan can 
adopt three distinct forms (oocyst, tachyzoite, and bradyzoite), and is capable of replicating both 
sexually and asexually. Felines are the parasite’s definitive host in which sexual replication 
occurs. After a replication process known as merogony occurs in the feline gut, male and female 
gametes are formed within the host cell. These gametes then fuse into a diploid oocyst, which are 
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then shed from the feces of the cat into the environment. 10, 24-25 These oocysts disseminate 
throughout the soil, water, and vegetation, where they can persist in nature for months in a cool 
dry environment.26-27 Ingestion of these spores, either from direct contact with cat feces or 
ingestion of oocyst-contaminated food, is a common route of infection for intermediate hosts. In 
the intermediate host, (shown in Figure 3 as rodents) the parasite undergoes asexual replication.  
Upon initial infection, the oocysts convert into a rapidly multiplying trophozoite form known as 
tachyzoites (Greek: tachos = fast). At this stage, the tachyzoite permeates the intestinal epithelial 
cells and subsequently enters the blood stream, allowing the parasite to disseminate throughout 
the host body. They undergo rapid division, causing inflammation, tissue destruction and further 
spread the infection through the host.  
 
 
Figure 4. SEM of a T. gondii bradyzoite cyst 
From the brain of an infected mouse. © David Ferguson 
 
Approximately a week post-infection, the host immune response forces the parasite to 
transition into a persistent tissue cyst. This slow growing cyst form known as the bradyzoite 
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(Figure 4, Greek: brady = slowly), is predominant in areas of the host where the immune 
response is weak, such as muscle, brain, retina, and testes.28-29  
 
The host immune response is key for the parasite life cycle for two reasons. First, in the 
absence of an immune response, the parasite would kill the host. Second, the pressure from the 
host immune system is what drives the tachyzoite to convert into the chronic bradyzoite form, 
where it can persist indefinitely, as the tissue cysts cannot be eliminated by the host immune 
system.30 When a feline ingests a rodent or bird carrying T. gondii bradyzoites in its muscle and 
brain tissues, the parasite reconverts back into its tachyzoite form and the cycle of sexual 
reproduction continues. As this parasite is capable of infecting nearly all warm-blooded 
mammals, humans become infected and serve and an intermediate host through the consumption 
of undercooked meat containing bradyzoite cysts, or oocysts in contaminated water. While most 
symptoms of infection in humans are mild, toxoplasmosis can cause serious health issues if the 
host immune system is compromised.31 
 
Toxoplasmosis In Humans 
- Statistics and Epidemiology 
Thanks to its multiple routes of infection and the ability to infect nearly all warm-blooded 
animals, T. gondii continues to be one of the most pervasive parasites in the world. It has been 
found throughout the animal kingdom and infection with this protozoan parasite is globally 
distributed amongst humans. Estimates suggest over 30% of the global human population is 
currently infected with human seroprevalence reaching as high as 90% in some countries.32-34 
Roughly 60 million persons in the United States (15-20% of the population) are infected with 
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Toxoplasma, imposing a health care burden estimated in 2012 of $3 billion annually due to the 
treatment and institutionalization of afflicted individuals.32, 35 Each year in the US, roughly 
800,000 cases of Toxoplasma infection are reported annually, resulting in an estimated 4428 
hospitalizations. This neurotropic protozoan is currently the second leading cause of death due to 
foodborne illness in the US (~327 deaths per year), and has been designated as one of five 
neglected parasitic infections targeted by the Center for Disease Control and Prevention for 
public health action.36  In patients with AIDS, one to five percent will develop toxoplasmic 
encephalitis.37  Furthermore, T. gondii is the most common cause of infectious necrotizing 
retinochroiditis, which manifests in 1-20% of patients with acquired systemic infections. In the 
United States, ocular toxoplasmosis affects an estimated 21,000 people each year, eventually 
leading to loss of vision in approximately 4,800 individuals annually.38 Significant differences 
are observed with Toxoplasma infection rates being higher in various geographic regions and in 
populations with lower socioeconomic status. One study found that Toxoplasma seroprevalence 
in the US was higher in the Northeast (29.2%) than in the South (22.8%), Midwest (20.5%), or 
West (17.5%) (p < 0.05).39 Infection in humans primarily occurs through ingestion of 
undercooked contaminated meat, especially pork and lamb. As such, T. gondii also has 
significant veterinary importance as toxoplasmosis in sheep and goats results in neonatal 




Figure 5. Global distribution of T. gondii infection rates 
From Pappas, G et. al. (2009)41  
 
At the international level, climate, socioeconomic factors, and food preparation habits play 
important roles in parasite distribution. In cooler climates, such as North America, South East 
Asia, and Northern Europe, low seroprevalences are observed ranging between 10 to 30%. 
Increased seroprevalence (30 to 50%) are often found in countries of Central and Southern 
Europe and high prevalences are common in Latin America and tropical African countries 
(Figure 5).31, 42  In many populations where undercooked meat is commonly consumed, such as 
those in El Salvador and France, the seropositivity rate is as high as 75%. As much as 90% of 
adults in Paris have been found to be seropositive for Toxoplasma infections. In certain regions 
of Western Europe and Africa, approximately 50 to 78% of individuals with HIV tested 
seropositive for T. gondii infection. Approximately 37% of AIDS patients in France displayed 
evidence of toxoplasmic encephalitis at autopsy. In general, older individuals are more likely to 
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manifest evidence of reactivated Toxoplasma gondii infection and congenitally acquired 
retinochroiditis is more likely to occur in person's over 40 years old. [36] 
 
Pathogenicity of Toxoplasma gondii 
- Immunocompetent Patients 
Most people (ca. 80%) who become infected with Toxoplasma gondii are asymptomatic. In 
some scenarios, patients will experience mild flu like symptoms including fever, myalgia, tender 
lymph nodes, and muscle aches. This initial disease state is caused by the rapidly replicating 
tachyzoite form. This stage typically lasts for a few weeks, at which point the host immune 
system drives that tachyzoites into their bradyzoite form and the parasite begins its latent 
infection. If the host maintains a healthy immune system this chronic infection generally presents 
few symptoms although a growing body of evidence suggests at this chronic stage infection may 
significantly contribute to a wide array of neuropsychiatric symptoms.43-46  Animal studies have 
shown that T. gondii infection can have an influence on host behavior, neuronal function, and 
mate choice.  These studies demonstrated that rats that are chronically infected with brain cysts 
have altered risk taking behavior, and unconditioned fear responses.47  Evolutionarily this makes 
sense, as this behavior leads to increased opportunities for the transmission of the parasite from a 
rodent host to the definitive feline host.  T. gondii has also been shown to enhance the sexual 
attractiveness of infected male rats.48  In humans, dozens of studies have linked chronic T. gondii 
infection to major mental illnesses including schizophrenia (odds ratio 2.7, P<0.000001), bipolar 
depression (odds ratio 2.4, P<0.05), and various other mood alterations.49-51  T. gondii 
seropositive schizophrenic patients also have worse symptoms, require more treatment, and have 
longer hospital stays compared to seronegative schizophrenics.52-55  The genotype of the 
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infecting parasite strain also plays a role in the severity of the infection. For example, North 
America and Europe are correlated with strains resulting in low prevalence and infection 
severity. Strains from South America or Brazil often lead to more severe infections. For 
example, toxoplasmosis infection accounts for higher levels of visual impairment in Brazil and is 
the leading cause of blindness in South America.56  There have been more recently reported 
cases of atypical strains, including one case in French Guiana, where Toxoplasma was shown to 
cause lethal infections in immunocompetent individuals.57-59 
 
- Congenital Infection 
If a woman has been infected prior to becoming pregnant, the unborn child is generally 
protected through the mother’s developed immune system. However, some of the more severe 
outcomes of Toxoplasma infection are observed when a woman becomes infected for the first 
time while pregnant.60  Post-primary infection, the mother vertically transmits the tachyzoites to 
her unborn baby.  The frequency of this transmission and resulting severity to the child differs 
between the stages of pregnancy. During the beginning of gestation, the placenta serves as an 
efficient barrier against the parasite, limiting the transmission rate to 15-20%. This rate is 
increased to 30-50% during the second trimester and reaches rates as high as 60-70% during the 
third trimester of pregnancy.41  Conversely the severity of infection is inversely proportional to 
the transmission rate, the most severe symptoms resulting from infection during the first 
trimester. This has been shown to lead to symptoms such as miscarriage, encephalomyelitis, still 
born children, hydrocephalus, microcephaly, jaundice, convulsions, and more. 61  For this reason, 
pregnant women are often counseled by physicians to avoid changing the cat litter box, in order 
to prevent contact with recently shed oocysts. Often, infants infected before birth often show no 
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symptoms at birth but develop them later in life with potential vision loss, mental disabilities, 
and seizures. Eye lesions due to congenital infection occur in 20-80% of infected persons by 
adulthood, however they manifest in less than 2% of persons infected after birth. In sheep and 
goats, congenital infections also are also responsible for a high percentage of spontaneous 
abortions.62 
 
- Immunocompromised Patients 
In its mammalian hosts, T. gondii exists in two principal forms, the tachyzoite and 
bradyzoite.29  The initial disease state is caused by the rapidly replicating tachyzoite form. This 
stage typically lasts for a several days to weeks during which the parasite disseminates to 
peripheral sites including the central nervous system (CNS).  T. gondii then transitions into a 
chronic bradyzoite cyst form within the CNS and muscle tissue to establish life-long infection. 
The host immune system is of critical importance to keep the T. gondii infection suppressed.  A 
person infected with Toxoplasma may experience severe symptoms if their immune system 
becomes compromised due to reasons such as HIV infection, immunosuppressive therapies, and 
cancer chemotherapies.  For example, Toxoplasma can reactivate in a patient infected with HIV 
and lead to severe symptoms including fever, confusion, headache, seizure, nausea, encephalitis, 
and death.63 Immuno-depression results in the rupture of the bradyzoite cysts in the tissues, 
which convert back into tachyzoites causing inflammation. In the CNS, this results in severe 
encephalitis, which is fatal if left untreated. Patients with HIV who have not previously been 
infected with the parasite, are more likely to develop a severe primary Toxoplasma infection. 
Toxoplasmic encephalitis (TE) is an HIV-indicative event in 35% of patients and an AIDS-
defining event in 75% of cases.64  Individuals who progress towards marked immunodeficiency 
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are prone to several opportunistic infections, but TE is the most common cerebral opportunistic 
disease in many countries.65-67  Pulmonary or disseminated toxoplasmosis are characteristic of 
infections acquired from organ transplants where the organ was received from a Toxoplasma-
seropositive donor.31 Serological screening of both donors and recipients should be performed to 
mitigate the potential risks of toxoplasmosis.68 The reactivation of T. gondii in 
immunocompromised pregnant women who were infected prior to their pregnancy, can lead to 
congenital infection.  
 
- Diagnosis of Toxoplasmosis 
A variety of methods are used to diagnose toxoplasmosis. In general the diagnosis of 
toxoplasmosis is typically done by serological testing that measures immunoglobulin G (IgG) 
and immunoglobulin M (IgM) via automated or semi-automated immunoassays.69-70 This can 
determine if the patient has been infected; however, the difficulty lies in determining whether the 
infection is in its chronic or acute stage. High levels of IgM antibodies indicate an acute phase 
infection while IgG antibodies are indicative of a chronic infection (Figure 6).71  
 
Figure 6. Kinetics of the antibody (Ab) response. 
Image derived from Hunter and Sibley (2012)23  
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This is of particular importance to pregnant women. Parasites can be isolated from the blood 
or other bodily fluids such as the cerebral spinal fluid to verify an acute infection; however, this 
technique is not frequently used due to the time required and the difficulty of isolating the 
parasite. Although congenital infection can be determined by the presence of cysts in the 
placenta or in the tissues of the fetus, isolation of the T. gondii cysts is inadequate in determining 
if the infection is still active or latent. Therefore, the diagnosis still relies on serological testing as 
well. Molecular techniques such as PCR are capable of detecting parasite DNA in the amniotic 
fluid and may be used in cases of possible congenital transmission. If the T gondii is determined 
to be in the early stages of infection, the diagnosis is followed up with early treatment to mitigate 
the risk of congenital infection. In the cases of ocular toxoplasmosis the diagnosis is made based 
on the appearance of lesions in the eye, disease symptoms, and serological testing.72 
 
Treatments and Prevention of Toxoplasmosis 
- Current Treatments 
In general, the treatment of toxoplasmosis in an immunocompetent patience is unnecessary. 
In immunocompromised patients, the standard treatment is a combination of pyrimethamine 
(inhibitor of the dihydrofolate reductase enzyme, Figure 7) given at 25-100 mg daily and a 
sulfonamide of the trisulfapyrimidine type given at 2-6 g daily, both for a month. The parasite 
synthesizes folates de novo and is unable to utilize dietary folates. This combination therapy 
blocks the biosynthesis of parasite folates (thus its nucleic acids) and consequently prevents 
synthesis of DNA and protein. Leucovorin (folinic acid) is used to decrease the toxic effects, 
such as bone marrow depression, caused by the pyrimethamine.73 However, these combination 
therapies are often not tolerated and can cause symptoms such as nausea, insomnia, headache, 
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lightheadedness, and blood problems in some severe cases. 
 
Figure 7. Current drugs used for the treatment of toxoplasmosis 
 
Clindamycin (Cleocin) can be used as an alternative treatment and has been shown to be 
effective at combating TE in AIDS patients.74-75 This lincosamide antibiotic functions via the 
inhibition of the 50s ribosomal subunit of bacteria, and thus targets the protozoan mitochondrion 
and a remnant non-photosynthetic chloroplast termed the apicoplast.76-77 Pyrimethamine 
combination therapies and Clindamycin only target efficiently proliferating tachyzoites during 
the acute phase of infection and is therefore ineffective against the bradyzoite cysts in the latent 
infection.78 Atovaquone (an inhibitor of the mitochondrial electron transport system) has been 
shown to reduce the number of brain cysts in infected hamsters and can be used in patients 
unable to tolerate sulfonamides and clindamycin.79-83 The teratogenic effects of pyrimethamine 
prevent its use in infected pregnant women. For women still in the acute phase of infection, the 
recommended treatment is spiramycin if the fetus has not yet acquired the infection.84-86 
Spiramycin localizes to the placenta and has been shown to reduce placental infection by 60%. 
Unfortunately, spiramycin has no effect on the infection if the fetus is already infected. 
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Additionally, it has teratogenic effects, and must be weighed against the risk of congenital 
infection. It is important to note that all of these treatment regimens have significant 
shortcomings including poor tolerance, allergic complications, and lack of efficacy against the 
chronic form of infection. The ability to preclude reactivation by reducing or eliminating the 
chronic T. gondii infection from at risk individuals remains a key unmet need. Currently, there is 
no efficacious T. gondii therapeutic capable of treating the chronic-phase infection. Given the 
limitations and current inadequacies of antiparasitic therapies, there is a serious need for the 
development of novel and alternative strategies for the treatment of chronic T. gondii infection.  
 
Challenges in Identifying Novel Target for the Treatment of Chronic Toxoplasmosis 
While the tachyzoite stage of Toxoplasma is used as a model system for Apicomplexans, it 
has been very difficult to identify new targets for the treatment of the chronic T. gondii infection 
due to several reasons. In the latent stage of infection, the bradyzoites grow very slowly in both 
culture and infected mice. This greatly impedes the workflow of researchers and dissuades many 
investigators. Clinically, this also precludes the use of many standard antiparasitics that target 
rapidly replicating parasites. Additionally, it is difficult to obtain the large quantities of the 
chronic T. gondii parasites needed for proteins analysis and drug discovery. Furthermore, many 
of the parasite strains fail to efficiently convert to the bradyzoite stage cysts in-vitro. Dr. Vern 
Carruthers and his lab have made substantial advancements in understanding mechanisms of 
chronic T. gondii infection, and optimized methods for culturing and harvesting chronic stage 
parasites.87-91  The genetic tools for differentiation of competent strains they developed have led 




Toxoplasma gondii Cathepsin L (TgCPL) as a Potential New Target 
- Discovery of TgCPL 
T. gondii has a complete endolysosomal system, including a lysosome-like vacuolar 
compartment (VAC).93 While in the latent phase, T. gondii retains an active endocytic system in 
which the VAC receives and degrades material derived from the cytoplasm of infected host 
cells.94-95 Recent studies revealed a key role for proteolysis within the parasite VAC in the 
turnover of autophagosomes and persistence during neural infection.96 T. gondii expresses five 
cysteine proteases. Two of these members are predominantly localized in the VAC. These have 
been termed Toxoplasma gondii cathepsin protease L (TgCPL; toxodb accession number 
TGME49_321530) and Toxoplasma gondii cathepsin protease B (TgCPB; TGME49_249670). 97  
The remaining three belong to the cathepsin C class of proteases (TgCPC, TgCPC2, and 
TgCPC3), with the former two being expressed in the tachyzoite stage, and the latter in the 
sporozoite form. None of the TgCPC’s have been detected in the bradyzoite stage.98  Upregulated 
expression of TgCPL and TgCPB in chronically infected mice suggests an active role for VAC 
proteolysis in Toxoplasma persistence.99 The maturation of TgCPB is dependent on TgCPL 
activity , thus ablating TgCPL effectively impairs both proteases97  The disruption of these 
cysteine proteases (primarily TgCPL) impedes the digestive function of the VAC and shows a 
notable impact on the chronic infection, implicating TgCPL as a potential new target in the 






- Proteases and Broader Classification 
Proteases are enzymes involved in protein catabolism through the catalytic hydrolysis of 
peptide bonds in macromolecules and oligomeric peptides. These enzymes, also known as 
peptide hydrolases, range from monomers as small as 10 kDa to large multimeric complexes of 
hundreds of kDa. These enzymes are found in nearly all biological systems, and genome 
sequencing projects have revealed that proteases comprise approximately 2% of all expressed 
genes.100-101 They are classified by the clans and families they belong to as well as by the 
catalytic mechanism used in protein hydrolysis. The main types are serine proteases, 
metalloproteinases, aspartic acid proteases, threonine proteases, cysteine proteases and other 
‘cryptic’ proteases may exist.102  The MEROPS database classifies these peptidase families by 
their catalytic type, the first character representing the catalytic type (ex. A, aspartic; C, cysteine; 




Figure 8. The catalytic mechanisms of different proteases 
A) Serine proteases, B) Cysteine proteases, C) Aspartic proteases, D) Metalloproteinase. Hydrogen bonds are shown 
in blue dotted lines. The oxygen anion in (A), (B) and (C), and the thiolate in (D) are positioned to attack the amide 
carbonyl in peptides (red arrows).103  
 
Serine Protease: A serine protease active site consists of a catalytic triad comprised of 3 key 
amino acids, His 57, Ser 195 and Asp 102, with the serine acting as the nucleophile. While these 
amino acids are located distally from each other on the primary sequence of the peptide, protein 
folding is assembled in a manner that holds these residues in the catalytic slight near each other 
(Figure 8A). In this catalytic triad the aspartic acid forms hydrogen bond with the histidine, 
increasing its ability to pull the proton from the serine residue. Lacking the hydrogen the Serine 
becomes a stronger nucleophile and readily attacks the carbonyl of the substrate amide bonds. 
Serine proteases are classified in 2 broad categories, chymotrypsin-like (trypsin-like) or 
subtilisin-like. 104 Some serine proteases have specificity that is determined by the amino acid 
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residues of the substrate. For example, chymotrypsin is a digestive enzyme found in pancreatic 
juice preferentially cleaves substrates where the P1 position is a large hydrophobic amino acid 
such as tyrosine, tryptophan, or phenylalanine. In humans, serine proteases are responsible for 
coordinating various physiological functions, including digestion, immune response, blood 
coagulation and reproduction.105  They have also been found to play an active role in ECM 
remodling.106-108 
 
Cysteine Protease: Cysteine proteases function through a mechanism like that of the serine 
proteases, however the nucleophile used in catalysis is a cysteine thiol rather than a serine 
oxygen. Once the histidine pulls the hydrogen away from the cysteine thiol, the anion readily 
cleaves the substrate in a mechanism like that of the serine protease (Figure 8B). Cysteine 
proteases play crucial roles in virtually every aspect of physiology and development 
 
Aspartic Protease: Aspartic proteases rely on a water molecule to catalyze the degradation of its 
substrate. (Figure 8C). The water is coordinated by 2 aspartic residues in the active site. In 
general, Aspartic proteases function optimally in low pH / acidic environment. For this reason, 
they are rarely reported to degrade extracellular proteins as the pH of extracellular space is 
generally neutral. Aspartic proteases are known to be involved in various biological functions 
such as blood pressure regulation (Renin), digestion (Pepsin), and HIV life cycle (HIV protease). 
 
Metalloproteinase: A metalloproteinase is an enzyme that uses coordinated metal, most often 
zinc, for active site catalysis. In this scenario water is used as a nucleophilic agent to attack the 
carbonyl oxygen of the substrate through interactions with the coordinated zinc and a glutamate 
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residue in the active site as shown in Figure 8D.  With over 50 different classification families, 
metalloproteases are the most diverse of the 4 main proteinase types. Matrix metalloproteinases 
(MMPs) are the main enzyme responsible for the degradation of extracellular matrix, and as 
such, are crucial in cell proliferation, morphogenesis, tissue remodeling and metastasis, 
migration (adhesion/dispersion), angiogenesis, apoptosis, and host defense.109 
 
 
Figure 9. Diagram representing the peptide substrate 
(Red) interaction with the active site pockets of a protease (Blue). 
 
Each subsite pocket of the protease binds to a corresponding residue in the substrate 
sequence. Substrate amino acid residues are consecutively numbered outward from the cleavage 
site as P1’-P2’-Pn’ toward the C-terminus, and P1-P2-Pn toward the N-terminus. The scissile bond 
is located between the P1 and P1’ positions. Similarly, the subsites are named corresponding to 
the residue it binds (S1-S1’-S2-S2’-Sn-Sn’). Proteases that cleave protein substrates adjacent to the 
N- or C- terminus are termed exopeptidases, while those that cleave anywhere else in the 
substrate are termed endopeptidases. 
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- Cathepsins and Their Classification 
Cathepsins are a group of proteolytic enzymes that are ubiquitous in the human body and 
nearly all living organisms. They were first discovered in 1929 as acid proteases distinct from 
pepsin in the gastric mucosa of pig and dog.110 Belonging to the papain super family of clan CA, 
cathepsin is derived from the Greek words, loosely meaning “to digest” (kata = "down" and 
hepsein = "boil”. In humans, the cathepsins are classified into various categories based on their 
structure, substrate specificities, and catalytic mechanisms. Cathepsins A, G are serine proteases, 
while cathepsins D, E are aspartate proteases. The remainder are lysosomal cysteine proteases, 
including the human isoforms B, C, F, H, K, L, O, S, V, X and W. Cathepsins function optimally 
in slightly acidic pH, corresponding to the lysosomal environment in which they are found. 
Cysteine cathepsins are generally considered to be intracellular enzymes that function in protein 
degradation and processing within lysosomes, late endosomes and vesicular compartments. The 
low pH in the lysosomes allows the protease to function optimally and protects the cysteine thiol 
from oxidation. More recently, cysteine cathepsins, namely B, K, and L, have been shown to 





Figure 10. Cleavage mechanism and subsite nomenclature of cathepsin cysteine proteases.  
The first step in the reaction mechanism, the active site thiol is deprotonated by an adjacent amino acid with a 
basic side chain, usually a histidine residue. The next step is nucleophilic attack by the deprotonated cysteine 
anion on the carbonyl of the substrate protein. The amine is then protonated and released from the complex, 
followed by the hydrolysis of the thioester to complete the catalytic cycle by releasing the carboxylic acid and 
restoring the enzyme free thiol. 
 
- Cysteine Proteases as Viable Antiparasitic and Clinical Targets 
Inhibition of vital cysteine proteases is an increasingly attractive approach for the treatment 
of various disease states caused by related protozoans such as Trypanosoma cruzi, Plasmodium 
falciparum, and others.102, 113-115 These parasitic organisms such as Toxoplasma gondii show a 
critical dependence on cysteine proteases for their survival.102, 116-117  Several protease inhibitors 
are showing promise in pre-clinical testing as agents against malaria and Chagas’ disease.118 
Further supporting the feasibility of protease inhibitor as drugs, many proteases are currently 
targeted for the treatment of various human disease states such as cancer, osteoperosis, diabetes, 
hypertension, myocardial infarction, acute lung injury, hepatitis C and AIDS. Several protease 
inhibitors are used clinically in antiretroviral therapies such as Darunavir targeting the HIV 
aspartyl protease, and Boceprevir and Telapreviris are used in the treatment of hepatitis C 
infections.119  Human cathepsin L is also being pursued as a target for cancer metastasis.  Given 
the close homology to their parasitic counterparts, the vast libraries of inhibitors originally 
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developed against human isoforms, can provide a fruitful source of lead anti-parasitic 
compounds.120  This offers an excellent starting position for utilizing a structure based medicinal 
chemistry approach in the development of small molecule inhibitors of T. gondii cathepsin L. 
 
Toxoplasma gondii Cathepsin L Classification, Structure, and Localization 
 
Figure 11. Crystal structure of activated Toxoplasma gondii cathepsin L 
Derived from PDB: 3F75 
 
TgCPL, also known as toxopain-2, is a cysteine hydrolase that is predominantly localized 
within the VAC (lysosome) of the Toxoplasma endolysosomal system in the apical region of the 
parasite.(Figure 11) TgCPL is a member of the C1 family, CA ‘papain-like” clan of cysteine 
proteases. It is the only Toxoplasma cathepsin encoded on chromosome Ib and contains four 
exons. Like the rest of the members of the papain family of proteases, TgCPL retains the 
conserved cysteine, histidine, asparagine catalytic triad within its active site. TgCPL is 422 
amino acids in length, with the C-terminal 75 residues comprising its inactivating pro-peptide 
tail. TgCPL is expressed as a zymogen and kept inactivated via its propeptide tail sterically 
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occluding the active site.  As an endopeptidase/auto-maturase, TgCPL self-activates via the 
catalyzed cleavage if its propeptide tail once it reaches a low pH environment. The 30 kDa 
mature form functions optimally in a low pH environment (5.5 - 6.0) and preferentially cleaves 
P2 hydrophobic substrates. It is expressed in both the tachyzoite and bradyzoite stages of the T. 
gondii life cycle.  
 
Genetic Validation of TgCPL as a Potential Target 
 
The VAC-resident cathepsin protease L (TgCPL) is responsible for degrading host-derived 
proteins. Loss of TgCPL function in T. gondii results in compromised parasite replication and 
attenuated virulence during the acute tachyzoite infection, suggesting an important role for the 
TgCPL in pathogenesis. TgCPL is substantially upregulated in bradyzoites, implying a key role 
in this stage. Recent studies have shown it to be critical to parasite survival during the chronic 
phase of infection.96, 121 Genetic and chemical ablation of TgCPL severely compromises T. 




Figure 12. Genetic validation of TgCPL as a target for chronic stage T. gondii infection 
(A) TgCPL deficient cysts are not viable in vitro. Parasites were stage converted to the chronic form for 2-wk before 
assessing viability using qPCR to measure total parasites and plaque assay to measure viable parasites. (B) Mice 
infected with TgCPL-deficient parasites have markedly fewer cysts. C57BL/6 mice were infected for 4-wk with the 
indicated dose, brain homogenates were blinded, and cysts were enumerated by GFP fluorescence microscopy.(†=no 
mice survived initial infection). (C) Pru∆cpl cysts contain deformed bradyzoites. Shown are representative cysts 
from mice infected with 105 Pru or 107 Pru∆cpl. Inset shows enlargement of two (Pru) or one (Pru∆cpl) bradyzoite. 
(D) Independent confirmation that TgCPL deficient cysts are highly compromised. A second strain of the parasite 
termed ME49 strain was used to create ME49∆cpl. Viability was assessed as in A. (E) Cyst burden depends on 
expression of TgCPL during the chronic phase. CBA/J mice were infected for 4-wk with 500 tachyzoites of each 
strain. Brain cysts were enumerated by phase contrast microscopy. Note the discontinuous y-axis. # indicates 
residual cysts appear degenerate. *, p<0.05 student’s t-test. (F) Residual ME49∆cpl cysts are degenerate. Phase 
contrast images of ME49 and ME49∆cpl cysts observed within mouse brain homogenates. (Results courtesy of Vern 
Carruthers lab) 
 
The Carruthers lab utilized a genetically amenable, cyst-forming strain (Prugniaud 
(Pru∆ku80; Pru hereafter)) to create TgCPL-deficient parasites (Pru∆ku80∆cpl; Pru∆cpl 
hereafter).92, 96 They also created parasite strains that re-express active TgCPL (Pru∆cplCPL) or 
inactive TgCPL (Pru∆cplCPL*) due to alanine substitution of the catalytic cysteine residue. A T. 
gondii mutant strain lacking TgCPL loses viability within 2 weeks of differentiating to the 
chronic stage in in vitro cultures (Fig. 12A), indicating that TgCPL is essential for survival of 
chronic stage parasites. Similar loss of parasite viability was seen in infected mice (data not 
shown). Restoring expression of an active allele of TgCPL rescues viability in an independently 
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created TgCPL deficient strain, but expression of a catalytically inactive allele fails to preclude 
death, underscoring the requirement for active TgCPL. Mouse infection showed that chronic 
stage cysts were readily detected in mice infected with 105 and 106 wild-type Pru tachyzoites, but 
few or no cysts were seen with TgCPL-deficient Pru∆cpl at these doses (Fig. 12B). Pru∆cpl cysts 
were observed in 107 infected mice, but these cysts were highly abnormal, with bloated and often 
misshapen bradyzoites (Fig. 12C). CRISPR-Cas9 genetic technology was used to create TgCPL 
deficient parasites in a second cyst forming strain called ME49. These efforts independently 
validated a crucial role for TgCPL for chronic stage viability (Fig. 12D-F), with >99% loss of 
TgCPL-deficient parasites after differentiation in culture and in mice. Using strains that express 
TgCPL in a stage-specific manner, this analysis also established that TgCPL expression, 
specifically during the chronic infection, is required for normal cysts (Fig. 12E). Taken together, 
these findings show that TgCPL activity is required for chronic T. gondii infection. 
 
Chemical Validation of TgCPL as a Potential Target 
Having genetically established a role for TgCPL in chronic T. gondii infection, the 
Carruthers lab moved to assess vulnerability of TgCPL to small molecule inhibition in the Pru 
strain, which expresses cytosolic GFP after differentiation to bradyzoite cysts. Cysts exposed in 
culture to a validated, irreversible TgCPL inhibitor termed LHVS lost cytosolic GFP 
fluorescence (Fig. 13A) and became degenerate similar to TgCPL-deficient cysts.121 A novel 
qPCR/plaque assay to directly assess cyst viability was used to measure the number of viable 
bradyzoites capable of forming plaques on a host cell monolayer and the total number of 
bradyzoites based on qPCR. Consistent with LHVS efficacy, no viable bradyzoites were detected 
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after a 3-wk treatment (Fig. 13B). These results provide in vitro proof-of-concept that TgCPL is 
a viable target for the treatment of chronic stage toxoplasmosis.  
 
 
Figure 13. CPL activity is required for cyst viability in vitro 
(A) TgCPL inhibitor treatment kills cysts based on GFP signal. Pru (WT) cysts were differentiated in culture for 1-
wk prior to treatment with solvent control (DMSO, left panel) or LHVS (right panel), fixed, viewed and enumerated 
for GFP by fluorescence microscopy. n=2 independent experiments. (B) CPL inhibitor treatment kills bradyzoites 
based on qPCR/plaquing. Parasites were inoculated into HFF cells, differentiated for 1-wk then treated with solvent 
(0.1% DMSO) or inhibitor (1 µM LHVS) for 3-wk 
 
Mouse gene knockout studies have shown that cathepsin L is dispensable in higher 
mammals. This is likely due to the functional redundancy with other cathepsin proteases.122 
Humans express a total of 11 Cathepsins proteases while Toxoplasma gondii only expresses five. 
As mentioned previously, only two of these, TgCPL and TgCPB, are expressed during the latent 
infection, leaving the parasite much more susceptible to cathepsin inhibition. This concept 
however, remains invalidated in an in vivo model of toxoplasmosis. LHVS does not cross the 
blood-brain barrier, precluding its use as an in vivo proof-of-concept treatment in infected mice.  
Fortunately, a crystal structure of TgCPL is available from our previous work, thus aiding 
rationale selection of candidate inhibitors from the literature as lead compounds.121  The next 
crucial step and the objective of this study is to identify and optimize CNS penetrable, lead 
compounds as a prelude to proof-of-concept studies in chronically infected animals.   
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Chapter 2 The Development of Dipeptide Nitrile Inhibitors of TgCPL 
 
Identification of New Lead Inhibitors of TgCPL 
- Computational Evaluation of Literature Cathepsin L Inhibitors 
An enormous amount of drug discovery and development has been done in regard to both 
human and parasitic cathepsins isoforms, and extensive mechanistic and structural information is 
available.123-130 Given the close homology between the human and parasitic isoforms of 
cathepsin L, we considered the vast libraries of inhibitors already developed against human 
isoforms to be a promising source of lead anti-parasitic compounds.120 To identify a better 
potential lead compound than LHVS, we conducted a broad literature search of structurally 
diverse cathepsin L inhibitors emphasizing physicochemical properties predictive of CNS 
permeability, selectivity over other human cathepsins, and potency (IC50 < 1 µM). 
 
Table 1. Comparison of calculated properties of lead inhibitors vs CNS and non-CNS drugs 
Compound MW SlogP tPSA HBA HBD RotB 
CNS drug 288 ± 88 2.8 ± 1.4 46 ± 26 2.6 ± 1.3 1.0 ± 0.9 4.0 ± 2.6 
non-CNS drug 383 ± 210 2.1 ± 2.9 98 ± 84 4.8 ± 4.1 2.8 ± 3.3 6.2 ± 5.5 
LHVS 527.69 3.6 104.8 5 2 14 
AZ-12878478 381.48 2.4 99.8 4 2 10 
Calculated using The Molecular Operating Environment (MOE), version 2008.10, Chemical Computing Group Inc., 
Montreal, Quebec, Canada.131 Mean values and standard deviations derived from 198 approved CNS drugs and 1015 





Rational and Selection of AZ-12878478 / CCG: 232877 as Lead Dipeptide Nitrile  
 
 
Figure 14. Literature lead cathepsin L inhibitors 
 
We ultimately selected our initial lead compound 232877 (Figure 14) based on its 
calculated properties: molecular weight (MW), topological polar surface area (tPSA), numbers of 
hydrogen bond acceptors and donors (HBA, HBD), and rotatable bonds (RotB), which are 
collectively closer to marketed CNS drugs vs non-CNS drugs than are those of LHVS and most 
other literature leads we considered (Table 1)132. In addition, we considered the ease with which 
we could expect to improve predicted BBB access by further lowering the tPSA.  
 
As the first ever SAR campaign targeting TgCPL, we elected to use a dipeptide nitrile 
scaffold as our lead, based on the extensive amount of dipeptide-type cathepsin inhibitors 
previously developed for related human isoforms.133-135  We believed the use of dipeptide probes 
would enable rapid elucidation of the pharmacophore necessary for the selective inhibition of 
TgCPL due to their synthetic accessibility and ease of diversity introduction.  
 
Another key rationale for selecting 232877 as our lead was the aminoacetonitrile “warhead”. 
The majority of small molecule protease inhibitors incorporate a functional group that can react 
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with the active site cysteine or serine in a covalent manner that imparts high affinity with 
relatively low off-target reactivity (Figure 15).133, 136-137 The aminoacetonitrile group has been 
extensively studied and is present in a number of FDA-approved drugs and advanced clinical 
candidates, including vildagliptin, saxagliptin, and odanacatib.130 In contrast to the irreversible 
inhibitor LHVS, the dipeptide nitriles function through a reversibly covalent mechanism (Figure 
15B), reducing the potential for off target effects, and its low molecular weight and relatively 
low tPSA were considered advantageous for achieving CNS permeability.  
 
 
Figure 15. Protease warheads 
A) Exemplary protease inhibitor electrophilic warheads. a) vinyl sulfone, b) α-chloro ketone, c) acyloxymethyl 
ketone, d) nitrile, e) aldehyde, f) epoxide. Red line indicates site of nucleophilic attacks by protease active site 




Figure 16. Ligplot diagram of 232877 in HsCPL 
LIGPLOT diagram generated in MOE, shows key interactions between 232877 and HsCPL. Hydrogen bonds: blue 
arrows, lipophilic interactions: blue spheres. Derived from PDB: 3HHA 
 
Figure 17. TgCPL and HsCPL active site comparison 
Comparison of 232877 bound to HsCPL (A, C) and a superposition of 232877 modeled into the active site of 
TgCPL (B, D) depicting key non-conserved residues. A) HsCPL with key residues colored. B) TgCPL with key 
residues colored C) Lipophilicity mapping of HsCPL (green: lipophilic; magenta: polar); D) Lipophilicity mapping 
of TgCPL. (Derived from PDB codes: 3HHA and 3F75) 
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We selected 232877 as a lead because of the availability of an X-ray co-crystal structure of 
it bound to human cathepsin L (HsCPL, (PDB: 3HHA).132 Opportunely, a crystal structure of 
TgCPL was also available from our previous work, which we expected would greatly facilitate 
the design of TgCPL-selective inhibitors.132, 138-141 The crystal structure of 232877 bound to 
HsCPL shows that the active site Cys25 is covalently added to the nitrile, consistent with other 
reversibly-covalent nitrile based inhibitors of cysteine proteases, and that the ligand makes 
hydrogen-bonding interactions with Asp162, Gly68, and Gln19 (Figure 16).133, 136  Importantly, 
the bound inhibitor 232877 can be overlaid on our crystal structure of TgCPL to identify 
proximal structural differences between the cathepsins that can be exploited to achieve selective 
inhibition of the T. gondii enzyme (Figure 17). 121 In particular this overlay reveals a smaller S2 
pocket for the Toxoplasma cathepsin, as well as four non-conserved residues (colored in Figures 
17A,B).  Further comparison of the protein sequence alignment of TgCPL and the human 
cathepsin isoforms A-X, revealed that these key residues are either unique to TgCPL, or 
generally non-conserved across human isoforms. The S2 pocket across the human cathepsins 
tends to be more uniformly lipophilic (colored green in Figures 17C,D) than TgCPL, and the 
inclusion of a basic residue in the P2 position, which we predicted might interact strongly with 
non-conserved Asp218 in TgCPL, is generally not tolerated. With the exception of human 
cathepsin B, which bears a Glu245 in this respective position, the overall topology in the S2 
subsite is thus substantially different than that of TgCPL.142 This provided excellent supporting 
evidence that optimization in the P2 position would be paramount in an effort to gain selectivity 
over the bulk of the human isoforms.  
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Our primary objectives in this preliminary work were: 1) to develop analogs with better 
predicted CNS permeability without losing potency; and 2) to determine if we can begin to shift 
the selectivity of 232877 away from HsCPL and towards TgCPL. Herein we report the 
development of a series of dipeptide nitrile probes that help to define pharmacophoric features 
key to improving both potency and selectivity for TgCPL, including one analog with CNS 
permeability in vivo.  
 
First Generation Dipeptide Nitrile Inhibitors of TgCPL 
- General Synthesis of Dipeptide Nitriles 
 
 
Scheme 1. General synthesis of dipeptide nitriles 
Reagents and conditions: a) H2SO4, MeOH, reflux; b) HATU, DIPEA, DMF; c) 1N LiOH(aq), THF, MeOH; d) 2-
aminoacetonitrile bisulfate, HATU, DIPEA, DCM, 0°C-rt 
 
Synthesis of dipeptide nitriles (Scheme 1) was performed analogous to the literature 
precedent for the peptide-nitrile cathepsin inhibitors.132-133, 135, 141 We began with the 
esterification of various commercially available L-amino acids 2.1a to afford their respective 
 34 
methyl esters 2.1b. Subsequent amide coupling to the appropriate aryl acids gave 2.1c. The 
methyl ester was then saponified under mild conditions with LiOH in a THF:MeOH system to 
afford the desired free acid 2.1d. Initial coupling with 2-aminoacetonitrile gave several unwanted 
side reactions and generally low yields when using DMF or THF as the solvent, regardless of the 
temperature or coupling reagent used. Upon changing to dichloromethane we found that, while 
solubility was not always ideal, the desired products (2.1e, 52 examples) were formed cleanly 
and in moderate yields. 
 
- Synthesis of Dimethyl-lysine Analog  
 
 
Scheme 2. Synthesis of dimethyl-lysine analog 
Reagents and conditions: a) 4-Fluorobenzoic acid, HATU, DIPEA, DMF, 98%; b) 4N HCl/dioxane, 99%; c) 
formaldehyde, sodium triacetoxyborohydride, MeOH, 32%; d) 1N LiOH(aq), THF, MeOH, 100%; e) 2-
aminoacetonitrile bisulfate, HATU, DIPEA, DCM, 0°C-rt, 11%. 
 
 
Synthesis of 257950 was achieved as shown in Scheme 2. Nε-Boc-L-lysine methyl ester 
hydrochloride 2.2a was coupled to 4-fluorobenzoic acid to provide intermediate 2.2b. Boc 
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removal from 2.2b afforded the HCl salt of 2.3c, which was immediately followed by 
dimethylation of the side chain to provide compound 2.3d. Saponification of 2.3d with lithium 
hydroxide provided 2.3e, and subsequent amide coupling using HATU gave the desired product 
257950. 
 
- Synthesis of Trifluoroethylamines 
 
 
Scheme 3. Synthesis of trifluoroethylamines 
Reagents and conditions: a) Leucine hydrochloride, K2CO3, MeOH, 50°C, 18h; b) Zn(BH4)2, ACN/DME, -40°C, 5h, 
87%; c) NaBH4, THF, 93%; d) 2-aminoacetonitrile bisulfate, or 1-aminocyclopropane-1-carbonitrile HCl, HATU, 
DIPEA, DCM, 0°C-rt, 45-89% 
 
Trifluoroethylamine analogs (258070, 258071, and 257951) were generally synthesized as 
shown in Scheme 3 following previously established methods in the development of 
odanacatib.143-144 Synthesis began with the condensation of the trifluoroacetophenone 2.3a and 
L-Leucine-methylester under basic conditions to afford the imine intermediate 2.3b. The R,S 
diastereomer 2.3d, was obtained via dropwise addition of NaBH4 dissolved in THF at -40°C in a 
10:1 dr. Alternatively the (S,S) diastereomer could be obtained through a chelation controlled 
reduction of the imine with zinc borohydride in acetonitrile/dimethoxyethane at -40°C, providing 
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2.3c in an 11:1 dr. The (S,S) and (R,S) compounds 258070, 258071, and 257951 were obtained 
in 45-94% yield through the previously described amide coupling conditions (Scheme 1). 
 
- Synthesis of Fluoroleucine Dipeptide Nitrile 
 
Scheme 4. Synthesis of fluoroleucine dipeptide nitriles 
Reagents and conditions: a) 4-fluorobenzoic acid, HATU, DIPEA, DMF, 34%; b) Selectfluor, Fe2(SO4)3, NaBH4, 
acetonitrile:water, 0°C-rt, 27%; c) 1N LiOH(aq), THF:EtOH, 0°C-rt, 100%; d) 2-aminoacetonitrile bisulfate, HATU, 
DIPEA, DCM, 0°C-rt, 18% 
 
 
Fluoroleucine analog 258861 was prepared as shown in Scheme 4 through a sequence 
derived from previously reported methods for analogous compounds.144-147 Dehydroleucine 2.4a, 
as the CSA salt, was coupled to 4-fluorobenzoic acid to provide intermediate amide 2.4b. 
Initially, we tried to achieve fluorination of 2.4c using a variety of the previously reported 
conditions, predominantly using reagents that are a source of nucleophilic fluorine such as 
HF:Urea or HF:Pyridine. However, these conditions generally suffered from poor yields and 
unwanted side reactions such as cyclization or elimination. We then opted to try an electrophilic 
source of fluorine as an alternative approach, derived from that reported by Fanelli et. al..148 
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Activation of the olefin with Fe(III), followed by the sequential addition of Selectfluor and 
NaBH4 provided the desired product 2.4c in moderate yield, which was then saponified to 2.4d 
and directly coupled to 2-aminoacetonitrile, affording the desired compound 258861.  
 
SAR Analysis  
 
- Initial Set of Dipeptide Nitriles. 
All compounds were evaluated in vitro for inhibition of both TgCPL and HsCPL activity by 
monitoring the rates of hydrolysis of Z-Leu-Arg-7-amino-4-methylcoumarin (Z-L-R-AMC). 
Results are summarized in Tables 2-5. We first re-synthesized literature lead 232877 to 
benchmark its relative potency against TgCPL versus HsCPL. In vitro testing revealed low 
micromolar potency against TgCPL, and 46-fold more potent inhibition against HsCPL (Table 
2).  
 
Initially we replaced the pyrazole heterocycle in the P3 position of 232877 with phenyl in 
order to remove two nitrogen atoms (232921) and rapidly lower the tPSA of 232877, thereby 
increasing the potential for CNS permeability. This exchange resulted in a 2-3-fold drop in 
potency against HsCPL while enhancing activity against TgCPL, improving the TgCPL-
selectivity about 4-fold.  The t-butyl group of 232921 was then replaced by trifluoromethyl to 
stabilize the now electron-rich P3 aromatic ring to potential oxidation by CYP450 enzymes, 
giving 232920.  This analog lost potency against TgCPL, but maintained effectiveness versus 
HsCPL.  Since both analogs had reduced selectivity for HsCPL compared to lead 232877 we 
retained both P3 groups during our initial survey of P2. 
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2.0 0.044 46.4 
232920 
  
2.4 0.11 22.5 
232921 
  
















4.6 0.24 18.8 
257101 
  
0.12 0.077 1.9 
257085 
  
0.12 0.32 0.4 
a,bIC50 for Toxoplasma gondii Cathepsin L (TgCPL) or human Cathepsin L (HsCPL). Values are mean of at least 3 
independent experiments.  cSelectivity ratio for human Cathepsin L as defined by TgCPL IC50/HsCPL IC50. 
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The vast majority of selectivity between human cathepsin isoforms comes from the P2-S2 
interaction.149 The S3 and S1 subsites also play significant roles in inhibitor selectivity, while the 
S’ subsites (toward the C-terminus of the scissile bond) are highly conserved between isoforms 
and generally difficult to exploit.124 Inspection of the cathepsin crystal structures revealed several 
active site residues unique to the T. gondii isoform vs the human isoform that could potentially 
be exploited to gain selectivity and potency. As noted above, the TgCPL S2 site contains a 
unique aspartate residue (Asp218), as opposed to the human isoform, which bears a hydrophobic 
alanine in this position (colored green in Figures 17A, B). Overlaying TgCPL with the co-crystal 
structure of our lead compound bound to HsCPL indicates that the 3-methylphenylalanine (3-
Me-Phe) core of 232877 sits approximately 3-4 Å from this key aspartate (Figure 17B). Due to 
the proximity of the core to Asp218 we hypothesized we might be able to build in a potential H-
bond to improve potency and selectivity.   
 
The P2 3-methylphenylalanine residue of analogs 232920 and 232921 was thus replaced with 
3-hydroxyphenyalanine or 3-methoxyphenylalanine (257162, 257163, 257165, and 257166) in 
an attempt to pick up a selective hydrogen bonding interaction with the non-conserved Asp218 
of TgCPL. We had hoped this would provide some initial gain in selectivity toward the parasite 
cathepsin, but the results were inconsequential changes in potency. This might be due to the 
Asp218 orienting the residue away from the S2 pocket and preventing a beneficial interaction. 




Figure 18. Overlay of 232877 and 258070 in TgCPL 
Overlay of 232877 (gray) and 258070 (orange) into the crystal structure of TgCPL (PDB 
code: 3F75) depicting clashes with 232877 in the S2 pocket.  Hydrogen bonds and clashes 
are represented as blue and orange dashed lines, respectively. Pocket surface coloration 
represents polar (purple), lipophilic (green), and solvent exposed (red) areas. 
 
Molecular modeling also identified several predicted clashes with HsCPL when the larger 
phenylalanine side chains are in the P2 position (232877 in Figure 18). We were pleased to 
discover that replacement of the entire aromatic P2 residue with a less bulky leucine (257101, 
and 257085) significantly reduced selectivity for HsCPL, consistent with the smaller S2 subsite 
in the TgCPL as compared to the human isoform (Table 2.3). With this single change, we 
reduced the selectivity of 232877 for HsCPL from 10-20 fold to <2 fold.  This is an excellent 




- SAR of Additional P3 Analogs 











0.35 0.11 3.3 
262484 
 
0.18 0.015 11.7 
257642 
 
0.36 0.048 7.6 
258072 
 
0.54 0.28 1.9 
258186 
 
0.53 0.14 3.8 
257646 
 
0.25 0.28 0.9 
a,b,cSee Table 2.2 for heading definitions. 
 
We then returned to optimization of the P3 position in an effort to reduce the molecular 
weight of 257085 while retaining a halogenated pendant for metabolic stability (Table 3). 
Removal of the trifluoromethyl from the P3 pendant to afford the simple phenyl (257102) 
unfortunately reversed the selectivity back to HsCPL over TgCPL. A similar trend was observed 
with analogs 262484, 257072, and 257186, which bear a 3-methyl, 2-chloro-4-fluoro, or 2,4-
dichloro substitution pattern, respectively, on the P3 pendant.  Replacement of the 3-
trifluoromethyl of 257085 with a fluorine (257642) also resulted in a large drop in potency for 
TgCPL and an increase for the human isoform. The 4-fluoro analog 257646, however, was 
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equipotent at TgCPL and HsCPL, and lowered the MW below 300, making this a more 
promising candidate for CNS permeability as compared to the somewhat more potent and 
TgCPL-selective 4-trifluoromethyl analog 257085.  
 
- SAR of P2 Analogs for Metabolic Stability and Selectivity 








for HsCPL c 
257945 
 
0.42 0.19 2.3 
257706 
 
6.6 1.2 5.7 
257950 
 
14 816 0.02 
258861 
 
4.0 2.5 1.6 
258681 
 
2.0 1.2 1.6 
258921 
 
1.2 3.5 0.3 
259042 
 
9.8 4.1 2.4 
a,b,cSee Table 2.2 for heading definitions. 
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We then explored a dimethyl lysine at P2 as a basic group to establish a salt bridge with the 
non-conserved Asp218 of TgCPL (257950 in Table 4). While this was predicted by modeling to 
be the optimal length to interact with the S2 aspartic acid, it nevertheless resulted in a major loss 
in potency against both isoforms. However, it should be noted that the loss in potency was 
significantly greater against the human isoform, demonstrating that despite the S2 pocket of 
these two enzymes being very similar, subtle differences at the P2 residue can offer drastic 
changes to the selectivity profile. Further exploration of basic residues at P2 is therefore 
warranted in future SAR studies. 
 
Cyclohexyl P2 analogs have been reported as inhibitors of human protease inhibitors that 
offered some improvement in either binding or metabolic stability.150 To further probe aliphatic 
SAR at the TgCPL P2 position, both were made (257945 and 257706, Table 4); however, neither 
offered any improvement. Rather, a decrease in potency and TgCPL selectivity was observed for 
both, more drastically in the case of 257706, which is a closer mimic of valine than leucine. 
Substitutions much larger than leucine were thus apparently not well tolerated in TgCPL, 
consistent with the poor activity we had observed earlier with our phenylalanine analogs, so we 
attempted to install isosteres that were closer in size to leucine. While the use of fluoroleucine to 
improve metabolic issues has been successfully demonstrated in the development of 
odanacatib144, we were surprised to see a drastic drop in potency against both TgCPL (IC50= 4.05 
µM) and HsCPL (IC50= 2.51 µM) with compound 258861. Similarly, exchange of the P2 leucine 
with either a neopentylglycine, or dehydroleucine (258921, 258681) resulted in a significant loss 
of potency (IC50= 1.19 µM and 2.00 µM respectively). Surprisingly, even the cyclopropyl analog 
259042 showed a large drop in potency as compared to 257646. While these structural changes 
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are minor, the substantial changes in potency clearly demonstrate the high level of sensitivity of 
the P2 position to steric modification. Within this initial set of dipeptide nitrile TgCPL inhibitors, 
leucine thus proved to be the most optimal residue in the P2 position for both potency and 
reduced selectivity for HsCPL. 
 
- SAR of Analogs Designed for Improved CNS Profile 













0.25 0.28 0.9 
257951 
  
0.66 0.59 1.1 
258071 
  
0.11 0.093 1.2 
258068 
  
0.40 0.14 2.9 
258070 
  
0.16 0.084 1.9 
See Table 2.2 for heading definitions. 
 
 Most CNS drugs do not tolerate more than 1 or 2 hydrogen bond donors. As shown in the 
LIGPLOT diagram from the co-crystal structure of HsCPL and compound 232877 (Figure 16), 
the carbonyl of the P2-P3 amide is not actively engaged by the enzyme and therefore may be 
unnecessary. Replacement of this amide with the well-established trifluoroethlyamine bioisostere 
offered an effective way to reduce our overall tPSA, greatly enhancing our chances for CNS 
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penetration.143-144, 151-152 We found that the (R,S) diastereomer 257951 gave a substantial drop in 
overall potency for both cathepsins (Table 5). The (S,S) diastereomer 258071, however, doubled 
the potency against both the Toxoplasma and human enzymes, providing the most potent nitrile-
based inhibitor to date against TgCPL with an IC50= 110 nM. This diastereomeric preference is 
consistent with literature reports of other dipeptide cathepsin inhibitors incorporating the 
trifluoroethyl amine bioisostere.143 
 
Metabolic Stability and Pharmacokinetics. 




















The metabolic stability of our dipeptide nitrile series was initially evaluated in mouse liver 
microsomes (MLM) to assess suitability for future in vivo studies and to further guide our 
design. Compound 257085 was evaluated to benchmark the dipeptide nitrile series (Table 6). 
We observed that compound 257085 had a reasonably long half-life (37 min). This parameter 
was further improved to >60 min with less lipophilic compound 257646, despite several 
metabolic liabilities predicted by SMARTCyp (Figure 19).153  
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Figure 19. SMARTCyp prediction of the 
top three sites of metabolism 
  
Interestingly, while replacement of the P2 amide with a trifluoroethylamine (258071) 
removed an amide that could be a metabolic liability, the half-life in mouse liver microsome 
decreased to 4.4 minutes. It is likely that the increased lipophilicity simply enhanced binding to 
metabolizing enzymes. Two of the most likely positions for metabolism of 258071 are oxidation 
alpha to the nitrile warhead and hydrolysis of the P1 amide bond.153 The incorporation of a 
cyclopropyl at the P1 position serves to block this site from oxidation and to slow hydrolysis of 
the P1 amide, a strategy successfully used in the development of odanacatib and other inhibitors 
of human cathepsins.144, 152, 154 Cyclopropyl analog 258070 indeed provided a significantly 
improved MLM half-life of 22 min, affording a compound more suitable for further in vivo 
analysis. It also retained potency for TgCPL, which is consistent with the predicted projection of 








Table 7. In Vivo Exposure of Compound 258070 Following IP or IV Administration to Micea 
Time Post-Dose (IP 10 mg/kg) 30 min 2 h 4 h 7 h 
Plasma Conc. (ng/mL) 110 138 10 BLQ 
Brain Conc. (ng/g) 54 BLQ BLQ BLQ 
Time Post-Dose (IV 1 mg/kg) 5 min 10 min 15 min 30 min 
Plasma Conc. (ng/mL) 109 50 31 8 
Brain Conc. (ng/g) BLQ BLQ BLQ BLQ 
a CD-1 mice were injected intraperitoneally with a single 10 mg/kg dose or intravenously with a 
single 1 mg/kg dose. The data shown are mean values from 2 mice at each time point. BLQ = 
Below Limit of Quantification. 
 
Compound 258070 was advanced to an abbreviated in vivo pharmacokinetic study in mice 
(Table 7). Our main objective was to determine if this chemotype could penetrate the CNS. 
Significantly, we were able to detect compound in the brain, with a brain/plasma ratio of 0.5 at 
30 minutes. Unfortunately, the overall levels in both brain and plasma were quite low, despite the 
fact that 258070 was shown to have good aqueous solubility (630 µM) and excellent plasma 
stability (~100% parent remaining after 24h).  The plasma levels and rapid disappearance 
indicates that this compound has a high volume of distribution, high clearance or both. Studies 




Synthesis and SAR of P3-CBZ Peptide Probes 
We also evaluated alternative methods and approaches to facilitate a rapid exploration of the 
TgCPL pharmacophore. Throughout the literature in the development of human cathepsin 
inhibitors, it has been demonstrated that either a Boc or CBZ group can be used as a surrogate 
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for the P3 pendant.155-156 This would allow for the rapid evaluation of commercially available 
amino acids and unnatural amino acids.  
 
 
Scheme 5. General synthesis of P3-CBZ P2 probes 
 
In general, analogs were synthesized via a one-step direct coupling of aminoacetonitrile to a 
commercially available CBZ-protected amino acid (Scheme 6).  
 
Table 8. P3 CBZ probes for rapid P2 analysis 
 
R =  
TgCPL IC50a 
(µM) 
HsCPL IC50b  
(µM) 
258064 i-Butyl 0.58 0.50 
258067 i-Propyl 8.9 4.6 
258066 Ethyl 59 16 
258065 Methyl 841 108 
258181 -H N/D* 80 
258182 Sec-Butyl 26 14 
258183 -CH2OH 72 44 
258184 4-Hydroxyphenyl 1.3 0.083 
a,bIC50 for Toxoplasma gondii Cathepsin L (TgCPL) or human Cathepsin L (HsCPL). Values are mean of at least 3 
independent experiments.  *N/D = No detectable activity 
 
While the overall potency was significantly reduced versus the dipeptidenitriles, we were 
pleased to find that the SAR trends observed for these P3-CBZ surrogates aligned with those 
observed for the dipeptide series. The P2 SAR trends for TgCPL favored the leucine side chain 
(258064) above all others. The affinity was stepwise decrease in correlation to the stepwise 
reduction of the size of the P2 side chain (258067, 258066, 258065, 258181). The Isoleucine 
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258182 and Serine 258183 were moderately tolerated by both human and parasite isoform.  In 
agreement with the dipeptide series, selectivity in favor of HsCPL was observed for the tyrosine 
analog 258184. This data offers validating support that this approach can be utilized to rapidly 
assess the potency of various P2 vectors, including unnatural amino acids that may give rise to 
improved potency or selectivity for TgCPL.  
 
Vinyl Sulfone (VS) Inhibitors of TgCPL 
 
We opted to pursue the dipeptide nitrile series based on the reasons previously explained. 
However, the dipeptide nitriles overall exhibited significantly lower potency versus the LHVS 
vinyl sulfone. Additionally, we wanted to have an irreversibly covalent control analog for 
comparison to the reversible analogs when moving forward into in vitro efficacy evaluation. To 
this end a small set of vinyl sulfone analogs was prepared (Scheme 7). 
 
- Synthesis of VS Analogs 
 
Scheme 6. Synthesis of dipeptide vinyl sulfone inhibitors of TgCPL 
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The optimal dipeptide methyl ester 2.6a, was saponified using 1N lithium hydroxide (aq.) in 
THF:Methanol to afford intermediate 2.6b. HATU coupling with a alkanolamines was then used 
to install the desired P1 R1-group (2.6c). Oxidation with Dess-Martin periodinane provided the 
intermediate aldehydes (2.6d) and subsequent HWE olefination afforded the desired vinyl 
sulfones (2.6f, 5 examples). 
 
- VS Trends and SAR 
 
Below, Figure 20 shows the summary set of dipeptide vinyl sulfones developed that were 
intended to be direct comparators to the dipeptide nitrile series. 
 
 
Figure 20. Vinyl sulfone inhibitors of TgCPL 
 
For direct comparison to the dipeptide nitrile with optimized P2/P3 (257646), the analogous 
vinyl sulfone (262585) was made. As expected, this compound was more potent as compared to 
the nitrile analog, given that it is irreversibly covalent. Interestingly, it was not as potent as 
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LHVS, suggesting that the nitriles and vinyl sulfones potentially bind in slightly different 
orientations, thus altering the affinity of the P2 and P3 vectors with the pockets. Alternative 
explanations for the loss in potency could be the stability of the vinyl sulfone conformational 
bias if the P1 methylene was left unsubstituted. The synthesis of 262585, suffered from low yield 
in the last olefination step, likely due to an undesirable aldol-type reaction of the aldehyde 
intermediate 26a. The addition of the methyl into the P1 position (262943) seemed to resolve this 
issue, as the synthesis became significantly easier during the HWE step, suffering from fewer 
side products. Substitution of the amide for a trifluoroethylamine (263044), while well tolerated, 
did not significantly alter the potency, implying that the high affinity conferred by the covalent 
vinyl sulfone outweighed the improvement in binding affinity from the trifluoro substitution. We 
were surprised to see that the incorporation of the cyclopropyl in the P1 position abolished 
almost all activity. A likely explanation for this is the cyclopropyl somehow precludes the active 
site cysteine from the necessary Michael addition to the vinyl sulfone, effectively eliminated the 
‘warhead’ functionality. Finally, we tried to exchange the phenyl sulfone for a methyl sulfone, as 
the reduction in molecular weight could help CNS penetrance, and perhaps could be used in 
place of LHVS for in vivo studies if it proved to be potent and crossed the BBB. Unfortunately, 
this resulted in retention of activity for the human isoform and two orders of magnitude loss in 
potency for TgCPL. We additionally synthesized a BODIPY-tagged vinyl sulfone for 






SAR of Additional Dipeptide Nitrile Inhibitors 
Many additional compounds were synthesized during the development of the previously 
listed dipeptide nitrile inhibitors of TgCPL. The following table summarizes the SAR trends for 
those that were less potent, selective or redundant with the former.  
 










for HsCPL c 
257084 
  












0.89 0.022 40.5 
257101 
  
















6.6 1.6 4.1 
257705 
  




26 372 0.07 
257946 
  
5.5 1.6 3.4 
257943 
  
0.17 0.053 3.2 
257944 
  
0.28 0.093 3.01 
257947 
  
0.98 0.27 3.6 
258761 
  
0.61 0.87 0.70 
259044 
  
0.82 0.53 1.5 
259041 
  
1.3 0.49 2.7 
262467 
  








4.0 0.99 4 
a,b,cSee Table 2 for heading definitions. 
 
Various combinations of the lead tBu-methyl-pyrazole (257084, 257164, 257167, and 
257088) were tested however all significantly favored HsCPL over TgCPL, highlighting the 
preference HsCPL has for this P3 vector. Analogs 257101 and 257086 were intended to lower 
the TPSA of the P3 pendant while retaining the tBu in the 3-position. Both offered an increase in 
potency for TgCPL (0.15 µM and 0.56 µM respectively) but exhibited significant preference for 
HsCPL. 3-trifluoromethyl-benzyl vectors in P3 (and 257704) generally were favorable for 
TgCPL (see Table 3) however, the phenylalanine isostere in P2 257087, 257088, 257101, and 
257086 were not well tolerated in TgCPL, showing over an order of magnitude in increased 
potency toward HsCPL. The same trend was observed with the P2 cyclohexylglycine vectors in 
analogs 257704, 257705, 257946. It is worth noting the analog 257946, bearing the 3-
dimethylaniline in P3, showed a loss of activity for HsCPL versus 257704, suggesting that 
perhaps a basic amine in P3 may not be tolerated in HsCPL and could be important for achieving 
TgCPL selectivity. For reasons unknown however, this trend is not directly reflected comparing 
257704 and 257947. The P2 dimethyl lysine analogs 257948 and 257949 were not tolerated in 
either isoform, with their IC50s landing in the µM range. Compounds 257943 (TgCPL IC50 = 0.17 
µM) and 257944 (TgCPL IC50 = 0.17 µM), bearing a P2 cyclohexylalanine vector, showed some 
of the more potent activity for TgCPL, yet still favored HsCPL. Compound 257947 decreased in 
potency (TgCPL IC50 = 0.98 µM, HsCPL IC50 = 0.27 µM) for both isoforms, like the other 
compounds with dimethylaniline P3 pendants. As we had established a general preference for P2 
leucine, several analogs were made to determine if more polar P3 vectors could provide some 
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selectivity for parasite over human isoform (see Figure 17C,D). Unfortunately, 258761, 259044, 
259041, and 262467 all failed to improve either the potency or selectivity for TgCPL. Finally, to 
determine the effects of an electron rich P3 ring, 262743 and 262744 were tested, however 
potency was significantly reduced (TgCPL IC50 = 0.86 µM and 4.0 µM respectively.) 
 
Table 10. Cathepsin L inhibitory activity of initial P2 and P3 analogs 
 




















































1.7 2.0 0.85 
a,b,cSee Table 2 for heading definitions. 
 
The alkyne analog 257161 was made as a comparator to lead compound 232877 to 
determine how much of the activity could be attributed to the nitrile ‘warhead’. Potency for both 
enzymes reduced by over an order of magnitude (TgCPL IC50 = 179 µM and HsCPL IC50 = 0.64 
µM, respectively) highlighting the need for the covalent interaction to gain inhibitory activity 
against cathepsins. Trifluoroethylamine analogs (257952, 258061, 258062, 258063, and 258069) 
were synthesized as both R,S and S,S diastereomers with either a benzyl or 3-fluorobenzyl 
pendant in P3. While the trend remains that S,S configuration is preferential over the R,S, none 
of these showed improved potency or selectivity for TgCPL. Similarly, 262608 and 262642, the 
S,S-trifluoroethylamines with a tert-butyl P2 vector all showed reduced activity from both 
enzymes, regardless of the nitrile warhead type. It is worth noting that the synthesis of these 
trifluoroethylamines with bulkier groups in P2 gave a much improved diastereomeric ratio (40:1, 
S,S:R,S) due to the added steric bulk better directing the zinc borohydride reduction. 
 
Conclusions 
In summary, we have demonstrated for the first time that it is possible to modify a well-
established chemotype for inhibition of human cathepsins (dipeptide nitrile) and shift selectivity 
away from the human isoform and towards the Toxoplasma gondii isoform, a novel target for 
toxoplasmosis.  Furthermore, we have demonstrated that the physical properties of the dipeptide 
can be adjusted to be more favorable for CNS penetration without loss of activity, particularly 
through reduction in tPSA and number of HBA. Key analogs in this campaign are summarized in 
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Figure 21. Initially, our lead compound 232877 was approximately 46-fold selective for HsCPL 
over TgCPL. We developed several compounds that either displayed equipotency for HsCPL and 
TgCPL (257646), or exhibited slight selectivity (up to 3-fold) for TgCPL over HsCPL (257085, 
258921). Notably, compound 257950 (Table 4) demonstrates the potential for achieving outright 
selectivity for TgCPL through the incorporation of a basic residue in the P2 position, an avenue 
we are exploring in future studies. Furthermore, we improved the potency of our inhibitors for 
the T. gondii enzyme from 2 µM to as low as 115 nM. Although we successfully demonstrated 
that compound 258070 can penetrate the blood brain barrier, it also exhibits rapid clearance in 
vivo. Current endeavors in our lab are aimed at further defining the pharmacophore for TgCPL 
via optimization of the P3 and P2 positions. Additionally, we are improving the pharmacokinetic 
profile for these inhibitors, so they may be advanced to in vivo murine infection studies in order 





















Chemistry General Information: All reagents were used without further purification as 
received from commercial sources unless noted otherwise. 1H NMR spectra were taken in 
DMSO-d6, MeOD, or CDCl3 at room temperature on Varian Inova 400 MHz or Varian Inova 
500 MHz instruments. Reported chemical shifts for the 1H NMR spectra were recorded in parts 
per million (ppm) on the δ scale from an internal standard of residual tetramethylsilane (0 ppm). 
Mass spectrometry data were obtained on either a Micromass LCT or Agilent Q-TOF. An 
Agilent 1100 series HPLC with an Agilent Zorbax Eclipse Plus−C18 column was used to 
determine purity of biologically tested compounds. All tested compounds were determined to be 
>95% pure using a 6 minute gradient of 10-90% acetonitrile in water followed by a 2 minute 
hold at 90% acetonitrile with detection at 254 nm. Flash chromatographic purifications were 
performed using a Teledyne ISCO Combiflash RF with Redisep Gold RF columns. 
 
General Procedure A: Fisher Esterification  
The starting amino acid (1.0 eq) was dissolved in MeOH (2-4 mL/1 mmol), and catalytic 
98% sulfuric acid (~0.1 eq) was then added. The mixture was heated to reflux overnight. The 
reaction solution was cooled to room temperature and concentrated in vacuo. The resulting crude 
residue was dissolved in a sat. NaHCO3 (aq) solution, and extracted with EtOAc. The combined 
organic layers were washed with sat. NaHCO3 (aq) and brine, dried over MgSO4 and concentrated 




General Procedure B: Amide Coupling  
The aryl acid (1 eq) was dissolved into DMF (1-3 mL/1 mmol) and cooled to 0°C. HATU 
(1.2 eq) and DIPEA (3.5 eq) were then added and reaction was stirred at 0°C for 5-10 min. The 
amino acid methyl ester (1 eq) was then added and reaction was allowed to warm and stir at 
room temperature overnight. Reaction was poured into water, and extracted with EtOAc. The 
organic layers were combined and washed with a 1N HCl (aq) solution, sat. NaHCO3 (aq) solution, 
and brine, dried over MgSO4, and concentrated in vacuo. The crude material was purified by 
flash chromatography (0-100% EtOAc:Hexanes gradient). 9-99% 
 
General Procedure C: Ester Saponification 
 The intermediate ester (1eq) was dissolved into a THF:MeOH:1N LiOH (aq) 1:1:1 
solution (2-3 mL/1 mmol) and stirred for 0.5-1 hr. Upon completion as determined by 
HPLC/TLC, the reaction was quenched with a 1N HCl (aq) solution and volatiles were removed 
in vacuo. The remaining aqueous portion was extracted with EtOAc. The combined organic layer 
was then washed with brine, dried over MgSO4, and concentrated in vacuo to afford the desired 
free acid. 95-99% 
 
General Procedure D: Amide Coupling of Nitrile Warhead 
The carboxylic acid intermediate (1 eq) was dissolved into DCM (1-3 mL/1 mmol) and 
cooled to 0°C. HATU (2 eq) and DIPEA (4 eq) were then added and reaction was stirred at 0°C 
for 5-10 min. 2-aminoacetonitrile bisulfate (2-5 eq) was then added and reaction was allowed to 
warm and stir at room temperature overnight. Upon completion, the reaction was poured into a 
1N HCl (aq) solution and extracted with DCM. The combined organic layers were washed with 
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1N HCl (aq) solution, NaHCO3 (aq) solution, and brine then dried over MgSO4, and concentrated. 
The crude material was purified by flash chromatography (0-100% EtOAc:Hexane gradient). 15-
89% 
 
Methyl (S)-2-amino-3-(m-tolyl)propanoate (4a) 
General Procedure A starting from 3-Methylphenylalanine (0.5 g, 2.79 mmol) gave methyl (S)-
2-amino-3-(m-tolyl)propanoate (547 mg, 85%); 1H NMR (500 MHz, DMSO-d6) δ 8.77 (br. s., 
3H), 7.19 (t, J = 7.34 Hz, 1H), 7.07 (d, J = 7.34 Hz, 1H), 7.03 (br. s., 1H), 7.00 (d, J = 6.85 Hz, 
1H), 4.18 (t, J = 6.11 Hz, 1H), 3.63 (s, 3H), 3.17 (dd, J = 5.38, 13.69 Hz, 1H), 3.05 (dd, J = 7.58, 




General Procedure B starting from methyl (S)-2-amino-3-(m-tolyl)propanoate (0.2 g, 0.871 
mmol), and 3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylic acid (0.159 g, 0.871 mmol). 
Chromatography (20-80% EtOAc:Hexanes gradient)  provided methyl (S)-2-(3-(tert-butyl)-1-
methyl-1H-pyrazole-5-carboxamido)-3-(m-tolyl)propanoate (227 mg, 87%); 1H NMR (500 
MHz, DMSO-d6) δ 8.23 (br. s., 1H), 7.14 (t, J = 7.34 Hz, 1H), 7.09 (s, 1H), 7.05 (d, J = 7.34 Hz, 
1H), 6.99 (d, J = 7.30 Hz, 1H), 6.77 (s, 1H), 4.54 - 4.64 (m, 1H), 3.88 (s, 3H), 3.63 (s, 3H), 3.10 - 
3.16 (m, 2H), 2.23 (s, 3H), 1.25 (s, 9H) 
 
(S)-2-(3-(tert-Butyl)-1-methyl-1H-pyrazole-5-carboxamido)-3-(m-tolyl)propanoic acid (6a) 
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General Procedure C starting from methyl (S)-2-(3-(tert-butyl)-1-methyl-1H-pyrazole-5-
carboxamido)-3-(m-tolyl)propanoate (270 mg, 0.755 mmol) gave (S)-2-(3-(tert-butyl)-1-methyl-
1H-pyrazole-5-carboxamido)-3-(m-tolyl)propanoic acid (228 mg, 0.664 mmol, 88 % yield); 1H 
NMR (400 MHz, MeOH-d4) δ 7.15 (t, J = 1.00 Hz, 1H), 7.08 (s, 1H), 7.03 (t, J = 7.60 Hz, 2H), 
6.58 (s, 1H), 4.77 (dd, J = 4.70, 9.78 Hz, 1H), 3.91 (s, 3H), 3.26 (t, J = 4.70 Hz, 1H), 3.00 (dd, J 




General Procedure D starting from (S)-2-(3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxamido)-
3-(m-tolyl)propanoic acid (150 mg, 0.437 mmol) gave (S)-3-(tert-butyl)-N-(1-
((cyanomethyl)amino)-1-oxo-3-(m-tolyl)propan-2-yl)-1-methyl-1H-pyrazole-5-carboxamide. 
(50.7 mg, 0.133 mmol, 30.4 % yield); 1H NMR (400 MHz, MeOH-d4) δ 7.14 (t, J = 7.43 Hz, 
1H), 7.08 (s, 1H), 7.04 (d, J = 7.43 Hz, 1H), 7.01 (d, J = 7.43 Hz, 1H), 6.63 (s, 1H), 4.73 (dd, J = 
6.26, 9.00 Hz, 1H), 4.16 (d, J = 17.61 Hz, 1H), 4.11 (d, J = 17.60 Hz, 1H), 3.89 (s, 3H), 3.20 (dd, 
J = 6.26, 13.69 Hz, 1H), 2.97 (dd, J = 9.39, 13.69 Hz, 1H), 2.27 (s, 3H), 1.27 (s, 9H);  13C NMR 
(101 MHz, MeOH-d4) δ 174.1, 162.0, 161.6, 139.3, 138.2, 136.7, 131.2, 129.6, 128.7, 127.5, 
117.5, 105.1, 56.2, 38.7, 33.0, 31.0, 28.2, 21.6; MS (ESI+) m/z: 382.1 [M+H]+ 
  
(S)-3-(m-Tolyl)-2-(3-(trifluoromethyl)benzamido)propanoic acid (6b) 
General Procedure B starting from (S)-3-(tert-butyl)-N-(1-((cyanomethyl)amino)-1-oxo-3-(m-
tolyl)propan-2-yl)-1-methyl-1H-pyrazole-5-carboxamide (0.1 g, 0.435 mmol), and 3-
(trifluoromethyl)benzoic acid (0.83 g, 0.435 mmol). gave methyl (S)-3-(m-tolyl)-2-(3-
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(trifluoromethyl)benzamido)propanoate  (158  mg). Compound was carried directly into General 
procedure C to afford (S)-3-(m-tolyl)-2-(3-(trifluoromethyl)benzamido)propanoic acid (151 mg, 
0.430 mmol, 99 % yield); 1H NMR (400 MHz, MeOH -d4) δ 8.18 (s, 1H), 8.12 (d, J = 7.83 Hz, 
1H), 7.85 (d, J = 7.83 Hz, 1H), 7.68 (t, J = 7.83 Hz, 1H), 4.62 - 4.72 (m, 1H), 1.67 - 1.88 (m, 




General Procedure D starting from (S)-3-(m-tolyl)-2-(3-(trifluoromethyl)benzamido)propanoic 
acid (150 mg, 0.427 mmol) provided (S)-N-(1-((cyanomethyl)amino)-1-oxo-3-(m-tolyl)propan-
2-yl)-3-(trifluoromethyl)benzamide (35.3 mg, 0.091 mmol, 21.23 % yield); 1H NMR (400 MHz, 
MeOH-d4) δ 8.04 (s, 1H), 7.98 (d, J = 7.83 Hz, 1H), 7.81 (d, J = 7.83 Hz, 1H), 7.62 (t, J = 7.83 
Hz, 1H), 7.15 (t, J = 7.04 Hz, 1H), 7.10 (s, 1H), 7.07 (d, J = 7.43 Hz, 1H), 7.01 (d, J = 7.43 Hz, 
1H), 4.79 (dd, J = 6.46, 8.80 Hz, 1H), 4.14 (dd, J = 17.22, 25.04 Hz, 2H), 3.24 (dd, J = 6.26, 
13.69 Hz, 1H), 3.02 (dd, J = 9.00, 13.69 Hz, 1H), 2.27 (s, 3H); 13C NMR (101 MHz, MeOH-d4) 
δ 174.1, 168.7, 139.4, 138.3, 136.3, 132.3, 131.8, 131.2, 130.7, 129.6, 129.5, 128.7, 127.5, 125.5, 
124.1, 117.5, 56.9, 38.7, 28.2, 21.6; MS (ESI+) m/z: 412.0 [M+H]+ 
 
Methyl (S)-2-(3-(tert-butyl)benzamido)-3-(m-tolyl)propanoate (5c) 
General Procedure B starting from methyl (S)-2-amino-3-(m-tolyl)propanoate (0.1 g, 0.435 
mmol), and 3-(tert-butyl)benzoic acid (0.078 g, 0.435 mmol). Chromatography (20-80 % 
EtOAc:Hexanes gradient)  provided methyl (S)-2-(3-(tert-butyl)benzamido)-3-(m-
tolyl)propanoate (95.3 mg, 0.270 mmol, 61.9 % yield); 1H NMR (500 MHz, CDCl3) δ 7.79 (s, 
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1H), 7.54 (d, J = 7.83 Hz, 1H), 7.46 (d, J = 7.83 Hz, 1H), 7.35 (t, J = 7.58 Hz, 1H), 7.20 (t, J = 
7.58 Hz, 1H), 7.08 (d, J = 7.34 Hz, 1H), 6.97 (s, 1H), 6.95 (d, J = 7.83 Hz, 1H), 6.52 (d, J = 6.85 
Hz, 1H), 5.07 (dd, J = 6.36, 12.72 Hz, 1H), 3.78 (s, 3H), 3.26 (dd, J = 5.87, 13.69 Hz, 1H), 3.20 
(dd, J = 5.38, 13.69 Hz, 1H), 2.31 (s, 3H), 1.34 (s, 9H) 
 
(S)-2-(3-(tert-Butyl)benzamido)-3-(m-tolyl)propanoic acid (6c) 
General Procedure C starting from methyl (S)-2-(3-(tert-butyl)benzamido)-3-(m-tolyl)propanoate 
(95 mg, 0.269 mmol) gave (S)-2-(3-(tert-butyl)benzamido)-3-(m-tolyl)propanoic acid (86 mg, 
0.253 mmol, 94 % yield); 1H NMR (400 MHz, MeOH-d4) δ 7.74 (s, 1H), 7.56 (d, J = 7.83 Hz, 
1H), 7.50 (d, J = 7.43 Hz, 1H), 7.34 (t, J = 7.83 Hz, 1H), 7.04 - 7.18 (m, 3H), 7.01 (d, J = 7.43 
Hz, 1H), 4.83 (dd, J = 4.89, 9.59 Hz, 1H), 3.30 (dd, J = 4.90, 13.70 Hz, 3H), 3.08 (dd, J = 9.78, 
13.69 Hz, 1H), 2.27 (s, 3H), 1.33 (s, 9H) 
 
(S)-3-(tert-Butyl)-N-(1-((cyanomethyl)amino)-1-oxo-3-(m-tolyl)propan-2-yl)benzamide (7b) 
General Procedure D starting from (S)-2-(3-(tert-butyl)benzamido)-3-(m-tolyl)propanoic acid 
(115 mg, 0.339 mmol) provided (S)-3-(tert-butyl)-N-(1-((cyanomethyl)amino)-1-oxo-3-(m-
tolyl)propan-2-yl)benzamide (55.3 mg, 0.146 mmol, 43.2 % yield) 1H NMR (400 MHz, MeOH-
d4) δ 7.77 (s, 1H), 7.55 (t, J = 7.83 Hz, 2H), 7.33 (t, J = 7.83 Hz, 1H), 7.15 (t, J = 7.43 Hz, 1H), 
7.10 (s, 1H), 7.07 (d, J = 7.43 Hz, 1H), 7.01 (d, J = 7.43 Hz, 1H), 4.75 - 4.82 (m, 1H), 4.12 (dd, J 
= 17.61, 26.61 Hz, 2H), 3.22 (dd, J = 6.26, 13.69 Hz, 1H), 3.04 (dd, J = 8.80, 13.50 Hz, 1H), 
2.27 (s, 3H), 1.27 - 1.37 (m, 9H); 13C NMR (101 MHz, MeOH-d4) δ 174.3, 170.8, 152.8, 139.4, 
138.3, 134.9, 131.3,  31.1, 130.2, 129.9, 129.5, 128.7, 127.4, 125.8, 125.5, 117.5, 56.9, 38.7, 
35.8, 31.7, 28.1, 21.8; MS (ESI+) m/z: 400.1 [M+Na]+ 
 65 
  
Methyl (S)-2-amino-3-(3-hydroxyphenyl)propanoate (4b) 
General Procedure A starting from (S)-2-amino-3-(3-hydroxyphenyl)propanoic acid (330 mg, 
1.821 mmol) gave methyl (S)-2-amino-3-(3-hydroxyphenyl)propanoate (113.2 mg, 0.580 mmol, 
31.8 % yield). 1H NMR (400 MHz, MeOH-d4) δ 7.10 (t, J = 7.83 Hz, 1H), 6.62 - 6.68 (m, 2H), 
6.61 (s, 1H), 3.68 - 3.71 (m, 1H), 3.67 (s, 3H), 2.93 (dd, J = 6.06, 13.50 Hz, 1H), 2.84 (dd, J = 
7.04, 13.30 Hz, 1H) 
 
(S)-3-(3-Hydroxyphenyl)-2-(3-(trifluoromethyl)benzamido)propanoic acid (6d) 
General Procedure B starting from methyl (S)-2-amino-3-(3-hydroxyphenyl)propanoate 
hydrochloride (83 mg, 0.358 mmol) and 3-(trifluoromethyl)benzoic acid (68.1 mg, 0.358 mmol) 
gave methyl (S)-3-(3-hydroxyphenyl)-2-(3-(trifluoromethyl)benzamido)propanoate (130 mg, 
0.354 mmol), which was carried directly into General Procedure C without further purification to 
afford (S)-3-(3-hydroxyphenyl)-2-(3-(trifluoromethyl)benzamido)propanoic acid (130 mg, 0.354 




General Procedure D starting from (S)-3-(3-hydroxyphenyl)-2-(3-(trifluoromethyl)benzamido) 
propanoic acid (84 mg, 0.238 mmol) and 2-aminoacetonitrile bisulfate (182 mg, 1.189 mmol) 
gave (S)-N-(1-((cyanomethyl)amino)-3-(3-hydroxyphenyl)-1-oxopropan-2-yl)-3-
(trifluoromethyl)benzamide (60.6 mg, 0.155 mmol, 65.1 % yield). 1H NMR (400 MHz, MeOH-
d4) δ 8.05 (s, 1H), 7.97 (d, J = 7.83 Hz, 1H), 7.79 (d, J = 7.83 Hz, 1H), 7.60 (t, J = 7.80 Hz, 1H), 
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7.08 (t, J = 8.02 Hz, 1H), 6.70 - 6.79 (m, 2H), 6.64 (d, J = 9.00 Hz, 1H), 4.81 (dd, J = 6.26, 9.00 
Hz, 1H), 4.14 (s, 2H), 3.21 (dd, J = 6.06, 13.50 Hz, 1H), 3.01 (dd, J = 9.39, 13.69 Hz, 1H); 13C 
NMR (101 MHz, MeOH-d4) δ 174.1, 168.7, 158.7, 139.8, 136.2, 132.4, 131.7, 130.7, 130.7, 
130.4, 129.2, 125.5, 121.5, 117.5, 117.1, 114.8, 57.0, 38.6, 28.2; MS (ESI+) m/z: 414.0 [M+Na]+ 
 
Methyl (S)-2-(3-(tert-butyl)benzamido)-3-(3-hydroxyphenyl)propanoate (5e) 
General Procedure B starting from methyl (S)-2-amino-3-(3-hydroxyphenyl)propanoate (100 
mg, 0.432 mmol) , and 3-(tert-butyl)benzoic acid (77 mg, 0.432 mmol) gave methyl (S)-2-(3-
(tert-butyl)benzamido)-3-(3-hydroxyphenyl)propanoate (143 mg, 0.402 mmol, 93 % yield). 
Product was subsequently hydrolyzed according to General procedure C, and carried directly to 
the next step without further purification. 1H NMR (500 MHz, MeOH-d4) δ 7.76 (s, 1H), 7.55 (d, 
J = 7.83 Hz, 1H), 7.52 (d, J = 7.83 Hz, 1H), 7.33 (t, J = 7.58 Hz, 1H), 7.09 (t, J = 7.58 Hz, 1H), 
6.73 - 6.79 (m, 2H), 6.65 (d, J = 7.83 Hz, 1H), 4.84 (dd, J = 4.89, 9.50 Hz, 1H), 3.27 (dd, J = 




General Procedure D starting from (S)-2-(3-(tert-butyl)benzamido)-3-(3-
hydroxyphenyl)propanoic acid (68 mg, 0.199 mmol) and 2-aminoacetonitrile bisulfate (153 mg, 
0.996 mmol) gave (S)-3-(tert-butyl)-N-(1-((cyanomethyl)amino)-3-(3-hydroxyphenyl)-1-
oxopropan-2-yl)benzamide (55.9 mg, 0.147 mmol, 74.0 % yield). 1H NMR (400 MHz, MeOH-
d4) δ 7.77 (s, 1H), 7.57 (d, J = 8.22 Hz, 1H), 7.54 (d, J = 8.22 Hz, 1H), 7.33 (t, J = 7.63 Hz, 1H), 
7.09 (t, J = 8.02 Hz, 1H), 6.71 - 6.79 (m, 2H), 6.65 (d, J = 9.00 Hz, 1H), 4.78 (dd, J = 6.26, 8.61 
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Hz, 1H), 4.13 (s, 2H), 3.20 (dd, J = 6.26, 13.69 Hz, 1H), 3.01 (dd, J = 9.00, 13.69 Hz, 1H), 1.31 
(s, 9H); 13C NMR (101 MHz, MeOH-d4) δ 174.3, 170.9, 158.7, 152.9, 139.9, 135.0, 129.9, 
125.9, 125.6, 121.5, 117.5, 117.3, 117.2, 115.1, 114.8, 56.8, 38.6, 35.8, 31.8, 31.7, 28.2; MS 
(ESI+) m/z: 402.1 [M+Na]+ 
 
Methyl (S)-2-amino-3-(3-methoxyphenyl)propanoate (4c) 
General Procedure A starting from (S)-2-amino-3-(3-methoxyphenyl)propanoic acid (440 mg, 
2.254 mmol) gave methyl (S)-2-amino-3-(3-methoxyphenyl)propanoate (244.5 mg, 1.168 mmol, 
51.8 % yield). 1H NMR (500 MHz, MeOH-d4) δ 7.19 (t, J = 8.07 Hz, 1H), 6.78 (d, J = 8.31 Hz, 
1H), 6.71 - 6.76 (m, 2H), 3.74 (s, 3H), 3.68 - 3.71 (m, 1H), 3.66 (s, 3H), 2.98 (dd, J = 5.87, 13.21 
Hz, 1H), 2.87 (dd, J = 7.09, 13.45 Hz, 1H) 
 
Methyl (S)-3-(3-methoxyphenyl)-2-(3-(trifluoromethyl)benzamido)propanoate (5f) 
General Procedure B starting from methyl (S)-2-amino-3-(3-methoxyphenyl)propanoate (81.5 
mg, 0.389 mmol) and 3-(trifluoromethyl)benzoic acid (74.1 mg, 0.389 mmol) gave methyl (S)-3-
(3-methoxyphenyl)-2-(3-(trifluoromethyl)benzamido)propanoate (145.5 mg, 0.382 mmol, 98 % 
yield) Product was subsequently hydrolyzed according to General Procedure C, and carried 
directly to the next step without further purification. 1H NMR (400 MHz, MeOH-d4) δ 8.01 (s, 
1H), 7.94 (d, J = 7.43 Hz, 1H), 7.75 (d, J = 7.83 Hz, 1H), 7.55 (t, J = 7.83 Hz, 1H), 7.15 (t, J = 
8.22 Hz, 1H), 6.81 - 6.88 (m, 2H), 6.69 - 6.76 (m, 1H), 4.91 (dd, J = 4.70, 9.78 Hz, 1H), 3.69 (s, 





General Procedure D starting from (S)-3-(3-methoxyphenyl)-2-(3-(trifluoromethyl)benzamido) 
propanoic acid (145.5 mg, 0.396 mmol) and 2-aminoacetonitrile bisulfate ((305 mg, 1.981 
mmol) gave (S)-N-(1-((cyanomethyl)amino)-3-(3-methoxyphenyl)-1-oxopropan-2-yl)-3-
(trifluoromethyl)benzamide (120.5 mg, 0.297 mmol, 75 % yield). 1H NMR (500 MHz, MeOH-
d4) δ 8.04 (s, 1H), 7.97 (d, J = 7.34 Hz, 1H), 7.80 (d, J = 7.83 Hz, 1H), 7.60 (t, J = 7.83 Hz, 1H), 
7.18 (t, J = 8.07 Hz, 1H), 6.84 - 6.89 (m, 2H), 6.76 (dd, J = 1.96, 8.31 Hz, 1H), 4.85 (s, 3H), 4.16 
(dd, J = 17.61, 23.97 Hz, 2H), 3.72 (s, 3H), 3.26 (dd, J = 5.87, 13.69 Hz, 1H), 3.05 (dd, J = 9.29, 
13.69 Hz, 1H); 13C NMR (126 MHz, MeOH-d4) δ 174.1, 168.7, 161.4, 139.9, 136.2, 132.3, 
130.7, 130.6, 129.4, 125.6, 122.7, 117.5, 115.9, 113.6, 56.8, 55.7, 38.7, 28.2; MS (ESI+) m/z: 
428.0 [M+Na]+ 
 
(S)-2-(3-(tert-Butyl)benzamido)-3-(3-methoxyphenyl)propanoic acid (6f)  
General Procedure B starting from  methyl (S)-2-amino-3-(3-methoxyphenyl)propanoate (81.5 
mg, 0.389 mmol) and 3-(tert-butyl)benzoic acid (69.4 mg, 0.389 mmol) gave methyl (S)-2-(3-
(tert-butyl)benzamido)-3-(3-methoxyphenyl)propanoate, which was was subsequently 
hydrolyzed according to General procedure C to afford (S)-2-(3-(tert-butyl)benzamido)-3-(3-
methoxyphenyl)propanoic acid (130 mg, 0.366 mmol, 94 % yield); 1H NMR (500 MHz, MeOH-
d4) δ 7.76 (s, 1H), 7.52 (d, J = 7.34 Hz, 2H), 7.30 (t, J = 7.83 Hz, 1H), 7.15 (t, J = 8.07 Hz, 1H), 
6.83 - 6.88 (m, 2H), 6.70 - 6.76 (m, 1H), 4.90 (dd, J = 4.89, 9.80 Hz, 1H), 3.64 - 3.72 (m, 4H), 





General Procedure D starting from (S)-2-(3-(tert-butyl)benzamido)-3-(3-methoxyphenyl) 
propanoic acid (149.5 mg, 0.421 mmol) and 2-aminoacetonitrile bisulfate (324 mg, 2.103 mmol) 
gave (S)-3-(tert-butyl)-N-(1-((cyanomethyl)amino)-3-(3-methoxyphenyl)-1-oxopropan-2-yl) 
benzamide (140 mg, 0.356 mmol, 85 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.77 (s, 1H), 
7.52 - 7.58 (m, 2H), 7.32 (t, J = 8.31 Hz, 1H), 7.17 (t, J = 8.07 Hz, 1H), 6.83 - 6.89 (m, 2H), 6.75 
(dd, J = 1.71, 8.07 Hz, 1H), 4.83 (s, 2H), 4.14 (d, J = 7.34 Hz, 1H), 3.70 (s, 3H), 3.25 (dd, J = 
5.87, 13.69 Hz, 1H), 3.06 (dd, J = 9.29, 13.69 Hz, 1H), 1.30 (s, 9H); 13C NMR (126 MHz, 
MeOH-d4) δ 174.2, 170.8, 161.3, 152.8, 140.0, 134.9, 130.6, 130.1, 129.4, 125.7, 125.7, 122.7, 
117.5, 116.0, 113.6, 56.6, 55.7, 38.7, 35.8, 31.8, 28.2, 14.6; MS (ESI+) m/z: 416.1 [M+Na]+ 
 
(S)-3-(tert-Butyl)-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)benzamide (7g) 
General Procedure D starting from (3-(tert-butyl)benzoyl)-L-leucine (218 mg, 0.748 mmol) and 
2-aminoacetonitrile (577 mg, 3.74 mmol), gave (S)-3-(tert-butyl)-N-(1-((cyanomethyl)amino)-4-
methyl-1-oxopentan-2-yl)benzamide (25.6 mg, 0.078 mmol, 10.39 % yield); 1H NMR (500 
MHz, MeOH-d4) δ 7.93 (s, 1H), 7.67 (d, J = 7.34 Hz, 1H), 7.60 (d, J = 7.83 Hz, 1H), 7.39 (t, J = 
7.83 Hz, 1H), 4.66 (dd, J = 4.65, 10.03 Hz, 1H), 4.16 (d, J = 6.85 Hz, 2H), 1.74 - 1.87 (m, 1H), 
1.63 - 1.74 (m, 2H), 1.35 (s, 9H), 1.00 (d, J = 6.36 Hz, 3H), 0.98 (d, J = 6.36 Hz, 3H); 13C NMR 
(126 MHz, MeOH-d4) δ 175.6, 171.0, 153.0, 134.9, 130.2, 129.4, 125.9, 125.8, 117.6, 53.7, 41.7, 





General Procedure A starting from ethyl L-leucinate, HCl (200 mg, 1.022 mmol) and 3-
(trifluoromethyl)benzoic acid (194 mg, 1.022 mmol) gave ethyl (3-(trifluoromethyl)benzoyl)-L-
leucinate, which was subsequently hydrolyzed according to General procedure C to afford (3-
(trifluoromethyl)benzoyl)-L-leucine (299 mg, 0.986 mmol, 99 % yield); 1H NMR (400 MHz, 
MeOH-d4) δ 8.18 (s, 1H), 8.12 (d, J = 7.83 Hz, 1H), 7.85 (d, J = 7.83 Hz, 1H), 7.68 (t, J = 7.83 





General Procedure D starting from (3-(trifluoromethyl)benzoyl)-L-leucine (100 mg, 0.330 
mmol) and 2-aminoacetonitrile bisulfate (252 mg, 1.649 mmol) gave (S)-N-(1-
((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)-3-(trifluoromethyl)benzamide (17.3 mg, 
0.051 mmol, 15.37 % yield); 1H NMR (400 MHz, MeOH-d4) δ 8.21 (s, 1H), 8.13 (d, J = 7.83 
Hz, 1H), 7.85 (d, J = 7.43 Hz, 1H), 7.68 (t, J = 7.83 Hz, 1H), 4.65 (dd, J = 4.70, 9.78 Hz, 1H), 
4.17 (dd, J = 17.61, 21.52 Hz, 2H), 1.63 - 1.87 (m, 3H), 0.98 (dd, J = 6.26, 10.56 Hz, 6H); 13C 
NMR (101 MHz, MeOH-d4) δ 175.4, 168.9, 136.3, 136.2, 132.5, 132.4, 130.7, 130.6, 129.6, 
125.7, 117.6, 53.9, 41.6, 28.2, 26.3, 23.5, 21.9;  MS (ESI+) m/z: 364.0 [M+Na]+ 
 
(S)-N-(1-((Cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)benzamide (7i) 
General Procedure A starting from ethyl L-leucinate, HCl (200 mg, 1.022 mmol) and benzoic 
acid (125 mg, 1.022 mmol) gave ethyl benzoyl-L-leucinate, which was subsequently hydrolyzed 
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according to General procedure C and directly coupled to 2-aminoacetonitrile bisulfate (547 
mg,3.57 mmol) according to General Procedure D to afford (S)-N-(1-((cyanomethyl)amino)-
4methyl-1-oxopentan-2-yl)benzamide (26.5 mg, 0.097 mmol, 13.6 % yield); 1H NMR (400 
MHz, MeOH-d4) δ 7.86 (d, J = 7.43 Hz, 2H), 7.53 (t, J = 7.43 Hz, 1H), 7.45 (t, J = 7.43 Hz, 2H), 
4.65 (dd, J = 5.48, 10.17 Hz, 1H), 4.16 (dd, J = 17.61, 21.13 Hz, 2H), 1.59 - 1.87 (m, 3H), 0.97 
(dd, J = 5.87, 10.56 Hz, 6H); 13C NMR (101 MHz, MeOH-d4) δ 175.5, 170.5, 135.1, 133.2, 
132.8, 129.8, 129.5, 128.8, 128.6, 117.7, 53.7, 41.7, 28.2, 26.2, 23.7, 23.5, 22.1, 21.9; MS (ESI+) 
m/z: 296.0 [M+Na]+ 
 
Ethyl (3-fluorobenzoyl)-L-leucinate (5k) 
General Procedure A starting from ethyl L-leucinate, HCl (200 mg, 1.022 mmol) and ethyl L-
leucinate, HCl (200 mg, 1.022 mmol) gave ethyl (3-fluorobenzoyl)-L-leucinate (285 mg, 1.012 
mmol, 99 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.68 (d, J = 7.83 Hz, 1H), 7.58 (d, J = 9.29 
Hz, 1H), 7.43 - 7.55 (m, 1H), 7.30 (dt, J = 2.45, 8.31 Hz, 1H), 4.64 (dd, J = 4.65, 10.03 Hz, 1H), 
4.19 (q, J = 7.01 Hz, 2H), 1.66 - 1.83 (m, 3H), 1.27 (t, J = 7.09 Hz, 3H), 0.99 (d, J = 6.36 Hz, 
3H), 0.94 - 0.98 (m, 3H) 
 
(S)-N-(1-((Cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)-3-fluorobenzamide (7k) 
General Procedure C starting from ethyl (3-fluorobenzoyl)-L-leucinate (280 mg, 0.995 mmol) 
gave (3-fluorobenzoyl)-L-leucine (250 mg, 0.987 mmol) which was subsequently coupled to 2-
aminoacetonitrile bisulfate (756 mg, 4.94 mmol) according to General Procedure D to afford (S)-
N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)-3-fluorobenzamide (139 mg, 0.477 
mmol, 48.3 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.68 (d, J = 7.83 Hz, 1H), 7.58 (d, J = 
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9.29 Hz, 1H), 7.45 (dt, J = 5.87, 7.83 Hz, 1H), 7.25 (dt, J = 2.45, 8.31 Hz, 1H), 4.65 (dd, J = 
4.65, 10.03 Hz, 1H), 4.13 - 4.23 (m, 2H), 1.61 - 1.85 (m, 3H), 0.98 (d, J = 6.36 Hz, 3H), 0.95 (d, 
J = 6.36 Hz, 3H); 13C NMR (126 MHz, MeOH-d4) δ 175.4, 168.8, 165.0, 163.0, 137.4, 131.5, 
124.5, 119.8, 117.6, 115.7, 53.7, 41.6, 28.2, 26.2, 23.5, 22.0; MS (ESI+) m/z: 314.1 [M+Na]+ 
 
Methyl (2-chloro-4-fluorobenzoyl)-L-leucinate (5l) 
General Procedure B starting from methyl L-leucinate (150 mg, 1.033 mmol) and 2-chloro-4-
fluorobenzoic acid (180 mg, 1.033 mmol) gave methyl (2-chloro-4-fluorobenzoyl)-L-leucinate 
(261 mg, 0.865 mmol, 84 % yield); 1H NMR (500 MHz, DMSO-d6) δ 6.71 (t, J = 7.34 Hz, 1H), 
6.50 (d, J = 8.80 Hz, 1H), 6.36 (t, J = 8.31 Hz, 1H), 3.84 (dd, J = 5.14, 10.03 Hz, 1H), 2.95 (s, 
3H), 0.99 (qd, J = 6.81, 13.33 Hz, 1H), 0.84 - 0.93 (m, 2H), 0.18 (d, J = 6.85 Hz, 6H) 
 
(2-Chloro-4-fluorobenzoyl)-L-leucine (6l) 
General Procedure C starting from methyl (2-chloro-4-fluorobenzoyl)-L-leucinate (130 mg, 
0.431 mmol) gave (2-chloro-4-fluorobenzoyl)-L-leucine (122 mg, 0.424 mmol, 98 % yield); 1H 
NMR (500 MHz, MeOH-d4) δ 7.48 - 7.60 (m, 1H), 7.27 - 7.39 (m, 2H), 7.17 (t, J = 8.56 Hz, 





General Procedure D starting from (2-chloro-4-fluorobenzoyl)-L-leucine (100 mg, 0.348 mmol) 
and 2-aminoacetonirile bisulfate (106 mg, 0.695 mmol) gave (S)-2-chloro-N-(1-
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((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)-4-fluorobenzamide (64.2 mg, 0.197 mmol, 
56.7 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.55 (dd, J = 6.36, 8.31 Hz, 1H), 7.31 (dd, J = 
2.45, 8.80 Hz, 1H), 7.17 (dt, J = 2.45, 8.31 Hz, 1H), 4.61 (dd, J = 5.14, 10.03 Hz, 1H), 4.23 (d, J 
= 17.20 Hz, 1H), 4.18 (d, J = 17.12 Hz, 1H), 1.76 - 1.86 (m, 1H), 1.68 - 1.76 (m, 1H), 1.58 - 1.66 
(m, 1H), 1.00 (d, J = 6.36 Hz, 6H); 13C NMR (126 MHz, MeOH-d4) δ 174.8, 169.2, 164.6, 




General Procedure D starting with (tert-butoxycarbonyl)-L-leucine (1 g, 4.32 mmol) gave tert-
butyl (S)-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (1100 mg, 4.08 mmol, 
94 % yield); 1H NMR (400 MHz, DMSO-d6) δ 8.56 (t, J = 5.09 Hz, 1H), 7.02 (d, J = 8.22 Hz, 
1H), 4.11 (d, J = 5.48 Hz, 2H), 3.89 - 4.00 (m, 1H), 1.50 - 1.68 (m, 1H), 1.40 - 1.48 (m, 2H), 
1.37 (s, 9H), 0.87 (d, J = 6.65 Hz, 3H), 0.84 (d, J = 6.26 Hz, 3H); Subsequently, in a dry round 
bottom flask under nitrogen, (S)-2-amino-N-(cyanomethyl)-4-methylpentanamide (27 mg, 0.160 
mmol) was dissolved into acetonitrile (5 mL). 3-methylbenzoic acid (21.72 mg, 0.160 mmol), 
HATU (91 mg, 0.239 mmol), and DIPEA (0.070 ml, 0.399 mmol) were added to the solution and 
the reaction was left to stir under overnight. The solution was extracted with 3 times with EtOAc, 
and the combined organic layer was washed with sat. aqueous sodium bicarbonate, and brine, 
dried over MgSO4 and concentrated in vacuo. Compound was purified via by flash 
chromatography (0-100% EtOAc:Hexanes gradient) to afford (S)-N-(1-((cyanomethyl)amino)-4-
methyl-1-oxopentan-2-yl)-3-methylbenzamide (10 mg, 0.035 mmol, 21.81 % yield); 1H NMR 
(400 MHz, MeOH-d4) d 7.69 (s, 1H), 7.65 (d, J = 7.04 Hz, 1H), 7.31 - 7.39 (m, 2H), 4.64 (dd, J 
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= 4.50, 9.98 Hz, 1H), 4.19 (d, J = 17.61 Hz, 1H), 4.14 (d, J = 17.60 Hz, 1H), 2.40 (s, 3H), 1.60 - 
1.86 (m, 3H), 0.99 (d, J = 6.26 Hz, 3H), 0.97 (d, J = 5.87 Hz, 3H); 13C NMR (101 MHz, MeOH-
d4) d 175.5, 170.7, 139.6, 135.2, 133.7, 129.6, 129.2, 125.9, 117.6, 53.7, 41.7, 28.2, 26.3, 23.6, 
22.1, 21.0; MS (ESI+) m/z: 288.1707 [M+H]+ 
 
(S)-2,4-Dichloro-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)benzamide (7m) 
General Procedure D starting with (tert-butoxycarbonyl)-L-leucine (1 g, 4.32 mmol) gave tert-
butyl (S)-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (1100 mg, 4.08 mmol, 
94 % yield); 1H NMR (400 MHz, DMSO-d6) δ 8.56 (t, J = 5.09 Hz, 1H), 7.02 (d, J = 8.22 Hz, 
1H), 4.11 (d, J = 5.48 Hz, 2H), 3.89 - 4.00 (m, 1H), 1.50 - 1.68 (m, 1H), 1.40 - 1.48 (m, 2H), 
1.37 (s, 9H), 0.87 (d, J = 6.65 Hz, 3H), 0.84 (d, J = 6.26 Hz, 3H); Subsequently, In a dry 
roundbottom flask under nitrogen, tert-butyl (S)-(1-((cyanomethyl)amino)-4-methyl-1-
oxopentan-2-yl)carbamate (600 mg, 2.228 mmol) was dissolved into THF (4 ml) and cooled to 
0°C. methanesulfonic acid (0.723 ml, 11.14 mmol) was added and reaction was placed under a 
light vacuum. Reaction was left to stir for 30min. THF was removed in vacuo and residue was 
brought to pH ~10 with 1N NaOH (aq). The solution was extracted with 3 times with EtOAc, 
and the combined organic layer was washed with sat. aqueous sodium bicarbonate, and brine, 
dried over MgSO4 and concentrated in vacuo to afford (S)-2-amino-N-(cyanomethyl)-4-
methylpentanamide (250 mg, 1.477 mmol, 66.3 % yield) as an oily/semisolid residue. The 
residue was carried directly into the subsequent coupling following General procedure B starting 
from 2,4-dichlorobenzoic acid (91 mg, 0.475 mmol) and (S)-3-amino-5-methylhexanenitrile (50 
mg, 0.396 mmol) gave (S)-2,4-dichloro-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-
yl)benzamide (12 mg, 0.035 mmol, 8.85 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.54 (d, J = 
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1.47 Hz, 1H), 7.49 (d, J = 8.31 Hz, 1H), 7.41 (dd, J = 1.47, 8.31 Hz, 1H), 4.61 (dd, J = 5.14, 
10.03 Hz, 1H), 4.23 (d, J = 17.12 Hz, 1H), 4.18 (d, J = 17.61 Hz, 1H), 1.76 - 1.86 (m, 1H), 1.67 - 
1.76 (m, 1H), 1.56 - 1.67 (m, 1H), 1.00 (br. s, 3H), 0.99 (br. s, 3H); 13C NMR (126 MHz, 
MeOH-d4) δ 174.8, 169.1, 137.5, 135.9, 133.2, 131.4, 130.8, 128.5, 117.6, 53.5, 41.7, 28.2, 26.1, 
23.5, 22.0; MS (ESI+) m/z: 364.1 [M+Na]+ 
 
Ethyl (4-fluorobenzoyl)-L-leucinate (5n) 
General Procedure B starting from ethyl L-leucinate, HCl (250 mg, 1.278 mmol) and 4-
fluorobenzoic acid (197 mg, 1.405 mmol) gave ethyl (4-fluorobenzoyl)-L-leucinate (350 mg, 
1.244 mmol, 97 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.91 (dd, J = 5.38, 8.31 Hz, 2H), 
7.19 (t, J = 8.56 Hz, 2H), 4.57 - 4.70 (m, 1H), 4.19 (q, J = 7.34 Hz, 2H), 1.70 - 1.80 (m, 2H), 




General Procedure C starting from ethyl (4-fluorobenzoyl)-L-leucinate (350 mg, 1.244 mmol) 
gave (4-fluorobenzoyl)-L-leucine (300 mg, 1.184 mmol, 95 % yield); 1H NMR (500 MHz, 
MeOH-d4) δ 7.77 - 7.99 (m, 2H), 7.18 (t, J = 8.56 Hz, 2H), 4.54 - 4.72 (m, 1H), 1.63 - 1.87 (m, 
3H), 0.99 (d, J = 5.87 Hz, 3H), 0.97 (d, J = 5.87 Hz, 3H) 
 
(S)-N-(1-((Cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)-4-fluorobenzamide (7n) 
General Procedure D starting from (4-fluorobenzoyl)-L-leucine (300 mg, 1.184 mmol) and 2-
aminonitrile bisulfate (907 mg, 5.92 mmol)gave (S)-N-(1-((cyanomethyl)amino)-4-methyl-1-
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oxopentan-2-yl)-4-fluorobenzamide (233 mg, 0.800 mmol, 67.5 % yield).1H NMR (500 MHz, 
MeOH-d4) δ 7.88 - 7.95 (m, 2H), 7.13 - 7.22 (m, 2H), 4.64 (dd, J = 4.89, 9.78 Hz, 1H), 4.12 - 
4.22 (m, 2H), 1.63 - 1.82 (m, 3H), 0.98 (d, J = 6.36 Hz, 3H), 0.95 (d, J = 6.36 Hz, 3H); 13C NMR 
(126 MHz, MeOH-d4) δ 175.5, 169.2, 167.4, 165.4, 131.4, 117.7, 116.4, 53.7, 41.7, 28.2, 26.2, 
23.5, 22.0; MS (ESI+) m/z: 314.1 [M+Na]+ 
 
Methyl (S)-3-cyclohexyl-2-(4-fluorobenzamido)propanoate (5o) 
General Procedure B starting from methyl (S)-2-amino-3-cyclohexylpropanoate, HCl (150 mg, 
0.677 mmol) and 4-fluorobenzoic acid (104 mg, 0.744 mmol) gave methyl (S)-3-cyclohexyl-2-
(4-fluorobenzamido)propanoate (200 mg, 0.651 mmol, 96 % yield). 1H NMR (500 MHz, MeOH-
d4) δ 7.91 (dd, J = 5.38, 8.80 Hz, 2H), 7.20 (t, J = 8.56 Hz, 2H), 4.69 (dd, J = 6.11, 9.05 Hz, 1H), 
3.74 (s, 3H), 1.84 (d, J = 12.72 Hz, 1H), 1.71 - 1.79 (m, 5H), 1.62 - 1.69 (m, 1H), 1.43 (dt, J = 
3.67, 6.97 Hz, 1H), 1.38 (dd, J = 4.16, 6.60 Hz, 1H), 1.26 - 1.34 (m, 1H), 1.17 - 1.23 (m, 1H), 
0.89 - 1.08 (m, 2H) 
 
(S)-3-Cyclohexyl-2-(4-fluorobenzamido)propanoic acid (6o) 
General Procedure C starting from methyl (S)-3-cyclohexyl-2-(4-fluorobenzamido)propanoate 
(140 mg, 0.455 mmol) gave (S)-3-cyclohexyl-2-(4-fluorobenzamido)propanoic acid (133 mg, 
0.453 mmol, 100 % yield); 1H NMR (500 MHz, DMSO-d6) δ 8.59 (d, J = 7.83 Hz, 1H), 7.95 
(dd, J = 5.62, 8.07 Hz, 2H), 7.30 (t, J = 8.80 Hz, 2H), 4.38 - 4.51 (m, 1H), 1.69 - 1.77 (m, 2H), 
1.60 - 1.69 (m, 4H), 1.59 (br. s., 1H), 1.33 - 1.42 (m, 1H), 1.07 - 1.23 (m, 4H), 0.95 (d, J = 10.76 




General Procedure D starting from (S)-3-cyclohexyl-2-(4-fluorobenzamido)propanoic acid (50 
mg, 0.170 mmol), and 2-aminonitrile bisulfate (104 mg, 0.682 mmol) gave (S)-N-(1-
((cyanomethyl)amino)-3-cyclohexyl-1-oxopropan-2-yl)-4-fluorobenzamide (41 mg, 0.124 mmol, 
72.6 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.88 - 7.98 (m, 2H), 7.16 - 7.26 (m, 2H), 4.65 
(dd, J = 5.87, 9.29 Hz, 1H), 4.12 - 4.23 (m, 2H), 1.84 (d, J = 12.72 Hz, 1H), 1.70 - 1.81 (m, 5H), 
1.62 - 1.70 (m, 1H), 1.42 (dd, J = 5.38, 7.83 Hz, 1H), 1.24 - 1.36 (m, 2H), 1.17 - 1.22 (m, 1H), 
0.85 - 1.08 (m, 2H); 13C NMR (126 MHz, MeOH-d4) δ 175.6, 169.3, 167.5, 165.5, 131.4, 131.3, 
117.6, 116.6, 116.4, 53.1, 40.3, 35.8, 34.9, 33.5, 28.2, 27.7, 27.5, 27.3; MS (ESI+) m/z: 354.1588 
[M+Na]+ 
 
Methyl 2-amino-2-cyclohexylacetate (4e) 
General Procedure A starting from  2-amino-2-cyclohexylacetic acid (500 mg, 3.18 mmol) gave 
methyl 2-amino-2-cyclohexylacetate (525 mg, 3.07 mmol, 96 % yield); 1H NMR (400 MHz, 
MeOH-d4) δ 3.88 (d, J = 4.70 Hz, 1H), 3.84 (s, 3H), 1.93 (ddd, J = 3.91, 7.92, 11.64 Hz, 1H), 
1.74 - 1.88 (m, 3H), 1.69 (t, J = 12.72 Hz, 2H), 1.07 - 1.35 (m, 5H) 
 
Methyl (S)-2-cyclohexyl-2-(4-fluorobenzamido)acetate (5p) 
General Procedure B starting from methyl (S)-2-amino-2-cyclohexylacetate (100 mg, 0.584 
mmol) and 4-fluorobenzoic acid (82 mg, 0.584 mmol) gave methyl (S)-2-cyclohexyl-2-(4-
fluorobenzamido)acetate (135 mg, 0.460 mmol, 79 % yield); 1H NMR (400 MHz, MeOH-d4) δ 
7.89 (dd, J = 5.28, 8.80 Hz, 2H), 7.19 (t, J = 8.80 Hz, 2H), 4.47 (d, J = 7.43 Hz, 1H), 3.70 - 3.77 
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(m, 3H), 1.92 (dtd, J = 3.91, 7.68, 11.25 Hz, 1H), 1.73 - 1.83 (m, 3H), 1.68 (br. s., 2H), 1.27 - 
1.38 (m, 3H), 1.07 - 1.20 (m, 2H) 
 
(S)-2-Cyclohexyl-2-(4-fluorobenzamido)acetic acid (6p) 
General Procedure C starting from methyl (S)-2-cyclohexyl-2-(4-fluorobenzamido)acetate (100 
mg, 0.341 mmol) gave (S)-2-cyclohexyl-2-(4-fluorobenzamido)acetic acid (93 mg, 0.333 mmol, 
98 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.90 (dd, J = 5.38, 8.80 Hz, 2H), 7.19 (t, J = 8.80 
Hz, 2H), 4.48 (d, J = 6.85 Hz, 1H), 1.89 - 1.98 (m, 1H), 1.79 (br. d, J = 9.80 Hz, 4H), 1.68 (br. d, 
J = 12.20 Hz, 1H), 1.26 - 1.35 (m, 2H), 1.14 - 1.22 (m, 3H) 
 
(S)-N-(2-((Cyanomethyl)amino)-1-cyclohexyl-2-oxoethyl)-4-fluorobenzamide (7p) 
General Procedure D starting from (S)-2-cyclohexyl-2-(4-fluorobenzamido)acetic acid (100 mg, 
0.358 mmol) and 2 aminoacetonitrile bisulfate (274 mg, 1.790 mmol) gave (S)-N-(2-
((cyanomethyl)amino)-1-cyclohexyl-2-oxoethyl)-4-fluorobenzamide (50 mg, 0.158 mmol, 44.0 
% yield); 1H NMR (500 MHz, MeOH-d4) δ 7.88 - 7.92 (m, 2H), 7.17 - 7.22 (m, 2H), 4.34 (d, J = 
8.31 Hz, 1H), 4.22 (d, J = 17.61 Hz, 1H), 4.13 (d, J = 17.61 Hz, 1H), 1.84 - 1.92 (m, 1H), 1.75 - 
1.83 (m, 3H), 1.63 - 1.74 (m, 2H), 1.18 - 1.28 (m, 3H), 1.06 - 1.18 (m, 2H); 13C NMR (126 MHz, 
MeOH-d4) δ 157.4, 156.9, 131.4, 131.3, 116.6, 116.4, 60.4, 41.3, 31.0, 30.6, 28.0, 27.4, 27.1; MS 
(ESI+) m/z: 340.1 [M+Na]+ 
 
Methyl (S)-5-((tert-butoxycarbonyl)amino)-2-(4-fluorobenzamido)pentanoate (9) 
General Procedure A starting from methyl (S)-2-amino-5-((tert-
butoxycarbonyl)amino)pentanoate, HCl (250 mg, 0.884 mmol) and 4-fluorobenzoic acid (136 
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mg, 0.973 mmol) gave methyl (S)-5-((tert-butoxycarbonyl)amino)-2-(4-
fluorobenzamido)pentanoate (320 mg, 0.869 mmol, 98 % yield); 1H NMR (500 MHz, DMSO-d6) 
δ 8.71 (d, J = 7.34 Hz, 1H), 7.94 (dd, J = 5.62, 8.56 Hz, 2H), 7.30 (t, J = 8.80 Hz, 2H), 6.76 (br. 
s., 1H), 4.37 (dd, J = 7.34, 14.67 Hz, 1H), 3.63 (s, 3H), 2.79 - 2.95 (m, 2H), 1.66 - 1.83 (m, 2H), 
1.35 - 1.43 (m, 3H), 1.33 (s, 9H), 1.25 - 1.32 (m, 1H) 
 
Methyl (4-fluorobenzoyl)-L-lysinate (10) 
In a dry round bottom flask, methyl N6-(tert-butoxycarbonyl)-N2-(4-fluorobenzoyl)-L-lysinate 
(630 mg, 1.647 mmol) was dissolved in a 6M HCl:dioxane solution and stirred at room 
temperature for 4h. The solvent was removed in vacuo and the resulting crude residue was 
purified by flash chromatography (10% MeOH in DCM + 1% triethylamine) to afford methyl (4-
fluorobenzoyl)-L-lysinate (460 mg, 1.629 mmol, 99 % yield); 1H NMR (500 MHz, MeOH-d4) δ 
7.95 (dd, J = 5.38, 7.83 Hz, 2H), 7.20 (t, J = 8.07 Hz, 2H), 4.53 - 4.66 (m, 1H), 3.65 (s, 3H), 2.95 
(t, J = 6.60 Hz, 2H), 2.85 (s, 2H), 1.96 - 2.06 (m, 1H), 1.89 - 1.96 (m, 1H), 1.68 - 1.81 (m, 2H), 
1.45 - 1.66 (m, 2H) 
 
Methyl N2-(4-fluorobenzoyl)-N6,N6-dimethyl-L-lysinate (11) 
In a dry round bottom flask under nitrogen, methyl (4-fluorobenzoyl)-L-lysinate (200 mg, 0.708 
mmol) was dissolved into MeOH (2 ml). Formalin (37%) (0.527 ml, 7.08 mmol) and glacial 
acetic acid (0.081 ml, 1.417 mmol) were then added, followed by the addition of sodium 
triacetoxyborohydride (601 mg, 2.83 mmol). The reaction was left to stir at room temperature 
overnight. The solvent was removed in vacuo and the resulting crude residue was purified by 
flash chromatography (10% MeOH in DCM + 1% triethylamine) to afford methyl N2-(4-
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fluorobenzoyl)-N6,N6-dimethyl-L-lysinate (70 mg, 0.226 mmol, 31.8 % yield); 1H NMR (500 
MHz, MeOH-d4) δ 7.92 (dd, J = 5.62, 8.56 Hz, 2H), 7.20 (t, J = 8.56 Hz, 2H), 4.59 (dd, J = 5.14, 
9.54 Hz, 1H), 3.74 (s, 3H), 2.57 (t, J = 7.58 Hz, 2H), 2.42 (s, 6H), 1.93 - 2.02 (m, 1H), 1.81 - 
1.93 (m, 1H), 1.56 - 1.70 (m, 2H), 1.39 - 1.56 (m, 2H); 13C NMR (126 MHz, MeOH-d4) δ 174.3, 




General Procedure C starting from methyl N2-(4-fluorobenzoyl)-N6,N6-dimethyl-L-lysinate (60 
mg, 0.193 mmol) gave N2-(4-fluorobenzoyl)-N6,N6-dimethyl-L-lysine (57.3 mg, 0.193 mmol). 
The crude residue was carried directly into general procedure D to afford (S)-N-(1-
((cyanomethyl)amino)-6-(dimethylamino)-1-oxohexan-2-yl)-4-fluorobenzamide (6.4 mg, 0.019 
mmol, 11.30 % yield); 1H NMR (400 MHz, MeOH-d4) δ 7.95 (dd, J = 5.48, 8.61 Hz, 2H), 7.20 
(t, J = 8.61 Hz, 2H), 4.56 (dd, J = 5.48, 9.00 Hz, 1H), 4.17 (d, J = 3.52 Hz, 2H), 2.90 (t, J = 8.02 
Hz, 2H), 2.69 (s, 6H), 1.94 - 2.03 (m, 1H), 1.87 (dd, J = 5.28, 9.19 Hz, 1H), 1.66 - 1.81 (m, 2H), 
1.39 - 1.57 (m, 2H); MS (ESI+) m/z: 335.2 [M+Na]+ 
 
Ethyl (S)-2-(4-fluorobenzamido)-4-methylpent-4-enoate (21) 
General Procedure B starting from dehydroleucine (D)-(+)-camphorsulfonic acid salt (1 g, 6.36 
mmol) and 4-fluorobenzoic acid (0.891 g, 6.36 mmol) gave ethyl (S)-2-(4-fluorobenzamido)-4-
methylpent-4-enoate (600 mg, 2.148 mmol, 33.8 % yield); 1H NMR (500 MHz, CDCl3) δ 7.77 
(dd, J = 5.38, 8.31 Hz, 2H), 7.08 (t, J = 8.56 Hz, 2H), 6.62 (d, J = 6.85 Hz, 1H), 4.87 (br. s., 1H), 
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4.82 - 4.86 (m, 1H), 4.79 (br. s, 1H), 4.22 (q, J = 6.85 Hz, 2H), 2.66 (dd, J = 5.62, 13.94 Hz, 1H), 
2.52 (dd, J = 8.31, 13.69 Hz, 1H), 1.78 (s, 3H), 1.29 (t, J = 7.34 Hz, 3H) 
 
(S)-N-(1-((Cyanomethyl)amino)-4-methyl-1-oxopent-4-en-2-yl)-4-fluorobenzamide (25) 
General Procedure C starting from ethyl (S)-2-(4-fluorobenzamido)-4-methylpent-4-enoate (100 
mg, 0.358 mmol) gave (S)-2-(4-fluorobenzamido)-4-methylpent-4-enoic acid (60 mg, 0.239 
mmol). Product was carried directly into general procedure D to afford (S)-N-(1-
((cyanomethyl)amino)-4-methyl-1-oxopent-4-en-2-yl)-4-fluorobenzamide (22 mg, 0.076 mmol, 
31.8 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.89 (dd, J = 5.38, 8.31 Hz, 2H), 7.18 (t, J = 
8.56 Hz, 2H), 4.84 (s, 1H), 4.83 (s, 1H), 4.76 (dd, J = 5.14, 10.03 Hz, 1H), 4.17 (s, 2H), 2.65 (dd, 
J = 4.89, 14.00 Hz, 1H), 2.52 (dd, J = 10.03, 13.94 Hz, 1H), 1.79 (s, 3H); 13C NMR (126 MHz, 
MeOH-d4) δ 174.6, 169.3, 166.5, 142.6, 131.4, 117.6, 116.5, 114.6, 53.4, 40.9, 28.2, 22.2; MS 
(ESI+) m/z: 290.1 [M+Na]+  
 
Ethyl (S)-4-fluoro-2-(4-fluorobenzamido)-4-methylpentanoate (22) 
Iron (III) sulfate monohydrate (344 mg, 0.859 mmol) was stirred in H2O (15 mL) until complete 
dissolution. The solution was cooled to 0 °C and degassed for 10 min. SELECTFLUOR (609 
mg, 1.719 mmol) and ACN (5 mL) were added to the reaction mixture. A solution of ethyl (S)-2-
(4-fluorobenzamido)-4-methylpent-4-enoate (240 mg, 0.859 mmol) In ACN (5 mL) was 
transferred into the reaction mixture, and sodium borohydride (104 mg, 2.75 mmol) was added at 
0 °c. After 2 min, the reaction was treated with an additional portion of sodium borohydride (104 
mg, 2.75 mmol). The resulting mixture was stirred for 30 min at 0 °C before being quenched by 
addition of 30% aq. NH4OH (~5mL). The mixture was extracted with DCM, the organic layer 
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was dried over MgSO4, and concentrated under reduced pressure. Flash chromatography (15% 
EtOAC:Hex isocratic gave ethyl (S)-4-fluoro-2-(4-fluorobenzamido)-4-methylpentanoate (70 
mg, 0.234 mmol, 27.2 % yield); 1H NMR (500 MHz, CDCl3) δ 7.79 (dd, J = 5.62, 8.07 Hz, 4H), 
7.08 (t, J = 8.56 Hz, 4H), 6.90 (br. s., 1H), 4.80 (q, J = 6.85 Hz, 1H), 4.21 (q, J = 6.85 Hz, 2H), 
2.12 - 2.31 (m, 2H), 1.47 (d, J = 9.29 Hz, 3H), 1.42 (d, J = 8.80 Hz, 3H), 1.28 (t, J = 7.09 Hz, 




General Procedure C starting from ethyl (S)-4-fluoro-2-(4-fluorobenzamido)-4-methylpentanoate 
(70 mg, 0.234 mmol) gave (S)-4-fluoro-2-(4-fluorobenzamido)-4-methylpentanoic acid (63.4 
mg, 0.234 mmol) (23). Product was carried directly into General Procedure D to afford(S)-N-(1-
((cyanomethyl)amino)-4-fluoro-4-methyl-1-oxopentan-2-yl)-4-fluorobenzamide (13 mg, 0.042 
mmol, 18.10 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.91 (dd, J = 5.38, 8.31 Hz, 2H), 7.20 
(t, J = 8.56 Hz, 2H), 4.81 (dd, J = 3.91, 9.78 Hz, 1H), 4.16 (s, 2H), 2.13 - 2.35 (m, 2H), 1.44 (d, J 
= 6.85 Hz, 3H), 1.40 (d, J = 6.85 Hz, 3H); 13C NMR (126 MHz, MeOH-d4) δ 174.7, 169.0, 
166.5, 131.4, 117.5, 116.5, 95.8, 52.1, 42.9, 28.3, 27.8, 26.9; 19F NMR (500 MHz, MeOH-d4) δ -
110.21 (1F), 138.99 (1F); MS (ESI+) m/z: 310.1 [M+H]+ 
 
Methyl (S)-2-(4-fluorobenzamido)-4,4-dimethylpentanoate (5q) 
General Procedure B starting from methyl (S)-2-amino-4,4-dimethylpentanoate (30 mg, 0.188 
mmol) and 4-fluorobenzoic acid (26.4 mg, 0.188 mmol) gave methyl (S)-2-(4-fluorobenzamido)-
4,4-dimethylpentanoate (45 mg, 0.160 mmol, 85 % yield); 1H NMR (500 MHz, CDCl3) δ 7.77 
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(dd, J = 5.38, 8.31 Hz, 2H), 7.06 (t, J = 8.56 Hz, 2H), 4.84 (dt, J = 3.40, 8.80 Hz, 1H), 3.73 (s, 
3H), 1.83 (dd, J = 3.18, 14.43 Hz, 1H), 1.61 (dd, J = 9.05, 14.43 Hz, 1H), 0.98 (s, 9H) 
 
(S)-N-(1-((Cyanomethyl)amino)-4,4-dimethyl-1-oxopentan-2-yl)-4-fluorobenzamide (7q) 
General Procedure C starting from methyl (S)-2-(4-fluorobenzamido)-4,4-dimethylpentanoate 
(45 mg, 0.160 mmol) gave (S)-2-(4-fluorobenzamido)-4,4-dimethylpentanoic acid (42 mg, 0.157 
mmol) (6q). Product was carried directly into General Procedure D to afford (S)-N-(1-
((cyanomethyl)amino)-4,4-dimethyl-1-oxopentan-2-yl)-4-fluorobenzamide (25 mg, 0.082 mmol, 
52.1 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.88 - 7.94 (m, 2H), 7.15 - 7.23 (m, 2H), 4.68 
(dd, J = 2.93, 8.80 Hz, 1H), 4.15 (s, 2H), 1.75 - 1.89 (m, 2H), 1.00 (s, 9H); 13C NMR (126 MHz, 
MeOH-d4) δ 175.7, 168.9, 166.5, 131.6, 131.3, 116.7, 116.4, 52.9, 45.9, 31.6, 30.2, 28.3; MS 
(ESI+) m/z: 306.2 [M+H]+ 
 
(S)-2-Amino-3-cyclopropylpropanoic acid (4h) 
General procedure A from(S)-2-amino-3-cyclopropylpropanoic acid (250 mg, 1.936 mmol) gave 
methyl (S)-2-amino-3-cyclopropylpropanoate, HCl (348 mg, 1.936 mmol, 100 % yield); 1H 
NMR (500 MHz, MeOH-d4) δ 4.13 (t, J = 6.10 Hz, 1H), 3.84 (s, 3H), 1.87 - 2.01 (m, 1H), 1.74 - 
1.84 (m, 1H), 0.77 - 0.93 (m, 1H), 0.53 - 0.63 (m, 2H), 0.15 - 0.25 (m, 2H) 
 
Methyl (S)-3-cyclopropyl-2-(4-fluorobenzamido)propanoate (5r) 
General procedure B starting from 4-fluorobenzoic acid (326 mg, 2.325 mmol) and methyl (S)-2-
amino-3-cyclopropylpropanoate, HCl (348 mg, 1.937 mmol) gave methyl (S)-3-cyclopropyl-2-
(4-fluorobenzamido)propanoate (150 mg, 0.565 mmol, 29.2 % yield); 1H NMR (500 MHz, 
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MeOH-d4) δ 7.91 (dd, J = 5.62, 8.56 Hz, 2H), 7.19 (t, J = 8.56 Hz, 2H), 4.67 (dd, J = 5.62, 8.56 
Hz, 1H), 3.74 (s, 3H), 1.84 (td, J = 7.46, 14.43 Hz, 1H), 1.69 - 1.76 (m, 1H), 0.81 - 0.89 (m, 1H), 
0.45 - 0.53 (m, 2H), 0.07 - 0.20 (m, 2H) 
 
(S)-N-(1-((Cyanomethyl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-4-fluorobenzamide (7r) 
General Procedure C starting from  (S)-3-cyclopropyl-2-(4-fluorobenzamido)propanoate (150 
mg, 0.565 mmol) gave (S)-3-cyclopropyl-2-(4-fluorobenzamido)propanoic acid (140 mg, 0.557 
mmol) (6r). Product was carried directly into General Procedure D to afford (S)-N-(1-
((cyanomethyl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-4-fluorobenzamide (97 mg, 0.335 
mmol, 60.2 % yield); 1H NMR (400 MHz, MeOH-d4) δ 7.89 - 7.96 (m, 2H), 7.18 (t, J = 8.61 Hz, 
2H), 4.60 (t, J = 7.43 Hz, 1H), 4.22 (d, J = 16.82 Hz, 1H), 4.15 (d, J = 17.22 Hz, 1H), 1.83 (d, J 
= 1.00 Hz, 1H), 1.60 - 1.75 (m, 1H), 0.72 - 0.89 (m, 1H), 0.44 - 0.59 (m, 2H), 0.06 - 0.25 (m, 
2H); MS (ESI+) m/z: 290.1 [M+H]+ 
 
Potassium ((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)-L-leucinate (16) 
In a dry roundbottom flask, methyl L-leucinate, HCl (520 mg, 2.86 mmol) and potassium 
carbonate (899 mg, 6.51 mmol) were dissolved in MeOH (8 ml). 2,2,2-trifluoro-1-(4-
fluorophenyl)ethan-1-one (0.365 ml, 2.60 mmol) was then added and the reaction was heated to 
50°C overnight. The solution was cooled to room temperature, filtered through a plug of Celite 
and diluted with anhydrous acetonitrile (80mL). The solution was then cooled to -40°C. In a 
separate flask under inert atmosphere, a solution of freshly formed Zn(BH4)2 (495 mg, 
5.21mmol) in DME (10mL) was cooled to -40, filtered through run through a plug of celite into 
an addition funnel, washed through with 10-20 mL of acetonitrile and slowly added to the 
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reaction mixture. The solution was placed left to stir under nitrogen at -40°C for 5 hours. 5-10 
mL of acetone was then added and the reaction was allowed to slowly warm to room temperature 
over 1 hour. 1N HCl was slowly added to the cloudy solution until the solution was quenched 
and became clear. The organic solvents were removed in vacuo and the resulting aqueous 
solution was extracted with EtOAc 3x. The combined organic layers were wash with brine 3x, 
dried over MgSO4, and concentrated to afford potassium ((S)-2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)-L-leucinate (0.859 g, 2.488 mmol, 87 % yield) as a white solid. dr = 11:1 
(S,S) as determined by 19F NMR. 1H NMR (500 MHz, MeOH-d4) δ 7.46 (dd, J = 5.38, 8.31 Hz, 
2H), 7.03 - 7.13 (m, 2H), 4.25 (d, J = 7.34 Hz, 1H), 4.22 (d, J = 7.34 Hz, 1H), 3.46 (t, J = 7.09 
Hz, 1H), 1.86 - 1.96 (m, 1H), 1.46 - 1.52 (m, 2H), 0.94 (d, J = 6.85 Hz, 3H), 0.92 (d, J = 6.85 
Hz, 3H); 13C NMR (126 MHz, MeOH-d4) δ 178.4, 173.1, 165.5, 163.5, 132.6, 131.8, 131.7, 
116.6, 116.4, 64.0, 63.7, 61.6, 60.1, 43.8, 26.0, 23.5, 23.4, 22.5, 21.0, 14.6; 19F NMR (470 MHz, 
MeOH-d4) δ -75.00; -114.7 
 
((R)-2,2,2-Trifluoro-1-(4-fluorophenyl)ethyl)-L-leucine (17) 
In a dry rb flask under nitrogen: methyl L-leucinate, HCl (150 mg, 0.826 mmol) and 2,2,2-
trifluoro-1-(4-fluorophenyl)ethan-1-one (159 mg, 0.826 mmol) were dissolved into anhydrous 
MeOH (10 mL). Potassium carbonate (228 mg, 1.651 mmol) was added and the reaction was 
heated to reflux overnight. Solvent was removed in vacuo and the residue was resuspended in 
anhydrous THF (5 mL). The suspension was then added to dry roundbottom flask charged with 
SODIUM BOROHYDRIDE (250 mg, 6.61 mmol). 5 mL of water:THF (v/v:2/8) was added via 
syringe pump over 3 hours. 1N HCl was added and solution was extracted with EtOAc 3x. The 
combined organic layer was washed with saturated sodium bicarbonate (aq) and brine, dried over 
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MgSO4 and concentrated to afford ((R)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)-L-leucine (236 
mg, 0.768 mmol, 93 % yield). dr = 12:1 (R,S) as determined by 19F NMR. 1H NMR (500 MHz, 
MeOH-d4) δ 7.50 (dd, J = 5.87, 8.31 Hz, 2H), 7.05 - 7.21 (m, 2H), 4.32 (q, J = 7.34 Hz, 1H), 
2.91 (dd, J = 5.38, 8.80 Hz, 1H), 1.79 - 1.92 (m, 1H), 1.38 - 1.54 (m, 2H), 0.92 - 1.01 (m, 2H), 
0.89 (d, J = 6.85 Hz, 3H), 0.75 (d, J = 6.36 Hz, 3H); 13C NMR (126 MHz, MeOH-d4) δ 178.5, 
165.9, 163.9, 132.7, 132.6, 116.6, 116.5, 63.7, 63.5, 62.5, 57.8, 44.1, 25.9, 23.6, 22.3; 19F NMR 




General Procedure D starting from ((R)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)-L-leucine (50 
mg, 0.163 mmol) and 2-aminoacetonitrile bisulfate (37.4 mg, 0.244 mmol) gave (S)-N-
(cyanomethyl)-4-methyl-2-(((R)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino)pentanamide (25 
mg, 0.072 mmol, 44.5 % yield). dr= 10:1 (R,S) as shown by 19F NMR; 1H NMR (400 MHz, 
MeOH-d4) δ 7.50 (dd, J = 5.48, 8.22 Hz, 2H), 7.15 (t, J = 8.61 Hz, 2H), 4.11 - 4.21 (m, 3H), 2.97 
(dd, J = 5.09, 9.00 Hz, 1H), 1.67 - 1.78 (m, 1H), 1.43 - 1.53 (m, 1H), 1.30 - 1.39 (m, 1H), 0.87 
(d, J = 6.65 Hz, 3H), 0.73 (d, J = 6.65 Hz, 3H); 13C NMR (101 MHz, MeOH-d4) δ 177.4, 166.1, 
163.6, 132.5, 131.1, 128.0, 125.2, 117.7, 116.5, 63.6, 59.1, 44.1, 27.9, 25.8, 23.6, 22.2; 19F NMR 








General Procedure D starting from ((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)-L-leucine (100 
mg, 0.325 mmol) and 2-aminoacetonitrile bisulfate (59.8 mg, 0.391 mmol) gave (S)-N-
(cyanomethyl)-4-methyl-2-(((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino)pentanamide 
(100 mg, 0.290 mmol, 89 % yield). dr= 7:1 (S,S) as shown by 19F NMR; 1H NMR (500 MHz, 
MeOH-d4) δ 7.45 (dd, J = 5.38, 8.31 Hz, 2H), 7.07 - 7.14 (m, 2H), 4.13 - 4.25 (m, 1H), 4.04 (d, J 
= 17.12 Hz, 1H), 3.99 (d, J = 17.61 Hz, 1H), 1.74 - 1.87 (m, 1H), 1.47 - 1.54 (m, 1H), 1.33 - 1.47 
(m, 1H), 0.94 (dd, J = 3.18, 6.60 Hz, 6H); 13C NMR (126 MHz, MeOH-d4) δ 177.6, 165.5, 
163.6, 132.4, 131.9, 117.5, 116.5, 64.1, 61.0, 44.1, 39.0, 27.9, 26.0, 23.4, 22.6; 19F NMR (470 




General Procedure D starting with (4-fluorobenzoyl)-L-leucine (250 mg, 0.987 mmol) and 1-
aminocyclopropane-1-carbonitrile, HCl (140 mg, 1.184 mmol) gave (S)-N-(1-((1-
cyanocyclopropyl)amino)-4-methyl-1-oxopentan-2-yl)-4-fluorobenzamide (229 mg, 0.721 
mmol, 73 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.90 (dd, J = 5.38, 8.31 Hz, 2H), 7.17 (t, J 
= 8.80 Hz, 2H), 4.44 - 4.60 (m, 1H), 1.67 - 1.82 (m, 2H), 1.57 - 1.66 (m, 1H), 1.49 (dd, J = 5.38, 
7.83 Hz, 2H), 1.24 (dd, J = 6.36, 8.31 Hz, 2H), 0.98 (d, J = 6.36 Hz, 3H), 0.95 (d, J = 6.36 Hz, 
3H); 13C NMR (126 MHz, MeOH-d4) δ 176.4, 169.3, 167.4, 165.4, 131.3, 121.4, 116.4, 53.7, 





General Procedure D starting with ((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)-L-leucine (100 
mg, 0.325 mmol) and 1-aminocyclopropane-1-carbonitrile, HCl (46.3 mg, 0.391 mmol) gave 
(S)-N-(1-cyanocyclopropyl)-4-methyl-2-(((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino) 
pentanamide (100 mg, 0.269 mmol, 83 % yield). dr= 11:1 (S,S) as shown by 19F NMR; 1H NMR 
(500 MHz, MeOD) δ 7.43 (dd, J = 5.38, 8.31 Hz, 2H), 7.11 (t, J = 8.80 Hz, 2H), 4.10 - 4.21 (m, 
1H), 3.28 (dd, J = 6.36, 8.31 Hz, 1H), 1.79 (td, J = 6.85, 13.69 Hz, 1H), 1.44 - 1.50 (m, 1H), 1.33 
- 1.42 (m, 3H), 0.99 - 1.04 (m, 1H), 0.93 (d, J = 6.85 Hz, 6H); 13C NMR (126 MHz, DMSO-d6) δ 
178.7, 165.6, 163.6, 131.9, 121.2, 116.7, 116.6, 64.3, 61.3, 44.2, 26.0, 23.4, 22.6, 21.1, 16.9, 




General Procedure B from ethyl L-leucinate, HCl (200 mg, 1.022 mmol) and 3-(tert-butyl)-1-
methyl-1H-pyrazole-5-carboxylic acid (186 mg, 1.022 mmol) gave ethyl (3-(tert-butyl)-1-
methyl-1H-pyrazole-5-carbonyl)-L-leucinate (323 mg, 0.999 mmol, 98 % yield); 1H NMR (500 
MHz, CDCl3) δ 6.33 (d, J = 8.31 Hz, 1H), 4.75 (d, J = 4.89 Hz, 1H), 4.23 (q, J = 7.34 Hz, 2H), 
4.10 (s, 3H), 1.71 - 1.76 (m, 1H), 1.60 (br. s., 1H), 1.43 - 1.50 (m, 1H), 1.26 - 1.34 (m, 12H), 
0.99 (t, J = 5.38 Hz, 6H) 
 
(3-(Tert-butyl)-1-methyl-1H-pyrazole-5-carbonyl)-L-leucine  
General Procedure C from ethyl (3-(tert-butyl)-1-methyl-1H-pyrazole-5-carbonyl)-L-leucinate 
(395 mg, 1.221 mmol) gave (3-(tert-butyl)-1-methyl-1H-pyrazole-5-carbonyl)-L-leucine (307 
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mg, 1.039 mmol, 85 % yield); 1H NMR (500 MHz, MeOH-d4) δ 6.81 (s, 1H), 4.60 (dd, J = 4.65, 
10.94 Hz, 1H), 4.06 (s, 3H), 1.67 - 1.82 (m, 3H), 1.33 (s, 9H), 1.00 (d, J = 5.93 Hz, 3H), 0.97 (d, 




General procedure D from (3-(Tert-butyl)-1-methyl-1H-pyrazole-5-carbonyl)-L-leucine (83 mg, 
0.281 mmol) and 2-aminoacetonitrile bisulfate (51.6 mg, 0.337 mmol) gave (S)-3-(tert-butyl)-N-
(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-methyl-1H-pyrazole-5-carboxamide 
(65.6 mg, 0.197 mmol, 70 % yield); 1H NMR (400 MHz, MeOH-d4) δ 6.78 (s, 1H), 4.51 - 4.63 
(m, 1H), 4.15 (s, 2H), 4.03 (s, 3H), 1.58 - 1.81 (m, 3H), 1.30 (s, 9H), 0.97 (dd, J = 6.06, 13.11 
Hz, 6H); 13C NMR (101 MHz, MeOH-d4) δ 175.4, 164.1, 161.7, 136.8, 117.6, 105.2, 53.1, 41.5, 
33.1, 31.0, 28.2, 26.2; MS (ESI+) m/z: 334.1 [M+H]+ 
 
Ethyl (3-(tert-butyl)benzoyl)-L-leucinate 
General Procedure B from ethyl L-leucinate, HCl (100 mg, 0.511 mmol) and 3-(tert-
butyl)benzoic acid (91 mg, 0.511 mmol) gave ethyl (3-(tert-butyl)benzoyl)-L-leucinate (102.7 
mg, 0.321 mmol, 62.9 % yield); Carried directly to next step without further purification. 
 
(3-(Tert-butyl)-1-methyl-1H-pyrazole-5-carbonyl)-L-leucine 
General Procedure C from ethyl (3-(tert-butyl)-1-methyl-1H-pyrazole-5-carbonyl)-L-leucinate 
(395 mg, 1.221 mmol) gave (3-(tert-butyl)-1-methyl-1H-pyrazole-5-carbonyl)-L-leucine (307 
mg, 1.039 mmol, 85 % yield); 1H NMR (500 MHz, MeOH-d4) δ 6.81 (s, 1H), 4.60 (dd, J = 4.65, 
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10.94 Hz, 1H), 4.06 (s, 3H), 1.67 - 1.82 (m, 3H), 1.33 (s, 9H), 1.00 (d, J = 5.93 Hz, 3H), 0.97 (d, 




General procedure D from (3-(tert-butyl)benzoyl)-L-leucine (218 mg, 0.748 mmol) and  
2-((tetraoxidanyl-l6-sulfanylidene)amino)acetonitrile (577 mg, 3.74 mmol) gave  
(S)-3-(tert-butyl)-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)benzamide (25.6 mg, 
0.078 mmol, 10.39 % yield); 1H NMR (500 MHz, MeOH-d4) δ  7.93 (s, 1H), 7.67 (d, J = 7.34 
Hz, 1H), 7.60 (d, J = 7.83 Hz, 1H), 7.39 (t, J = 7.83 Hz, 1H), 4.66 (dd, J = 4.65, 10.03 Hz, 1H), 
4.16 (d, J = 6.85 Hz, 2H), 1.74 - 1.87 (m, 1H), 1.63 - 1.74 (m, 2H), 1.35 (s, 9H), 1.00 (d, J = 6.36 
Hz, 3H), 0.98 (d, J = 6.36 Hz, 3H);  13C NMR (126 MHz, MeOH-d4) δ 175.6, 171.0, 153.0, 
134.9, 130.2, 129.4, 125.9, 125.8, 117.6, 53.7, 41.7, 35.9, 31.8, 28.2, 26.3, 23.6, 22.1; MS (ESI+) 




General procedure B from methyl L-phenylalaninate hydrochloride (111 mg, 0.515 mmol) and  
3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylic acid (94 mg, 0.515 mmol) gave methyl (S)-2-
(3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxamido)-3-(3-hydroxyphenyl)propanoate (180 mg, 
0.501 mmol, 97 % yield); 1H NMR (500 MHz, MeOH-d4) δ 7.08 (t, J = 7.83 Hz, 1H), 6.69 - 6.76 
(m, 2H), 6.64 (d, J = 9.78 Hz, 1H), 6.61 (s, 1H), 4.79 (dd, J = 4.65, 9.54 Hz, 1H), 3.92 (s, 3H), 





General Procedure C from (S)-2-(3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxamido)-3-(3-
hydroxyphenyl)propanoate (180 mg, 0.501 mmol) gave (S)-2-(3-(tert-butyl)-1-methyl-1H-
pyrazole-5-carboxamido)-3-(3-methoxyphenyl)propanoic acid (0.501 mmol, 100% yield). 




General procedure D from (S)-2-(3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxamido)-3-(3-
hydroxyphenyl)propanoic acid (82.3 mg, 0.238 mmol) and aminoacetonitrile bisulfate  (182 mg, 
1.191 mmol) gave (S)-3-(tert-butyl)-N-(1-((cyanomethyl)amino)-3-(3-hydroxyphenyl)-1-
oxopropan-2-yl)-1-methyl-1H-pyrazole-5-carboxamide (14 mg, 0.037 mmol, 15.32 % yield); 1H 
NMR (400 MHz, MeOH-d4) δ 7.08 (t, J = 7.83 Hz, 1H), 6.68 - 6.77 (m, 2H), 6.59 - 6.66 (m, 
2H), 4.74 (dd, J = 6.06, 9.19 Hz, 1H), 4.14 (s, 2H), 3.91 (s, 3H), 3.18 (dd, J = 5.87, 13.69 Hz, 
1H), 2.94 (dd, J = 9.39, 13.69 Hz, 1H), 1.27 (s, 9H); 13C NMR (101 MHz, MeOH-d4) δ 174.1, 
162.1, 161.6, 158.7, 139.8, 136.8, 130.7, 121.5, 117.5, 117.2, 115.0, 105.1, 56.2, 38.7, 33.0, 31.1, 





General procedure B starting from methyl (S)-2-amino-3-(3-methoxyphenyl)propanoate (81.5 
mg, 0.389 mmol) and 3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylic acid (71.0 mg, 0.389 
mmol) followed directly by general procedure C gave (S)-2-(3-(tert-butyl)-1-methyl-1H-
pyrazole-5-carboxamido)-3-(3-methoxyphenyl)propanoic acid (136.6 mg, 0.380 mmol, 98 % 
yield) over two steps. 1H NMR (500 MHz, MeOH-d4) δ 7.15 (t, J = 8.07 Hz, 1H), 6.82 (br. s., 
2H), 6.73 (d, J = 8.31 Hz, 1H), 6.62 (s, 1H), 4.84 (dd, J = 4.65, 10.30 Hz, 1H), 3.90 (s, 3H), 3.70 




General procedure D from (S)-2-(3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxamido)-3-(3-
methoxyphenyl)propanoic acid (136.6 mg, 0.380 mmol) and 2-((tetraoxidanyl-l6-
sulfanylidene)amino)acetonitrile (293 mg, 1.900 mmol) gave (S)-3-(tert-butyl)-N-(1-
((cyanomethyl)amino)-3-(3-methoxyphenyl)-1-oxopropan-2-yl)-1-methyl-1H-pyrazole-5-
carboxamide (126 mg, 0.317 mmol, 83 % yield); 1H NMR (500 MHz, MeOH-d4) δ  7.17 (t, J = 
8.07 Hz, 1H), 6.82 - 6.87 (m, 2H), 6.73 - 6.78 (m, 1H), 6.63 (s, 1H), 4.77 (dd, J = 5.87, 9.29 Hz, 
1H), 4.15 (d, J = 2.45 Hz, 2H), 3.89 (s, 3H), 3.72 (s, 3H), 3.22 (dd, J = 5.87, 13.69 Hz, 1H), 2.99 
(dd, J = 9.29, 13.69 Hz, 1H), 1.27 (s, 9H); 13C NMR (126 MHz, MeOH-d4) δ 174.0, 162.0, 
161.6, 161.3, 139.9, 136.7, 130.7, 122.7, 117.5, 116.0, 113.6, 105.2, 56.0, 55.7, 38.8, 33.0, 31.0, 




General procedure B from methyl (S)-2-amino-3-(3-bromophenyl)propanoate, HCl (100 mg, 
0.339 mmol) and 3-(tert-butyl)benzoic acid (60.5 mg, 0.339 mmol) gave methyl (S)-3-(3-
bromophenyl)-2-(3-(tert-butyl)benzamido)propanoate (140 mg, 0.335 mmol, 99 % yield) Carried 
directly to next step. 
 
(S)-3-(3-Bromophenyl)-2-(3-(tert-butyl)benzamido)propanoic acid  
General procedure C from methyl (S)-3-(3-bromophenyl)-2-(3-(tert-butyl)benzamido)propanoate 
(140 mg, 0.335 mmol) gave (S)-3-(3-bromophenyl)-2-(3-(tert-butyl)benzamido)propanoic acid 




Gerneral procedure D from (S)-3-(3-bromophenyl)-2-(3-(tert-butyl)benzamido)propanoic acid 
(140 mg, 0.346 mmol) and 2-aminoacetonitrile bisulfate (267 mg, 1.731 mmol) gave (S)-N-(3-
(3-bromophenyl)-1-((cyanomethyl)amino)-1-oxopropan-2-yl)-3-(tert-butyl)benzamide (160 mg, 
0.362 mmol, 104 % yield); 1H NMR (400 MHz, MeOH-d4) δ  7.77 (s, 1H), 7.54 (d, J = 7.43 Hz, 
1H), 7.57 (d, J = 7.83 Hz, 1H), 7.49 (s, 1H), 7.31 - 7.38 (m, 2H), 7.26 (d, J = 7.43 Hz, 1H), 7.18 
(t, J = 7.63 Hz, 1H), 4.81 (dd, J = 5.87, 9.39 Hz, 1H), 4.15 (d, J = 3.13 Hz, 2H), 3.28 (t, J = 1.00 
Hz, 1H), 3.05 (dd, J = 9.59, 13.89 Hz, 1H), 1.32 (s, 9H);  13C NMR (101 MHz, MeOH-d4) δ 
173.9, 171.0, 152.9, 141.3, 134.9, 133.6, 133.5, 131.4, 131.1, 130.2, 129.4, 125.7, 125.6, 123.5, 




General procedure B from methyl (S)-2-amino-3-(3-bromophenyl)propanoate, HCl (500 mg, 
1.697 mmol) and 3-(trifluoromethyl)benzoic acid (323 mg, 1.697 mmol gave methyl (S)-3-(3-
bromophenyl)-2-(3-(trifluoromethyl)benzamido)propanoate (715 mg, 1.662 mmol, 98 % yield) 
Carried directly to next step. 
 
(S)-3-(3-Bromophenyl)-2-(3-(trifluoromethyl)benzamido)propanoic acid 
General procedure C from methyl (S)-3-(3-bromophenyl)-2-(3-(trifluoromethyl) 
benzamido)propanoate (715 mg, 1.662 mmol) gave (S)-3-(3-bromophenyl)-2-(3-trifluoromethyl) 




General procedure D from (S)-3-(3-bromophenyl)-2-(3-(trifluoromethyl)benzamido)propanoic 
acid (300 mg, 0.721 mmol), 2-aminoacetonitrile bisulfate (556 mg, 3.60 mmol) gave (S)-N-(3-
(3-bromophenyl)-1-((cyanomethyl)amino)-1-oxopropan-2-yl)-3-(trifluoromethyl)benzamide (22 
mg, 0.048 mmol, 6.72 % yield) 1H NMR (400 MHz, MeOH-d4) δ  8.06 (s, 1H), 7.99 (d, J = 7.83 
Hz, 1H), 7.83 (d, J = 7.83 Hz, 1H), 7.61 - 7.74 (m, 1H), 7.49 (s, 1H), 7.36 (d, J = 8.22 Hz, 1H), 
7.26 (d, J = 7.43 Hz, 1H), 7.19 (t, J = 7.83 Hz, 1H), 4.82 (dd, J = 5.87, 9.39 Hz, 1H), 4.08 - 4.21 
(m, 2H), 3.27 (d, J = 5.87 Hz, 1H), 2.93 - 3.12 (m, 1H), 2.80 (s, 1H); 13C NMR (101 MHz, 
MeOH-d4) δ 173.7, 168.8, 141.2, 136.2, 133.6, 133.5, 132.3, 132.2, 131.5, 131.2, 130.6, 129.5, 




General procedure B from methyl (S)-2-amino-3-(3-bromophenyl)propanoate and 3-(tert-butyl)-
1-methyl-1H-pyrazole-5-carboxylic acid gave methyl (S)-3-(3-bromophenyl)-2-(3-(tert-butyl)-1-
methyl-1H-pyrazole-5-carboxamido)propanoate (140 mg, 0.331 mmol, 98 % yield) as off-white  
solid. 1H NMR (400 MHz, MeOH-d4) δ 7.77 (s, 1H), 7.54 (d, J = 7.43 Hz, 1H), 7.57 (d, J = 7.83 
Hz, 1H), 7.49 (s, 1H), 7.31 - 7.38 (m, 2H), 7.26 (d, J = 7.43 Hz, 1H), 7.18 (t, J = 7.63 Hz, 1H), 
4.81 (dd, J = 5.87, 9.39 Hz, 1H), 4.15 (d, J = 3.13 Hz, 2H), 3.28 (t, J = 1.00 Hz, 1H), 3.05 (dd, J 




General procedure C from methyl (S)-3-(3-bromophenyl)-2-(3-(tert-butyl)-1-methyl-1H-
pyrazole-5-carboxamido)propanoate (140 mg, 0.331 mmol) gave (S)-3-(3-bromophenyl)-2-(3-
(tert-butyl)-1-methyl-1H-pyrazole-5-carboxamido)propanoic acid (135 mg, 0.331 mmol, 100 % 




General procedure D from (S)-3-(3-bromophenyl)-2-(3-(tert-butyl)-1-methyl-1H-pyrazole-5-
carboxamido)propanoic acid (140 mg, 0.343 mmol),2-aminoacetonitrile bisulfate (264 mg, 1.714 
mmol) gave (S)-N-(3-(3-bromophenyl)-1-((cyanomethyl)amino)-1-oxopropan-2-yl)-3-(tert-
butyl)-1-methyl-1H-pyrazole-5-carboxamide (52 mg, 0.117 mmol, 34.0 % yield); 1H NMR (400 
MHz, MeOH-d4) δ 7.49 (s, 1H), 7.35 (d, J = 7.83 Hz, 1H), 7.25 (d, J = 7.43 Hz, 1H), 7.18 (t, J = 
7.63 Hz, 1H), 6.63 (s, 1H), 4.78 (dd, J = 5.67, 9.59 Hz, 1H), 4.17 (s, 2H), 3.89 (s, 3H), 3.25 (dd, 
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J = 5.48, 13.69 Hz, 1H), 2.99 (dd, J = 9.98, 13.50 Hz, 1H), 1.27 (s, 9H); 13C NMR (101 MHz, 
MeOH-d4) δ 173.7, 162.0, 161.6, 141.2, 136.6, 133.7, 131.5, 131.1, 129.3, 123.4, 117.5, 105.3, 
55.7, 38.9, 38.2, 33.0, 31.1, 28.2; MS (ESI+) m/z: 445.9 [M+H]+ 
 
Methyl (S)-2-cyclohexyl-2-(3-(trifluoromethyl)benzamido)acetate 
General procedure B from 3-(trifluoromethyl)benzoic acid (100 mg, 0.526 mmol) and methyl 
(S)-2-amino-2-cyclohexylacetate (90 mg, 0.526 mmol) gave Methyl (S)-2-cyclohexyl-2-(3-
(trifluoromethyl)benzamido)acetate. (yield not calcd); 1H NMR (500 MHz, MeOH-d4) δ 8.15 (s, 
1H), 8.10 (d, J = 7.83 Hz, 1H), 7.85 (d, J = 7.83 Hz, 1H), 7.66 - 7.71 (m, 1H), 4.50 (d, J = 7.34 
Hz, 1H), 3.74 (s, 3H), 1.90 - 1.99 (m, 1H), 1.78 (d, J = 10.76 Hz, 3H), 1.70 (t, J = 13.45 Hz, 2H), 
1.26 - 1.39 (m, 3H), 1.10 - 1.21 (m, 2H) 
 
(S)-2-Cyclohexyl-2-(3-(trifluoromethyl)benzamido)acetic acid  
General procedure C from methyl (S)-2-cyclohexyl-2-(3-(trifluoromethyl)benzamido)acetate 
(208 mg, 0.606 mmol) gave (S)-2-cyclohexyl-2-(3-(trifluoromethyl)benzamido)acetic acid (200 
mg, 0.607 mmol, 100 % yield); 1H NMR (500 MHz, MeOH-d4) δ 8.16 (s, 1H), 8.10 (d, J = 7.83 
Hz, 1H), 7.85 (d, J = 7.34 Hz, 1H), 7.64 - 7.71 (m, 1H), 4.50 (d, J = 6.85 Hz, 1H), 1.96 (dd, J = 
3.42, 6.85 Hz, 1H), 1.77 - 1.84 (m, 4H), 1.69 (d, J = 12.23 Hz, 1H), 1.27 - 1.40 (m, 3H), 1.14 - 







General procedure D from (S)-2-cyclohexyl-2-(3-(trifluoromethyl)benzamido)acetic acid (200 
mg, 0.607 mmol) and 2-aminoacetonitrile bisulfate (465 mg, 3.04 mmol) gave (S)-N-(2-
((cyanomethyl)amino)-1-cyclohexyl-2-oxoethyl)-3-(trifluoromethyl)benzamide (75 mg, 0.204 
mmol, 33.6 % yield); 1H NMR (400 MHz, MeOH-d4) δ 8.17 (s, 1H), 8.10 (d, J = 7.83 Hz, 1H), 
7.85 (d, J = 7.83 Hz, 1H), 7.68 (t, J = 7.63 Hz, 1H), 4.31 - 4.42 (m, 1H), 4.23 (d, J = 16.43 Hz, 
1H), 4.13 (d, J = 17.61 Hz, 1H), 1.84 - 1.98 (m, 2H), 1.79 (d, J = 10.56 Hz, 2H), 1.70 (br. s., 
2H), 1.26 - 1.37 (m, 3H), 1.06 - 1.21 (m, 2H); 13C NMR (126 MHz, MeOH-d4) δ 192.9, 136.5, 
132.4, 130.7, 129.4, 117.5, 60.6, 41.1, 30.9, 30.7, 28.0, 27.4, 27.2, 27.1; MS (ESI+) m/z: 368.1 
[M+H]+ 
 
(S)-2-Cyclohexyl-2-(3-fluorobenzamido)acetate (137 mg, 0.467 mmol, 80 % yield) 
General procedure B from 3-fluorobenzoic acid (82 mg, 0.584 mmol and methyl (S)-2-amino-2-
cyclohexylacetate (100 mg, 0.584 mmol) gave methyl (S)-2-cyclohexyl-2-(3-
fluorobenzamido)acetate (137 mg, 0.467 mmol, 80 % yield); 1H NMR (400 MHz, MeOH-d4) δ 
7.66 (d, J = 7.83 Hz, 1H), 7.57 (d, J = 9.78 Hz, 1H), 7.49 (dt, J = 5.87, 8.02 Hz, 1H), 7.29 (dt, J 
= 1.96, 8.41 Hz, 1H), 4.42 - 4.53 (m, 1H), 3.73 (s, 3H), 1.92 (dtd, J = 3.72, 7.61, 11.20 Hz, 1H), 
1.78 (d, J = 9.78 Hz, 3H), 1.69 (br. s., 2H), 1.27 - 1.40 (m, 3H), 1.07 - 1.21 (m, 2H) 
 
(S)-2-cyclohexyl-2-(3-fluorobenzamido)acetic acid 
General procedure C from methyl (S)-2-cyclohexyl-2-(3-fluorobenzamido)acetate (100 mg, 
0.341 mmol) gave (S)-2-cyclohexyl-2-(3-fluorobenzamido)acetic acid (92 mg, 0.329 mmol, 97 
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% yield); 1H NMR (500 MHz, MeOH-d4) δ 7.67 (d, J = 7.83 Hz, 1H), 7.57 (d, J = 9.29 Hz, 1H), 
7.45 - 7.52 (m, 1H), 7.29 (dt, J = 2.20, 8.44 Hz, 1H), 4.48 (d, J = 6.85 Hz, 1H), 1.90 - 1.98 (m, 




General procedure D from (S)-2-cyclohexyl-2-(3-fluorobenzamido)acetic acid (100 mg, 0.358 
mmol) and 2 aminoacetonitrile bisulfate (274 mg, 1.790 mmol) gave (S)-N-(2-
((cyanomethyl)amino)-1-cyclohexyl-2-oxoethyl)-3-fluorobenzamide (35 mg, 0.110 mmol, 30.8 
% yield); 1H NMR (500 MHz, MeOH-d4) δ 7.67 (d, J = 7.83 Hz, 1H), 7.58 (d, J = 9.78 Hz, 1H), 
7.46 - 7.52 (m, 1H), 7.29 (dt, J = 2.20, 8.44 Hz, 1H), 4.35 (d, J = 8.31 Hz, 1H), 4.22 (d, J = 17.61 
Hz, 1H), 4.13 (d, J = 17.61 Hz, 1H), 1.83 - 1.95 (m, 2H), 1.75 - 1.83 (m, J = 10.80 Hz, 2H), 1.70 
(br. s., 2H), 1.21 - 1.31 (m, 3H), 1.06 - 1.20 (m, 2H); 13C NMR (126 MHz, MeOH-d4) δ 174.2, 
165.2, 131.7, 131.6, 124.6, 124.6, 119.8, 119.7, 117.5, 115.8, 115.6, 60.4, 41.2, 30.9, 30.7, 28.0, 
27.4, 27.2, 27.1; MS (ESI+) m/z: 340.1 [M+H]+ 
 
Methyl N6-(tert-butoxycarbonyl)-N2-(3-(trifluoromethyl)benzoyl)-L-lysinate 
General procedure B from 3-(trifluoromethyl)benzoic acid and methyl N6-(tert-butoxycarbonyl)-
L-lysinate gave methyl N6-(tert-butoxycarbonyl)-N2-(3-(trifluoromethyl)benzoyl)-L-lysinate 
(1.4 g, 3.24 mmol, 96 % yield) as an orange sticky oil. Next, methyl N6-(tert-butoxycarbonyl)-
N2-(3-(trifluoromethyl)benzoyl)-L-lysinate (700 mg, 1.619 mmol) was dissolved into 5ml HCl 
(6N) in dioxane and stirred at rt for 2h to afford methyl N6-(tert-butoxycarbonyl)-N2-(3-
(trifluoromethyl)benzoyl)-L-lysinate (700 mg, 1.619 mmol). Carried directly to next step. 
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Methyl N6,N6-dimethyl-N2-(3-(trifluoromethyl)benzoyl)-L-lysinate  
Methyl (3-(trifluoromethyl)benzoyl)-L-lysinate (500 mg, 1.505 mmol) was dissolved into a 
solution of FORMALDEHYDE (560 µl, 7.52 mmol) and FORMIC ACID (577 µl, 15.05 mmol) 
and headed to reflux overnight. Reaction was cooled, acidified with 1mL 6N HCl (aq) and 
concentrated in vacuo. The crude residue was dissolved into iPrOH, crashed out with Et2O and 
placed in freezer for 1h. Precipitate could not be filtered, so residue was freebased with 
DCM/triethylamine, absorbed onto silica and purified via biotage 5-10% MeOH:DCM +1%TEA 
gradient to afford methyl N6,N6-dimethyl-N2-(3-(trifluoromethyl)benzoyl)-L-lysinate as a 
yellow oil. (yield not calcd); 1H NMR (500 MHz, MeOH-d4) δ 8.18 (s, 1H), 8.12 (d, J = 7.83 Hz, 
1H), 7.87 (d, J = 7.83 Hz, 1H), 7.69 (t, J = 7.83 Hz, 1H), 4.62 (dd, J = 5.14, 9.54 Hz, 1H), 3.75 
(s, 3H), 2.48 (t, J = 7.83 Hz, 2H), 2.35 (s, 6H), 1.95 - 2.00 (m, 1H), 1.89 (dt, J = 4.40, 9.29 Hz, 
1H), 1.56 - 1.66 (m, 2H), 1.42 - 1.54 (m, 2H); 13C NMR (126 MHz, MeOH-d4) δ 174.2, 168.9, 




General procedure C from methyl N6,N6-dimethyl-N2-(3-(trifluoromethyl)benzoyl)-L-lysinate 
gave N6,N6-dimethyl-N2-(3-(trifluoromethyl)benzoyl)-L-lysine (99 % yield). Next, General 
procedure D from N6,N6-dimethyl-N2-(3-(trifluoromethyl)benzoyl)-L-lysine (500 mg, 1.444 
mmol) and 2-aminoacetonitrile bisulfate (1105 mg, 7.22 mmol) Followed by purification via 
prep TLC 10%MeOH:DCM + 1%TEA (Rf~0.4) gave (S)-N-(1-((cyanomethyl)amino)-6-
(dimethylamino)-1-oxohexan-2-yl)-3-(trifluoromethyl)benzamide (yield<5%); 1H NMR (400 
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MHz, MeOH-d4) δ 8.22 (s, 1H), 8.15 (d, J = 7.83 Hz, 1H), 7.87 (d, J = 7.43 Hz, 1H), 7.69 (t, J = 
7.83 Hz, 1H), 4.58 (dd, J = 5.48, 9.00 Hz, 1H), 4.11 - 4.26 (m, 2H), 2.76 (t, J = 7.83 Hz, 2H), 
2.58 (s, 6H), 1.93 - 2.03 (m, 1H), 1.83 - 1.90 (m, 1H), 1.61 - 1.76 (m, 2H), 1.40 - 1.56 (m, 2H); 
HRMS (ESI+) m/z: 385.1843 [M+H]+ 
 
Methyl N6-(tert-butoxycarbonyl)-N2-(3-fluorobenzoyl)-L-lysinate 
General procedure B from 3-fluorobenzoic acid (260 mg, 1.853 mmol) and methyl N6-(tert-
butoxycarbonyl)-L-lysinate, HCl (500 mg, 1.685 mmol) gave methyl N6-(tert-butoxycarbonyl)-
N2-(3-fluorobenzoyl)-L-lysinate (644 mg, 1.684 mmol, 100 % yield); 1H NMR (400 MHz, 
MeOH-d4) δ 7.69 (d, J = 7.83 Hz, 1H), 7.59 (d, J = 9.78 Hz, 1H), 7.43 - 7.53 (m, 1H), 7.28 (dt, J 
= 2.15, 8.31 Hz, 1H), 4.52 - 4.64 (m, 1H), 3.69 - 3.76 (m, 3H), 3.04 (t, J = 6.46 Hz, 2H), 1.88 - 
1.99 (m, 1H), 1.85 (td, J = 4.40, 9.19 Hz, 1H), 1.43 - 1.56 (m, 3H), 1.38 - 1.43 (m, 9H), 1.31 - 
1.38 (m, 1H) 
 
Methyl (3-fluorobenzoyl)-L-lysinate 
Methyl N6-(tert-butoxycarbonyl)-N2-(3-fluorobenzoyl)-L-lysinate (600 mg, 1.569 mmol) was 
dissolved in 6M HCl:dioxane solution and stirred at rt for 4h. Solvent was removed in vacuo and 
crude residue was basified w/ MeOH/TEA, absorbed onto silica, and purified via FC 10% 
MeOH/DCM + 1% TEA to afford methyl (3-fluorobenzoyl)-L-lysinate (400 mg, 1.417 mmol, 90 
% yield); 1H NMR (500 MHz, DMSO-d6) δ 8.93 (d, J = 7.34 Hz, 1H), 7.78 (d, J = 7.83 Hz, 1H), 
7.73 (d, J = 9.78 Hz, 1H), 7.49 - 7.57 (m, 1H), 7.37 - 7.44 (m, 1H), 4.35 - 4.47 (m, 1H), 3.65 (s, 
3H), 2.77 (t, J = 7.34 Hz, 2H), 1.74 - 1.90 (m, 2H), 1.53 - 1.67 (m, 2H), 1.33 - 1.53 (m, 2H), 1.05 
(t, J = 7.34 Hz, 1H) 
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Methyl N2-(3-fluorobenzoyl)-N6,N6-dimethyl-L-lysinate 
Methyl (3-fluorobenzoyl)-L-lysinate (170 mg, 0.602 mmol) was dissolved into MeOH (2 ml). 
FORMALDEHYDE (0.448 ml, 6.02 mmol) and ACETIC ACID (0.069 ml, 1.204 mmol) were 
added, followed by the addition of SODIUM TRIACETOXYBOROHYDRIDE (510 mg, 2.409 
mmol). Reaction was left to stir at rt overnight and monitored by HPLC. Purified by FC 
10%MeOH in DCM + 1% TEA to afford methyl N2-(3-fluorobenzoyl)-N6,N6-dimethyl-L-
lysinate (175 mg, 0.564 mmol, 94 % yield); 1H NMR (400 MHz, MeOH-d4) δ 7.69 (d, J = 7.43 
Hz, 1H), 7.60 (d, J = 9.39 Hz, 1H), 7.44 - 7.53 (m, 1H), 7.26 - 7.34 (m, 1H), 4.59 (dd, J = 5.09, 
9.39 Hz, 1H), 3.74 (s, 3H), 2.44 (t, J = 7.63 Hz, 2H), 2.32 (s, 6H), 1.80 - 2.05 (m, 2H), 1.39 - 
1.65 (m, 4H); 13C NMR (126 MHz, MeOH-d4) δ 174.3, 169.4, 167.5, 165.5, 131.4, 131.3, 116.6, 




General procedure D from N2-(3-fluorobenzoyl)-N6,N6-dimethyl-L-lysinate (167 mg, 0.565 
mmol) and 2-aminonitrile bisulfate (433 mg, 2.83 mmol). Purification by FC (10-15% 
MeOH:DCM+ 1%TEA) followed by prep TLC 10%MeOH:DCM + 1%TEA gave (S)-N-(1-
((cyanomethyl)amino)-6-(dimethylamino)-1-oxohexan-2-yl)-3-fluorobenzamide. (Yield not 
calcd <5%) HPLC: Rt=3.942; 1H NMR (400 MHz, MeOH-d4) δ 7.72 (d, J = 7.83 Hz, 1H), 7.63 
(d, J = 9.78 Hz, 1H), 7.46 - 7.53 (m, 1H), 7.26 - 7.35 (m, 1H), 4.56 (dd, J = 5.48, 9.00 Hz, 1H), 
4.12 - 4.25 (m, 2H), 2.93 (t, J = 7.83 Hz, 2H), 2.71 (s, 6H), 1.93 - 2.03 (m, 1H), 1.82 - 1.90 (m, 





General procedure B from 3-(dimethylamino)benzoic acid (200 mg, 1.211 mmol) and methyl 
(S)-2-amino-2-cyclohexylacetate (249 mg, 1.453 mmol) was directly followed by General 
procedure C and General procedure D from (S)-2-cyclohexyl-2-(3-(dimethylamino) 
benzamido)acetic acid (96 mg, 0.315 mmol) and 2-aminoacetonitrile bisulfate (241 mg, 1.577 
mmol) to afford (S)-N-(2-((cyanomethyl)amino)-1-cyclohexyl-2-oxoethyl)-3-(dimethylamino) 
benzamide (95 mg, 0.277 mmol, 88 % yield); 1H NMR (400 MHz, (400 MHz, MeOH-d4) δ 7.23 
- 7.31 (m, 1H), 7.19 (s, 1H), 7.12 (d, J = 7.43 Hz, 1H), 6.92 (dd, J = 1.96, 8.22 Hz, 1H), 4.36 (d, 
J = 8.61 Hz, 1H), 4.23 (d, J = 17.61 Hz, 1H), 4.12 (d, J = 17.22 Hz, 1H), 2.92 - 3.03 (m, 6H), 
1.83 - 1.95 (m, 2H), 1.78 (d, J = 10.96 Hz, 2H), 1.69 (br. s., 2H), 1.06 - 1.36 (m, 5H); 13C NMR 
(101 MHz, (400 MHz, MeOH-d4) δ 174.5, 171.4, 152.3, 132.0, 130.1, 117.6, 117.1, 112.9, 
112.6, 111.6, 60.2, 41.3, 40.8, 39.2, 38.9, 38.1, 28.0; MS (ESI+) m/z: 343.2129 [M+H]+ 
 
(S)-3-Cyclohexyl-2-(3-(trifluoromethyl)benzamido)propanoate  
General procedure B from 3-(trifluoromethyl)benzoic acid (94 mg, 0.496 mmol) and methyl (S)-
2-amino-3-cyclohexylpropanoate, HCl (100 mg, 0.451 mmol) gave methyl (S)-3-cyclohexyl-2-
(3-(trifluoromethyl)benzamido)propanoate (150 mg, 0.420 mmol, 93 % yield); 1H NMR (500 
MHz, MeOH-d4) δ 8.18 (s, 1H), 8.12 (d, J = 7.83 Hz, 1H), 7.87 (d, J = 7.83 Hz, 1H), 7.70 (t, J = 
7.83 Hz, 1H), 4.68 - 4.77 (m, 1H), 3.74 (s, 3H), 1.85 (d, J = 12.72 Hz, 1H), 1.70 - 1.81 (m, 5H), 
1.62 - 1.69 (m, 1H), 1.39 - 1.49 (m, 1H), 1.34 - 1.39 (m, 1H), 1.27 - 1.34 (m, 1H), 1.17 - 1.22 (m, 
1H), 0.91 - 1.08 (m, 2H) 
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(S)-3-Cyclohexyl-2-(3-(trifluoromethyl)benzamido)propanoic acid  
General procedure C from methyl (S)-3-cyclohexyl-2-(3-(trifluoromethyl)benzamido)propanoate 
(150 mg, 0.420 mmol) gave (S)-3-cyclohexyl-2-(3-(trifluoromethyl)benzamido)propanoic acid 
(131 mg, 0.382 mmol, 91 % yield); 1H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 7.83 Hz, 1H), 
8.23 (s, 1H), 8.19 (d, J = 7.83 Hz, 1H), 7.87 - 7.96 (m, 1H), 7.68 - 7.79 (m, 1H), 4.43 - 4.57 (m, 
1H), 1.70 - 1.79 (m, 2H), 1.60 - 1.70 (m, 4H), 1.58 (br. s., 1H), 1.31 - 1.44 (m, 1H), 1.07 - 1.26 




General procedure D from (S)-3-cyclohexyl-2-(3-(trifluoromethyl)benzamido)propanoic acid (50 
mg, 0.146 mmol) and 2-aminoacetonitrile bisulfate (89 mg, 0.583 mmol) gave (S)-N-(1-
((cyanomethyl)amino)-3-cyclohexyl-1-oxopropan-2-yl)-3-(trifluoromethyl)benzamide (50 mg, 
0.131 mmol, 90 % yield); HPLC Rt: 7.276 min; 1H NMR (500 MHz, MeOH-d4) δ 8.22 (s, 1H), 
8.14 (d, J = 7.83 Hz, 1H), 7.87 (d, J = 7.83 Hz, 1H), 7.69 (t, J = 7.58 Hz, 1H), 4.67 (dd, J = 5.87, 
9.78 Hz, 1H), 4.13 - 4.23 (m, 2H), 1.85 (d, J = 12.72 Hz, 1H), 1.71 - 1.81 (m, 5H), 1.68 (br. s., 
1H), 1.36 - 1.49 (m, 1H), 1.27 - 1.35 (m, 1H), 1.21 - 1.26 (m, 2H), 0.93 - 1.09 (m, 2H); 13C NMR 
(126 MHz, MeOH-d4) δ 175.4, 168.9, 136.3, 132.4, 130.7, 129.5, 125.7, 125.7, 117.6, 53.2, 40.2, 
35.8, 34.9, 33.5, 28.2, 27.7, 27.5, 27.4; MS (ESI+) m/z: 404.1558 [M+H]+ 
 
Methyl (S)-3-cyclohexyl-2-(3-fluorobenzamido)propanoate  
General procedure B from 3-fluorobenzoic acid (69.5 mg, 0.496 mmol) and methyl (S)-2-amino-
3-cyclohexylpropanoate, HCl (110 mg, 0.500 mmol) Gave methyl (S)-3-cyclohexyl-2-(3-
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fluorobenzamido)propanoate (200 mg, 0.651 mmol, 144 % yield); 1H NMR (500 MHz, MeOH-
d4) δ 7.69 (d, J = 7.83 Hz, 1H), 7.59 (d, J = 9.29 Hz, 1H), 7.45 - 7.55 (m, 1H), 7.30 (dt, J = 1.96, 
8.31 Hz, 1H), 4.70 (dd, J = 5.87, 9.29 Hz, 1H), 3.74 (s, 3H), 1.84 (d, J = 12.23 Hz, 1H), 1.69 - 
1.80 (m, 5H), 1.61 - 1.69 (m, 1H), 1.35 - 1.48 (m, 1H), 1.24 - 1.33 (m, 2H), 1.16 - 1.22 (m, 1H), 
0.89 - 1.09 (m, 2H) 
 
(S)-3-Cyclohexyl-2-(3-fluorobenzamido)propanoic acid  
General procedure C from  methyl (S)-3-cyclohexyl-2-(3-fluorobenzamido)propanoate (140 mg, 
0.455 mmol) gave (S)-3-cyclohexyl-2-(3-fluorobenzamido)propanoic acid (134 mg, 0.457 mmol, 
100 % yield); 1H NMR (500 MHz, DMSO-d6) δ 8.67 (d, J = 7.34 Hz, 1H), 7.75 (d, J = 6.85 Hz, 
1H), 7.69 (d, J = 9.29 Hz, 1H), 7.54 (br. d, J = 6.40 Hz, 1H), 7.34 - 7.44 (m, 1H), 4.46 (br. s., 
1H), 1.73 (d, J = 10.27 Hz, 2H), 1.65 (br. s., 4H), 1.59 (br. s., 1H), 1.38 (br. s., 1H), 1.05 - 1.28 




General procedure D from (S)-3-cyclohexyl-2-(3-fluorobenzamido)propanoic acid (50 mg, 0.170 
mmol and 2-aminoacetonitrile bisulfate (104 mg, 0.682 mmol) gave (S)-N-(1-((cyanomethyl) 
amino)-3-cyclohexyl-1-oxopropan-2-yl)-3-fluorobenzamide (37 mg, 0.112 mmol, 65.5 % yield); 
1H NMR (500 MHz, MeOH-d4) δ 7.70 (d, J = 7.34 Hz, 1H), 7.61 (d, J = 9.78 Hz, 1H), 7.45 - 
7.54 (m, 1H), 7.29 (t, J = 7.83 Hz, 1H), 4.65 (q, J = 7.34 Hz, 1H), 4.09 - 4.27 (m, 2H), 1.83 (d, J 
= 12.23 Hz, 1H), 1.68 - 1.80 (m, 5H), 1.67 (br. s., 1H), 1.41 (br. s., 1H), 1.23 - 1.34 (m, 2H), 
1.14 - 1.21 (m, 1H), 0.90 - 1.08 (m, 2H); 13C NMR (126 MHz, MeOH-d4) δ 175.6, 169.1, 165.2, 
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163.2, 131.7, 131.6, 124.6, 124.6, 119.9, 119.7, 117.6, 115.8, 115.6, 53.2, 40.3, 35.8, 34.9, 33.5, 
28.3, 27.7, 27.5, 27.3; MS (ESI+) m/z: 354.1589 [M+H]+ 
 
Methyl (S)-3-cyclohexyl-2-(3-(dimethylamino)benzamido)propanoate 
General procedure B from methyl (S)-2-amino-3-cyclohexylpropanoate (100 mg, 0.540 mmol) 
and 3-(dimethylamino)benzoic acid (98 mg, 0.594 mmol) gave methyl (S)-3-cyclohexyl-2-(3-
(dimethylamino)benzamido)propanoate (175 mg, 0.526 mmol, 98 % yield); 1H NMR (500 MHz, 
MeOH-d4) δ 7.28 (t, J = 7.83 Hz, 1H), 7.22 (s, 1H), 7.15 (d, J = 7.34 Hz, 1H), 6.94 (dd, J = 2.45, 
8.31 Hz, 1H), 4.70 (dd, J = 5.38, 9.78 Hz, 1H), 3.74 (s, 3H), 2.98 (s, 6H), 1.85 (d, J = 12.72 Hz, 
1H), 1.70 - 1.80 (m, 5H), 1.63 - 1.69 (m, 1H), 1.39 - 1.50 (m, 1H), 1.32 - 1.35 (m, 1H), 1.29 (dd, 
J = 2.93, 9.78 Hz, 1H), 1.17 - 1.23 (m, 1H), 0.89 - 1.08 (m, 2H) 
 
(S)-3-Cyclohexyl-2-(3-(dimethylamino)benzamido)propanoic acid 
General procedure C from methyl (S)-3-cyclohexyl-2-(3-(dimethylamino)benzamido)propanoate 
(175 mg, 0.526 mmol) gave (S)-3-cyclohexyl-2-(3-(dimethylamino)benzamido)propanoic acid 




General procedure D from (S)-3-cyclohexyl-2-(3-(dimethylamino)benzamido)propanoic acid (75 
mg, 0.236 mmol) and 2-aminoacetonitrile bisulfate (144 mg, 0.942 mmol). Purified on reverse 
phase C-18 (10-50% ACN in H2O+ 0.1% TFA) to afford (S)-N-(1-((cyanomethyl)amino)-3-
cyclohexyl-1-oxopropan-2-yl)-3-(dimethylamino)benzamide (50 mg, 0.140 mmol, 59.6 % yield); 
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HPLC Rt=5.561 min; 1H NMR (500 MHz, MeOH-d4) δ 8.00 (s, 1H), 7.85 (d, J = 7.34 Hz, 1H), 
7.67 (d, J = 7.83 Hz, 1H), 7.61 (t, J = 8.31 Hz, 1H), 4.67 (dd, J = 5.38, 9.78 Hz, 1H), 4.18 (dd, J 
= 18.10, 22.99 Hz, 2H), 3.26 (s, 6H), 1.69 - 1.88 (m, 6H), 1.67 (br. s., 1H), 1.38 - 1.49 (m, 1H), 
1.16 - 1.33 (m, 3H), 0.92 - 1.08 (m, 2H); 13C NMR (126 MHz, MeOH-d4) δ 175.6, 169.0, 146.3, 
137.3, 131.7, 127.1, 123.2, 119.4, 117.7, 53.3, 45.8, 40.3, 35.7, 34.9, 33.5, 28.3, 27.7, 27.5, 27.3 
 
Methyl (morpholine-4-carbonyl)-L-leucinate 
To a dry rb flask was added, methyl L-leucinate, HCl (250 mg, 1.376 mmol) and DCM (3 ml). 
solution was cooled to 0°C then morpholine-4-carbonyl chloride (0.161 ml, 1.376 mmol) and 
DIPEA (0.481 ml, 2.75 mmol) were added.  The reaction was allowed to warm to rt and left to 
stir under nitrogen overnight. Reaction was diluted 3x with DCM and washed with 1N HCl then 
brine, dried over mgso4, and conc to afford methyl (morpholine-4-carbonyl)-L-leucinate (240 
mg, 0.929 mmol, 67.5 % yield) as a white solid.; 1H NMR (500 MHz, CDCl3) δ 4.52 (s, 1H), 
3.72 (s, 3H), 3.66 - 3.70 (m, 4H), 3.31 - 3.43 (m, 4H), 1.58 - 1.74 (m, 2H), 1.47 - 1.55 (m, 1H), 
0.95 (d, J = 2.93 Hz, 3H), 0.94 (d, J = 3.42 Hz, 3H)  
 
(Morpholine-4-carbonyl)-L-leucine  
General procedure C from methyl (morpholine-4-carbonyl)-L-leucinate (200 mg, 0.774 mmol) 







General procedure D from (morpholine-4-carbonyl)-L-leucine (125 mg, 0.512 mmol) gave (S)-
N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)morpholine-4-carboxamide.; 1H NMR 
(400 MHz, MeOH-d4) δ 4.29 (dd, J = 5.28, 9.98 Hz, 1H), 4.08 - 4.20 (m, 2H), 3.57 - 3.71 (m, 
4H), 3.32 - 3.48 (m, 4H), 1.49 - 1.76 (m, 3H), 0.96 (d, J = 6.26 Hz, 3H), 0.93 (d, J = 6.26 Hz, 
3H); 13C NMR (101 MHz, MeOH-d4) δ 176.8, 159.8, 117.7, 67.7, 54.6, 45.4, 41.9, 28.2, 26.1, 
23.6, 22.0; MS (ESI+) m/z: 283.1766 [M+H]+ 
 
Methyl (S)-2-isocyanato-4-methylpentanoate  
To a mixture of L-leucine methyl ester hydrochloride (3.62 g, 20 mmol) in saturated NaHCO3 
(72 mL) and DCM (72 mL) was added triphosgene (1.96 g, 6.6 mmol). The reaction mixture was 
vigorously stirred under ice-water bath for 1 h and the organic layer was collected. The water 
layer was extracted with DCM for three times and the organic phase was combined and dried 
with MgSO4. After the solvent removed under vacuum, the residue was dissolved in DCM (20 
mL). This solution was then added to corresponding ortho-substituted anilines or benzylamines 
(21 mmol) in DCM (80 mL) under ice bath. The reaction mixture was stirred at room 
temperature for 12 h and then the solvent was removed under low pressure. The residue was 
taken up with ethyl acetate (100 mL) and washed with 1 N HCl (30 mL) and brine (30 mL). The 
organic phase was dried with MgSO4. After the solvent removed, the residue without 
purification was directly added to a solution of potassium hydroxylamine (8.37 g, 56 mmol) in 
methanol (20 mL). The reaction mixture was stirred at room temperature for 1 h and then 
removed methanol under low pressure. The residue was taken up with 1 N HCl and extracted 
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with ethyl acetate. The organic phase was washed with brine and dried with MgSO4. After the 
solvent removed under low pressure, the residue was separated by silica gel column 
chromatography to afford desired product. Carried directly to next step without further 
purification. 
 
Methyl (4-methylpiperazine-1-carbonyl)-L-leucinate  
methyl (S)-2-isocyanato-4-methylpentanoate (0.942 g, 5.50 mmol) was dissolved in DCM (20 
ml) and the solution was cooled to 0°C. 1-methylpiperazine (0.671 ml, 6.05 mmol) was then 
added and reaction was allowed to warm to rt over 2.5 hours. Reaction was conc. in vacuo and 
purified on silica gel via chromatography w/ 5%MeOH in DCM +1% triethylamine to afford 
methyl (4-methylpiperazine-1-carbonyl)-L-leucinate (1.1 g, 4.05 mmol, 73.7 % yield); 1H NMR 
(500 MHz, MeOH-d4) δ 4.32 (dd, J = 5.14, 10.03 Hz, 1H), 3.69 (s, 3H), 3.40 - 3.55 (m, 4H), 2.35 
- 2.47 (m, 4H), 2.30 (s, 3H), 1.61 - 1.76 (m, 2H), 1.51 - 1.60 (m, 1H), 0.92 (d, J = 6.36 Hz, 3H), 
0.96 (d, J = 6.85 Hz, 3H) 
 
(4-Methylpiperazine-1-carbonyl)-L-leucine 
General procedure C from methyl (4-methylpiperazine-1-carbonyl)-L-leucinate (250 mg, 0.921 
mmol) gave (4-methylpiperazine-1-carbonyl)-L-leucine (237 mg, 0.921 mmol, 100 % yield). 







General procedure D from (4-methylpiperazine-1-carbonyl)-L-leucine (237 mg, 0.921 mmol) 
and 2-aminoacetonitrile bisulfate (169 mg, 1.105 mmol). Purified  via silica gel column, 5-10% 
MeOH:DCM gradient + 1% TEA. Desired compound came out during the final wash w/ 10% 
MeOH to afford (S)-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)-4-
methylpiperazine-1-carboxamide (100 mg, 0.339 mmol, 36.8 % yield);  1H NMR (500 MHz, 
MeOH-d4) δ 4.23 - 4.32 (m, 1H), 4.17 (d, J = 18.10 Hz, 1H), 4.12 (d, J = 18.59 Hz, 1H), 3.63 
(br. s., 4H), 2.94 (br. s., 4H), 2.66 (s, 3H), 1.61 - 1.79 (m, 2H), 1.50 - 1.61 (m, 1H), 0.97 (d, J = 
5.38 Hz, 3H), 0.93 (d, J = 5.38 Hz, 3H); 13C NMR (126 MHz, MeOH-d4) δ 176.7, 159.1, 117.8, 
54.9, 54.8, 44.8, 43.4, 41.8, 28.2, 26.1, 23.6, 22.0 
 
(S)-N-(1-((Cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)nicotinamide (259041) 
General procedure B from nicotinic acid (407 mg, 3.30 mmol) and methyl L-leucinate, HCl (500 
mg, 2.75 mmol) gave methyl nicotinoyl-L-leucinate (600 mg, 2.397 mmol, 87 % yield). Next, 
General procedure C from methyl nicotinoyl-L-leucinate (600 mg, 2.397 mmol) gave nicotinoyl-
L-leucine (566 mg, 2.396 mmol, 100 % yield). Finally, General procedure D from nicotinoyl-L-
leucine (250 mg, 1.058 mmol) and 2-aminoacetonitrile bisulfate (324 mg, 2.116 mmol) followed 
by purification by FC (1-10% MeOH in DCM +1%TEA) gave (S)-N-(1-((cyanomethyl)amino)-
4-methyl-1-oxopentan-2-yl)nicotinamide (130 mg, 0.474 mmol, 44.8 % yield); 1H NMR (400 
MHz, MeOH-d4) δ 9.01 (s, 1H), 8.69 (d, J = 3.91 Hz, 1H), 8.26 - 8.31 (m, 1H), 7.54 (dd, J = 
5.09, 7.43 Hz, 1H), 4.64 (dd, J = 4.50, 9.98 Hz, 1H), 4.20 (d, J = 17.61 Hz, 1H), 4.15 (d, J = 
17.61 Hz, 1H), 1.61 - 1.85 (m, 2H), 1.34 - 1.39 (m, 1H), 0.99 (d, J = 5.87 Hz, 3H), 0.97 (d, J = 
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5.87 Hz, 3H);  13C NMR (101 MHz, MeOH-d4) δ 175.3, 168.1, 152.9, 149.5, 137.4, 131.6, 125.2, 
117.6, 53.8, 41.6, 28.2, 26.2, 23.5, 22.0; MS (ESI+) m/z: 275.1566 [M+H]+ 
 
(S)-N-(1-((Cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)isonicotinamide (262467) 
General procedure B from isonicotinic acid (254 mg, 2.066 mmol) and methyl L-leucinate (250 
mg, 1.722 mmol) gave methyl isonicotinoyl-L-leucinate (415 mg, 1.658 mmol, 96 % yield). 
Next General procedure C from methyl isonicotinoyl-L-leucinate (415 mg, 1.658 mmol) gave 
isonicotinoyl-L-leucine (392 mg, 1.659 mmol, 100 % yield). Finally, General procedure D from  
isonicotinoyl-L-leucine (392 mg, 1.659 mmol) and 2-aminoacetonitrile bisulfate (508 mg, 3.32 
mmol) gave (S)-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)isonicotinamide (360 
mg, 1.312 mmol, 79 % yield); 1H NMR (500 MHz, MeOH-d4) δ 8.68 (d, J = 4.89 Hz, 2H), 7.81 
(d, J = 5.87 Hz, 2H), 4.65 (dd, J = 4.89, 10.27 Hz, 1H), 4.21 (d, J = 17.61 Hz, 1H), 4.17 (d, J = 
17.61 Hz, 1H), 1.64 - 1.84 (m, 3H), 0.99 (d, J = 5.87 Hz, 3H), 0.96 (d, J = 5.87 Hz, 3H);  13C 
NMR (126 MHz, MeOH-d4) δ 175.1, 168.0, 151.0, 143.3, 123.2, 117.6, 53.8, 41.6, 28.3, 26.2, 
23.5, 22.0; MS (ESI+) m/z: 275.1504 [M+H]+ 
 
Benzyl (S)-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate  
General procedure D from ((benzyloxy)carbonyl)-L-leucine (2 g, 7.54 mmol) and 2-
aminoacetonitrile bisulfate (2.309 g, 15.08 mmol) gave benzyl (S)-(1-((cyanomethyl)amino)-4-
methyl-1-oxopentan-2-yl)carbamate (1.5 g, 4.94 mmol, 65.6 % yield) as a white solid.; 1H NMR 
(500 MHz, MeOH-d4) δ 7.23 - 7.44 (m, 5H), 5.04 - 5.16 (m, 2H), 4.04 - 4.20 (m, 3H), 1.62 - 1.78 




In a dry rb flask under nitrogen, benzyl (S)-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate (600 mg, 1.978 mmol) was dissolved into acetonitrile (10 ml). Palladium on carbon 
5% (421 mg, 0.198 mmol) was added to the solution. Nitrogen was removed by vacuum (water 
asiprator) and vessel was fixed with a hydrogen balloon. Reaction was stirred at rt for 2h, at 
which time HPLC indicated reaction was complete. Hydrogen was removed, and vessel was 
purged w/ nitrogen. Solution was filtered through celite and washed 2x with CAN to afford (S)-
2-amino-N-(cyanomethyl)-4-methylpentanamide (335 mg, 1.978 mmol, 100 % yield) carried 




After filtering (S)-2-amino-N-(cyanomethyl)-4-methylpentanamide (100 mg, 0.591 mmol) into a 
new flask, post-debenzylation rxn, 4-chloro-2-methoxybenzoic acid (110 mg, 0.591 mmol), 
HATU (337 mg, 0.886 mmol), and DIPEA (0.258 ml, 1.477 mmol) were added to the solution 
and left to stir under nitrogen at rt overnight. Solvent was removed via rotovap, and crude 
residue was dissolved into EtOAc (10mL) and washed 2x each with 1N HCl, Sat. NaHCO3 (aq), 
and brine. dried over mgso4 and concentrated onto silica gel. Purified via biotage 30-50% 
EtOAc:Hex gradient to afford (S)-4-Chloro-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-
2-yl)-2-methoxybenzamide (Yield not calcd); 1H NMR (500 MHz, DMSO-d6) δ 7.87 (d, J = 7.83 
Hz, 1H), 7.21 (s, 1H), 7.08 (d, J = 8.31 Hz, 1H), 4.59 - 4.68 (m, 1H), 4.20 (d, J = 17.61 Hz, 1H), 
4.16 (d, J = 17.61 Hz, 1H), 4.00 (s, 3H), 1.61 - 1.82 (m, 3H), 1.00 (d, J = 6.85 Hz, 3H), 0.98 (d, J 
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= 6.36 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 175.2, 167.1, 159.9, 140.1, 133.6, 122.4, 




After filtering (S)-2-amino-N-(cyanomethyl)-4-methylpentanamide (100 mg, 0.591 mmol) into a 
new flask after the debenzylation rxn, 2-chloro-4-methoxybenzoic acid (110 mg, 0.591 mmol), 
HATU (337 mg, 0.886 mmol), and DIPEA (0.258 ml, 1.477 mmol) were added to the solution 
and left to stir under nitrogen at rt overnight. Solvent was removed via rotovap, and crude 
residue was dissolved into EtOAc (10mL) and washed 2x each with 1N HCl, Sat. NaHCO3 (aq), 
and brine. dried over mgso4 and concentrated onto silica gel. Purified via biotage 30-50% 
EtOAc:Hex gradient to afford (S)-2-chloro-N-(1-((cyanomethyl)amino)-4-methyl-1-oxopentan-
2-yl)-4-methoxybenzamide (Yield not calcd); 1H NMR (500 MHz, MeOH-d4) δ 7.48 (d, J = 8.80 
Hz, 1H), 7.00 (d, J = 1.96 Hz, 1H), 6.94 (dd, J = 2.45, 8.80 Hz, 1H), 4.57 (dd, J = 5.14, 10.03 
Hz, 1H), 4.21 (d, J = 17.61 Hz, 1H), 4.17 (d, J = 17.61 Hz, 1H), 3.83 (s, 3H), 1.75 - 1.84 (m, 
1H), 1.67 - 1.75 (m, 1H), 1.58 - 1.66 (m, 1H), 0.98 (d, J = 6.36 Hz, 6H); 13C NMR (126 MHz, 
MeOH-d4) δ 175.1, 170.0, 163.0, 133.2, 131.6, 128.8, 117.6, 116.6, 113.8, 56.4, 53.7, 41.6, 28.2, 




General procedure D from (S)-2-(3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxamido)-3-(m-
tolyl)propanoic acid (137 mg, 0.399 mmol) and prop-2-yn-1-amine (0.077 ml, 1.197 mmol) gave 
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(S)-3-(tert-butyl)-1-methyl-N-(1-oxo-1-(prop-2-yn-1-ylamino)-3-(m-tolyl)propan-2-yl)-1H-
pyrazole-5-carboxamide (85 mg, 0.223 mmol, 56.0 % yield). 1H NMR (400 MHz, MeOH-d4) δ 
7.11 - 7.18 (m, 1H), 7.09 (s, 1H), 7.01 (d, J = 7.43 Hz, 1H), 7.05 (d, J = 7.83 Hz, 1H), 6.61 (s, 
1H), 4.72 (dd, J = 5.87, 9.39 Hz, 1H), 3.96 (d, J = 1.96 Hz, 2H), 3.90 (s, 3H), 3.18 (dd, J = 5.87, 
13.69 Hz, 1H), 2.93 (dd, J = 9.39, 13.69 Hz, 1H), 2.59 (t, J = 2.35 Hz, 1H), 2.28 (s, 3H), 1.28 (s, 
9H);  13C NMR (101 MHz, MeOH-d4) δ 173.4, 162.0, 161.7, 139.2, 138.5, 136.9, 131.4, 129.6, 




In a dry rb flask under nitrogen, methyl L-leucinate, HCl (200 mg, 1.101 mmol), 2,2,2-trifluoro-
1-phenylethan-1-one (155 µl, 1.101 mmol), potassium carbonate (304 mg, 2.202 mmol) were 
heated to reflux in anhydrous MeOH overnight. Reaction was cooled to rt, filtered through celite, 
wash with MeOH, and concentrated to afford potassium (S,Z)-4-methyl-2-((2,2,2-trifluoro-1-
phenylethylidene)amino)pentanoate (358 mg, 1.101 mmol, 100 % yield). Carried directly to next 
step without further purification. 
 
((S)-2,2,2-trifluoro-1-phenylethyl)-L-leucine  
Potassium (S,Z)-4-methyl-2-((2,2,2-trifluoro-1-phenylethylidene)amino)pentanoate (896 mg, 
2.75 mmol) was dissolved with ~1mL anhydrous MeOH and diluted with 10mL or ACN to form 
a white slurry. Vessel was placed under nitrogen and cooled to -40°C in ACN dry ice bath. Zinc 
borohydride (3305 µl, 3.30 mmol) in Et2O was added dropwise via addition cannula under a 
flow on nitrogen. Reaction was stirred for 2-4h are -40°C then allowed to warm to rt. 
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rxn was quenched slowly using 1N HCl. More 1N HCl was added and compound was extracted 
with EtOAc 3x. Organic layer was dried over MgSO4 and concentrated to afford ((S)-2,2,2-
trifluoro-1-phenylethyl)-L-leucine (743 mg, 2.57 mmol, 93 % yield)  dr = 1:3 (1-R,S : 3-S,S); 1H 
NMR (500 MHz, MeOH-d4) δ 7.35 - 7.51 (m, 5H), 4.99 - 5.08 (m, 1H), 4.31 (d, J = 7.34 Hz, 
1H), 4.19 (q, J = 7.34 Hz, 1H), 4.10 (q, J = 7.34 Hz, 1H), 3.46 (t, J = 6.85 Hz, 1H), 1.98 - 2.03 
(m, 1H), 1.91 (td, J = 6.79, 13.33 Hz, 1H), 1.45 - 1.54 (m, 2H), 1.23 (t, J = 7.09 Hz, 1H), 0.91 - 
0.98 (m, 3H), 0.88 (d, J = 6.85 Hz, 1H), 0.74 (d, J = 6.85 Hz, 1H); 19F NMR MeOH-d4) δ ppm -




General procedure D from ((S)-2,2,2-trifluoro-1-phenylethyl)-L-leucine (190 mg, 0.657 mmol) 
and 2-aminoacetonitrile bisulfate (201 mg, 1.314 mmol) gave (S)-N-(cyanomethyl)-4-methyl-2-
(((S)-2,2,2-trifluoro-1-phenylethyl)amino)pentanamide (200 mg, 0.611 mmol, 93 % yield) 
dr=1:3); 1H NMR (500 MHz, MeOH-d4) δ 7.33 - 7.44 (m, 5H), 4.16 (s, 1H), 3.98 (dd, J = 17.61, 
30.32 Hz, 2H), 3.33 - 3.44 (m, 1H), 1.74 - 1.86 (m, 1H), 1.46 - 1.54 (m, 1H), 1.37 - 1.46 (m, 1H), 
0.94 (dd, J = 2.69, 6.60 Hz, 6H); MS (ESI+) m/z: 328.1634 [M+H]+ 
 
((R)-2,2,2-Trifluoro-1-phenylethyl)-L-leucine 
Potassium (S,Z)-4-methyl-2-((2,2,2-trifluoro-1-phenylethylidene)amino)pentanoate (358 mg, 
1.100 mmol) was suspended in 5ml THF and added to dry rb flask charged with sodium 
tetrahydroborate (333 mg, 8.80 mmol). 5mL of water:THF (v/v:2/8) was added via syringe pump 
over 3h. 1N HCl was added and rxn was extracted with EtOAc 3x. Organic layer was washed 
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with bicarb and brine, dried over MgSO4, and concentrated to afford ((R)-2,2,2-trifluoro-1-




General procedure D from ((R)-2,2,2-trifluoro-1-phenylethyl)-L-leucine (135 mg, 0.467 mmol) 
and 2-aminoacetonitrile bisulfate (143 mg, 0.933 mmol gave (S)-N-(cyanomethyl)-4-methyl-2-
(((R)-2,2,2-trifluoro-1-phenylethyl)amino)pentanamide. dr = 1:15 (S,S : R,S), (yield not calcd).; 
1H NMR (400 MHz, MeOH-d4) δ 7.43 - 7.51 (m, 2H), 7.34 - 7.43 (m, 3H), 4.15 (s, 2H), 4.06 - 
4.14 (m, 1H), 3.00 (dd, J = 5.28, 8.80 Hz, 1H), 1.62 - 1.78 (m, 1H), 1.41 - 1.53 (m, 1H), 1.26 - 
1.39 (m, 1H), 0.86 (d, J = 6.65 Hz, 3H), 0.71 (d, J = 6.65 Hz, 3H); 13C NMR (101 MHz, MeOH-
d4) δ 177.6, 135.1, 130.5, 130.1, 129.7, 117.7, 64.1, 59.2, 44.2, 27.9, 25.8, 23.5, 22.3; MS (ESI+) 




In a dry round bottom flask under nitrogen, methyl L-leucinate, HCl (130 mg, 0.716 mmol), 
2,2,2-trifluoro-1-(3-fluorophenyl)ethan-1-one (100 µl, 0.716 mmol), and potassium carbonate 
(198 mg, 1.431 mmol) were heated to reflux in anhydrous MeOH overnight. Reaction was 
cooled to rt, filtered through celite, wash with MeOH, and concentrated to afford potassium 
(S,Z)-4-methyl-2-((2,2,2-trifluoro-1-(3-fluorophenyl)ethylidene)amino)pentanoate (246 mg, 




A dry round bottom flask was charged with sodium tetrahydroborate (16.53 mg, 0.437 mmol) 
and THF (3 ml) was then added. Potassium (S,Z)-4-methyl-2-((2,2,2-trifluoro-1-(3-
fluorophenyl)ethylidene)amino)pentanoate (150 mg, 0.437 mmol) was dissolved into THF:H2O 
(10:1) and added via syringe pump over 2h at rt. Reaction was quenched with 1N HCl and THF 
was removed in vacuo. Extracted w/ EtOAc 3x, washed organic layer 2x with 1N HCl and brine, 
dried over mgso4 and conc to afford ((R)-2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)-L-leucine (120 
mg, 0.391 mmol, 89 % yield) and an off-white/yellow crystaline solid.; 1H NMR (500 MHz, 
MeOH-d4) δ 7.35 - 7.43 (m, 1H), 7.22 - 7.29 (m, 2H), 7.13 (t, J = 8.80 Hz, 1H), 4.35 (q, J = 7.01 
Hz, 1H), 2.95 (dd, J = 5.38, 8.80 Hz, 1H), 1.79 - 1.94 (m, 1H), 1.38 - 1.54 (m, 2H), 0.88 (d, J = 




((R)-2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)-L-leucine (120 mg, 0.391 mmol), 2-
aminoacetonitrile bisulfate (120 mg, 0.781 mmol), DIPEA (0.205 ml, 1.172 mmol), HATU (163 
mg, 0.430 mmol) gave (S)-N-(cyanomethyl)-4-methyl-2-(((R)-2,2,2-trifluoro-1-(3-
fluorophenyl)ethyl)amino)pentanamide. (yield not calcd) 1:12 dr (S,S:R,S) by 18F-NMR; 1H 
NMR (500 MHz, MeOH-d4) δ 7.43 (s, 1H), 7.24 - 7.31 (m, 2H), 7.15 (dt, J = 1.96, 8.31 Hz, 1H), 
4.17 - 4.22 (m, 1H), 4.17 (s, 2H), 3.01 (dd, J = 5.14, 9.05 Hz, 1H), 1.73 (td, J = 6.85, 13.69 Hz, 
1H), 1.48 (ddd, J = 5.62, 8.80, 13.94 Hz, 1H), 1.36 (ddd, J = 5.38, 8.31, 13.69 Hz, 1H), 0.87 (d, J 
= 6.36 Hz, 3H), 0.73 (d, J = 6.36 Hz, 3H); 13C NMR (126 MHz, MeOH-d4) δ 177.4, 165.4, 
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163.5, 137.9, 131.7, 126.4, 117.7, 117.3, 116.9, 63.9, 59.3, 44.1, 28.0, 25.8, 23.5, 22.2; HRMS 
(ESI+) m/z: 346.1541 [M+H]+ 
 
((S)-2,2,2-Trifluoro-1-(3-fluorophenyl)ethyl)-L-leucine (200 mg, 0.651 mmol, 91 % yield) 
Potassium (S,Z)-4-methyl-2-((2,2,2-trifluoro-1-(3-fluorophenyl)ethylidene)amino) pentanoate 
(246 mg, 0.716 mmol) was dissolved with ~1mL anhydrous MeOH and diluted with 10mL or 
ACN to form a white slurry. Vessel was placed under nitrogen and cooled to -40°C in ACN dry 
ice bath. Zinc Borohydride (3582 µl, 0.716 mmol) in Et2O was added dropwise via addition 
cannula under a flow on nitrogen. Reaction was stirred for 2-4h are -40°C then allowed to warm 
to rt. Reation was quenched slowly using 1N HCl. More 1N HCl was added and compound was 
extracted with EtOAc 3x. Organic layer was dried over MgSO4 and concentrated to afford ((S)-
2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)-L-leucine (200 mg, 0.651 mmol, 91 % yield). Dr = 2:1 
(S,S:R,S). Carried to final step. 1H NMR (400 MHz, MeOH-d4) δ 7.33 - 7.44 (m, 1H), 7.17 - 
7.30 (m, 2H), 6.99 - 7.16 (m, 1H), 5.05 (q, J = 7.04 Hz, 1H), 4.07 (q, J = 7.17 Hz, 1H), 1.92 - 
2.06 (m, 8H), 1.78 - 1.92 (m, 1H), 1.41 - 1.57 (m, 1H), 1.10 - 1.34 (m, 2H), 0.81 - 0.98 (m, 3H), 
0.66 - 0.78 (m, 1H); 19F NMR (MeOH-d4) δ ppm -115.08, (s) -114.38, (s), -79.62, -75.73 (s) -




General procedure D from ((S)-2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)-L-leucine (200 mg, 
0.651 mmol) and 2- aminoacetonitrile bisulfate (299 mg, 1.953 mmol) gave (S)-N-
(cyanomethyl)-4-methyl-2-(((S)-2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)amino)pentanamide 
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(yield not calcd) dr = 2:1 (S,S:R,S); 1H NMR (400 MHz, MeOH-d4) δ 7.40 (s, 1H), 7.24 - 7.30 
(m, 1H), 7.18 - 7.24 (m, 1H), 7.06 - 7.17 (m, 1H), 4.18 - 4.26 (m, 1H), 4.13 - 4.18 (m, 1H), 3.92 - 
4.07 (m, 2H), 1.66 - 1.87 (m, 1H), 1.29 - 1.56 (m, 2H), 0.92 (dd, J = 2.54, 6.46 Hz, 6H); 13C 
NMR (126 MHz, MeOH-d4) δ 177.5, 165.2, 163.2, 138.8, 131.6, 125.8, 117.5, 117.1, 116.7, 




General procedure D from ((S)-2,2,2-trifluoro-1-phenylethyl)-L-leucine (100 mg, 0.346 mmol) 
and 1-aminocyclopropane-1-carbonitrile, HCl (49.2 mg, 0.415 mmol) gave (S)-N-(1-
cyanocyclopropyl)-4-methyl-2-(((S)-2,2,2-trifluoro-1-phenylethyl)amino)pentanamide as a white 
solid. (Yield not calcd); dr= 3:1 (S,S:R,S) by 18F-NMR; 1H NMR (500 MHz, MeOH-d4) δ 7.34 - 
7.48 (m, 5H), 4.09 - 4.15 (m, 1H), 1.74 - 1.86 (m, 1H), 1.41 - 1.52 (m, 2H), 1.28 - 1.41 (m, 3H), 
1.14 - 1.21 (m, 1H), 0.90 - 0.97 (m, 6H); 13C NMR (126 MHz, MeOH-d4) δ 178.7, 136.6, 130.4, 
130.2, 129.9, 129.9, 129.8, 121.2, 64.9, 61.5, 44.2, 39.0, 26.0, 23.4, 22.6, 21.1, 17.0, 16.8; 




In a dry rb flask, 2,2,2-trifluoro-1-(4-fluorophenyl)ethan-1-one (500 mg, 2.60 mmol), methyl 
(S)-2-amino-4,4-dimethylpentanoate, HCl (560 mg, 2.86 mmol), potassium carbonate (899 mg, 
6.51 mmol) were added and refluxed overnight in anhydrous methanol. Reaction was cooled to 
rt, filtered through celite, washed with MeOH, and concentrated to afford potassium (R,E)-4,4-
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dimethyl-2-((2,2,2-trifluoro-1-(4-fluorophenyl)ethylidene)amino)pentanoate (930 mg, 2.60 




In a dry round bottom flask, zinc (II) chloride (709 mg, 5.20 mmol) freshly fused (3x) dissolved 
in DME (~10-15mL) and , sodium tetrahydroborate (394 mg, 10.41 mmol) was added and left at 
rt overnight. Potassium (R,E)-4,4-dimethyl-2-((2,2,2-trifluoro-1-(4-fluorophenyl)ethylidene) 
amino)pentanoate (930 mg, 2.60 mmol) was cooled to rt and filtered through  a plug of celite 
into a dry 250ml rb flask. ~80 mL dry ACN (dry over 3Å sieves) was then added. Vessel was 
cooled to -40°C in dry ice/ACN bath and fixed with dry addition funnel. The Zn(BH4)2 solution 
was cooled to -40, run through a plug of celite into the addition funnel and slowly added to the 
reaction mixture then washed through 2x w/ anhydrous ACN (2x 5-10mL each). The reaction 
was placed under nitrogen and left to stir at -40°C for 5h. ~5-10mL acetone was added and the 
reaction was left to warm to rt over 1hr. 1N HCl was slowly added to cloudy solution (became 
clear upon quench) and organic solvent was removed via rotovap. Extraction w/ EtOAc 3x, 
washed with brine, dried over MgSO4, and conc to afford potassium (S)-4,4-dimethyl-2-(((S)-
2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino)pentanoate (640 mg, 1.781 mmol, 68.4 % yield); 
40:1 dr (S,S:R,S) by 19F-NMR; 1H NMR (500 MHz, MeOH-d4) δ 7.45 (dd, J = 5.62, 8.07 Hz, 
2H), 7.10 (t, J = 8.56 Hz, 2H), 4.85 (br. s., 2H), 4.18 (q, J = 7.66 Hz, 1H), 3.49 (dd, J = 4.40, 
7.34 Hz, 1H), 1.62 (dd, J = 4.40, 14.18 Hz, 1H), 1.46 (dd, J = 7.34, 14.18 Hz, 1H), 1.00 (s, 9H); 






General procedure D from potassium (S)-4,4-dimethyl-2-(((S)-2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)amino)pentanoate (100 mg, 0.278 mmol) and 2-aminoacetonitrile bisulfate 
(128 mg, 0.835 mmol) gave (S)-N-(cyanomethyl)-4,4-dimethyl-2-(((S)-2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)amino)pentanamide (87.8 mg, 0.244 mmol, 88 % yield); 1H NMR (500 MHz, 
MeOH-d4) δ 7.43 (dd, J = 5.62, 7.58 Hz, 2H), 7.10 (t, J = 8.80 Hz, 2H), 4.13 (dd, J = 6.85, 14.67 
Hz, 1H), 4.00 (d, J = 17.10 Hz, 1H), 3.94 (d, J = 17.12 Hz, 1H), 3.40 (t, J = 6.11 Hz, 1H), 1.45 - 
1.56 (m, 2H), 0.99 (s, 9H); 13C NMR (126 MHz, MeOH-d4) δ 177.9, 177.9, 163.6, 164.5, 132.4, 




General procedure D from potassium (S)-4,4-dimethyl-2-(((S)-2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)amino)pentanoate (100 mg, 0.278 mmol) and 1-aminocyclopropane-1-
carbonitrile, HCl (99 mg, 0.835 mmol) gave (S)-N-(1-cyanocyclopropyl)-4,4-dimethyl-2-(((S)-
2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino)pentanamide (75 mg, 0.195 mmol, 69.9 % yield); 
1H NMR (500 MHz, MeOH-d4) δ 7.38 - 7.45 (m, 2H), 7.11 (t, J = 8.56 Hz, 2H), 4.10 (q, J = 7.50 
Hz, 1H), 3.32 - 3.37 (m, 1H), 1.48 (d, J = 5.90 Hz, 2H), 1.35 - 1.43 (m, 2H), 1.00 - 1.04 (m, 1H), 
0.98 (s, 9H), 0.80 - 0.90 (m, 1H); 13C NMR (126 MHz, MeOH-d4) δ 178.9, 164.7, 132.6, 131.9, 





The X-ray structure of TgCPL complexed with its propeptide (PDB: 3F75) was superposed with 
the X-ray structure of HsCPL complexed with AZ-12878478 (PDB 3HHA), using The 
Molecular Operating Environment (MOE), version 2008.10, Chemical Computing Group Inc., 
Montreal, Quebec, Canada. The X-ray structure of HsCPL and the propteptide chain of TgCPL 
were removed to generate the figures shown.  
 
 
TgCPL and HsCPL Inhibition Assay: Compound potency and selectivity was evaluated in 
vitro for both TgCPL and HsCPL activity in a fluorescence based assay by monitoring the 
hydrolysis of Cbz-Leu-Arg-aminomethylcoumarin (Z-L-R-AMC). Protein was expressed and 
purified as previously described. The substrate hydrolysis results in the release of fluorescent 7-
amino-4-methylcoumarin (AMC) that can be monitored spectrophotometrically with linear 
kinetics for up to 60 min. Inhibitors were serial diluted in DMSO in a 1-to-3 dilution, spanning at 
least 10 concentration points in either duplicate or triplicate. The enzyme was pre-incubated with 
the inhibitory compounds for 5 min at 23°C, followed by the addition of the AMC substrate. The 
assay final conditions had a total volume of 200 µL, consisting of 90 µL enzyme (conc.=50 
ng/mL ), 100 µL ZLR-AMC substrate (conc.= 80 µM), and 10 µL inhibitor or DMSO. The 
relative fluorescence of the AMC generation is measured over the course of 5 min (Excitation: 
380 nm, Emission: 460 nm). LHVS and DMSO were used as positive and negative controls, 
respectively. All dose response data was obtained with at least independent three replicates 
(n=3). Graphpad Prism software was used to visualize inhibition curves and calculate IC50 values 
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from the reaction mean ν. Assay final concentrations in each well: 40 µM ZLR-AMC, TgCPL or 
HsCPL (final conc= 0.0225 ng/µL). Assay Buffer: 100 mM NaAc, 2 mM EDTA, 900 mM NaCl, 
50 mM DTT. Substrate: Cbz-Leu-Arg-AMC (Bachem, purchased as HCl salt).  
 
Metabolic Stability in Mouse Liver Microsomes: The metabolic stability was assessed using 
CD-1 mouse liver microsomes. One micromolar of each compound was incubated with 0.5 
mg/mL microsomes and 1.7 mM cofactor -NADPH in 0.1 M phosphate buffer (pH = 7.4) 
containing 3.3 mM MgCl2 at 37 °C. The DMSO concentration was less than 0.1% in the final 
incubation system. At 0, 5, 10, 15, 30, 45, and 60 min of incubation, 40 µL of reaction mixture 
were taken out, and the reaction is quenched by adding 3-fold excess of cold acetonitrile 
containing 100 ng/mL of internal standard for quantification. The collected fractions were 
centrifuged at 15000 rpm for 10 min to collect the supernatant for LC−MS/ MS analysis, from 
which the amount of compound remaining was determined. The natural log of the amount of 
compound remaining was plotted against time to determine the disappearance rate and the half-
life of tested compounds.  
 
Pharmacokinetic Studies in Mice: All animal experiments in this study were approved by the 
University of Michigan Committee on Use and Care of Animals and Unit for Laboratory Animal 
Medicine. The abbreviated pharmacokinetics for 18b was determined in female CD-1 mice 
following intraperitoneal (ip) injection at 10 mg/kg. Compound was dissolved in the vehicle 
containing 15% (v/v) DMSO, 15% (v/v) PEG-400, and 70% (v/ v) PBS. Four blood samples (50 
μL) were collected over 7 h (at 0.5h, 2h, 4h, and 7h), centrifuged at 3500 rpm for 10 min, and 
plasma was frozen at -80˚C for later analysis. Plasma concentrations of the compounds were 
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determined by the LC−MS/MS method developed and validated for this study. The LC−MS/MS 
method consisted of a Shimadzu HPLC system, and chromatographic separation of tested 
compound which was achieved using a Waters Xbridge-C18 column (5 cm × 2.1 mm, 3.5 μm). 
An AB Sciex QTrap 4500 mass spectrometer equipped with an electrospray ionization source 
(ABI-Sciex, Toronto, Canada) in the positive-ion multiple reaction monitoring (MRM) mode 
was used for detection. All pharmacokinetic parameters were calculated by non-compartmental 
methods using WinNonlin, version 3.2 (Pharsight Corporation, Mountain View, CA, USA). 
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Chapter 3 The Identification and Optimization of Triazine Nitrile Inhibitors of TgCPL  
 
Rationale 
Through the development of the first SAR for the inhibition of TgCPL with our series of 
dipeptide nitriles, we were able to gain insight into the pharmacophore necessary for TgCPL 
inhibition and to improve the potency and selectivity over human isoforms. However, we were 
unable to advance the dipeptide series toward in vivo target validation due to the sub-optimal PK 
properties. Our optimized lead 258070 (Figure 22) was potent in vitro and CNS penetrant, but 
the drug was rapidly cleared in vivo. Although the dipeptide-nitriles are convenient to investigate 
SAR in the cathepsin pockets, they often exhibit less than desirable physiochemical properties 
for gaining blood-brain barrier (BBB) permeability, such as several rotational bonds, extensive 
hydrogen bonding, and high TPSA.157 We thus began searching for alternative scaffolds that 
might exhibit better physiochemical properties to improve upon the in vivo PK, while 
maintaining the pharmacophore elements for TgCPL inhibition and BBB penetration.   
 
 




Identification of Triazine Nitriles via High-Throughput Screen 
  The Carruthers lab conducted a high throughput screen for TgCPL inhibitors at the 
Center for Chemical Genomics at the University of Michigan on over 140,000 small molecules. 
From this we identified several inhibitor classes that demonstrated promising inhibitory activity 
against TgCPL, reasonable synthetic approachability, and physiochemical profiles optimal for 
use as a lead scaffold in a CNS targeted campaign. To minimize potential DMPK issues in later 
development, we chose to exclude compounds that were peptidic in structure, or irreversibly 
covalent. After rigorous triage had identified several potential lead molecules, we searched the 
literature to determine if any of these chemotypes had any previously demonstrated activity 
against cysteine proteases. An extensive amount of study has been done on inhibitors of human 
cathepsin L (HsCPL). Since Toxoplasma gondii cathepsin L shares high homology with HsCPL 
(60% similarity and 40% identity) we considered chemotypes with precedent for inhibiting 
HsCPL as good potential leads. Among the several potential lead molecules discovered in the 
screen, we selected a modestly active triazine nitrile 26067 (TgCPL IC50 = 2.5 µM, HsCPL IC50 
= 2.3 µM) as a lead candidate (Figure 22), given its small size, chemical profile, and literature 
precedent as a cathepsin inhibitor class. Several recent publications have reported triazine nitrile-
based inhibitors of human cathepsins, and additionally demonstrated potent inhibition of 
rhodesain and falcipain.158-160 The activity reported for these analogous cysteine proteases from 
related apicomplexan parasites P. falciparum and T. brucei further supports the potential of this 
chemotype as an antiparasitic agent. Additional triazine nitriles, pyrazolopyrimidine nitriles, and 





Figure 23. Structural overlay and active sites of TgCPL 
 (Cyan; PDB-3F75) and HsCPL (Orange PDB-5MAJ) 
 
Scaffold Hop from Dipeptide to Triazine Nitrile 
Although these recent studies have established the potential of this chemotype as a clinically 
relevant antiparasitic agent, Toxoplasma gondii, as well as other protozoan parasites such as T. 
brucei, establish a chronic infection in the central nervous system (CNS). Compounds with CNS 
targets have a somewhat constrained physiochemical profile as compared to peripheral drugs. 
Key among these are the minimization of hydrogen bond donors and decreasing TPSA which 
increase the rate of BBB penetration and unbound-drug brain concentration. Additionally, CNS 
drugs exhibit low MW (<450), high lipophilicity (logP <5), exclusion of acid moieties, and 
reduced number of rotatable bonds (RotB) (<8). The triazinyl-peptidomimetic scaffold (26067) 
was promising in that it could both retain the structural motifs necessary for binding in the S2 
and S3 pockets, which we elucidated in our previous work, and potentially improve the 
pharmacokinetic profile by reducing the rotational degrees of freedom and hydrogen bonding as 
compared to the dipeptide nitrile inhibitor class (Figure 24). To the best of our knowledge, no 
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one has yet demonstrated that these triazine nitrile inhibitors targeting parasitic cathepsins are 
able to cross the BBB. As such, this remained one of our overarching goals in the development 
of TgCPL inhibitors. 
 
Figure 24. Scaffold hop from dipeptide nitrile to triazine nitrile 
Molecular overlay of dipeptide nitrile (258070, Yellow) and triazine nitrile (262962, Teal) 
demonstrating good structural alignment. PDB: 3F75; HBD= Hydrogen bond donor; HBA= 
Hydrogen bond acceptor; Rot B= rotatable bonds. 
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Synthesis of Triazine Nitriles 
 
Scheme 7. General synthesis for triazine nitrile inhibitors 
a) NaBH4, DCM, rt, or Titanium (IV) isopropoxide, Na(OAc)3BH, DCM, 0°C-rt, O/N; b) cyanuric chloride, DIPEA, 
DCM, -10°C, 1-2h; c) morpholine, DIPEA, DCM, 0°C-rt, 4h; d) KCN, DMSO:H2O (9:1), 80°C, O/N. 
 
Under anhydrous conditions, the desired arylaldehyde or acetophenone (3.1a) was 
condensed with the desired alkylamine overnight, at which point the formed amine was reduced 
with sodium triacetoxyborohydride (Scheme 7). Next, the reaction between the secondary amine 
(3.1b) and cyanuric chloride provides intermediates (3.1c). Subsequent SNAr with morpholine 
provides intermediates (3.1d). In the case of 263392, oxetanamine was used as the P1 
solubilizing group in place of morpholine. Finally, cyanation of the scaffold with potassium 
cyanide in DMSO provided the desired final compounds (3.1e). 
 
 
Scheme 8. Alternative triazine nitrile synthetic scheme 
a) 1. Cyanuric chloride, DIPEA, DCM, -10°C, 1-2 hr; 2. Morpholine, DIPEA, DCM, 0°C-rt, 4 hr; b) KCN, 
DMSO:H2O (9:1), 80°C, O/N; c) NaH, DMF, 0°C 30 min, then ArCH2X when X=Br, Cl, Ts, or Ms; d) TFA:DCM 
(1:2), rt, 0.5-1 hr. 
 
To expedite rapid production of diverse analogs, synthetic strategy analogous to that 
reported by Giroud et. al. for the synthesis of triazine-nitrile HsCPL inhibitors was employed.158 
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First, cyanuric chloride underwent SNAr reactions with the desired benzyl or alkyl amines (3.2a) 
to set the various S2 and S3 vectors for intermediates (3.2b, Scheme 8). A second SNAr step was 
employed to install a morpholine as a P1 solubilizing group. Cyanation of the intermediate was 
performed with potassium cyanide in DMSO, to afford 3.2c. Subsequently, the anion of 
intermediates (3.2c) was generated using sodium hydride and the desired alkyl/benzyl halide was 
added to provide analogs (3.2d). In the case of analogs bearing a Boc-protected amine side chain, 
TFA:DCM deprotection was employed to provide the desired final compounds (3.2e). 
 
Results 
- Docking of Triazine Lead with TgCPL 
The initial IC50 for the triazine nitrile (26067, Table 11) we identified in our HTS was 
benchmarked at 3.5 µM and 2.3 µM against TgCPL and HsCPL respectively. Considering this 
lead bears an ethyl as the only potential P2/3 vector, it left obvious room for improvement.  
Based on our previous work in exploring the SAR for selective and potent TgCPL inhibition with 
the dipeptide nitrile chemotype, we elected to first synthesize the triazine nitrile (262962) 
analogous to an optimum dipeptide nitrile from our previous work, as we expected it would bind 
within the previously developed pharmacophore (Figures 24 and 25).  The triazine nitrile 
replaces the P1-P2 amide bond and retains the reversibly covalent nitrile interaction with the 
active site cysteine. In the P2 position, we previously found that leucine is the optimal amino 
acid, so in the respective position, we placed an isoamyl amine to achieve the same length into 
the S2 pocket. In P3, our most active compound previously bore a 4-fluorobenzyl, and as such, 
we place the same in the respective position for the triazine nitrile scaffold. An additional feature 
found both in our HTS lead and known literature analogs was the P1 morpholine. While the S1 
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pocket in TgCPL is absent, the morpholine in the P1 position projects into solvent and has been 
shown to improve the solubility of this chemotype (Figure 25). 
       
Figure 25. Covalent docking of 262962 into TgCPL and HsCPL 
Covalent docking of 262962 into TgCPL active site and electrostatic surface mapping. Red= polar negative, 
White = neutral, Blue= polar positive. (Derived from PDB: 3F75); Right: Overlay of 262962 in HsCPL (PDB: 
5MAJ). Pocket view; Red= polar negative, White= neutral, Green= lipophilic 
 
The installment of these two pendants indeed provided over a 100-fold improvement in 
potency, affording an IC50 of 34 nM and 32 nM for TgCPL and HsCPL respectively. We were 
pleased to see that the pharmacophore developed for the dipeptide nitrile series, readily 









- SAR of P3 Vectors 












26067 (HTS Lead) H 3.5 2.3 1.5 3 
262962 
 
0.034 0.032 1.1 20+ 
263587 
 
0.055 0.022 2.5 2 
263588 
 
0.049 0.019 2.6 2 
263579 
 
0.51 0.039 13 2 
264180 
 
0.060 0.043 1.4 2 
264181 
 
0.064 0.04 1.6 2 
264301 
 
0.14 0.087 1.6 2 
263466 
 
0.15 0.076  2 2 
263589 
 
0.16 0.044 3.6 2 
263580 
 
92.1 0.013 7,084 2 
263581 
 
11 0.025 440 2 
263462 
 
0.088 0.034 2.6 2 
263464 
 
0.042 0.006 7 2 
263468 
 
0.13 0.039 3.3 2 
263578 
 
0.039 0.003 13 2 
263582 
 



























0.086 0.16 0.54 2 
263590 
 
0.068 0.030 2.3 2 
263591 
 
0.014 0.006 2.3 2 
263583 
 
0.037 0.041 0.9 3 
263584 
 
0.017 0.047 0.36 3 
263586 
 
0.018 0.004 4.5 2 
263585 
 
0.047 0.006 7.8 2 
263659 
 
0.29 0.100 2.9 2 
263660 
 
0.12 0.028 4.3 2 
263686 
 
0.19 0.43 0.44 2 
263684 
 
0.25 0.35 0.71 2 
263592 
 
0.027 0.103 0.26 4 
263593 
 
0.055 0.019 2. 9 2 
263594 
 
0.041 0.030 1.4 2 
264179 
 
0.154 0.081 1.9 2 
264184 
 
1.42 0.361 3.9 2 
264185 
 
0.14 0.122 1.2 2 
264186 
 
1.42 0.087 16 2 
a,bIC50 for Toxoplasma gondii Cathepsin L (TgCPL) or human Cathepsin L (HsCPL). Values are mean 
of at least 2 independent experiments.  cSelectivity ratio for human Cathepsin L as defined by TgCPL 
IC50/HsCPL IC50. 
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To further explore the SAR trends for the triazine nitriles and elucidate features necessary 
for isoform selectivity, we decided to keep an isoamyl P2 vector and first vary the P3 position 
(Table 11). A scan of fluorine mono- substitution of the P3 benzyl (263587 and 263588) showed 
retention of activity, but no significant improvement in either overall potency or selectivity. A 
similar trend was seen with the P3 di-fluoro analogs 263579, 264180, and 264181. The non-
fluorinated P3 benzyl pendant 264301 exhibited roughly a 4-fold loss of potency (TgCPL IC50 = 
0.14 µM) versus the 4-fluoro lead 262962. Homologation of the linker from methyl to ethyl 
(263466) or propyl (263589), while better tolerated for the human isoform, resulted in the same 
reduced potency for TgCPL. An even greater loss of potency for the parasitic enzyme was seen 
when large bulky pendants like the quinoline or naphthyl of 2635780 and 263581 were installed. 
Taken together, this demonstrates that the parasitic isoform does not tolerate large steric vectors 
in the P3 position.  
 
The P3 pocket of TgCPL is topologically more polar versus the human isoform. With this 
in mind, we tried the 2-, 3-, and 4-pyridyl pendants (263462, 263464, and 263468) in P3, with 
the hope that it would improve our selectivity for the parasite, as well as potentially improve our 
metabolic profile by decreasing the clogP. Of these, the 3-pyridyl (263464) retained potency 
(TgCPL IC50 = 39 nM), but unfortunately did not offer any improvement in either metabolic 
stability (MLM t1/2 = 6 min), or selectivity over the human isoform (HsCPL IC50 = 6 nM). 
Anilines 263659, 263660, and 263686 were evaluated. We had hoped to gain a meaningful 
interaction with Asp78, Gln69, or Glu75, but none of the anilines were very potent for TgCPL. 
However, analog 263686 did afford a small measure of selectivity toward TgCPL (TgCPL IC50 = 
190 nM, HsCPL IC50 = 430 nM). Similarly, analog 263684 was tested to determine if a basic 
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amine might afford some difference in selectivity, but resulted in over a 5-fold loss in potency 
versus parent. 
 
As a comparison to our 4-fluorobenzyl pendant, we tested the 4-chlorobenzyl analog 
263578 to determine if the larger halogen might provide any improvement. While equally 
effective in TgCPL to the 4-fluoro, this change afforded an order of magnitude improvement in 
potency for HsCPL (TgCPL IC50 = 39 nM, HsCPL IC50 = 3 nM). Analog 263582 was 
synthesized to assess the effects of a moderately electron withdrawing acetophenone, but 
afforded a mild reduction in potency against TgCPL (IC50 = 86 nM). A methyl scan was 
performed to probe the space around the ring and determine if any of the substitution patterns 
may lead toward some selectivity for TgCPL. While 264183 and 263590 did not offer any 
improvement in potency, 263591 was nearly twice as potent (TgCPL IC50 = 14 nM) as the parent 
scaffold 262962, but more significantly improved HsCPL inhibition (HsCPL IC50= 6 nM). It is 
worth noting that the o-methyl benzyl, while less potent than the 4-flurobenzyl, showed some 
selectivity for TgCPL (2-fold over HsCPL) for the first time in this series. Dimethyl analogs 
263583 and 263584 provided more potent inhibitors and stayed consistent with the trend that an 
ortho substitution (263584) may be slightly selective for TgCPL. Undesirably, these also 
increased overall molecular weight and potential metabolic hotspots, and therefore were not 
further pursued. The electron withdrawing 3-trifluoromethyl 263586 provided one of the more 
potent TgCPL inhibitors, but exhibited selectivity in favor of HsCPL. The increased MW versus 
262962 was also undesirable in trying to remain within the calculated properties for BBB 
permeability. The corresponding 3-methoxy analog 263585 was also tested to assess the effects 
of electron donation into the ring, however this did not seem to offer any significant difference in 
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potency or selectivity as compared to 263586. Interestingly, a nitro scan in analogs 263592, 
263593, and 263594, we found that the o-nitrobenzyl P3 vector of 263592 exhibited a 4-fold 
selectivity over the human isoform (TgCPL IC50 = 27 nM, HsCPL IC50 = 103 nM). As this was 
the first analog that demonstrated significant selectivity in favor of TgCPL, analogs 264179, 
264184, 264185, and 264186 were synthesized in an effort to better explain the selectivity. The 
nitrile (264179), trifluoromethyl (264184), and methyl ester (264184) vectors were tested as 
isosteres of the nitro. Unfortunately, none of these substituents reproduced the selectivity we saw 
with the o-nitro vector. The o-methoxy analog 264186 was also synthesized to determine if the 
observed effects were due to the electron withdrawing nature of the nitro, or a conformational 
change due to sterics. While tolerated in HsCPL (IC50 = 87 nM), the potency significantly 
decreased against TgCPL (IC50 = 1,420 nM). Based on our modeling (Figure 26), it appears that 
the P3 pendant may have the ability to bind outside of the S3 pocket and interact with lipophilic 
backbone of Asp166, giving rise to high vector tolerance. 
 
Figure 26. Potential flip of binding mode for triazine nitriles 
(e.g. 262962). Derived from PDB: 3F75. 
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- SAR Analysis of P2 Vectors 















0.034 0.032 1.1 20+ 
263256 
 
0.23 0.079 2.9 2 
263898 
 
0.18 0.035 5.1 2 
263255 
 
0.19 0.071 2.7 2 
263918 
 
0.041 0.034 1.2 1 
263043 
 
0.067 0.023 29 3 
263939 
 
0.37 0.40 0.925 1 
263257 
 
1.4 0.28 5 1 
264084 
 
7.1 3.1 2.3 1 
264082 
 









We then turned our attention to evaluating the SAR in the S2 vectors for the triazine 
nitrile series. In general, the papain family proteases determine their substrate specificity from 
interactions in the S2 pocket.124, 161 Based on our previous SAR studies with the dipeptide 
nitriles, we had determined that leucine was the optimal amino acid for the P2 position. We were 
pleased to find that with (262962), the isoamyl sidechain in the respective position for the 
triazine nitriles afforded a huge improvement in potency (TgCPL IC50 = 34 nM) as compared to 
the dipeptide nitriles. We wanted to determine if the previous SAR trends we found tracked in a 
similar fashion with this new chemotype. Initially, we evaluated the effects of shorter, aliphatic 
vectors. The n-propyl, n-butyl, and n-butene (263256, 263898, and 263255) were tolerated in in 
HsCPL, but all decreased in potency for TgCPL. Consistent with our previous SAR, the isobutyl 
S2 vector in 263043, which closely mimics a valine residue, slightly decreased activity for 
TgCPL to 67 nM, but enhanced HsCPL inhibition (IC50 = 2 nM). Interestingly, the 
dehydroleucine analog 263918 retained nearly equivalent potency (TgCPL IC50 = 41 nM) to 
262962, a trend that was not observed in the dipeptide series. This indicated to us that while 
similar, the SAR between the dipeptide and triazine chemotypes was not identical and that 
binding with the triazine nitrile series may be somewhat more accommodating to changes. 
264083 
 
1.7 0.76 2.2 2 
263661 
 
2.1 1.8 1.2 2 
a,bIC50 for Toxoplasma gondii Cathepsin L (TgCPL) or human Cathepsin L (HsCPL). Values are 
mean of at least 2 independent experiments.  cSelectivity ratio for human Cathepsin L as defined by 
TgCPL IC50/HsCPL IC50. 
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Extension of the S2 sidechain by one carbon in 263939 resulted in a significant loss of potency, 
we believe this may be due to a clash in the back of the S2 pocket disallowing elongated 
sidechains in the position. Compound 263257 was made to determine if the S2 pocket could 
tolerate a less lipophilic group thereby reducing overall clogP and improving compound 
solubility. Unfortunately, this resulted in a large decrease in potency for both enzymes (TgCPL 
IC50 = 1.4 µM, HsCPL IC50 = 0.28 µM). Given that TgCPL bears a unique Asp218 versus the 
Ala214 in HsCPL (Figure 23), we hoped the inclusion of a polar or basic group in the S2 
position might afford some selectivity, as well as improve compound solubility. As such, 
compounds 264084, 264082, 264083, and 263661 were synthesized. We had hoped that the 
stepwise increase in side chain length might elucidate the ideal distance required to gain a 
meaningful interaction with Asp2148. Unfortunately, these changes were not well tolerated and 
resulted in a drastic drop in potency down to the low micromolar range for both enzymes, 
indicating that perhaps these compounds are not binding as predicted, or the Asp218 is not 
oriented that way it appears in the model.  
 
 
Figure 27. Metabolic liabilities for 262962 
A) Predicted key hotspots by SmartCYP).153 B) Metabolite ID results identifying the isoamyl S2 
vector as the primary site of oxidation.  
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While the improvement in both potency and predicted CNS profile of the triazine 
scaffold was encouraging, it resulted in a significant reduction in metabolic stability compared to 
the dipeptide series, as measured by MLM t1/2. (6 min versus 22 min). To aid the PK 
optimization of this new triazine nitrile series, a metabolite ID study was completed for 262962.  
Figure 27 shows that the hotspots for metabolism are predominantly oxidation of the P2 isoamyl 
vector, and the P3 benzylic methylene. With this guidance in mind, analogs were designed to 
retain the physiochemical profile of a CNS drug and simultaneously circumvent these potential 
metabolic liabilities.  
 
- P2 Vectors for Improved Metabolic Profile and Selectivity 
























































































































We installed an α-methyl in analog 263251 to determine if substitution on the benzyl 
position was tolerated, as it may be necessary to modulate the metabolic profile. We were happy 
to see that this change was well tolerated and provided a small improvement in overall potency, 
however the potency improvement was 2-fold greater for HsCPL. Due to the added MW and 
lipophilicity, compound solubility significantly decreased versus the parent compound (262962 = 
41.9 µM, 263251 = 16.4 µM). To resolve this, we tried replacing the S1 morpholine group with 
oxetanamine in analog 263392. While the potency decreased to 119 nM for TgCPL, the MW was 




















2.8 1.2 2.3 3 
264504 H 
 









1.7 0.75 2.3 2 
a,bIC50 for Toxoplasma gondii Cathepsin L (TgCPL) or human Cathepsin L (HsCPL). Values are mean of 
at least 2 independent experiments.  cSelectivity ratio for human Cathepsin L as defined by TgCPL 
IC50/HsCPL IC50. *S1 vector = oxetanamine in place of morpholine 
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synthesized with the intent of blocking oxidation of the isoamyl CH. The cyclopropyl leucine 
mimic (263698) lost an order of magnitude in potency (TgCPL IC50 = 190 nM compared to 
262962), and the tertbutyl analog, 263806, while 2-fold selective for TgCPL, decreased to 68 nM 
at TgCPL. It should be noted however, that these respective changes in the dipeptide nitrile series 
were not tolerated nearly as well, giving us confidence that the triazine nitriles are a superior 
scaffold with regards to potential for improving DMPK properties. Furthermore, this data 
suggests these two chemotypes are not binding in the same manner. Compound 264079 was 
synthesized to determine if the cyclopropyl and 4-fluoro-α-methylbenzyl combination in P2 and 
P3 respectively would be sufficient to slow metabolism. Unfortunately, this decreased the 
compound half-life in mouse liver microsomes to 4.37 min, indicating a switch to another 
metabolic site, such as N-dealkylation of the P2 sidechain or the P1-morpholine. Compound 
263919, bearing a fluoroleucine in S2 (a vector also not tolerated in the dipeptide series), 
demonstrated excellent potency for TgCPL (IC50 = 19 nM) and HsCPL (IC50 = 30 nM), although 
MLM stability was decreased to t1/2 = 3.2 min, further indicating that blocking the primary 
metabolic site alone is insufficient for improving stability. The ethyl-cyclohexyl vector of 
263682 resulted in a significant decrease in potency for both cathepsins, likely due to the same 
steric clash in the S2 pocket observed for compound 263939 (Table 12). We were excited to 
discover that shortening the pendant by one carbon to the methyl-cyclohexyl (263683) both 
retained potency for TgCPL (IC50 = 26 nM) and achieved 4-fold selectivity for the parasite 
isoform over human. The P2 cyclopentyl in 264503 is close to the cyclohexyl in terms of 
potency, but slightly less selective. The smaller ring size in analogs 263253 and 263254, 




Docking of 263683 showed that the P2 cyclohexyl ring was 3-4Å from Asp218. In hopes 
of gaining a favorable ionic interaction with this residue, compounds 264182 and 264081 were 
synthesized. Interestingly, the 4-piperidine of 264182 resulted in lost activity against both 
enzymes, while the 3-piperidine 264081 demonstrated moderate selectivity (10-fold) for TgCPL. 
Despite a slight decrease in overall potency to 0.107 µM, 264081 exhibited a vastly improved 
microsomal stability with t1/2 > 60 minutes. The addition of an extra carbon in the sidechain for 
analog 264039 decreased potency to 2.2 µM for TgCPL, analogous to the ethyl cyclohexane 
analog 263682. The ethyl 4-piperidine P2 vector 264038 similarly resulted in a decrease of 
potency, although not as drastically (TgCPL IC50 = 0.29). It is difficult to explain the potency 
differences between, 263682, 264038, and 264039, but is likely the result of changes in binding 
mode placing the P2 vector outside the S2 site, perhaps in the S3 pocket. The respective 
tetrahydropyran (THP) analogs 264224 and 264239 were made to determine if the basic amine 
was important for this observed activity. These displayed a similar potency and selectivity 
profile, with heteroatom being tolerated at the 3-position (264239 TgCPL IC50 = 0.040 µM), but 
not at the 4-position (264224 TgCPL IC50 = 0.60 µM).  Unfortunately, compound 264239 was 
not stable to mouse liver microsomes. Reduction of the piperidine ring size to a pyrrolidine in 
analog 264225 abolished the selectivity and potency profile (TgCPL IC50 = 0.93 µM). We were 
curious if we might see an enhanced selectivity ratio if only the 3-piperidine sidechain was 
utilized, removing the S2-S3 mutually preferable 4-fluorobenzyl P3 vector. As such, analog 
264504 was tested, but activity was reduced to the low micromolar range for both parasite and 
human isoforms. We were also interested in combining the most selective P2 (methyl 3-
piperidine) and P3 (o-nitro benzyl) vectors we have seen in analog 264261.  Unfortunately, these 
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effects were not synergistic and resulted in a loss of both selectivity and potency, strongly 
suggesting that the two congeners are not binding the same way. In an attempt to elucidate the 
preferred enantiomer of the P2 3-piperidine analog, compounds 264501 and 264502 were 
synthesized. Curiously, activity for both decrease to the low micromolar range and they no 
longer exhibited the selectivity found in the racemate 264081. While only n=2, these compounds 
as well as the parent racemate are currently being evaluated in the biochemical assay to rule out 
any potential issues with the previous assay runs.  
 
At this point we questioned if the P2 and P3 vectors could rotate about the triazine 
carbon-nitrogen bond to exchange positions in the active site, offering variable biding modes 
between the enzymes and potentially explaining the high P2 tolerance in HsCPL. As we 
previously found with the dipeptide nitriles, HsCPL can bind aromatic phenylalanine-like 
pendants in P2, while TgCPL prefers leucine residues. Analog 264521 was synthesized, 
combining the TgCPL P2 preferred isoamyl with the 3-piperidine. While it appears the 
piperidine pendant is tolerated as a P3 vector, we observed an overall loss in potency for both 









Microsomal Stability and Pharmacokinetics 
 
















propylcyclopropane Morpholine 4.4 
263464 3-pyridyl isoamyl Morpholine 2 
263683 4-Fluorobenzyl methyl-cyclohexyl Morpholine 15 








Figure 28. Mouse liver microsome half-life of select inhibitors 
 
The previously developed dipeptide nitrile 258070 exhibited a fair level of stability 
toward mouse liver microsomes with half-life of t1/2 = 22 min (Figure 28). The scaffold hop to 
the triazine nitrile 262962 resulted in a significant drop in metabolic stability (t1/2 = 7 min). The 
predicted metabolic liabilities by SmartCyp (Figure 27A) led us to install the α-methyl and 
exchange the P1 solublizing group with an oxetane in analog 263392. Unfortunately, this did not 
offer any improvement to the microsomal stability profile for this series (t1/2 = 5 min). Our 
subsequent metabolite ID study (Figure 27B) indicated that the primary site of metabolism was 
the isoamyl P2 vector. Compound 263919 was synthesized, as the fluoroleucine has been shown 
to be an effective strategy in blocking the metabolism of a leucine sidechain in the development 
of odanacatib.162 This exchange resulted in a decrease in compound half-life to t1/2 = 3.5 min. In 
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an attempt to block both the P2 and benzylic oxidation sites, compound 264079 was made. 
Unfortunately, this did not seem to have any improvement on microsomal stability with at t1/2 = 
4.4 min. Compound 263464 was tested to determine if metabolism could be reduced by 
decreasing lipophilicity. Compound lipophilicity was lowered to clogP = 1.90 (versus clogP = 
3.39 for 262962) but resulted in an even worse half-life (t1/2 = 2 min). We were pleased to find 
that the methyl-cyclohexyl analog 263683 offered an improvement in metabolic stability (t1/2 = 
15 min), likely due to steric bulk of P2 impeding CYP binding, as well as retained potency and 
gained 4-fold selectivity for TgCPL. The related P2 3-piperidine analog 264081 drastically 
improved the microsomal stability to t1/2 > 60 min, presumably due simply to reducing ClogD. 
Similarly, the 3-tetrahydropyran analog 264239 was tested, but exhibited a significantly worse 
stability (t1/2 = 3.5 min). The drastic improvement seen for compound 264081 is likely due to the 




Figure 29. Initial Pharmacokinetic studies 
Pharmacokinetic study measuring plasma (solid, ng/mL) and brain (striped, ng/g) exposure. 
 
Compound 262962 was evaluated in a mouse PK study to benchmark the CNS profile of 
the triazine nitrile chemotype and compare it to that of the dipeptide nitrile 258070 (Figure 29). 
We were pleased to find that this 262962 does in fact access the brain with approximately a 1:1 
ratio brain/plasma at 2h. However, the compound levels are decreased rather quickly, likely due 
to a combination of high volume of distribution and metabolic instability. Nonetheless, this was a 
promising result indicating that the triazine nitrile scaffold has the physiochemical profile needed 
to cross the BBB. We hoped that by increasing the metabolic stability of the scaffold, we might 
gain a better pharmacokinetic profile. We attempted to evaluate compound 263683, as this 
analog exhibited an improved half-life, retained potency, and demonstrated some selectivity for 
TgCPL, but unfortunately its poor solubility precluded in vivo dosing. As mentioned above, the 
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replacement of the P1 morpholine of 263251 with a 3-amino-oxetane in compound 263392, 
offered an improvement in solubility (16.4 µM to 42.2 µM respectively). We decided to run a 
short PK study on 263392 to determine if the additional hydrogen bond donor of the 
oxetanamine would impact our CNS penetrance, or if this could be a viable strategy to improve 
the solubility of future compounds (Figure 30).  
 
 
Figure 30. Additional pharmacokinetic studies 
Pharmacokinetic study measuring plasma (solid) and brain (striped) exposure. 
 
We were very pleased to find that in addition to retaining a brain to plasma ratio of ~1 
after 2 hr, the overall exposure levels were significantly increased compared to 262962 (Figure 
30). Often, the incorporation of a basic amine can improve the CNS access of a drug, as well as 
increase compound solubility. Given that the 3-piperidine P2 vector in 264081 significantly 
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improved the metabolic stability of this compound, we decided to also profile this analog in a 
short PK. While the exposure levels were improved in plasma versus 262962, this compound no 
longer exhibited BBB penetrance. The difluoro-3-piperidine compound 264522 was synthesized 
with the intent of tuning the basicity of this sidechain in an effort to overcome the PgP efflux 
(Table 14) observed with 264081. Unfortunately, this change was not well tolerated and potency 
was reduced to low micromolar for this compound (TgCPL IC50 = 1.7 µM). 
 
- MDR1/MDCK Permeability and Efflux 
Because of their strikingly divergent brain:plasma ratios observed in the PK studies, 
compounds 264801 and 263392 were assessed in vitro to determine whether they are potential 
substrates of P-glycoprotein (P-gp). We suspected this might be the case, as the incorporation of 
the basic amine in 264801 impedes CNS access and is often associated with P-gp substrates. 
Evaluation in an MDR1/MDCK permeability assay demonstrates that compound 263392 is 
favorably permeable toward the basal chamber with a concentration ratio of 4.25 (Table 14) and 
does not appear to be PgP substrate. This would be expected to translate to good CNS 
penetrance, which is in agreement with our PK results. 264801 conversely showed a 
concentration ratio of 0.06, indicating this compound is incapable of CNS penetrance and is 
likely a PgP substrate.  
 






263392 (A-B) 0.017 ± 0.004 
0.24 
263392 (B-A) 0.004 ± 0.001 
264801 (A-B) 0.012 ± 0.002 
15 
264801 (B-A) 0.18 ± 0.08 
a Concentration is shown as the average of two sample measurements of the acceptor 
wells from three replicate assays. 
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Conclusions 
A high throughput screen was conducted to identify new chemotypes capable of the 
inhibition of Toxoplasma gondii cathepsin L. The low µM triazine nitrile scaffold (26067) was 
selected based on the previously established literature precedent of this chemotype as inhibitors 
of human cathepsins and the predicted BBB penetrant properties of this scaffold. Translation of 
the pharmacophore developed from the dipeptide nitrile series to the triazine nitrile scaffold 
resulted is an instantaneous gain of potency (TgCPL IC50 = 34 nM), but reduced metabolic 
stability relative to the corresponding dipeptide. 71 analogs in this series were synthesized with 
varying S2 and S3 vectors to optimize metabolic stability, CNS permeability, and selectivity 
over human isoforms. Out of the nine analogs bearing an amine in P2, all exhibited IC50s for 
HsCPL of >0.5 µM, supporting that the human isoform does not tolerate a basic amine in this 
position. TgCPL, conversely, appears to be able to better accommodate either a nitrogen or 
oxygen in S2. Future analogs will be designed to exploit these features and further explore the 
SAR trends with various basic and polar groups in P2. Overall, we improved potency against 
TgCPL to as low as 5 nM and identified features that can be exploited to gain selectivity vs 
HsCPL (up to 5-8 fold), and significantly improved metabolic stability (up to t1/2 >60 min in 
MLM). While CNS penetrant (1:1 B/P over 2 hr) with moderate initial exposure, 263392 was 
probably cleared too rapidly for efficacy studies in vivo (Figure 30). By design, we were able to 
improve selectivity and microsomal stability with analog 264081 (t1/2>60 min; Tg/Hs IC50 = 
0.10), however this analog is an apparent Pgp substrate, precluding in vivo target validation. 
Synthesis of new analogs to circumvent this issue is currently underway to advance this series 




Chemistry General Information: All reagents were used without further purification as 
received from commercial sources unless noted otherwise. 1H NMR spectra were taken in 
DMSO-d6, MeOD, or CDCl3 at room temperature on Varian Inova 400 MHz or Varian Inova 
500 MHz instruments. Reported chemical shifts for the 1H NMR spectra were recorded in parts 
per million (ppm) on the δ scale from an internal standard of residual tetramethylsilane (0 ppm). 
Mass spectrometry data were obtained on either a Micromass LCT or Agilent Q-TOF. An 
Agilent 1100 series HPLC with an Agilent Zorbax Eclipse Plus−C18 column was used to 
determine purity of biologically tested compounds. Unless otherwise noted, all tested compounds 
were determined to be >95% pure using a 6 minute gradient of 10-90% acetonitrile in water 
followed by a 2 minute hold at 90% acetonitrile with detection at 254 nm. Flash chromatographic 
purifications were performed using a Teledyne ISCO Combiflash RF with Redisep Gold RF 
columns. 
 
General Procedure A1: Reductive Amination 
To a dry round bottom flask with DCM was added arylaldehyde (1 eq), followed by the 
addition of the desired primary amine (1 eq), final reaction concentration of 0.1-0.3 mM. The 
vessel was then stirred under a nitrogen atmosphere at room temperature overnight. Sodium 
triacetoxyborohydride (3 eq) was then added and reaction was stirred at room temperature for 1-
3 hr. The reaction was quenched slowly with water then poured into water and extracted 3x with 
DCM. The combined organic layer was dried over sodium sulfate and concentrated in-vacuo. 
The crude product was further purified by column chromatography (0-10% MeOH in DCM + 
0.1% TEA) to afford the desired secondary amine. 
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General Procedure A2: SNAr 
Under a dry nitrogen atmosphere, cyanuric chloride (1 eq) was added a roundbottom 
flask along with DCM (final conc. = 0.1-0.3 mM). The vessel was cooled to -10°C (Ice/Brine) 
and the desired secondary amine (1 eq) and DIPEA (1 eq) were then added. Reaction was stirred 
at -10°C for 1 h. The reaction was poured into water and extracted 3x with DCM. Combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The crude product was further 
purified by column chromatography (0-100% EtOAc in Hexanes gradient) to afford the desired 
intermediate. 
 
General Procedure A3: SNAr 
Under a dry nitrogen atmosphere, dichloro triazine intermediate (1 eq) was added a 
roundbottom flask along with DCM to a final reaction concentration of 0.1 mM. The vessel was 
cooled to -10°C (Ice/Brine) and DIPEA (1 eq) and morpholine (1 eq) were then added. Reaction 
was stirred and allowed to warm to room temperature over 6-12 h. The reaction was poured into 
water and extracted 3x with DCM. Combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was further purified by column chromatography (0-
100% EtOAc in Hexanes gradient) to afford the desired intermediate. 
 
General Procedure A4: Cyanation 
A dry pressure vessel was charged with the appropriate triazinyl chloride (1.0 eq), and 
suspended in DMSO/H2O 9:1. KCN (1.1 eq.) and 1,4-diazabicyclo[2.2.2]octane (DABCO, 2.0 
eq.) were added and the reaction was heated to 80°C. Reaction was left to stir at this temperature 
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until LC/MS showed completion of the reaction (6-12 h). Reaction was cooled to room 
temperature, diluted with EtOAc, and washed thoroughly with brine (3-5 x). The organic layer 
was separated, dried over MgSO4, filtered, and evaporated. The crude product was further 
purified by column chromatography (0-100% EtOAc in Hexanes gradient) to afford the desired 
product. 
 
General Procedure B1: One-pot double SNAr 
Under a dry nitrogen atmosphere, cyanuric chloride (1 eq) was added a roundbottom 
flask along with DCM (final conc. = 0.1-0.3 mM). The vessel was cooled to -10°C (Ice/Brine) 
and DIPEA (1 eq) followed by the desired primary amine (1eq) were then added. Reaction was 
stirred at for 1-3 hr, until TLC/HPLC indicated substitution was complete. Next, DIPEA (1 eq) 
was added followed by morpholine (1 eq) and reaction was allowed to stir and warm to rt over 4-
12h until TLC/HPLC indicated substitution was complete. The reaction was poured into water 
and extracted 3x with DCM. Combined organic layers were dried over MgSO4 and concentrated 
in vacuo. The crude product was further purified by column chromatography (0-100% EtOAc in 
Hexanes gradient) to afford the desired intermediate. 
 
General Procedure B2: Cyanation 
A dry pressure vessel was charged with the appropriate triazinyl chloride (1.0 eq), and 
suspended in DMSO/H2O 9:1. KCN (1.1 eq) and 1,4-diazabicyclo[2.2.2]octane (DABCO, 2.0 
eq) were added and the reaction was heated to 80°C. Reaction was left to stir at this temperature 
until LC/MS showed completion of the reaction (6-12 h). Reaction was cooled to room 
temperature, diluted with EtOAc and washed thoroughly with brine (3-5 x). The organic layer 
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was separated, dried over MgSO4, filtered, and evaporated. The crude product was further 
purified by column chromatography (0-100% EtOAc in Hexanes gradient) to afford the desired 
secondary amine. 
 
General Procedure B3: Alkylation with NaH and aryl/alkyl X/Ms/Ts 
The triazinyl-nitrile (1 eq) was dissolved in DMF and cooled to -10°C (Ice/Brine bath). 
60% NaH in mineral oil (1-1.5 eq) was added and reaction was stirred for 30 min. The 
appropriate alkyl or aryl Br/Cl/Ms/Ts (1-2 eq) was then added. The reaction was allowed to 
slowly warm to room temperature and left to stir (2-12 hr) until HPLC indicated reaction was 
complete. The solution was poured into EtOAc, washed 3x with brine, dried over NaSO4, and 
concentrated. Crude residue was purified by flash chromatography EtOAc:Hexanes 0-100% 
gradient. 
 
General Procedure B4: Boc-Deprotection 
The Boc-protected amine (1 eq) was dissolved into a 1:2 mixture of TFA:DCM (~0.1-0.3 
mM) and allowed to stir at room temperature for 0.5-2h,  until HPLC or TLC indicated reaction 
was complete. Solvent was removed in vacuo and compound was purified by reverse phase 
chromatography (C18, 10-100% ACN in water + 0.1% TFA gradient) and concentrated to afford 
desired product as the TFA salt. 






General Procedure A1 from 4-fluorobenzaldehyde (0.5 ml, 4.66 mmol), 3-methylbutan-1-amine 
(0.541 ml, 4.66 mmol), and sodium triacetoxyborohydride (2470 mg, 11.65 mmol) gave N-(4-
fluorobenzyl)-3-methylbutan-1-amine (870 mg, 4.46 mmol, 96 % yield).; 1H NMR (CDCl3, 500 
MHz) δ 7.27 (dd, J = 5.62, 8.07 Hz, 2H), 6.99 (t, J = 8.56 Hz, 2H), 3.75 (s, 2H), 2.62 (t, J = 7.34 
Hz, 2H), 1.56 - 1.69 (m, 1H), 1.34 - 1.45 (m, 2H), 0.89 (d, J = 6.36 Hz, 6H) 
 
4,6-Dichloro-N-(4-fluorobenzyl)-N-isopentyl-1,3,5-triazin-2-amine 
General Procedure A2 from 2,4,6-trichloro-1,3,5-triazine (142 mg, 0.768 mmol), N-(4-
fluorobenzyl)-3-methylbutan-1-amine (150 mg, 0.768 mmol), and DIPEA (0.134 ml, 0.768 
mmol) gave 4,6-dichloro-N-(4-fluorobenzyl)-N-isopentyl-1,3,5-triazin-2-amine (243 mg, 0.708 
mmol, 92 % yield).; 1H NMR (CDCl3, 500 MHz) δ 7.23 (dd, J = 5.38, 8.31 Hz, 2H), 7.03 (t, J = 
8.56 Hz, 2H), 4.79 (s, 2H), 3.51 - 3.56 (m, 2H), 1.49 - 1.61 (m, 1H), 1.40 - 1.48 (m, 2H), 0.92 (d, 
J = 6.36 Hz, 6H) 
 
4-Chloro-N-(4-fluorobenzyl)-N-isopentyl-6-morpholino-1,3,5-triazin-2-amine 
General procedure A3 from 4,6-dichloro-N-(4-fluorobenzyl)-N-isopentyl-1,3,5-triazin-2-amine 
(243 mg, 0.708 mmol), morpholine (0.062 ml, 0.708 mmol), and DIPEA (0.124 ml, 0.708 mmol) 
gave 4-chloro-N-(4-fluorobenzyl)-N-isopentyl-6-morpholino-1,3,5-triazin-2-amine (205 mg, 
0.520 mmol, 73.5 % yield). Product could be recrystallized from hot EtOAc:Hexanes (2:1).; 1H 
NMR (CDCl3, 500 MHz) δ 7.15 - 7.25 (m, 2H), 6.99 (t, J = 8.56 Hz, 2H), 4.74 (s, 2H), 3.73 - 
3.88 (m, 4H), 3.60 - 3.73 (m, 5H), 3.49 - 3.56 (m, 1H), 3.39 - 3.46 (m, 1H), 1.47 - 1.61 (m, 1H), 





General Procedure A4 starting from 4-chloro-N-(4-fluorobenzyl)-N-isopentyl-6-morpholino-
1,3,5-triazin-2-amine (200 mg, 0.508 mmol) and DABCO (114 mg, 1.016 mmol) gave 4-((4-
fluorobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (136 mg, 0.354 
mmol, 69.7 % yield); 1H NMR (CDCl3, 400 MHz) δ 7.13 - 7.25 (m, 2H), 7.00 (t, J = 8.22 Hz, 
2H), 4.73 (d, J = 19.17 Hz, 2H), 3.74 - 3.87 (m, 4H), 3.60 - 3.74 (m, 6H), 3.52 (t, J = 7.43 Hz, 
1H), 3.43 (t, J = 7.83 Hz, 1H), 1.48 - 1.60 (m, 1H), 1.37 - 1.48 (m, 2H), 0.90 (t, J = 5.87 Hz, 6H); 
13C NMR (DMSO-d6, 101 MHz, 80°C) δ 163.2, 162.7, 161.1, 150.9, 133.2, 129.0, 115.0, 114.6, 




General procedure B1 from 2,4,6-trichloro-1,3,5-triazine (1 g, 5.42 mmol), (4-
fluorophenyl)methanamine (0.620 ml, 5.42 mmol), DIPEA (1.894 ml, 10.84 mmol), and 
morpholine (0.472 ml, 5.42 mmol) gave 4-chloro-N-(4-fluorobenzyl)-6-morpholino-1,3,5-
triazin-2-amine (1.07 g, 3.30 mmol, 60.9 % yield). Product could be recrystallized from hot 
EtOAc:Hexanes (2:1).; 1H NMR (CDCl3, 500 MHz) δ 7.17 - 7.35 (m, 2H), 6.89 - 7.11 (m, 2H), 






General procedure B2 from 4-chloro-N-(4-fluorobenzyl)-6-morpholino-1,3,5-triazin-2-amine (4, 
12.35 mmol), potassium cyanide (0.885 g, 13.59 mmol), and DABCO (2.77 g, 24.71 mmol) gave 
4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (2.7 g, 8.59 mmol, 69.5 % 
yield).; 1H NMR (CDCl3, 500 MHz) δ 7.21 - 7.30 (m, 2H), 6.93 - 7.06 (m, 2H), 4.49 - 4.61 (m, 
2H), 3.73 - 3.86 (m, 4H), 3.69 (br. s., 4H) 
 
4-Chloro-N-isopentyl-6-morpholino-1,3,5-triazin-2-amine 
General procedure B1 from 2,4,6-trichloro-1,3,5-triazine (5, 27.1 mmol), 3-methylbutan-1-amine 
(3.15 ml, 27.1 mmol), DIPEA (9.48 ml, 54.2 mmol), and morpholine (2.362 ml, 27.1 mmol) 
gave 4-chloro-N-isopentyl-6-morpholino-1,3,5-triazin-2-amine (7.5 g, 26.2 mmol, 97 % yield). 
Product could be recrystallized from hot EtOAc:Hexanes (2:1). 1H NMR (CDCl3, 500 MHz) δ 
6.06 (br. s., 1H), 3.63 - 3.88 (m, 8H), 3.33 - 3.46 (m, 2H), 1.56 - 1.68 (m, 1H), 1.44 (q, J = 7.01 
Hz, 2H), 0.91 (d, J = 6.36 Hz, 6H) 
 
4-(Isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
General procedure B2 from 4-chloro-N-isopentyl-6-morpholino-1,3,5-triazin-2-amine (3.24 g, 
11.34 mmol), potassium cyanide (0.812 g, 12.47 mmol), and DABCO (2.54 g, 22.68 mmol) gave 
4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (2.1 g, 7.60 mmol, 68.7 % yield).; 
1H NMR (CDCl3, 500 MHz) δ 3.77 - 3.91 (m, 3H), 3.64 - 3.77 (m, 5H), 3.32 - 3.49 (m, 2H), 1.65 





General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol),  sodium hydride (15.92 mg, 0.398 mmol), and 1-
(bromomethyl)-2-fluorobenzene (68.4 mg, 0.362 mmol) gave 4-((2-fluorobenzyl) 
(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (67.6 mg, 0.176 mmol, 48.6 % 
yield) 1H NMR (CDCl3, 500 MHz) δ 7.24 - 7.30 (m, 1H), 7.14 - 7.21 (m, 1H), 7.01 - 7.12 (m, 
2H), 4.86 (s, 1H), 4.80 (s, 1H), 3.82 (br. s., 1H), 3.78 (br. s., 2H), 3.70 - 3.75 (m, 2H), 3.67 (br. 
s., 2H), 3.64 (br. s., 1H), 3.55 - 3.60 (m, 1H), 3.46 - 3.52 (m, 1H), 1.56 (qd, J = 6.60, 16.38 Hz, 
1H), 1.41 - 1.49 (m, 2H), 0.91 (t, J = 7.34 Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 164.2, 164.1, 
163.6, 163.4, 161.9, 161.8, 160.0, 159.8, 130.0, 129.9, 129.2, 129.0, 128.9, 124.3, 124.2, 115.6, 
115.5, 115.4, 115.2, 66.7, 66.4, 45.6, 45.0, 43.9, 43.4, 43.3, 36.26, 35.43, 26.01, 25.88, 22.51, 
22.47; HRMS–ESI (m/z): [M+H]+ calcd for C20H25FN6O, 385.2147; found, 385.2150 
 
4-((3-Fluorobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263588) 
General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-
(bromomethyl)-3-fluorobenzene (68.4 mg, 0.362 mmol) gave 4-((3-
fluorobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (104 mg, 0.271 
mmol, 74.8 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.21 - 7.32 (m, 1H), 6.97 - 7.02 (m, 1H), 
6.93 - 6.97 (m, 1H), 6.91 (d, J = 9.29 Hz, 1H), 4.79 (s, 1H), 4.72 (s, 1H), 3.81 - 3.85 (m, 1H), 
3.79 (br. s., 2H), 3.71 - 3.75 (m, 2H), 3.68 (br. s., 1H), 3.60 - 3.66 (m, 2H), 3.51 - 3.60 (m, 1H), 
3.41 - 3.50 (m, 1H), 1.48 - 1.60 (m, 1H), 1.39 - 1.48 (m, 2H), 0.90 (t, J = 7.09 Hz, 6H); 13C NMR 
(CDCl3, 126 MHz) δ 164.2, 164.0, 163.9, 163.6, 163.4, 161.9, 152.0, 151.9, 140.2, 140.1, 140.0, 
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139.9, 130.1, 130.0, 123.2, 122.8, 122.7, 115.5, 114.4, 114.3, 114.2, 114.1, 114.0, 66.6, 66.3, 
49.4, 49.3, 45.5, 44.8, 43.9, 43.8, 43.4, 36.2, 35.4, 26.0, 25.8, 22.5, 22.4; HRMS–ESI (m/z): 




General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol), sodium hydride (28.9 mg, 0.724 mmol), and 2-
(bromomethyl)-1,3-difluorobenzene (74.9 mg, 0.362 mmol) gave 4-((2,6-
difluorobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (51.6 mg, 0.128 
mmol, 35.4 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.20 - 7.34 (m, 1H), 6.79 - 6.94 (m, 2H), 
4.95 (s, 1H), 4.85 (s, 1H), 3.74 - 3.86 (m, 4H), 3.66 - 3.74 (m, 4H), 3.55 (t, J = 7.80 Hz, 1H), 
3.43 (t, J = 7.80 Hz, 1H), 1.46 - 1.59 (m, 1H), 1.34 - 1.46 (m, 2H), 0.90 (d, J = 6.36 Hz, 3H), 
0.87 (d, J = 6.85 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 163.8, 163.7, 163.6, 163.4, 163.0, 
163.0, 162.9, 162.8, 161.0, 160.9, 160.8, 151.9, 151.6, 129.8, 129.7, 129.6, 129.5, 115.6, 112.9, 
111.5, 111.4, 111.3, 66.7, 66.4, 45.1, 44.2, 43.9, 43.4, 37.9, 36.1, 35.2, 26.0, 25.9, 22.5; HRMS–




General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (50 mg, 0.181 mmol), sodium hydride (7.96 mg, 0.199 mmol), and 4-
(bromomethyl)-1,2-difluorobenzene (0.023 ml, 0.181 mmol) gave 4-((3,4-
 160 
difluorobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (62 mg, 0.154 
mmol, 85 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.10 (q, J = 8.80 Hz, 1H), 7.00 - 7.06 (m, 1H), 
6.89 - 6.98 (m, 1H), 4.73 (s, 1H), 4.68 (s, 1H), 3.76 - 3.87 (m, 3H), 3.62 - 3.74 (m, 5H), 3.50 - 
3.56 (m, 1H), 3.41 - 3.48 (m, 1H), 1.48 - 1.58 (m, 1H), 1.38 - 1.46 (m, 2H), 0.90 (t, J = 6.60 Hz, 
6H); 13C NMR (CDCl3, 126 MHz) δ 164.2, 164.0, 163.6, 163.5, 152.1, 151.9, 151.3, 150.7, 
150.6, 149.3, 148.8, 148.6, 148.5, 134.5, 134.4, 123.7, 123.6, 123.2, 123.1, 117.4, 117.3, 117.2, 
116.6, 116.4, 116.2, 116.1, 115.5, 115.4, 66.6, 66.3, 48.9, 45.4, 44.8, 44.0, 43.9, 43.4, 36.2, 35.4, 
31.5, 26.0, 25.9, 22.6, 22.5, 22.4; 19F NMR (CDCl3, 470 MHz) δ -137.2 (m), -139.53 (m); 




General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (75 mg, 0.271 mmol), sodium hydride (11.94 mg, 0.299 mmol), and 1-
(bromomethyl)-2,4-difluorobenzene (0.033 ml, 0.271 mmol) gave 4-((2,4-
difluorobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (86 mg, 0.214 
mmol, 79 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.13 - 7.33 (m, 1H), 6.78 - 6.86 (m, 2H), 4.80 
(s, 1H), 4.75 (s, 1H), 3.76 - 3.86 (m, 3H), 3.63 - 3.74 (m, 5H), 3.52 - 3.60 (m, 1H), 3.45 - 3.52 
(m, 1H), 1.51 - 1.60 (m, 1H), 1.40 - 1.49 (m, 2H), 0.92 (t, J = 6.36 Hz, 6H); 13C NMR (CDCl3, 
126 MHz) δ 164.2, 164.1, 163.6, 163.5, 163.4, 163.3, 163.1, 162.0, 161.9, 161.8, 161.7, 161.4, 
161.3, 161.2, 160.0, 159.9, 159.8, 159.7, 152.0, 151.8, 131.2, 131.1, 130.0, 129.9, 120.4, 120.3, 
120.2, 115.5, 111.6, 111.5, 111.4, 111.3, 104.0, 103.9, 103.8, 103.7, 103.6, 103.5, 66.7, 66.4, 
45.6, 45.1, 44.0, 43.4, 42.9, 42.8, 36.3, 35.5, 26.0, 25.9, 22.5, 22.4; 19F NMR (CDCl3, 470 MHz) 
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General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol) and (bromomethyl)benzene (92.8 mg, 0.543 mmol) gave 4-
(benzyl(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (89.1 mg, 0.243 mmol, 67.2 
% yield); 1H NMR (CDCl3, 500 MHz) δ 7.37 – 7.16 (m, 4H), 4.78 (d, J = 27.6 Hz, 2H), 3.89 – 
3.58 (m, 8H), 3.58 – 3.50 (m, 1H), 3.50 – 3.39 (m, 1H), 1.54 (m, 1H), 1.44 (qd, J = 7.0, 1.4 Hz, 
2H), 0.90 (dd, J = 7.8, 6.5 Hz, 6H). ); 13C NMR (CDCl3, 126 MHz) δ 164.05, 163.69, 163.54, 
152.05, 137.43, 137.31, 128.61, 128.58, 127.77, 127.50, 127.39, 127.32, 115.61, 49.74, 45.29, 
44.67, 36.23, 35.37, 26.05, 25.91, 22.56, 22.51. HRMS–ESI (m/z): [M+H]+ calcd for 
C20H26N6O, 367.2241; found, 367.2284 
 
4-(Isopentyl(phenethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263466) 
General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol), sodium hydride (28.9 mg, 0.724 mmol), and (2-
bromoethyl)benzene (49.2 µl, 0.362 mmol) gave 4-(isopentyl(phenethyl)amino)-6-morpholino-
1,3,5-triazine-2-carbonitrile (15.2 mg, 0.040 mmol, 11.04 % yield); 1H NMR (CDCl3, 500 MHz) 
δ 7.27 (dd, J = 4.65, 6.11 Hz, 1H), 7.21 (d, J = 6.85 Hz, 1H), 4.75 (br. s., 7H), 3.78 (br. s., 3H), 
3.58 - 3.73 (m, 4H), 3.42 - 3.52 (m, 1H), 3.33 - 3.42 (m, 1H), 2.85 (br. s., 1H), 2.03 (br. s., 2H), 
1.49 - 1.62 (m, 1H), 1.36 - 1.47 (m, 2H), 0.77 - 1.00 (m, 6H); 13C NMR (CDCl3, 126 MHz) δ 
163.5, 163.4, 151.7, 138.9, 138.8, 128.8, 128.6, 128.5, 128.4, 126.4, 126.3, 115.6, 66.6, 66.3, 
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49.2, 48.8, 46.0, 45.9, 43.8, 43.3, 39.0, 38.0, 36.6, 35.9, 34.3, 33.5, 25.9, 25.8, 22.5, 22.4; 
HRMS–ESI (m/z): [M+H]+ calcd for, C21H28N6O; 381.2403; found, 381.2401 
 
4-(Isopentyl(3-phenylpropyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263589) 
General Procedure B3 starting from4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and (3-
bromopropyl)benzene (72.0 mg, 0.362 mmol) gave  4-(isopentyl(3-phenylpropyl)amino)-6-
morpholino-1,3,5-triazine-2-carbonitrile (113 mg, 0.286 mmol, 79 % yield); 1H NMR (CDCl3, 
500 MHz) δ 7.25 - 7.34 (m, 2H), 7.14 - 7.25 (m, 3H), 3.80 (br. s., 1H), 3.76 (br. s., 2H), 3.69 - 
3.73 (m, 2H), 3.67 (br. s., 1H), 3.63 (br. s., 1H), 3.50 - 3.58 (m, 2H), 3.41 - 3.50 (m, 3H), 2.60 - 
2.70 (m, 2H), 1.87 - 1.97 (m, 2H), 1.49 - 1.62 (m, 1H), 1.35 - 1.48 (m, 2H), 0.93 (t, J = 7.58 Hz, 
6H); 13C NMR (CDCl3, 126 MHz) δ 163.4, 163.3, 151.7, 141.3, 128.3, 128.2, 125.9, 125.8, 
115.6, 66.6, 66.3, 46.8, 46.4, 45.7, 45.5, 43.8, 43.7, 43.3, 43.1, 36.6, 35.8, 33.2, 32.9, 29.2, 28.4, 




General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol), sodium hydride (28.9 mg, 0.724 mmol), and 8-
(bromomethyl)quinoline (80 mg, 0.362 mmol) gave 4-(isopentyl(quinolin-8-ylmethyl)amino)-6-
morpholino-1,3,5-triazine-2-carbonitrile (41.3 mg, 0.099 mmol, 27.3 % yield); 1H NMR (CDCl3, 
500 MHz) δ 8.90 - 8.98 (m, 1H), 8.14 - 8.22 (m, 1H), 7.74 (d, J = 7.83 Hz, 1H), 7.40 - 7.52 (m, 
3H), 5.52 (s, 1H), 5.48 (s, 1H), 3.82 (br. s., 2H), 3.73 (br. s., 3H), 3.66 - 3.70 (m, 1H), 3.57 - 3.66 
 163 
(m, 2H), 3.45 (br. s., 2H), 1.49 - 1.63 (m, 3H), 0.90 (d, J = 5.87 Hz, 3H), 0.88 (d, J = 5.87 Hz, 
3H); 13C NMR (CDCl3, 126 MHz) δ 164.3, 163.6, 163.5, 151.9, 149.4, 146.5, 146.3, 136.4, 
136.2, 135.4, 135.1, 128.2, 127.2, 127.1, 126.9, 126.4, 126.3, 121.1, 115.7, 115.6, 66.7, 66.6, 
66.4, 66.2, 46.1, 46.0, 45.6, 43.9, 43.8, 43.4, 43.2, 36.5, 35.6, 26.1, 25.9, 22.5; HRMS–ESI 




General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-
(bromomethyl)naphthalene (80 mg, 0.362 mmol) gave 4-(isopentyl(naphthalen-1-
ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (41.3 mg, 0.099 mmol, 27.4 % 
yield); 1H NMR (CDCl3, 500 MHz) δ 7.96 - 8.05 (m, 1H), 7.85 - 7.93 (m, 1H), 7.81 (d, J = 8.31 
Hz, 1H), 7.48 - 7.57 (m, 2H), 7.39 - 7.45 (m, 1H), 7.22 - 7.29 (m, 1H), 5.29 (s, 1H), 5.22 (s, 1H), 
3.85 (br. s., 1H), 3.79 (br. s., 2H), 3.73 (br. s., 2H), 3.68 (br. s., 1H), 3.59 (br. s., 1H), 3.50 - 3.57 
(m, 2H), 3.40 - 3.48 (m, 1H), 1.45 - 1.56 (m, 1H), 1.36 - 1.45 (m, 2H), 0.86 (d, J = 6.85 Hz, 3H), 
0.84 (d, J = 6.36 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 194.0, 193.9, 164.2, 164.0, 163.6, 
163.5, 152.6, 152.6, 152.0, 151.9, 143.5, 133.4, 133.1, 133.0, 132.9, 126.3, 125.8, 124.7, 124.1, 
123.9, 115.6, 115.5, 82.3, 66.7, 66.4, 49.0, 45.5, 44.7, 44.3, 44.2, 44.0, 43.9, 43.4, 38.9, 28.3, 








General Procedure A4 from 4-chloro-N-(1-(4-fluorophenyl)ethyl)-N-isopentyl-6-morpholino-
1,3,5-triazin-2-amine (200 mg, 0.490 mmol), DABCO (110 mg, 0.981 mmol), and potassium 
cyanide (35.1 mg, 0.539 mmol) in DMSO (2 ml) gave 4-((1-(4-
fluorophenyl)ethyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (72 mg, 0.181 
mmol, 36.9 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.21 - 7.30 (m, 2H), 7.01 (t, J = 8.56 Hz, 
2H), 6.15 (q, J = 6.85 Hz, 0.5H), 5.93 (q, J = 6.85 Hz, 0.5H), 3.67 - 3.85 (m, 8H), 3.31 - 3.41 (m, 
0.5H), 3.21 - 3.29 (m, 0.5H), 3.02 - 3.18 (m, 1H), 1.51 - 1.63 (m, 3H), 1.38 - 1.49 (m, 1H), 1.29 - 
1.38 (m, 1H), 1.11 - 1.23 (m, 1H), 0.76 - 0.85 (m, 6H); 13C NMR (CDCl3, 126 MHz) δ 163.7, 
163.6, 163.5, 163.4, 163.0, 161.1, 152.0, 151.7, 136.6, 136.4, 129.0, 128.7, 128.6, 115.6, 115.3, 
115.1, 66.7, 66.4, 52.2, 51.9, 44.0, 43.4, 42.5, 41.9, 37.7, 36.6, 26.7, 26.4, 22.5, 22.4, 22.3, 17.0, 
16.9; HRMS–ESI (m/z): [M+H]+ calcd for, C21H27FN6O; 399.2303; found, 399.2302 
 
N-(1-(4-Fluorophenyl)ethyl)-3-methylbutan-1-amine 
1-(4-Fluorophenyl)ethan-1-one (0.5 ml, 4.12 mmol), 3-methylbutan-1-amine (1.434 ml, 12.36 
mmol), and titanium(iv) isopropoxide (1.810 ml, 6.18 mmol) were added to a flask containing 
MeOH (5 ml) and allowed to stir at room temperature overnight. The next morning, the reaction 
was cooled to 0°C and sodium borohydride (467 mg, 12.36 mmol) was added slowly. The 
reaction was allowed to warm back to room temperature and stirred for 4-6 h. Reaction was then 
quenched slowly with H2O and solvent was removed in vacuo. Crude residue was taken up in 
aqueous bicarbonate, extracted with EtOAc 3x, dried over MgSO4 and concentrated to afford N-
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(1-(4-fluorophenyl)ethyl)-3-methylbutan-1-amine (745 mg, 3.56 mmol, 86 % yield); 1H NMR 
(CDCl3, 500 MHz) δ 7.20 - 7.30 (m, 2H), 7.13 (d, J = 4.40 Hz, 1H), 7.00 (br. t, J = 7.80 Hz, 2H), 
6.14 (br. d, J = 6.80 Hz, 1H), 4.92 - 5.08 (m, 1H), 4.76 - 4.92 (m, 2H), 4.58 - 4.73 (m, 2H), 3.19 - 
3.39 (m, 1H), 2.98 - 3.17 (m, 1H), 1.52 - 1.59 (m, 3H), 1.39 - 1.48 (m, 1H), 1.28 - 1.37 (m, 1H), 




General procedure B1 from 2,4,6-trichloro-1,3,5-triazine (100 mg, 0.542 mmol), N-(1-(4-
fluorophenyl)ethyl)-3-methylbutan-1-amine (114 mg, 0.542 mmol), DIPEA (189 µl, 1.085 
mmol), and oxetan-3-amine (39.6 mg, 0.542 mmol) gave 6-chloro-N2-(1-(4-fluorophenyl)ethyl)-
N2-isopentyl-N4-(oxetan-3-yl)-1,3,5-triazine-2,4-diamine (155 mg, 0.394 mmol, 72.6 % yield); 
1H NMR (CDCl3, 500 MHz) δ 7.20 - 7.30 (m, 2H), 7.13 (d, J = 4.40 Hz, 1H), 7.00 (br. t, J = 7.80 
Hz, 2H), 6.14 (br. d, J = 6.80 Hz, 1H), 4.92 - 5.08 (m, 1H), 4.76 - 4.92 (m, 2H), 4.58 - 4.73 (m, 
2H), 3.19 - 3.39 (m, 1H), 2.98 - 3.17 (m, 1H), 1.52 - 1.59 (m, 3H), 1.39 - 1.48 (m, 1H), 1.28 - 
1.37 (m, 1H), 1.12 - 1.20 (m, 1H), 0.75 - 0.87 (m, 6H) 
 
4-((1-(4-Fluorophenyl)ethyl)(isopentyl)amino)-6-(oxetan-3-ylamino)-1,3,5-triazine-2-
carbonitrile (11-90 (263392)) 
General procedure B2 from 6-chloro-N2-(1-(4-fluorophenyl)ethyl)-N2-isopentyl-N4-(oxetan-3-
yl)-1,3,5-triazine-2,4-diamine (155 mg, 0.394 mmol), potassium cyanide (28.2 mg, 0.433 mmol), 
and DABCO (88 mg, 0.787 mmol) gave 4-((1-(4-fluorophenyl)ethyl)(isopentyl)amino)-6-
(oxetan-3-ylamino)-1,3,5-triazine-2-carbonitrile (72 mg, 0.187 mmol, 47.6 % yield); 1H NMR 
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(DMSO-d6, 400 MHz) δ 7.30 - 7.37 (m, 2H), 7.12 (t, J = 8.80 Hz, 2H), 5.91 (br. s., 1H), 4.86 (br. 
s., 1H), 4.70 (br. s., 2H), 4.53 (br. s., 2H), 3.31 (br. s., 1H), 3.20 (br. s., 1H), 2.99 (br. s., 1H), 
1.55 (d, J = 7.04 Hz, 3H), 1.40 - 1.50 (m, 1H), 1.28 - 1.40 (m, 1H), 1.05 - 1.15 (m, 1H), 0.81 (d, 
J = 7.04 Hz, 3H), 0.79 (d, J = 7.00 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 178.1, 163.8, 163.6, 
163.4, 163.2, 162.8, 160.8, 151.4, 135.9, 128.8, 128.5, 128.4, 115.2, 115.1, 114.9, 78.1, 77.6, 
72.2, 61.3, 52.1, 51.8, 45.6, 42.2, 41.8, 40.1, 39.9, 39.6, 39.4, 37.3, 36.5, 26.4, 26.1, 22.2, 16.8; 




General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (50 
mg, 0.181 mmol), sodium hydride (14.47 mg, 0.362 mmol), and 2-(bromomethyl)pyridine, HBr 
(45.8 mg, 0.181 mmol) gave 4-(isopentyl(pyridin-2-ylmethyl)amino)-6-morpholino-1,3,5-
triazine-2-carbonitrile (16.8 mg, 0.046 mmol, 25.3 % yield); 1H NMR (CDCl3, 500 MHz) δ 8.55 
(d, J = 4.40 Hz, 1H), 7.64 (d, J = 6.85 Hz, 1H), 7.23 (d, J = 7.83 Hz, 0.5H), 7.16 - 7.22 (m, 1H), 
7.11 (d, J = 7.83 Hz, 0.5H), 4.90 (s, 1H), 4.84 (s, 1H), 3.75 - 3.85 (m, 3H), 3.70 - 3.75 (m, 2H), 
3.63 - 3.70 (m, 2H), 3.54 - 3.61 (m, 3H), 1.51 - 1.64 (m, 1H), 1.42 - 1.51 (m, 2H), 0.93 (d, J = 
6.36 Hz, 3H), 0.90 (d, J = 6.85 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 164.2, 164.0, 163.6, 
163.4, 157.6, 157.4, 152.0, 151.9, 149.3, 136.7, 136.6, 122.4, 122.2, 122.0, 120.8, 115.6, 115.5, 
66.7, 66.6, 66.4, 66.3, 52.3, 51.9, 46.3, 45.6, 44.0, 43.4, 36.4, 35.5, 26.0, 25.9, 22.6, 22.5; 





General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (50 
mg, 0.181 mmol), sodium hydride (14.47 mg, 0.362 mmol), and 3-(bromomethyl)pyridine, HBr 
(45.8 mg, 0.181 mmol), gave 4-(isopentyl(pyridin-2-ylmethyl)amino)-6-morpholino-1,3,5-
triazine-2-carbonitrile (35 mg, 0.095 mmol, 52.6 % yield); 1H NMR (CDCl3, 500 MHz) δ 8.47 - 
8.56 (m, 2H), 7.45 - 7.64 (m, 1H), 7.21 - 7.29 (m, 1H), 4.79 (s, 1H), 4.74 (s, 1H), 3.83 (br. s., 
1H), 3.78 (br. s., 2H), 3.70 - 3.74 (m, 2H), 3.68 (br. s., 1H), 3.63 (br. s., 2H), 3.53 - 3.59 (m, 1H), 
3.43 - 3.49 (m, 1H), 1.49 - 1.63 (m, 1H), 1.38 - 1.49 (m, 2H), 0.91 (d, J = 6.60 Hz, 3H), 0.90 (d, 
J = 6.60 Hz, 4H); 13C NMR (CDCl3, 126 MHz) δ 164.2, 164.1, 163.6, 163.4, 152.0, 151.9, 149.2, 
149.1, 149.0, 148.9, 135.6, 134.8, 133.1, 133.0, 123.5, 115.5, 115.4, 66.7, 66.6, 66.4, 66.3, 47.6, 
47.5, 45.7, 44.9, 44.0, 43.9, 43.4, 36.3, 35.5, 26.0, 25.9, 22.5; HRMS–ESI (m/z): [M+H]+ calcd 




General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (28.9 mg, 0.724 mmol), and 4-(chloromethyl)pyridine, HCl 
(59.4 mg, 0.362 mmol) gave 4-(isopentyl(pyridin-4-ylmethyl)amino)-6-morpholino-1,3,5-
triazine-2-carbonitrile (82.4 mg, 0.224 mmol, 62.0 % yield); 1H NMR (CDCl3, 500 MHz) δ 8.48 
- 8.59 (m, 2H), 7.09 (dd, J = 4.89, 9.78 Hz, 2H), 4.78 (s, 1H), 4.70 (s, 1H), 3.82 (br. s., 1H), 3.74 
- 3.80 (m, 2H), 3.71 (br. s., 2H), 3.65 (br. s., 1H), 3.51 - 3.61 (m, 3H), 3.41 - 3.50 (m, 1H), 1.48 - 
1.62 (m, 1H), 1.36 - 1.48 (m, 2H), 0.90 (d, J = 6.85 Hz, 3H), 0.88 (d, J = 6.85 Hz, 3H); 13C NMR 
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(CDCl3, 126 MHz) δ 164.3, 164.2, 163.5, 163.3, 152.0, 151.9, 149.9, 146.7, 146.5, 122.2, 121.8, 
115.4, 115.3, 66.6, 66.5, 66.3, 66.2, 49.3, 49.1, 46.1, 45.3, 43.9, 43.8, 43.4, 43.3, 36.4, 35.5, 25.9, 
25.8, 22.5, 22.4; HRMS–ESI (m/z): [M+H]+ calcd for, C19H25N7O; 368.2193; found, 368.2195 
 
4-((4-Chlorobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263578) 
General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (28.9 mg, 0.724 mmol), and 1-(bromomethyl)-4-
chlorobenzene (74.4 mg, 0.362 mmol) gave 4-((4-chlorobenzyl)(isopentyl)amino)-6-morpholino-
1,3,5-triazine-2-carbonitrile (60.6 mg, 0.151 mmol, 41.8 % yield); 1H NMR (CDCl3, 500 MHz) δ 
7.25 - 7.32 (m, 2H), 7.11 - 7.19 (m, 2H), 4.76 (s, 1H), 4.70 (s, 1H), 3.83 (br. s., 1H), 3.79 (br. s., 
2H), 3.71 - 3.75 (m, 2H), 3.69 (br. s., 1H), 3.64 (br. s., 2H), 3.53 (t, J = 7.80 Hz, 1H), 3.44 (t, J = 
7.80 Hz, 1H), 1.48 - 1.59 (m, 1H), 1.39 - 1.47 (m, 2H), 0.90 (t, J = 6.60 Hz, 6H); 13C NMR 
(CDCl3, 126 MHz) δ 164.2, 164.0, 163.6, 163.5, 152.1, 151.9, 135.9, 135.8, 133.3, 133.1, 131.5, 
129.1, 128.7, 128.6, 115.6, 115.5, 66.7, 66.4, 49.2, 45.4, 44.7, 44.0, 43.4, 36.2, 35.4, 26.0, 25.9, 
22.5; HRMS–ESI (m/z): [M+H]+ calcd for, C20H25CIN6O; 401.1857; found, 401.1867 
 
4-((4-Acetylbenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263582) 
From 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 mg, 0.362 mmol), 
sodium hydride (21.71 mg, 0.543 mmol), and 1-(4-(bromomethyl)phenyl)ethan-1-one (77 mg, 
0.362 mmol) gave 4-((4-acetylbenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (31.1 mg, 0.076 mmol, 21.04 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.91 (d, J = 
7.34 Hz, 2H), 7.23 - 7.32 (m, 2H), 4.84 (s, 1H), 4.78 (s, 1H), 3.83 (br. s., 1H), 3.79 (br. s., 1H), 
3.73 (d, J = 4.40 Hz, 2H), 3.64 - 3.70 (m, 2H), 3.59 - 3.64 (m, 2H), 3.56 (t, J = 7.80 Hz, 1H), 
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3.46 (t, J = 7.80 Hz, 1H), 2.59 (s, 3H), 1.49 - 1.61 (m, 1H), 1.38 - 1.49 (m, 2H), 0.90 (t, J = 7.58 
Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 197.6, 164.3, 164.1, 163.6, 163.4, 152.0, 151.9, 143.0, 
142.9, 136.4, 136.3, 129.8, 128.7, 127.9, 127.6, 127.2, 115.5, 70.7, 70.6, 70.4, 70.3, 69.2, 68.7, 
66.7, 66.6, 66.4, 66.3, 49.7, 45.7, 45.1, 44.0, 43.9, 43.4, 36.3, 35.4, 26.6, 26.0, 25.9, 22.5; 
HRMS–ESI (m/z): [M+H]+ calcd for, C22H28N6O; 409.2347; found, 409.2350 
 
4-(isopentyl(2-methylbenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (264183) 
General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol) and 1-(bromomethyl)-2-methylbenzene (100 mg, 0.543 
mmol) gave 4-(isopentyl(2-methylbenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(78.7 mg, 0.207 mmol, 57.2 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.22 – 7.10 (m, 3H), 7.08 – 
6.98 (m, 1H), 4.79 (d, J = 28.6 Hz, 2H), 3.91 – 3.56 (m, 8H), 3.52 (s, 1H), 3.49 – 3.40 (m, 1H), 
2.30 (d, J = 4.5 Hz, 3H), 1.59 – 1.48 (m, 1H), 1.48 – 1.37 (m, 2H), 0.90 (dd, J = 6.6, 5.3 Hz, 6H). 
13C NMR (CDCl3, 126 MHz) δ 164.03, 163.70, 151.96, 136.29, 135.91, 134.88, 134.78, 130.50, 
130.43, 127.36, 127.31, 127.19, 127.17, 126.11, 126.02, 115.60, 66.37, 47.73, 47.52, 44.97, 
44.64, 36.15, 35.32, 26.12, 25.98, 22.58, 22.53, 19.21. HRMS–ESI (m/z): [M+H]+ calcd for 
C21H28N6O, 381.2397; found, 381.2401 
 
4-(Isopentyl(3-methylbenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263590) 
General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-(bromomethyl)-3-
methylbenzene (67.0 mg, 0.362 mmol) gave 4-(isopentyl(3-methylbenzyl)amino)-6-morpholino-
1,3,5-triazine-2-carbonitrile (69.7 mg, 0.183 mmol, 50.6 % yield); 1H NMR (CDCl3, 500 MHz) δ 
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7.21 (t, J = 7.58 Hz, 1H), 7.09 (d, J = 7.34 Hz, 1H), 6.97 - 7.04 (m, 2H), 4.77 (s, 1H), 4.72 (s, 
1H), 3.83 (br. s., 1H), 3.80 (br. s., 2H), 3.71 - 3.75 (m, 2H), 3.69 (br. s., 2H), 3.65 (br. s., 1H), 
3.51 - 3.57 (m, 1H), 3.43 - 3.48 (m, 1H), 2.34 (d, J = 2.93 Hz, 3H), 1.49 - 1.60 (m, 1H), 1.40 - 
1.48 (m, 2H), 0.91 (t, J = 7.09 Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 164.1, 163.9, 163.6, 
163.5, 152.0, 151.9, 138.2, 137.3, 137.1, 128.5, 128.4, 128.2, 128.1, 128.0, 115.6, 66.7, 66.6, 
66.4, 49.6, 49.5, 45.1, 44.5, 43.9, 43.4, 36.1, 35.3, 26.0, 25.9, 22.5, 21.4; HRMS–ESI (m/z): 
[M+H]+ calcd for, 381.2397; C21H28N6O; found, 381.2398  
 
4-(Isopentyl(4-methylbenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263591) 
General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-(bromomethyl)-4-
methylbenzene (67.0 mg, 0.362 mmol) gave 4-(isopentyl(4-methylbenzyl)amino)-6-morpholino-
1,3,5-triazine-2-carbonitrile (88 mg, 0.231 mmol, 63.9 % yield); 1H NMR (CDCl3, 500 MHz) δ 
7.07 - 7.20 (m, 4H), 4.76 (s, 1H), 4.71 (s, 1H), 3.82 (br. s., 1H), 3.79 (br. s., 2H), 3.71 - 3.74 (m, 
2H), 3.69 (br. s., 2H), 3.65 (br. s., 1H), 3.49 - 3.57 (m, 1H), 3.40 - 3.49 (m, 1H), 2.34 (s, 3H), 
1.50 - 1.59 (m, 1H), 1.41 - 1.50 (m, 2H), 0.91 (t, J = 6.36 Hz, 6H); 13C NMR (CDCl3, 126 MHz) 
δ 164.1, 163.9, 163.6, 163.5, 152.0, 151.9, 137.1, 137.0, 134.2, 129.2, 127.7, 127.3, 115.6, 66.6, 
66.4, 60.3, 49.4, 49.3, 45.0, 44.5, 43.9, 43.8, 43.4, 36.1, 35.3, 26.0, 25.9, 22.5, 21.1, 21.0; 







General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol) and 1-(bromomethyl)-3,5-
dimethylbenzene (72.0 mg, 0.362 mmol) gave 4-((3,5-dimethylbenzyl)(isopentyl)amino)-6-
morpholino-1,3,5-triazine-2-carbonitrile (34.4 mg, 0.087 mmol, 24.10 % yield); 1H NMR 
(CDCl3, 500 MHz) δ 6.92 (s, 1H), 6.83 (s, 2H), 4.74 (s, 1H), 4.69 (s, 1H), 3.78 - 3.87 (m, 3H), 
3.68 - 3.76 (m, 4H), 3.62 - 3.68 (m, 1H), 3.51 - 3.57 (m, 1H), 3.42 - 3.49 (m, 1H), 2.31 (br. s., 
3H), 2.30 (br. s., 3H), 1.55 (td, J = 6.66, 13.57 Hz, 1H), 1.41 - 1.49 (m, 2H), 0.93 (d, J = 7.10 
Hz, 3H), 0.91 (d, J = 7.10 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 164.1, 163.9, 163.6, 163.5, 
152.0, 151.9, 138.1, 138.1, 137.2, 137.0, 129.1, 129.0, 125.4, 125.1, 115.6, 115.6, 66.6, 66.4, 
49.4, 49.4, 45.0, 44.4, 43.9, 43.4, 36.1, 35.2, 26.0, 25.9, 22.5, 22.5, 21.3; HRMS–ESI (m/z): 




General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-(bromomethyl)-2,3-
dimethylbenzene (72.0 mg, 0.362 mmol) gave 4-((2,3-dimethylbenzyl)(isopentyl)amino)-6-
morpholino-1,3,5-triazine-2-carbonitrile (63.5 mg, 0.161 mmol, 44.5 % yield); 1H NMR (CDCl3, 
500 MHz) δ 7.10 (d, J = 7.34 Hz, 1H), 7.05 (t, J = 7.58 Hz, 1H), 6.89 (dd, J = 7.58, 15.41 Hz, 
1H), 4.82 (s, 1H), 4.77 (s, 1H), 3.82 (d, J = 14.18 Hz, 3H), 3.74 (d, J = 4.40 Hz, 2H), 3.69 (br. s., 
1H), 3.64 (br. s., 2H), 3.45 - 3.50 (m, 1H), 3.40 - 3.45 (m, 1H), 2.31 (s, 3H), 2.18 (d, J = 6.36 Hz, 
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3H), 1.52 (qd, J = 6.66, 13.27 Hz, 1H), 1.37 - 1.46 (m, 2H), 0.89 (d, J = 3.91 Hz, 3H), 0.88 (d, J 
= 3.91 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 163.9, 163.7, 163.5, 152.0, 151.9, 137.2, 137.1, 
134.8, 134.6, 134.5, 129.1, 125.5, 125.4, 125.3, 125.1, 115.7, 115.6, 66.7, 66.4, 48.2, 47.9, 44.6, 
44.4, 43.9, 43.4, 36.0, 35.2, 26.1, 25.9, 22.5, 20.5, 20.4, 14.8; HRMS–ESI (m/z): [M+H]+ calcd 
for, C22H30N6O; 395.2554; found, 395.2555 
 
4-(Isopentyl(3-methoxybenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263585) 
General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-(bromomethyl)-3-
methoxybenzene (72.8 mg, 0.362 mmol) gave 4-(isopentyl(3-methoxybenzyl)amino)-6-
morpholino-1,3,5-triazine-2-carbonitrile (70.2 mg, 0.177 mmol, 48.9 % yield); 1H NMR (CDCl3, 
500 MHz) δ 7.17 - 7.30 (m, 1H), 6.74 - 6.83 (m, 3H), 4.77 (s, 1H), 4.71 (s, 1H), 3.82 (br. s., 1H), 
3.79 (d, J = 6.36 Hz, 5H), 3.70 - 3.74 (m, 2H), 3.68 (br. s., 2H), 3.63 (br. s., 1H), 3.51 - 3.58 (m, 
1H), 3.42 - 3.49 (m, 1H), 1.49 - 1.60 (m, 1H), 1.40 - 1.49 (m, 2H), 0.91 (t, J = 6.85 Hz, 6H); 13C 
NMR (CDCl3, 126 MHz) δ 164.1, 164.0, 163.6, 163.5, 159.8, 152.0, 151.9, 139.0, 138.9, 129.6, 
129.5, 120.0, 119.6, 115.6, 115.5, 113.6, 113.4, 112.4, 112.1, 66.7, 66.3, 55.2, 49.6, 45.2, 44.7, 
43.9, 43.8, 43.4, 36.2, 35.3, 26.0, 25.9, 22.5; HRMS–ESI (m/z): [M+H]+ calcd for, C21H28N6O2; 




General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-(bromomethyl)-3-
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(trifluoromethyl)benzene (86 mg, 0.362 mmol) gave 4-(isopentyl(3-
(trifluoromethyl)benzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (119 mg, 0.274 
mmol, 76 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.52 - 7.58 (m, 1H), 7.43 - 7.52 (m, 2H), 7.36 
- 7.43 (m, 1H), 4.85 (s, 1H), 4.78 (s, 1H), 3.82 - 3.88 (m, 1H), 3.77 - 3.82 (m, 2H), 3.71 - 3.77 
(m, 2H), 3.68 (br. s., 1H), 3.56 - 3.66 (m, 3H), 3.45 - 3.51 (m, 1H), 1.50 - 1.61 (m, 1H), 1.37 - 
1.50 (m, 2H), 0.92 (d, J = 6.36 Hz, 3H), 0.90 (d, J = 6.36 Hz, 3H); 13C NMR (CDCl3, 126 MHz) 
δ 164.2, 164.1, 163.6, 163.4, 152.0, 151.9, 138.7, 138.4, 131.0, 130.7, 130.4, 129.1, 124.3, 124.2, 
124.1, 115.5, 115.4, 66.6, 66.3, 66.2, 49.7, 49.5, 45.8, 44.9, 43.9, 43.4, 43.3, 36.3, 35.4, 26.0, 
25.8, 22.5, 22.4; HRMS–ESI (m/z): [M+H]+ calcd for,C21H25F3N6O; 435.2115; found, 435.2095 
 
4-(Isopentyl(2-nitrobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263592) 
General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (150 
mg, 0.543 mmol), sodium hydride (32.6 mg, 0.814 mmol), 1-(bromomethyl)-2-nitrobenzene 
(117 mg, 0.543 mmol) gave 4-(isopentyl(2-nitrobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (46.8 mg, 0.114 mmol, 20.95 % yield); 1H NMR (CDCl3, 500 MHz) δ 8.01 - 8.13 
(m, 1H), 7.57 (t, J = 7.58 Hz, 1H), 7.39 - 7.48 (m, 1H), 7.20 (t, J = 9.30 Hz, 1H), 5.15 (s, 1H), 
5.03 (s, 1H), 3.82 (br. s., 2H), 3.73 (br. s., 3H), 3.57 - 3.67 (m, 2H), 3.46 - 3.57 (m, 2H), 3.42 (br. 
s., 1H), 1.53 - 1.62 (m, 1H), 1.45 - 1.53 (m, 2H), 0.92 (d, J = 6.36 Hz, 3H), 0.90 (d, J = 6.36 Hz, 
3H); 13C NMR (CDCl3, 126 MHz) δ 164.4, 164.3, 163.5, 163.3, 152.0, 151.9, 148.3, 148.2, 
133.6, 133.4, 133.3, 128.1, 128.0, 127.9, 127.8, 125.3, 125.0, 115.4, 115.2, 66.6, 66.5, 66.3, 66.1, 
47.8, 47.7, 46.5, 45.9, 43.9, 43.8, 43.4, 43.2, 36.4, 35.5, 26.0, 25.9, 22.5, 22.4; HRMS–ESI 




General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (150 
mg, 0.543 mmol), sodium hydride (32.6 mg, 0.814 mmol), and 1-(bromomethyl)-3-nitrobenzene 
(117 mg, 0.543 mmol) gave 4-(isopentyl(3-nitrobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (43.2 mg, 0.105 mmol, 19.34 % yield); 1H NMR (CDCl3, 500 MHz) δ 8.09 (br. s., 
1H), 7.99 - 8.08 (m, 1H), 7.56 (t, J = 7.83 Hz, 1H), 7.49 (t, J = 8.31 Hz, 1H), 4.86 (s, 1H), 4.80 
(s, 1H), 3.75 - 3.84 (m, 3H), 3.70 (br. s., 2H), 3.54 - 3.66 (m, 4H), 3.44 - 3.53 (m, 1H), 1.52 (tt, J 
= 6.60, 12.96 Hz, 1H), 1.39 - 1.48 (m, 2H), 0.88 (t, J = 6.36 Hz, 6H); 13C NMR (CDCl3, 126 
MHz) δ 164.1, 164.0, 163.4, 163.3, 151.9, 151.8, 148.2, 139.8, 139.7, 133.6, 133.2, 129.5, 122.3, 
122.2, 122.1, 122.0, 115.3, 66.5, 66.4, 66.2, 66.1, 60.2, 49.3, 49.2, 45.8, 45.1, 43.8, 43.3, 36.2, 




General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-(bromomethyl)-4-
nitrobenzene (78 mg, 0.362 mmol) gave 4-(isopentyl(4-nitrobenzyl)amino)-6-morpholino-1,3,5-
triazine-2-carbonitrile (49 mg, 0.119 mmol, 32.9 % yield); 1H NMR (CDCl3, 500 MHz) δ 8.18 
(d, J = 7.83 Hz, 2H), 7.32 - 7.41 (m, 2H), 4.88 (s, 1H), 4.82 (s, 1H), 3.84 (br. s., 1H), 3.79 (br. s., 
2H), 3.72 - 3.74 (m, 2H), 3.68 (br. s., 1H), 3.55 - 3.62 (m, 3H), 3.46 - 3.52 (m, 1H), 1.52 - 1.60 
(m, 1H), 1.39 - 1.50 (m, 2H), 0.91 (t, J = 6.85 Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 164.4, 
164.2, 163.6, 163.5, 152.1, 152.0, 147.4, 147.3, 145.2, 145.1, 128.2, 127.7, 123.9, 115.4, 66.7, 
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66.6, 66.4, 66.2, 49.6, 46.0, 45.3, 44.0, 43.9, 43.5, 43.4, 36.4, 35.5, 26.0, 25.9, 22.5; HRMS–ESI 
(m/z): [M+H]+ calcd for, C20H25N7O3; 412.2092; found, 412.2097 
 
4-((2-Aminobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263659) 
In a round bottom flask, 4-(isopentyl(2-nitrobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (50 mg, 0.122 mmol) was dissolved into acetone (10 ml). Zinc dust (159 mg, 2.430 
mmol) was then added, followed by the addition of aq. ammonium chloride (0.694 ml, 4.86 
mmol). Reaction was left to stir for 30 min until TLC indicated starting material was consumed. 
Reaction was poured into water and extracted 3x with EtOAc. Combined organic layers were 
dried over sodium sulfate and concentrated in vacuo. Crude residue was purified by flash 
chromatography (0-100% EtOAc:Hexanes gradient) to afford 4-((2-aminobenzyl) 
(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (42 mg, 0.110 mmol, 91 % yield); 
1H NMR (CDCl3, 500 MHz) δ 7.09 - 7.17 (m, 1H), 7.06 (d, J = 7.34 Hz, 1H), 6.70 (q, J = 7.83 
Hz, 1H), 6.65 (d, J = 7.83 Hz, 1H), 4.68 (br. s, 2H), 4.34 (br. s., 1H), 3.83 (br. s., 2H), 3.76 (br. 
s., 2H), 3.71 (br. s., 4H), 3.39 - 3.50 (m, 2H), 1.47 - 1.57 (m, 1H), 1.33 - 1.44 (m, 2H), 0.89 (d, J 
= 6.36 Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 163.5, 163.4, 163.1, 152.2, 151.6, 146.0, 145.6, 
131.4, 131.4, 129.4, 129.3, 119.7, 119.6, 117.8, 117.5, 115.7, 115.4, 115.4, 66.7, 66.4, 47.3, 47.0, 
44.0, 43.8, 43.6, 43.5, 35.4, 34.7, 26.2, 26.0, 22.5, 22.5; HRMS–ESI (m/z): [M+H]+ calcd for, 
C20H27N7O; 382.2350; found, 382.2344 
 
4-((3-Aminobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263660) 
In a round bottom flask, 4-(isopentyl(3-nitrobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (50 mg, 0.122 mmol) was dissolved into acetone (10 ml). Zinc dust (159 mg, 2.430 
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mmol) was then added, followed by the addition of aq. ammonium chloride (0.694 ml, 4.86 
mmol). Reaction was left to stir for 30 min until TLC indicated starting material was consumed. 
Reaction was poured into water and extracted 3x with EtOAc. Combined organic layers were 
dried over sodium sulfate and concentrated in vacuo. Crude residue was purified by flash 
chromatography (0-100% EtOAc:Hexanes gradient) to afford 4-((3-aminobenzyl) 
(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (32 mg, 0.084 mmol, 69.0 % 
yield); 1H NMR (CDCl3, 500 MHz) δ 7.03 - 7.16 (m, 1H), 6.56 - 6.63 (m, 2H), 6.54 (s, 0.5H), 
6.49 (s, 0.5H), 4.71 (s, 1H), 4.66 (s, 1H), 3.82 (br. s., 1H), 3.79 (br. s., 2H), 3.71 - 3.75 (m, 2H), 
3.62 - 3.71 (m, 5H), 3.50 - 3.56 (m, 1H), 3.41 - 3.47 (m, 1H), 1.48 - 1.59 (m, 1H), 1.39 - 1.48 (m, 
2H), 0.91 (t, J = 7.09 Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 164.1, 163.9, 163.6, 163.5, 152.0, 
151.9, 146.7, 138.6, 138.5, 129.5, 129.4, 118.0, 117.5, 115.6, 115.6, 114.3, 114.1, 114.1, 113.5, 
66.7, 66.7, 66.4, 49.5, 49.5, 45.1, 44.5, 43.9, 43.9, 43.4, 36.1, 35.3, 26.0, 25.9, 22.6, 22.5; 
HRMS–ESI (m/z): [M+H]+ calcd for, C20H27N7O; 382.2350; found, 382.2348 
 
4-((4-Aminobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263686) 
In a round bottom flask, 4-(isopentyl(4-nitrobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.243 mmol) was dissolved into acetone (10 ml). Zinc dust (318 mg, 4.86 
mmol) was then added, followed by the addition of aq. ammonium chloride (1.389 ml, 9.72 
mmol). Reaction was left to stir for 30 min until TLC indicated starting material was consumed. 
Reaction was poured into water and extracted 3x with EtOAc. Combined organic layers were 
dried over sodium sulfate and concentrated in vacuo. Crude residue was purified by flash 
chromatography (0-100% EtOAc:Hexanes gradient) to afford   4-((4-aminobenzyl)(isopentyl) 
amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (45.6mg, 0.120 mmol, 49.2 % yield); 1H 
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NMR (CDCl3, 500 MHz) δ 7.04 (d, J = 8.31 Hz, 1H), 7.01 (d, J = 8.31 Hz, 1H), 6.63 (d, J = 7.34 
Hz, 2H), 4.67 (s, 1H), 4.63 (s, 1H), 3.80 (br. s., 2H), 3.76 (br. s., 2H), 3.69 - 3.73 (m, 3H), 3.67 
(br. s., 3H), 3.46 - 3.53 (m, 1H), 3.39 - 3.45 (m, 1H), 1.47 - 1.59 (m, 1H), 1.36 - 1.45 (m, 2H), 
0.90 (t, J = 6.11 Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 163.9, 163.7, 163.6, 163.5, 151.9, 
151.8, 145.8, 129.2, 128.7, 127.0, 115.6, 115.0, 66.7, 66.4, 49.2, 49.0, 44.7, 44.2, 43.9, 43.9, 





General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol), sodium hydride (21.71 mg, 0.543 mmol), and 1-(2-chloroethyl)pyrrolidine 
(48.4 mg, 0.362 mmol). Compound was purified by flash chromatography (1-10% MeOH:DCM) 
to afford 4-(isopentyl(2-(pyrrolidin-1-yl)ethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(25 mg, 0.067 mmol, 18.50 % yield); 1H NMR (CDCl3, 500 MHz) δ 3.71 - 3.84 (m, 4H), 3.66 - 
3.71 (m, 4H), 3.56 - 3.66 (m, 2H), 3.45 - 3.56 (m, 2H), 2.62 (t, J = 7.09 Hz, 2H), 2.51 - 2.58 (m, 
4H), 1.70 - 1.84 (m, 4H), 1.48 - 1.62 (m, 1H), 1.37 - 1.48 (m, 2H), 0.91 (t, J = 5.62 Hz, 6H); 13C 
NMR (CDCl3, 126 MHz) δ 163.5, 151.7, 115.6, 66.6, 66.4, 57.8, 54.4, 54.3, 54.1, 53.7, 52.9, 
51.2, 46.3, 46.2, 46.1, 45.9, 43.8, 43.3, 36.6, 35.8, 26.0, 25.8, 23.4, 22.5; HRMS–ESI (m/z): 






General procedure B3 from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 
mg, 0.362 mmol),sodium hydride (15.92 mg, 0.398 mmol), and 2-(bromomethyl)benzonitrile 
(70.9 mg, 0.362 mmol) gave 4-((2-cyanobenzyl)(isopentyl)amino)-6-morpholino-1,3,5-triazine-
2-carbonitrile (108 mg, 0.276 mmol, 76 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.64 (d, J = 
7.34 Hz, 1H), 7.49 - 7.58 (m, 1H), 7.33 - 7.40 (m, 1H), 7.29 (dd, J = 7.83, 24.94 Hz, 1H), 5.00 
(s, 1H), 4.93 (s, 1H), 3.79 (br. s., 2H), 3.74 (br. s., 1H), 3.70 (br. s., 2H), 3.53 - 3.66 (m, 4H), 
3.45 - 3.53 (m, 1H), 1.54 (s, 1H), 1.39 - 1.50 (m, 2H), 0.89 (t, J = 6.85 Hz, 6H); 13C NMR 
(CDCl3, 126 MHz) δ 164.1, 163.4, 163.2, 151.9, 151.7, 141.4, 141.2, 133.0, 132.9, 132.7, 128.0, 
127.8, 127.6, 127.2, 117.2, 117.1, 115.3, 115.2, 111.5, 111.1, 66.4, 66.2, 66.1, 48.1, 47.9, 46.0, 
45.3, 43.8, 43.7, 43.3, 43.2, 36.2, 35.3, 25.8, 25.7, 22.3; HRMS–ESI (m/z): [M+H]+ calcd for, 




General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol) and 1-(bromomethyl)-2-(trifluoromethyl)benzene (130 mg, 
0.543 mmol) gave 4-(isopentyl(2-(trifluoromethyl)benzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (89.8 mg, 0.207 mmol, 57.1 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.67 (d, J = 7.6 
Hz, 1H), 7.55 – 7.45 (m, 1H), 7.36 (s, 1H), 7.19 (d, J = 7.8 Hz, 1H), 4.97 (d, J = 46.9 Hz, 2H), 
3.90 – 3.69 (m, 4H), 3.69 – 3.37 (m, 5H), 1.65 – 1.40 (m, 3H), 1.25 (t, J = 7.1 Hz, 1H), 0.91 (dd, 
J = 16.1, 6.5 Hz, 6H). 13C NMR (CDCl3, 126 MHz) δ 164.44, 163.70, 163.47, 152.10, 136.15, 
132.15, 132.07, 131.59, 127.81, 127.21, 127.08, 127.05, 126.04, 125.99, 115.58, 115.44, 66.58, 
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66.25, 46.59, 46.56, 46.18, 46.08, 46.06, 45.16, 44.01, 43.90, 43.49, 43.28, 36.34, 35.33, 26.04, 
25.93, 22.46, 22.44. 19F NMR (470 MHz, Chloroform-d) δ -58.77, -59.85, -60.32. HRMS–ESI 




General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (250 mg, 0.905 mmol) and methyl 2-(bromomethyl)benzoate (311 mg, 1.36 mmol) 
gave methyl 2-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(isopentyl)amino)methyl)benzoate 
(41.2 mg, 0.097 mmol, 10.7 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.99 (ddd, J = 12.2, 7.8, 1.4 
Hz, 1H), 7.45 (td, J = 7.6, 1.4 Hz, 1H), 7.36 – 7.28 (m, 1H), 7.11 (d, J = 7.9 Hz, 1H), 5.22 (s, 
1H), 5.13 (s, 1H), 3.92 (d, J = 4.0 Hz, 3H), 3.87 – 3.68 (m, 4H), 3.68 – 3.40 (m, 5H), 1.63 – 1.43 
(m, 3H), 1.33 – 1.19 (m, 1H), 0.90 (dd, J = 9.0, 6.4 Hz, 6H). 13C NMR (CDCl3, 126 MHz) δ 
164.33, 163.67, 163.49, 152.00, 139.49, 139.48, 132.49, 132.44, 131.14, 130.96, 128.78, 128.53, 
126.96, 126.91, 126.77, 126.66, 115.65, 66.72, 66.43, 66.32, 52.10, 48.54, 48.43, 46.21, 45.70, 
43.96, 43.84, 43.45, 43.30, 36.41, 35.52, 26.12, 25.98, 22.55, 22.50. HRMS–ESI (m/z): [M+H]+ 
calcd for C22H28N6O3, 425.2296; found, 425.2301 
 
4-(Isopentyl(2-methoxybenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (264186) 
General Procedure B3 starting from 4-(isopentylamino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.362 mmol) and 1-(chloromethyl)-2-methoxybenzene (85.0 mg, 0.543 
mmol) gave 4-(isopentyl(2-methoxybenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(47.8 mg, 0.121 mmol, 33.3 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.29 – 7.16 (m, 1H), 7.16 – 
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7.04 (m, 1H), 6.96 – 6.81 (m, 2H), 4.80 (d, J = 24.9 Hz, 2H), 3.85 (s, 3H), 3.83 – 3.59 (m, 7H), 
3.59 – 3.45 (m, 2H), 1.60 – 1.51 (m, 1H), 1.50 – 1.43 (m, 2H), 0.92 (dd, J = 6.5, 4.4 Hz, 6H). 13C 
NMR (CDCl3, 126 MHz) δ 164.11, 163.66, 157.40, 128.51, 128.46, 128.34, 128.07, 125.40, 
125.22, 120.52, 120.48, 115.69, 110.26, 110.23, 55.29, 45.54, 45.19, 44.55, 44.34, 36.34, 35.52, 




In a dry reaction vial, 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (50 
mg, 0.159 mmol) was dissolved into DMF (1 ml). Cesium carbonate (104 mg, 0.318 mmol) and 
1-bromopropane (0.029 ml, 0.318 mmol) were added to the solution and the reaction was left to 
stir at 80°C overnight. Reaction was cooled to room temperature, poured into EtOAc and washed 
3x with brine. Organic layers were combined, dried over sodium sulfate, and concentrated. 
Crude residue was purified by flash chromatography (0-100% EtOAc:Hexanes gradient) to 
afford 4-((4-fluorobenzyl)(propyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (24 mg, 
0.067 mmol, 42.3 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.11 - 7.25 (m, 2H), 6.97 - 7.04 (m, 
2H), 4.77 (s, 1H), 4.72 (s, 1H), 3.82 (br. s., 1H), 3.77 (br. s., 1H), 3.71 - 3.74 (m, 2H), 3.62 - 3.71 
(m, 3H), 3.44 - 3.51 (m, 1H), 3.35 - 3.43 (m, 1H), 1.53 - 1.59 (m, 2H), 0.85 - 0.91 (m, 3H); 13C 
NMR (CDCl3, 126 MHz) δ 164.2, 164.1, 163.6, 163.5, 163.1, 163.0, 161.2, 161.1, 152.0, 151.9, 
133.1, 129.4, 128.9, 128.8, 115.6, 115.5, 115.3, 68.2, 66.6, 66.4, 66.3, 49.3, 49.2, 48.5, 48.0, 
43.9, 43.7, 43.4, 20.7, 20.1, 11.5, 11.2, 10.4; HRMS–ESI (m/z): [M+H]+ calcd for, C18H21FN6O; 




General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (19.09 mg, 0.477 mmol) and 1-bromobutane 
(43.6 mg, 0.318 mmol) gave 4-(butyl(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (97 mg, 0.262 mmol, 82 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.14 - 7.25 (m, 
2H), 6.99 (t, J = 8.56 Hz, 2H), 4.76 (s, 1H), 4.72 (s, 1H), 3.75 - 3.88 (m, 3H), 3.59 - 3.75 (m, 
5H), 3.51 (t, J = 7.58 Hz, 1H), 3.43 (t, J = 7.58 Hz, 1H), 1.53 (t, J = 7.34 Hz, 2H), 1.23 - 1.37 
(m, 2H), 0.86 - 0.97 (m, 3H); 13C NMR (CDCl3, 126 MHz) δ 164.2, 164.0, 163.6, 163.4, 163.1, 
163.0, 161.2, 161.0, 152.0, 151.9, 133.1, 129.4, 129.3, 128.9, 128.8, 115.5, 115.4, 115.3, 115.2, 
66.6, 66.3, 49.1, 46.5, 45.9, 43.9, 43.4, 29.5, 28.8, 20.1, 19.9, 13.8, 13.7; 19F NMR (CDCl3, 470 
MHz) δ -115.01; HRMS–ESI (m/z): [M+H]+ calcd for, C19H23FN6O; 371.1990; found, 371.1989 
 
4-(But-3-en-1-yl(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263255) 
In a dry reaction vessel, 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(50 mg, 0.159 mmol) was dissolved into DMF (1 ml). Potassium carbonate (44.0 mg, 0.318 
mmol) and 4-bromobut-1-ene (43.0 mg, 0.318 mmol) were added to the solution and the reaction 
was left to stir at 80°C overnight. Reaction was cooled to room temperature, poured into EtOAc 
and washed 3x with brine. Organic layers were combined, dried over sodium sulfate, and 
concentrated. Crude residue was purified by flash chromatography (0-100% EtOAc:Hexanes 
gradient) to afford 4-(but-3-en-1-yl(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (25 mg, 0.068 mmol, 42.7 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.15 - 7.24 (m, 
2H), 6.97 - 7.04 (m, 2H), 5.66 - 5.84 (m, 1H), 5.00 - 5.09 (m, 2H), 4.78 (s, 1H), 4.73 (s, 1H), 
3.75 - 3.87 (m, 3H), 3.63 - 3.75 (m, 5H), 3.59 (t, J = 7.34 Hz, 1H), 3.50 (t, J = 7.34 Hz, 1H), 2.25 
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- 2.36 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 164.1, 163.5, 152.0, 143.6, 135.0, 134.9, 133.0, 
129.5, 129.0, 128.9, 117.1, 116.9, 115.6, 115.4, 49.6, 49.5, 46.4, 46.0, 44.0, 43.9, 43.4, 32.0, 




General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (19.09 mg, 0.477 mmol), and  3-methylbut-
3-en-1-yl 4-methylbenzenesulfonate (76 mg, 0.318 mmol) gave 4-((4-fluorobenzyl)(3-
methylbut-3-en-1-yl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (50.3 mg, 0.132 mmol, 
41.3 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.14 - 7.25 (m, 2H), 6.95 - 7.07 (m, 2H), 4.77 (br. 
s., 2H), 4.73 (s, 1H), 4.66 (br. s., 1H), 3.76 - 3.86 (m, 3H), 3.72 (br. s., 3H), 3.59 - 3.69 (m, 3H), 
3.54 (t, J = 7.58 Hz, 1H), 2.24 (q, J = 7.83 Hz, 2H), 1.74 (d, J = 21.52 Hz, 3H); 13C NMR 
(CDCl3, 126 MHz) δ 164.2, 164.0, 163.6, 163.5, 163.2, 163.1, 161.3, 152.0, 142.6, 142.5, 133.0, 
129.5, 129.5, 129.0, 128.9, 115.6, 115.5, 115.4, 112.2, 66.7, 66.4, 66.3, 49.4, 49.2, 45.4, 45.2, 
44.0, 43.9, 43.4, 35.6, 34.8, 22.5, 22.4; HRMS–ESI (m/z): [M+H]+ calcd for, C20H23FN6O; 
383.1990; found, 383.1989 
 
4-((4-Fluorobenzyl)(isobutyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263043) 
General procedure A4 from 4-chloro-N-(4-fluorobenzyl)-N-isobutyl-6-morpholino-1,3,5-triazin-
2-amine (65 mg, 0.171 mmol), DABCO (38.4 mg, 0.342 mmol), and potassium cyanide (12.26 
mg, 0.188 mmol) gave 4-((4-fluorobenzyl)(isobutyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (48 mg, 0.130 mmol, 76 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.08 - 7.23 (m, 
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2H), 6.98 (t, J = 8.31 Hz, 2H), 4.78 (s, 1H), 4.73 (s, 1H), 3.77 (br. s., 3H), 3.70 (br. s., 3H), 3.63 
(br. s., 2H), 3.37 (d, J = 7.34 Hz, 1H), 3.27 (d, J = 7.34 Hz, 1H), 2.05 - 2.14 (m, 1H), 0.83 - 0.94 
(m, 6H); 13C NMR (CDCl3, 126 MHz) δ 164.6, 164.6, 163.4, 161.1, 151.9, 151.9, 133.0, 132.9, 
129.4, 129.3, 128.8, 128.8, 115.5, 115.5, 115.4, 115.3, 115.3, 66.6, 66.4, 66.3, 53.8, 53.4, 49.7, 
49.6, 46.5, 43.8, 43.3, 37.1, 36.6, 31.5, 27.0, 26.7, 21.0, 20.3, 20.0, 20.0, 14.8, 14.1, 14.0, 13.9; 




General Procedure B3 starting from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (70.0 mg, 0.223 mmol) and 1-bromo-4-methylpentane (55.1 mg, 0.334 mmol) gave 
4-((4-fluorobenzyl)(4-methylpentyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (48.0 mg, 
0.120 mmol, 54.1 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.14-7.24 (m, 2H), 7.00 (t, J = 8.61 
Hz, 2H), 4.76 (s, 1H), 4.72 (s, 1H), 3.74 - 3.86 (m, 3H), 3.61 - 3.74 (m, 5H), 3.48 (t, J = 7.43 Hz, 
1H), 3.39 (t, J = 7.63 Hz, 1H), 1.46 - 1.60 (m, 3H), 1.05 - 1.19 (m, 2H), 0.86 (d, J = 6.65 Hz, 
3H), 0.84 (d, J = 6.70 Hz, 3H). 13C NMR (CDCl3, 126 MHz) δ 164.2, 164.0, 163.6, 163.5, 163.4, 
163.3, 152.0, 151.9, 133.1, 129.7, 129.6, 129.2, 128.7, 128.7, 115.7, 115.6, 115.6, 115.5, 115.4, 
115.1, 66.7, 66.4, 49.6, 49.4, 49.3, 49.1, 47.0, 46.8, 46.7, 43.9, 43.4, 36.3, 36.1, 35.9, 35.7, 35.5, 
27.7, 27.6, 27.5, 25.2, 24.4, 22.7, 22.5, 22.4, 22.2. 19F NMR (376 MHz, Chloroform-d) δ -






In a dry reaction vessel, 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(50 mg, 0.159 mmol) was dissolved into DMF (0.5 ml). Potassium carbonate (44.0 mg, 0.318 
mmol) and (bromomethyl)cyclopropane (0.031 ml, 0.318 mmol) were added to the solution and 
the reaction was left to stir at 80°C overnight. Reaction was cooled to room temperature, poured 
into EtOAc and washed 3x with brine. Organic layers were combined, dried over sodium sulfate, 
and concentrated. Crude residue was purified by flash chromatography (0-100% EtOAc:Hexanes 
gradient) to afford 4-((cyclopropylmethyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-
2-carbonitrile (15 mg, 0.041 mmol, 25.6 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.15 - 7.25 (m, 
2H), 7.01 (t, J = 8.56 Hz, 2H), 4.89 (s, 1H), 4.85 (s, 1H), 3.63 - 3.86 (m, 8H), 3.46 (d, J = 6.85 
Hz, 1H), 3.37 (d, J = 6.85 Hz, 1H), 0.98 - 1.08 (m, 1H), 0.49 (dd, J = 5.38, 12.72 Hz, 2H), 0.25 
(q, J = 4.89 Hz, 1H), 0.19 (q, J = 4.89 Hz, 1H); 13C NMR (CDCl3, 126 MHz) δ 164.3, 163.6, 
163.5, 163.1, 163.0, 161.2, 161.0, 152.0, 133.2, 133.1, 129.3, 129.2, 128.8, 128.7, 115.5, 115.4, 
115.3, 115.2, 115.0, 71.5, 66.6, 66.4, 66.3, 50.9, 50.3, 49.2, 49.1, 43.9, 43.7, 43.4, 14.2, 9.6, 9.1, 




In a dry reaction vial, 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (50 
mg, 0.159 mmol) was dissolved into DMF (1 ml). Potassium carbonate (44.0 mg, 0.318 mmol) 
and (bromomethyl)cyclobutane (47.4 mg, 0.318 mmol) were added to the solution and the 
reaction was left to stir at 80°C overnight. Reaction was cooled to room temperature, poured into 
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EtOAc and washed 3x with brine. Organic layers were combined, dried over sodium sulfate, and 
concentrated. Crude residue was purified by flash chromatography (0-100% EtOAc:Hexanes) to 
afford 4-((cyclobutylmethyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(17 mg, 0.044 mmol, 27.9 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.10 - 7.22 (m, 2H), 7.00 (t, J 
= 7.83 Hz, 2H), 4.76 (s, 1H), 4.71 (s, 1H), 3.80 (br. s., 3H), 3.73 (br. s., 2H), 3.69 (br. s., 1H), 
3.64 (br. s., 2H), 3.60 (d, J = 7.34 Hz, 1H), 3.51 (d, J = 7.34 Hz, 1H), 2.53 - 2.69 (m, 1H), 1.97 
(br. s., 2H), 1.79 - 1.92 (m, 2H), 1.64 - 1.79 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 164.5, 
164.4, 163.6, 163.5, 163.2, 161.2, 161.1, 152.0, 151.9, 133.2, 129.3, 129.3, 128.7, 128.7, 115.6, 
115.5, 115.3, 66.6, 66.4, 66.3, 51.7, 51.1, 49.5, 43.9, 43.4, 34.3, 34.0, 26.8, 26.5, 18.6, 18.5; 
HRMS–ESI (m/z): [M+H]+ calcd for, C20H23FN6O; 383.1990; found, 383.1994 
 
4-(Cyclopentyl(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (263022) 
General procedure A4 from 4-chloro-N-cyclopentyl-N-(4-fluorobenzyl)-6-morpholino-1,3,5-
triazin-2-amine (150 mg, 0.383 mmol), DABCO (86 mg, 0.766 mmol), and potassium cyanide 
(27.4 mg, 0.421 mmol) gave 4-(cyclopentyl(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-
2-carbonitrile (20.5 mg, 0.054 mmol, 14.00 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.04 - 7.22 
(m, 2H), 6.90 - 7.01 (m, 2H), 4.68 - 4.79 (m, 1H), 4.61 (s, 1H), 3.56 - 3.90 (m, 6H), 3.48 (d, J = 
15.16 Hz, 2H), 1.75 - 1.92 (m, 2H), 1.63 - 1.75 (m, 2H), 1.43 - 1.63 (m, 6H); 13C NMR (CDCl3, 
126 MHz) δ 164.3, 163.3, 162.6, 160.6, 151.8, 134.3, 128.1, 127.5, 115.6, 115.1, 66.6, 57.2, 







General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (14.00 mg, 0.350 mmol), and 
(bromomethyl)cyclopentane (0.039 ml, 0.318 mmol) gave 4-((cyclopentylmethyl)(4-
fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (31.6 mg, 0.080 mmol, 25.05 % 
yield); 1H NMR (CDCl3, 500 MHz) δ 1.22 (m) 1.54 (m) 1.64 (m) 2.27 (m) 3.42 (d) 3.51 (d) 3.66 
(m) 3.72 (m) 3.79 (m) 4.76 (s) 4.81 (s) 7.00 (t) 7.18 (m); 13C NMR (CDCl3, 126 MHz) δ 164.5, 
163.5, 163.1, 163.0, 161.2, 161.0, 151.9, 133.1, 133.0, 129.4, 129.3, 128.8, 128.7, 115.6, 115.5, 
115.3, 66.7, 66.4, 66.3, 50.9, 50.3, 49.3, 49.2, 43.9, 43.4, 38.7, 38.2, 30.5, 30.3, 24.9, 24.8; 19F 
NMR (CDCl3, 470 MHz) δ -115.16 (m); HRMS–ESI (m/z): [M+H]
+ calcd for, C21H25FN6O ; 




General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol, sodium hydride (15.27 mg, 0.382 mmol), and 
(bromomethyl)cyclohexane (0.043 ml, 0.318 mmol) gave 4-((cyclohexylmethyl)(4-
fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (105 mg, 0.256 mmol, 80 % 
yield); 1H NMR (CDCl3, 500 MHz) δ 7.11 - 7.22 (m, 2H), 6.92 - 7.05 (m, 2H), 4.79 (s, 1H), 4.73 
(s, 1H), 3.78 - 3.87 (m, 2H), 3.76 (br. s., 1H), 3.71 - 3.75 (m, 2H), 3.60 - 3.70 (m, 3H), 3.40 (d, J 
= 7.83 Hz, 1H), 3.30 (d, J = 7.34 Hz, 1H), 1.68 - 1.83 (m, 3H), 1.57 - 1.68 (m, 3H), 1.15 - 1.24 
(m, 3H), 0.88 - 1.04 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 164.7, 164.6, 164.1, 163.8, 163.5, 
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161.2, 161.1, 152.0, 151.9, 133.1, 133.0, 129.4, 128.8, 115.6, 115.5, 115.4, 115.3, 66.7, 66.4, 
66.3, 52.6, 52.2, 49.8, 49.7, 44.0, 43.4, 36.5, 36.3, 31.2, 30.7, 26.3, 25.8; HRMS–ESI (m/z): 




General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (19.09 mg, 0.477 mmol), and 2-
cyclopropylethyl 4-methylbenzenesulfonate (76 mg, 0.318 mmol) gave 4-((2-
cyclopropylethyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (58 mg, 
0.152 mmol, 47.7 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.13 - 7.26 (m, 2H), 7.00 (t, J = 8.31 
Hz, 2H), 4.78 (s, 1H), 4.73 (s, 1H), 3.75 - 3.85 (m, 3H), 3.70 - 3.74 (m, 2H), 3.68 (br. s., 2H), 
3.65 (br. s., 1H), 3.59 (t, J = 7.40 Hz, 1H), 3.51 (t, J = 7.34 Hz, 1H), 1.40 - 1.51 (m, 2H), 0.52 - 
0.69 (m, 1H), 0.43 (d, J = 7.83 Hz, 2H), 0.02 - 0.07 (m, 1H), -0.02 - 0.02 (m, 1H); 13C NMR 
(CDCl3, 126 MHz) δ 164.1, 164.0, 163.6, 163.5, 163.0, 161.2, 161.1, 152.0, 151.9, 133.1, 133.1, 
129.5, 129.4, 128.9, 115.6, 115.5, 115.3, 66.7, 66.6, 66.4, 66.3, 49.5, 47.1, 46.4, 43.9, 43.4, 32.5, 





General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (19.09 mg, 0.477 mmol), and 1-bromo-3,3-
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dimethylbutane (0.068 ml, 0.477 mmol) gave 4-((3,3-dimethylbutyl)(4-fluorobenzyl)amino)-6-
morpholino-1,3,5-triazine-2-carbonitrile (26 mg, 0.065 mmol, 20.51 % yield); 1H NMR (CDCl3, 
500 MHz) δ 7.15 - 7.25 (m, 2H), 6.98 - 7.04 (m, 2H), 4.74 (s, 1H), 4.69 (s, 1H), 3.76 - 3.86 (m, 
3H), 3.72 (br. s., 3H), 3.63 - 3.70 (m, 2H), 3.47 - 3.53 (m, 1H), 3.39 - 3.47 (m, 1H), 1.37 - 1.46 
(m, 2H), 0.91 (d, J = 7.83 Hz, 9H); 13C NMR (CDCl3, 126 MHz) δ 163.7, 163.5, 162.8, 162.7, 
156.1, 151.9, 133.1, 129.6, 129.5, 129.1, 129.0, 115.6, 115.4, 66.7, 66.4, 49.1, 43.5, 43.4, 42.8, 
40.5, 39.6, 29.6, 29.3; 19F NMR (CDCl3, 470 MHz) δ -114.89 (m); HRMS–ESI (m/z): [M+H]
+ 




4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (100 mg, 0.318 mmol), 
sodium hydride (19.09 mg, 0.477 mmol), and 3-fluoro-3-methylbutyl 4-methylbenzenesulfonate 
(83 mg, 0.318 mmol) gave 4-((3-fluoro-3-methylbutyl)(4-fluorobenzyl)amino)-6-morpholino-
1,3,5-triazine-2-carbonitrile (59 mg, 0.147 mmol, 46.1 % yield); 1H NMR (CDCl3, 500 MHz) δ 
7.17 - 7.25 (m, 2H), 7.00 (t, J = 8.31 Hz, 2H), 4.76 (s, 1H), 4.72 (s, 1H), 3.75 - 3.87 (m, 3H), 
3.67 - 3.74 (m, 4H), 3.63 - 3.67 (m, 1H), 3.60 - 3.63 (m, 1H), 3.54 - 3.60 (m, 1H), 1.77 - 1.91 (m, 
2H), 1.37 (d, J = 18.10 Hz, 3H), 1.33 (d, J = 18.10 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 
164.1, 163.9, 163.6, 163.4, 163.2, 163.1, 161.2, 161.1, 152.0, 151.9, 132.9, 129.6, 129.5, 129.1, 
115.5, 115.4, 115.3, 95.1, 94.8, 93.8, 93.4, 66.6, 66.3, 49.3, 49.2, 43.9, 43.7, 43.4, 42.5, 42.0, 
41.9, 38.3, 38.2, 37.6, 37.4, 26.8, 26.7, 26.6, 26.5; 19F NMR (CDCl3, 470 MHz) δ -114.71 (m), -





General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (19.09 mg, 0.477 mmol), and (2-
bromoethyl)cyclohexane (122 mg, 0.636 mmol) gave 4-((2-cyclohexylethyl)(4-
fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (84.1 mg, 0.198 mmol, 62.3 % 
yield); 1H NMR (CDCl3, 500 MHz) δ 7.14 - 7.26 (m, 2H), 7.00 (t, J = 8.56 Hz, 2H), 4.75 (s, 1H), 
4.71 (s, 1H), 3.76 - 3.88 (m, 3H), 3.60 - 3.76 (m, 5H), 3.49 - 3.57 (m, 1H), 3.39 - 3.49 (m, 1H), 
1.59 - 1.74 (m, 5H), 1.36 - 1.48 (m, 2H), 1.11 - 1.24 (m, 4H), 0.82 - 0.98 (m, 2H); 13C NMR 
(CDCl3, 126 MHz) δ 164.1, 163.9, 163.6, 163.5, 163.2, 163.0, 161.2, 161.1, 152.0, 151.9, 133.1, 
129.5, 129.4, 129.0, 128.9, 115.5, 115.3, 66.7, 66.4, 49.0, 44.8, 44.2, 43.9, 43.4, 35.5, 35.3, 34.7, 





In a dry reaction vial, 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (50 
mg, 0.159 mmol) was dissolved into DMF (1 ml). Cesium carbonate (104 mg, 0.318 mmol) and 
3-(bromomethyl)-3-methyloxetane (0.037 ml, 0.318 mmol) were added to the solution and the 
reaction was left overnight at 80°C. Crude was purified by FC (1-100% EtOAc:Hexanes 
gradient) to afford 4-((4-fluorobenzyl)((3-methyloxetan-3-yl)methyl)amino)-6-morpholino-
1,3,5-triazine-2-carbonitrile (16.9 mg, 0.042 mmol, 26.7 % yield); 1H NMR (CDCl3, 500 MHz) δ 
7.09 - 7.19 (m, 2H), 7.01 (t, J = 8.56 Hz, 2H), 4.78 (s, 1H), 4.71 (s, 1H), 4.50 - 4.63 (m, 2H), 
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4.36 - 4.42 (m, 1H), 4.24 - 4.30 (m, 2H), 3.82 (dd, J = 4.89, 9.78 Hz, 2H), 3.69 - 3.79 (m, 4H), 
3.65 (d, J = 7.34 Hz, 2H), 2.93 (s, 2H), 1.36 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 165.1, 
163.5, 155.5, 152.0, 151.9, 132.3, 129.2, 129.1, 128.7, 115.7, 115.6, 115.5, 115.3, 115.2, 81.5, 
81.3, 79.5, 79.3, 72.4, 69.3, 66.6, 66.3, 52.7, 51.5, 50.3, 50.2, 43.9, 43.5, 43.4, 41.0, 40.7, 39.3, 





General Procedure B3 starting from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (150 mg, 0.477 mmol) and tert-butyl (2-bromoethyl)carbamate (160 mg, 0.716 
mmol) gave tert-butyl(2-((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-fluorobenzyl)amino) 
ethyl)carbamate (25.0 mg, 0.055 mmol, 11 % yield). Carried directly through General Procedure 
B4 to give 4-((2-aminoethyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(4.0 mg, 0.055 mmol, 20.0 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.21 (t, J = 7.2 Hz, 2H), 7.01 
(t, J = 8.3 Hz, 2H), 4.75 (s, 2H), 3.86 – 3.59 (m, 9H), 3.13 (s, 2H), 1.33 – 1.17 (m, 2H). 13C 
NMR (CDCl3, 126 MHz) δ 163.20, 132.03, 129.42, 129.35, 115.92, 115.75, 66.53, 49.84, 44.12, 
43.67, 14.20, 1.01. 19F NMR (470 MHz, Chloroform-d) δ -75.70, -113.97. HRMS–ESI (m/z): 









General Procedure B3 starting from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (150 mg, 0.477 mmol) and tert-butyl (3-bromopropyl)carbamate (170 mg, 0.716 
mmol) gave tert-butyl(3-((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-fluorobenzyl)amino) 
propyl)carbamate (97.6 mg, 0.207 mmol, 43.4 % yield). Carried directly through General 
Proceure B4 to give 4-((3-aminopropyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (19.0 mg, 0.085 mmol, 60.0 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.23 – 7.09 (m, 
2H), 6.99 (t, J = 8.5 Hz, 2H), 4.82 – 4.64 (m, 2H), 3.90 – 3.43 (m, 9H), 2.93 (s, 2H), 1.90 (s, 3H), 
1.26 (s, 1H). 13C NMR (CDCl3, 126 MHz) δ 164.42, 162.98, 161.36, 151.47, 132.19, 129.16, 
129.09, 115.82, 115.65, 66.51, 66.21, 49.08, 43.65, 42.48, 25.02. 19F NMR (470 MHz, 
Chloroform-d) δ -74.98, -76.05, -113.87 – -115.03 (m). HRMS–ESI (m/z): [M+H]+ calcd for 




General Procedure B3 starting from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (150 mg, 0.477 mmol) and tert-butyl (4-bromobutyl)carbamate (180 mg, 0.716 
mmol) gave tert-butyl(4-((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-fluorobenzyl)amino) 
butyl)carbamate (40 mg, 0.082 mmol, 17 % yield). Carried directly through General Procedure 
B4 to give 4-((4-aminobutyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile 
(4.9 mg, 0.013 mmol, 15 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.19 (d, J = 6.3 Hz, 2H), 7.00 
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(d, J = 4.4 Hz, 2H), 4.73 (d, J = 15.5 Hz, 2H), 3.91 – 3.58 (m, 8H), 3.50 (s, 2H), 2.95 (d, J = 54.8 
Hz, 2H), 1.62 (s, 4H). 13C NMR (CDCl3, 126 MHz) δ 164.20, 163.32, 151.81, 129.50, 129.08, 
129.01, 115.68, 115.51, 49.27, 45.42, 39.34, 24.04. 19F NMR (470 MHz, Chloroform-d) δ -




General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (19.09 mg, 0.477 mmol), and 1-(2-
chloroethyl)pyrrolidine (85 mg, 0.636 mmol) gave 4-((4-fluorobenzyl)(2-(pyrrolidin-1-
yl)ethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (92 mg, 0.224 mmol, 70.3 % yield); 
1H NMR (CDCl3, 500 MHz) δ 7.15 - 7.25 (m, 2H), 6.94 - 7.05 (m, 2H), 4.80 (s, 1H), 4.78 (s, 
1H), 3.81 (br. s., 1H), 3.78 (br. s., 2H), 3.68 - 3.74 (m, 3H), 3.62 - 3.68 (m, 3H), 3.58 (t, J = 7.34 
Hz, 1H), 2.56 - 2.67 (m, 2H), 2.42 - 2.56 (m, 4H), 1.76 (br. s., 4H); 13C NMR (CDCl3, 126 MHz) 
δ 164.2, 164.1, 163.6, 163.5, 163.2, 163.0, 161.2, 161.1, 152.0, 151.9, 133.1, 133.0, 129.6, 129.5, 
129.0, 128.9, 115.5, 115.3, 66.6, 66.4, 66.3, 54.4, 54.3, 53.6, 52.7, 49.8, 49.7, 45.7, 45.4, 43.9, 




General procedure B4 from tert-butyl 3-(2-((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)ethyl)piperidine-1-carboxylate (80 mg, 0.152 mmol) gave 4-((4-
fluorobenzyl)(2-(piperidin-3-yl)ethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (45.6 
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mg, 0.107 mmol, 70.4 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.12 - 7.24 (m, 2H), 6.92 - 7.09 
(m, 2H), 4.57 - 4.86 (m, 2H), 3.53 - 3.99 (m, 10H), 3.31 - 3.52 (m, 2H), 2.84 (br. s., 1H), 2.56 
(br. s., 1H), 1.85 - 2.02 (m, 2H), 1.78 (br. s., 2H), 1.35 - 1.62 (m, 2H), 1.03 - 1.26 (m, 1H); 13C 
NMR (CDCl3, 126 MHz) δ 169.9, 168.6, 164.4, 164.1, 164.0, 163.6, 163.4, 161.3, 161.0, 160.8, 
151.9, 129.5, 129.0, 115.7, 115.5, 107.8, 66.6, 66.3, 49.0, 44.7, 44.0, 43.6, 43.4, 31.6, 31.5, 30.8, 
30.5, 28.9, 28.8, 22.0; 19F NMR (CDCl3, 470 MHz) δ  -114.80 (s), -75.85 (s); HRMS–ESI (m/z): 




General procedure B4 from tert-butyl 4-(2-((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)ethyl)piperidine-1-carboxylate (80 mg, 0.152 mmol) gave 4-((4-
fluorobenzyl)(2-(piperidin-4-yl)ethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (12 mg, 
0.028 mmol, 18.53 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.15 - 7.24 (m, 2H), 7.02 (t, J = 8.31 
Hz, 2H), 4.77 (s, 1H), 4.72 (s, 1H), 3.84 (br. s, 2H), 3.70 - 3.78 (m, 4H), 3.63 - 3.70 (m, 2H), 
3.56 (t, J = 7.09 Hz, 1H), 3.44 - 3.52 (m, 1H), 3.24 - 3.34 (m, 2H), 2.69 - 2.86 (m, 2H), 1.73 - 
1.92 (m, 2H), 1.39 - 1.58 (m, 5H); 19F NMR (CDCl3, 470 MHz) δ -114.58 (m) -75.84 (m); 




General procedure B4 from tert-butyl 3-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)methyl) piperidine-1-carboxylate (80 mg, 0.156 mmol) gave 4-((4-
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fluorobenzyl)(piperidin-3-ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile, TFA (47 
mg, 0.089 mmol, 57.2 % yield). 1H NMR (CDCl3, 500 MHz) δ 7.10 - 7.24 (m, 2H), 7.00 (t, J = 
7.83 Hz, 2H), 4.84 - 4.99 (m, 1H), 4.49 - 4.68 (m, 1H), 3.60 - 3.93 (m, 9H), 3.22 - 3.54 (m, 4H), 
2.81 - 3.02 (m, 1H), 2.57 - 2.81 (m, 1H), 2.29 (br. s., 1H), 1.93 (br. s., 1H), 1.70 - 1.87 (m, 2H), 
1.14 - 1.40 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 164.9, 164.8, 163.4, 163.3, 163.2, 161.3, 
152.0, 151.8, 132.2, 132.1, 129.5, 129.1, 129.0, 115.8, 115.5, 115.3, 115.2, 66.5, 66.2, 49.5, 49.1, 
48.3, 47.7, 47.2, 44.6, 44.5, 43.9, 43.5, 43.3, 32.5, 32.4, 28.1, 26.8, 26.3, 21.8, 21.3; 19F NMR 
(CDCl3, 470 MHz) δ -75.94, -114.44; HRMS–ESI (m/z): [M+H]
+ calcd for, C21H26FN7O; 




General procedure B4 from tert-butyl 4-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)methyl)piperidine-1-carboxylate (33 mg, 0.065 mmol) gave 4-((4-
fluorobenzyl)(piperidin-4-ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile, TFA 
(23.5 mg, 0.045 mmol, 69.3 % yield). 1H NMR (CDCl3, 500 MHz) δ 7.12 - 7.24 (m, 2H), 7.01 (t, 
J = 8.31 Hz, 2H), 4.79 (s, 1H), 4.74 (s, 1H), 3.82 (br. s., 2H), 3.72 (br. s., 4H), 3.67 (br. s., 2H), 
3.34 - 3.53 (m, 4H), 2.86 (br. s., 2H), 1.94 - 2.16 (m, 1H), 1.72 - 1.90 (m, 2H), 1.57 (br. s., 2H); 
13C NMR (CDCl3, 126 MHz) δ 165.0, 164.8, 163.5, 163.4, 161.4, 161.3, 152.0, 132.4, 129.5, 
129.4, 129.0, 128.9, 115.8, 115.7, 115.6, 115.3, 66.6, 66.3, 51.5, 50.6, 50.4, 49.8, 44.0, 43.9, 
43.5, 43.4, 32.9, 32.8, 26.6, 26.4; 19F NMR (CDCl3, 470 MHz) δ -75.82(m), -114.32 (m); 





General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (15.27 mg, 0.382 mmol) and 4-
(bromomethyl)tetrahydro-2H-pyran (0.042 ml, 0.318 mmol) gave 4-((4-
fluorobenzyl)((tetrahydro-2H-pyran-4-yl)methyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (68 mg, 0.165 mmol, 51.8 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.11 - 7.23 (m, 
2H), 6.99 (t, J = 8.31 Hz, 2H), 4.79 (s, 1H), 4.74 (s, 1H), 3.89 - 4.02 (m, 2H), 3.58 - 3.86 (m, 
9H), 3.43 (d, J = 7.34 Hz, 1H), 3.37 (d, J = 7.34 Hz, 1H), 3.26 - 3.35 (m, 2H), 1.93 - 2.02 (m, 
1H), 1.46 - 1.57 (m, 2H), 1.27 - 1.41 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 164.8, 164.7, 
163.5, 163.2, 163.1, 161.3, 161.1, 152.0, 132.9, 132.8, 129.4, 128.9, 128.8, 115.6, 115.5, 115.4, 
77.3, 77.1, 76.8, 67.6, 66.6, 66.4, 66.3, 52.4, 51.5, 50.2, 49.8, 44.0, 43.4, 34.0, 33.8, 31.0, 30.6 
19F NMR (CDCl3, 470 MHz) δ -114.74 (m); HRMS–ESI (m/z): [M+H]
+ calcd for, C21H25FN6O2; 




General procedure B4 from tert-butyl 3-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)methyl)pyrrolidine-1-carboxylate (30 mg, 0.060 mmol) gave 4-((4-
fluorobenzyl)(pyrrolidin-3-ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile, TFA (23 
mg, 0.045 mmol, 74.6 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.12 - 7.24 (m, 2H), 7.00 (t, J = 
8.31 Hz, 2H), 4.64 - 4.85 (m, 2H), 3.77 - 3.88 (m, 2H), 3.53 - 3.75 (m, 8H), 3.45 (br. s., 1H), 
3.32 (br. s., 2H), 2.94 - 3.13 (m, 1H), 2.65 - 2.84 (m, 1H), 1.99 - 2.15 (m, 1H), 1.67 - 1.82 (m, J 
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= 7.60, 12.00 Hz, 1H); 13C NMR (CDCl3, 126 MHz) δ 164.8, 163.5, 163.3, 161.4, 161.3, 152.0, 
151.8, 132.4, 132.3, 129.5, 129.0, 115.8, 115.6, 115.3, 115.2, 66.6, 66.3, 49.8, 48.6, 48.0, 47.4, 
45.2, 45.0, 44.0, 43.5, 43.4, 37.3, 37.0, 28.5, 28.1; 19F NMR (CDCl3, 470 MHz) δ -75.83 (m), -




General procedure B3 from 4-((4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (100 mg, 0.318 mmol), sodium hydride (15.27 mg, 0.382 mmol), and (tetrahydro-
2H-pyran-3-yl)methyl 4-methylbenzenesulfonate (86 mg, 0.318 mmol) gave 4-((4-
fluorobenzyl)((tetrahydro-2H-pyran-3-yl)methyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (57 mg, 0.138 mmol, 43.4 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.52 - 7.58 (m, 
1H), 7.43 - 7.52 (m, 2H), 7.36 - 7.43 (m, 1H), 4.85 (s, 1H), 4.78 (s, 1H), 3.82 - 3.88 (m, 1H), 
3.77 - 3.82 (m, 2H), 3.71 - 3.77 (m, 2H), 3.68 (br. s., 1H), 3.56 - 3.66 (m, 3H), 3.45 - 3.51 (m, 
1H), 1.50 - 1.61 (m, 1H), 1.37 - 1.50 (m, 2H), 0.92 (d, J = 6.36 Hz, 3H), 0.90 (d, J = 6.36 Hz, 
3H); 13C NMR (CDCl3, 126 MHz) δ 164.2, 164.1, 163.6, 163.4, 152.0, 151.9, 138.7, 138.4, 
131.0, 130.7, 130.4, 129.1, 124.3, 124.2, 124.1, 115.5, 115.4, 66.6, 66.3, 66.2, 49.7, 49.5, 45.8, 
44.9, 43.9, 43.4, 36.3, 35.4, 26.0, 25.8, 22.5, 22.4; HRMS–ESI (m/z): [M+H]+ calcd for, 







General procedure B4 from tert-butyl (R)-3-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)methyl)piperidine-1-carboxylate (10.5 mg, 0.021 mmol) gave (R)-4-((4-
fluorobenzyl)(piperidin-3-ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile, TFA (5 
mg, 9.51 µmol, 46.4 % yield). 1H NMR (CDCl3, 500 MHz) δ 7.10 - 7.24 (m, 2H), 7.00 (t, J = 
7.83 Hz, 2H), 4.84 - 4.99 (m, 1H), 4.49 - 4.68 (m, 1H), 3.60 - 3.93 (m, 9H), 3.22 - 3.54 (m, 4H), 
2.81 - 3.02 (m, 1H), 2.57 - 2.81 (m, 1H), 2.29 (br. s., 1H), 1.93 (br. s., 1H), 1.70 - 1.87 (m, 2H), 
1.14 - 1.40 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 164.9, 164.8, 163.4, 163.3, 163.2, 161.3, 
152.0, 151.8, 132.2, 132.1, 129.5, 129.1, 129.0, 115.8, 115.5, 115.3, 115.2, 66.5, 66.2, 49.5, 49.1, 
48.3, 47.7, 47.2, 44.6, 44.5, 43.9, 43.5, 43.3, 32.5, 32.4, 28.1, 26.8, 26.3, 21.8, 21.3; 19F NMR 
(CDCl3, 470 MHz) δ -75.94, -114.44; HRMS–ESI (m/z): [M+H]
+ calcd for, C21H26FN7O; 
412.2256 ; found, 412.2255 
 
(S)-4-((4-fluorobenzyl)(piperidin-3-ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile (264502)  
General procedure B4 from tert-butyl (S)-3-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)methyl)piperidine-1-carboxylate (26.7 mg, 0.052 mmol) gave  (S)-4-((4-
fluorobenzyl)(piperidin-3-ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile (20 mg, 
0.049 mmol, 93 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.10 - 7.24 (m, 2H), 7.00 (t, J = 7.83 
Hz, 2H), 4.84 - 4.99 (m, 1H), 4.49 - 4.68 (m, 1H), 3.60 - 3.93 (m, 9H), 3.22 - 3.54 (m, 4H), 2.81 
- 3.02 (m, 1H), 2.57 - 2.81 (m, 1H), 2.29 (br. s., 1H), 1.93 (br. s., 1H), 1.70 - 1.87 (m, 2H), 1.14 - 
1.40 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 164.9, 164.8, 163.4, 163.3, 163.2, 161.3, 152.0, 
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151.8, 132.2, 132.1, 129.5, 129.1, 129.0, 115.8, 115.5, 115.3, 115.2, 66.5, 66.2, 49.5, 49.1, 48.3, 
47.7, 47.2, 44.6, 44.5, 43.9, 43.5, 43.3, 32.5, 32.4, 28.1, 26.8, 26.3, 21.8, 21.3; 19F NMR (CDCl3, 





General procedure B1 from 2,4,6-trichloro-1,3,5-triazine (0.25 g, 1.356 mmol), tert-butyl 3-
(aminomethyl)piperidine-1-carboxylate (0.292 ml, 1.356 mmol), DIPEA (0.474 ml, 2.712 mmol) 
and morpholine (0.118 ml, 1.356 mmol) gave tert-butyl 3-(((4-chloro-6-morpholino-1,3,5-
triazin-2-yl)amino)methyl)piperidine-1-carboxylate (300 mg, 0.727 mmol, 53.6 % yield).; 1H 
NMR (CDCl3, 500 MHz) δ 3.71 - 3.83 (m, 5H), 3.59 - 3.71 (m, 6H), 3.22 - 3.41 (m, 3H), 1.72 - 




General procedure B2 from tert-butyl 3-(((4-chloro-6-morpholino-1,3,5-triazin-2-
yl)amino)methyl)piperidine-1-carboxylate (722 mg, 1.749 mmol), potassium cyanide (125 mg, 
1.923 mmol), and DABCO (392 mg, 3.50 mmol) gave tert-butyl 3-(((4-cyano-6-morpholino-






General procedure B4 from tert-butyl 3-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(2-
nitrobenzyl)amino)methyl)piperidine-1-carboxylate (40 mg, 0.074 mmol) gave 4-morpholino-6-
((2-nitrobenzyl)(piperidin-3-ylmethyl)amino)-1,3,5-triazine-2-carbonitrile, TFA (25 mg, 0.045 
mmol, 60.9 % yield); 1H NMR (CDCl3, 500 MHz) δ 8.03 - 8.12 (m, 1H), 7.58 (t, J = 7.34 Hz, 
1H), 7.46 (t, J = 6.85 Hz, 1H), 7.15 (br. s., 1H), 5.14 - 5.30 (m, 1H), 4.93 - 5.13 (m, 1H), 3.86 
(br. s., 1H), 3.78 (d, J = 18.59 Hz, 4H), 3.67 (br. s., 1H), 3.56 (br. s., 1H), 3.34 - 3.51 (m, 3H), 
3.03 (br. s., 1H), 2.89 (br. s., 1H), 2.28 - 2.50 (m, 1H), 1.94 - 2.06 (m, 1H), 1.74 - 1.94 (m, 2H), 
1.35 - 1.49 (m, 1H), 1.16 - 1.35 (m, 2H); 13C NMR (CDCl3, 126 MHz) δ 165.3, 165.0, 163.4, 
163.2, 152.0, 151.8, 148.4, 133.9, 133.8, 132.5, 132.2, 128.5, 128.4, 128.1, 127.7, 125.5, 125.3, 
115.0, 66.5, 66.1, 49.5, 49.4, 48.1, 47.9, 47.2, 44.9, 44.7, 43.9, 43.3, 33.0, 32.7, 26.8, 26.2, 21.8, 
21.2, 17.7; 19F NMR (CDCl3, 470 MHz) δ -75.82; HRMS–ESI (m/z): [M+H]
+ calcd for, 
C21H26N8O3; 439.2201; found, 439.2208 
 
4-Morpholino-6-((piperidin-3-ylmethyl)amino)-1,3,5-triazine-2-carbonitrile, TFA (264504) 
General procedure B4 from tert-butyl 3-(((4-cyano-6-morpholino-1,3,5-triazin-2-
yl)amino)methyl)piperidine-1-carboxylate (80 mg, 0.198 mmol) gave 4-morpholino-6-
((piperidin-3-ylmethyl)amino)-1,3,5-triazine-2-carbonitrile, TFA (80 mg, 0.192 mmol, 97 % 
yield); 1H NMR (CDCl3, 500 MHz) δ 8.78 (br. s., 0.5H), 8.41 (br. s., 0.5H), 6.50 (br. s., 2H), 
3.76 - 3.85 (m, 4H), 3.73 (br. s., 4H), 3.37 - 3.52 (m, 3H), 3.23 - 3.35 (m, 1H), 2.79 - 2.91 (m, 
1H), 2.62 (q, J = 10.92 Hz, 1H), 2.11 - 2.27 (m, 1H), 1.86 - 2.01 (m, 2H), 1.72 - 1.86 (m, 1H), 
1.17 - 1.36 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 163.9, 162.9, 161.4, 161.1, 150.6, 116.7, 
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114.8, 114.4, 66.5, 66.2, 47.5, 44.4, 44.1, 43.6, 43.3, 33.9, 26.5, 21.8; HRMS–ESI (m/z): 




General procedure B4 from tert-butyl 3-(((4-cyano-6-morpholino-1,3,5-triazin-2-
yl)(isopentyl)amino)methyl)piperidine-1-carboxylate gave 4-(isopentyl(piperidin-3-
ylmethyl)amino)-6-morpholino-1,3,5-triazine-2-carbonitrile, TFA (98 % yield); 1H NMR 
(CDCl3, 500 MHz) δ 8.80 - 9.12 (m, 2H), 3.68 - 3.84 (m, 8H), 3.64 (dd, J = 8.31, 14.18 Hz, 1H), 
3.47 - 3.58 (m, 1H), 3.31 - 3.46 (m, 3H), 3.18 - 3.31 (m, 1H), 2.77 - 2.94 (m, 1H), 2.57 - 2.74 (m, 
1H), 2.22 - 2.40 (m, 1H), 1.92 (br. s., 1H), 1.74 - 1.89 (m, 2H), 1.55 (tt, J = 6.30, 13.02 Hz, 1H), 
1.37 - 1.48 (m, 2H), 1.18 - 1.37 (m, 1H), 0.85 - 0.99 (m, 6H); 13C NMR (CDCl3, 126 MHz) δ 
164.3, 164.1, 163.3, 151.8, 151.6, 115.5, 115.3, 66.6, 66.3, 49.3, 49.0, 47.4, 47.0, 46.4, 45.8, 
44.3, 44.2, 43.9, 43.4, 36.1, 35.3, 33.0, 32.9, 26.9, 26.6, 26.1, 25.9, 22.5, 22.4, 21.8, 21.6; 
HRMS–ESI (m/z): [M+H]+ calcd for, C19H31N7O; 374.2663; found, 374.2666 
 
4-(((5,5-difluoropiperidin-3-yl)methyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-
2-carbonitrile, TFA (264522) 
General procedure B4 from tert-butyl 5-(((4-cyano-6-morpholino-1,3,5-triazin-2-yl)(4-
fluorobenzyl)amino)methyl)-3,3-difluoropiperidine-1-carboxylate (31.6 mg, 0.058 mmol) gave 
4-(((5,5-difluoropiperidin-3-yl)methyl)(4-fluorobenzyl)amino)-6-morpholino-1,3,5-triazine-2-
carbonitrile, TFA (29 mg, 0.052 mmol, 89 % yield); 1H NMR (CDCl3, 500 MHz) δ 7.13 - 7.23 
(m, 2H), 7.02 (t, J = 8.31 Hz, 2H), 4.83 - 4.97 (m, 1H), 4.55 - 4.75 (m, 1H), 3.77 - 3.94 (m, 2H), 
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3.65 - 3.77 (m, 7H), 3.60 (br. s., 1H), 3.40 - 3.55 (m, 1H), 3.34 (d, J = 12.23 Hz, 1H), 3.07 - 3.26 
(m, 1H), 2.85 (t, J = 11.98 Hz, 1H), 2.66 - 2.78 (m, 1H), 2.59 (br. s., 1H), 2.25 (br. s., 1H), 1.67 - 
1.91 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 165.1, 165.0, 163.5, 163.3, 152.1, 151.9, 131.9, 
129.7, 129.6, 129.2, 129.1, 115.9, 115.9, 115.8, 115.7, 115.1, 66.6, 66.2, 49.8, 49.1, 47.5, 47.3, 
46.0, 45.7, 44.1, 43.6, 43.5, 30.6, 30.3; 19F NMR (CDCl3, 470 MHz) δ ppm -113.98 (s) -101.29 
(s) -100.74 (s) -100.27 (s) -99.79 (s) -99.25 (s) -98.70 (s) -75.80 (s); HRMS–ESI (m/z): [M+H]+ 
calcd for, C19H31N7O; 448.2069; found, 448.2069 
 
 
Computational Modeling: The X-ray structure of mature TgCPL in complex with its propeptide 
(PDB: 3F75) was superposed with the X-ray structure of HsCPL (PDB: 5MAJ) using The 
Molecular Operating Environment (MOE), version 2008.10, Chemical Computing Group Inc., 
Montreal, Quebec, Canada. Ligands The X-ray structure of HsCPL and the propteptide chain of 
TgCPL were removed to generate the docking model for figures shown.  
 
 
TgCPL and HsCPL Inhibition Assay: Compound potency and selectivity was evaluated in 
vitro for both TgCPL and HsCPL activity in a fluorescence based assay by monitoring the 
hydrolysis of Cbz-Leu-Arg-aminomethylcoumarin (Z-L-R-AMC). Protein was expressed and 
purified as previously described. The substrate hydrolysis results in the release of fluorescent 7-
amino-4-methylcoumarin (AMC) that can be monitored spectrophotometrically with linear 
kinetics for up to 60 min. Inhibitors were serial diluted in DMSO in a 1-to-3 dilution, spanning at 
least 10 concentration points in either duplicate or triplicate. The enzyme was pre-incubated with 
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the inhibitory compounds for 5 min at 23°C, followed by the addition of the AMC substrate. The 
assay final conditions had a total volume of 200 µL, consisting of 90 µL enzyme (conc.=50 
ng/mL ), 100 µL ZLR-AMC substrate (conc.= 80 µM), and 10 µL inhibitor or DMSO. The 
relative fluorescence of the AMC generation is measured over the course of 5 min (Excitation: 
380 nm, Emission: 460 nm). LHVS and DMSO were used as positive and negative controls, 
respectively. All dose response data was obtained with at least independent three replicates 
(n=3). Graphpad Prism software was used to visualize inhibition curves and calculate IC50 values 
from the reaction mean ν. Assay final concentrations in each well: 40 µM ZLR-AMC, TgCPL or 
HsCPL (final conc= 0.0225 ng/µL). Assay Buffer: 100 mM NaAc, 2 mM EDTA, 900 mM NaCl, 
50 mM DTT. Substrate: Cbz-Leu-Arg-AMC (Bachem, purchased as HCl salt).  
 
 
Metabolic Stability in Mouse Liver Microsomes: The metabolic stability was assessed using 
CD-1 mouse liver microsomes. One micromolar of each compound was incubated with 0.5 
mg/mL microsomes and 1.7 mM cofactor -NADPH in 0.1 M phosphate buffer (pH = 7.4) 
containing 3.3 mM MgCl2 at 37 °C. The DMSO concentration was less than 0.1% in the final 
incubation system. At 0, 5, 10, 15, 30, 45, and 60 min of incubation, 40 µL of reaction mixture 
were taken out, and the reaction is quenched by adding 3-fold excess of cold acetonitrile 
containing 100 ng/mL of internal standard for quantification. The collected fractions were 
centrifuged at 15000 rpm for 10 min to collect the supernatant for LC−MS/ MS analysis, from 
which the amount of compound remaining was determined. The natural log of the amount of 
compound remaining was plotted against time to determine the disappearance rate and the half-
life of tested compounds.  
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Pharmacokinetic Studies in Mice: All animal experiments in this study were approved by the 
University of Michigan Committee on Use and Care of Animals and Unit for Laboratory Animal 
Medicine. The abbreviated pharmacokinetics for compounds was determined in female CD-1 
mice following intraperitoneal (ip) injection at 10 mg/kg. Compound was dissolved in the 
vehicle containing 15% (v/v) DMSO, 15-20% (v/v) PEG-400, and 70% (v/ v) PBS. Four blood 
samples (50 μL) were collected over 7 h (at 0.5h, 2h, 4h, and 7h), centrifuged at 3500 rpm for 10 
min, and plasma was frozen at -80˚C for later analysis. Plasma concentrations of the compounds 
were determined by the LC−MS/MS method developed and validated for this study. The 
LC−MS/MS method consisted of a Shimadzu HPLC system, and chromatographic separation of 
tested compound which was achieved using a Waters Xbridge-C18 column (5 cm × 2.1 mm, 3.5 
μm). An AB Sciex QTrap 4500 mass spectrometer equipped with an electrospray ionization 
source (ABI-Sciex, Toronto, Canada) in the positive-ion multiple reaction monitoring (MRM) 
mode was used for detection. All pharmacokinetic parameters were calculated by non-
compartmental methods using WinNonlin, version 3.2 (Pharsight Corporation, Mountain View, 
CA, USA). 
 
MDR1/MDCK Assay: A 12-well transwell plate was seeded with MDCKII-MDR1 cells (0.5 
million/well) and cultured for 24h. Cells were washed with DMEM 3 times (both sides). 0.5 ml 
of 1µM CCG drug in DMEM was added to apical side (A to B) or basolateral side (B to A) 
(donor side) and 0.5ml of DMEM+0.1% DMSO to basolateral side (A to B). Cells were 
incubated for 4h and 2 x 200µL was sampled from the receiving sides and stored at -20ºC for 
future use. For calibration standard, compound standards were dissolved in DMSO then further 
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diluted in acetonitrile to a concentration of 10 µg/mL. Calibration standards were prepared from 
this stock with internal standard (5 nM CE302). Samples were prepared by protein precipitation 
from media followed by addition of internal standard. Samples were analyzed by LC−MS/MS. 
The LC−MS/MS method consisted of a Shimadzu HPLC system, and chromatographic 
separation of tested compound which was achieved using a Waters Xbridge-C18 column (5 cm × 
2.1 mm, 3.5 μm). An AB Sciex QTrap 4500 mass spectrometer equipped with an electrospray 
ionization source (ABI-Sciex, Toronto, Canada) in the positive-ion multiple reaction monitoring 
(MRM) mode was used for detection. 
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Chapter 4 Design of Fluorescent Probes and In Vitro Activity   
 
Dipeptides, Bradyzoite Viability, and Rationale 
 
The Carruthers lab has developed an in vitro assay to assess the effects of compounds on 
bradyzoite viability. In this assay, human foreskin fibroblast cells (HFF) are infected with T. 
gondii, and the parasite is converted from tachyzoite to bradyzoite life stage. Following 
conversion, the parasite is treated daily with the inhibitor of interest for 1 week, replacing the 
conversion media containing the inhibitor/compound of interest every 24 hours. The parasite cyst 
is then harvested from the HFF cells, and subsequently assessed for viability in a plaque 
formation assay. The number of plaques formed, due to the parasite infection, is normalized to 
the T. gondii genomes per dose (as measured by qPCR) to provide the number of plaques per 
1000 genomes as a measure of parasite viability. While this provides a good measure of 
compound efficacy, this assay is unfortunately very low throughput (~ 4-5 wks/assay), and 
therefore only select analogs were evaluated in this manner. 
 
Our dipeptide nitrile inhibitor (258070) was a potent TgCPL inhibitor in vitro with an 
improved CNS profile versus LHVS. Curiously, treatment of intracellular bradyzoite cysts failed 
to decrease parasite viability (Figure 31).  A similar results was observed for the dipeptide vinyl 




Figure 31. Bradyzoite viability assay results for dipeptide nitriles and vinyl 
sulfones 
DPN = dipeptide nitrile 258070, DPVS = dipeptide vinyl sulfone 262943 
 
We reasoned that this lack of efficacy in bradyzoite cysts may be a result of the dipeptide 
compounds being unable to reach the target enzyme localized within the parasite vacuole. While 
these compounds were potent against TgCPL in our biochemical assay, there are several 
potential barriers to accessing the desired site of action. To reach TgCPL, these inhibitors need to 
be able to pass through the host cell membrane, cystic wall, parasite cell membrane, and enter 
the parasite vacuole. The inability to reduce intracellular cyst viability may be due to a lack of 
permeability in the human fibroblast host cells. 
 
An additional possibility posed was that the inhibition of TgCPL by a reversible inhibitor 
(258070), may be inadequate for complete TgCPL inhibition. The viability reduction exhibited 
by LHVS could be due to the irreversible covalent inhibition of the vinyl sulfone warhead. 
However, the vinyl sulfone analog 262943 also failed to reduce bradyzoite viability. This 
indicates that the lack of activity may be due to other issues such as permeability. Second 
generation triazine nitrile analogs exhibited both improved potency and significantly higher 
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exposure levels versus the dipeptide nitrile 258070, and a 1:1 brain:plasma ratio at 2 hr. While 
these features were improved, the triazine nitrile is also a reversibly covalent inhibitor. As such, 
we wanted to confirm two things before advancing this series further. First, we needed to verify 
that these compounds were able to reach and bind TgCPL in the parasite. Second, we wanted to 
understand if irreversible inhibition of TgCPL was necessary to reduce parasite viability. To this 
purpose, a set of BODIPY-linked fluorescent probes 263252 (Vinyl sulfone / irreversible) and 
263473 (Triazine nitrile / reversible) were synthesized.  
 
Synthesis of BODIPY-CO2H 
 
Scheme 9. Synthesis of BODPIY-CO2H 
Synthesis derived from Giessler et. al.163 
 
1H-pyrrole-2-carbaldehyde (4.1a) underwent a Wittig olefination with methyl 
(triphenylphosphoranylidene)acetate to provide intermediate 4.1b. The product was then reduced 
over Pd/C 10% to afford 4.1c. The intermediate then was subjected to Vilsmeier-type reaction 
with 3,5-dimethyl-1H-pyrrole-2-carbaldehyde to form the conjugate dipyrromethene 
intermediate. Treatment with boron trifluoride etherate formed the chelated BODIPY complex, 
which was subsequently hydrolyzed under acidic conditions with 4.5 M HCl to provide the 





Synthesis of VS-BODIPY Probe 
 
Scheme 10. Synthesis of BODIPY-tagged dipeptide vinyl-sulfone 263252 
a) diethyl ((phenylsulfonyl)methyl) phosphonate, NaH, THF, 0°C.; b) HCl 4N in dioxane.; c) N-Boc-leucine, 
HATU, DIPEA, DMF, rt.; d) HCl 4N in dioxane.; e) BODIPY-CO2H (4.1d), HATU, DIPEA, DMF, 0-rt. 
 
A Horner–Wadsworth–Emmons reaction between Boc-L-alaninal (4.2a) and diethyl 
((phenylsulfonyl)methyl) phosphonate provides intermediate vinyl sulfone 4.2b. Removal of the 
Boc to afford amine 4.2c and subsequent HATU coupling provides the dipeptide 4.2d. 
Deprotection with HCl dioxane gave 4.2e, which underwent a final HATU coupling with 








Synthesis of Triazine Nitrile BODIPY Probe 
 
Scheme 11. Synthesis of BODIPY-tagged triazine nitrile probe 263473 
a) Isoamylamine, Ti(iPrO)4, NaBH4, MeOH, rt, O/N; b) (i) Cyanuric chloride, (ii) 
ethylenediamine, DIPEA, DCM, -10°C-rt, O/N; c) Boc-anhydride, DIPEA, DCM, 0-rt, O/N; d) 
KCN, DABCO, DMSO:H2O (9:1), 80°C, O/N; e) 4N HCl, dioxane, rt, 1 hr; f) BODIPY-CO2H, 
HATU, DIPEA, DMF, 0oC-rt, O/N. 
 
4-Fluoro acetophenone (4.3a) was condensed overnight with isoamylamine in the 
presence of titanium isopropoxide, and the resulting imine was subsequently reduced with 
sodium borohydride to afford secondary amine 4.3b. Subsequent reaction with cyanuric chloride, 
followed by a second SNAr with ethylenediamine in one pot provided intermediate 4.3c. Amine 
4.3c was then protected with Boc-anhydride (4.3d) and subjected to cyanation with potassium 
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cyanide in DMSO:H2O to give 4.3e. Finally, deprotection and subsequent amide coupling to 
BODIPY-CO2H gave the triazine nitrile fluorescent probe 4.3g (263473; TgCPL IC50= 503 nM).  
 
Puncta Formation and Autophagy in TgCPL Deficient Bradyzoite Cysts 
T. gondii cathepsin L (TgCPL) is localized in the plant-like vacuole (VAC), a lysosomal- like 
organelle within the apical region of the parasite. This digestive enzyme plays a key role within 
the VAC and is necessary for persistence during neural infection. It is critical in the turnover of 
autophagosomes, a key structure found during the intracellular degradation cytoplasmic contents 
(autophagy). The formation of small, dark puncta has been observed in the CPL knockout strain 
of T. gondii, or when the bradyzoite cysts are treated with covalent inhibitor LHVS (Figure 
32A). Presumably these are the buildup of autophagosomes, indicating the parasite is unable to 
properly turnover its organelles. While not a direct measure of parasite viability, as described 
above, it has been assumed that the buildup of these puncta are a prelude to cyst death and 
indicative of lysosomal dysfunction. As this response takes significantly less time than the 
complete viability assay, it was used as an initial evaluation for compound efficacy. Curiously, 
treatment of the bradyzoite cysts with select triazine nitriles from Chapter 3 did not result in the 
formation of these dark granules observed in other instances of TgCPL deficiency (Figure 32B). 
Similar to the viability assay with the dipeptide nitrile 258070, we wondered if this is a result of 












Figure 32. Puncta formation in lysosomal dysfunction 
A) Example formation of dark puncta in bradyzoite cysts when treated with covalent inhibitor LHVS as compared 
to DMSO control.  B) Graph of mean puncta size and area relative to total bradyzoite cyst area for LHVS and 
selected triazine nitriles. Puncta area relative to cyst area is given as the percentage of the cyst area that is occupied 
by puncta. 
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As a follow up to this observed lack of puncta formation, compounds were evaluated via 
Cyto-ID to better visualize the presence (or lack thereof) of autophagosomes. The Cyto-ID 
autophagy detection kit (Enzo life sciences) selectively stains accumulated autophagic vacuoles 
and monitors autophagic flux in lysosomally inhibited live cells. These “autolysosomes” are 
formed during the cellular process of autophagocytosis in which the cell disassembles 
unnecessary or dysfunctional components. Staining of bradyzoite cysts with CytoID shows a 
similar result observed with the dark granule formation observed by microscopy (Figure 33). 
 
 
Figure 33. CytoID staining of bradyzoite cysts 
CytoID staining of bradyzoite cysts treated with Triazine nitrile TgCPL inhibitors. CytoID stains for autophagy 
(stains for autolysosomes). Thus, CPL knockout bradyzoites and LHVS-treated bradyzoites are cytoID positive. 
This is likely due to the loss of autophagosome turnover in these bradyzoites, resulting in an increase in 
“autolysosomes”. 
 
The TgCPL knockout bradyzoites and LHVS-treated bradyzoites are cytoID positive. This 
increase in autophagic vacuoles is likely due to the loss of autophagosome turnover in these 
bradyzoites due to the loss of the digestive enzyme TgCPL. It is unclear why we do not see the 
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same phenotypic response when the cysts are treated with triazine nitrile inhibitors. One 
possibility could be that the inhibitors fail to reach the cathepsin target within the parasite.  
 
BODIPY Labeling of TgCPL in Bradyzoite Cysts 
To determine if our inhibitors of TgCPL were able to reach the target organelle (VAC), 
bradyzoite cysts (ME49 strain) were incubated with BODIPY tagged inhibitors of TgCPL (BO-
LHVS and 263252) as shown in Figure 34. 
 
 
Figure 34. BODIPY vinyl sulfone probe 263252 enters bradyzoite cyst and binds to TgCPL 
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The BO-LHVS control is positive for green fluorescence (distinct puncta) and has 
previously been shown to primarily label TgCPL.121 The lack of fluorescence in the DPVS 
(262943) negative control is to demonstrate that the fluorescence shown in other samples is the 
result of the BODIPY tag. After incubation of the bradyzoites with 263252 (BO-DPVS), 
fluorescent puncta are detectable within 30 minutes of treatment, suggesting that BO-DPVS gets 
into the cyst within 30 mins. The puncta appear to be localizing to discrete organelles within the 
parasite, presumably the vacuolar compartment. In the ME49ΔCPL knockout strain of T. gondii, 
minimal fluorescence is observed when treated with BO-DPVS. This demonstrates that positive 
fluorescence in other BO-DPVS treated samples correlates with the presence of TgCPL in the 
parental cell line. In contrast, this fluorescent labeling of intracellular bradyzoites in human 
fibroblast cells was not observed with the BODIPY tagged triazine nitrile 263473.  
 
This data still does not answer the question as to why we do not observe the formation of 
inclusion bodies following treatment with the triazine nitrile inhibitors. Taken together, this data 
highlights a few key features. First, dark puncta as well as autophagosome accumulation is 
observed with inhibition by vinyl sulfones (LHVS) or TgCPL knockout, but not with the 
reversible nitrile inhibitors. Second, it appears the BODIPY tagged inhibitors bearing a covalent, 
irreversible warhead are capable of labeling TgCPL in intracellular cysts, while the BODIPY 
triazine nitrile 263473 failed to label the bradyzoites when subjected to the same assay. This 
could be a result of poor solubility, or permeability due to the increased lipophilicity added by 
the BODIPY tag. More plausible, is that the accumulation of puncta in the BODIPY assay is a 
result of the irreversibility of the vinyl sulfone tagged probes. 
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Fluorescent Labeling Competition Assay 
 
One way to determine if the unlabeled probes are reaching TgCPL in the bradyzoites is 
through competition experiments with the BODIPY tags that are successful at labeling TgCPL 
(i.e. the VS probes). To demonstrate that our untagged inhibitors primarily target TgCPL, we 
performed a competition assay in which ex vivo bradyzoites were treated with both BODIPY-
labeled and unlabeled inhibitors, with stepwise increases in the concentration of the latter. The ex 
vivo bradyzoites were harvested from the brains of mice infected with Toxoplasma and treated 
with compounds directly, effectively circumventing the additional barrier of the HFF cells in the 
intracellular cysts used in the previous labeling assays. Figure 35 shows that the dipeptide-vinyl 
sulfone 262943 (right) can compete with the labeling of TgCPL by 263252, similar to LHVS 
(left) and BO-LHVS.  Fluorescent signals can be competed away with increasing concentrations 





Figure 35. Competition assay between labeled and unlabeled TgCPL vinyl sulfone inhibitors 
indicates they compete for the same target. Ex vivo T. gondii cysts were pre-incubated with LHVS (left) or 
dipeptide vinyl sulfone 262943 (right) (200 nM for 1:1, or 2 µM for 1:10) for 30 min, then 200 nM Bo-dipeptide 
vinyl sulfone 263252, or 200 nM Bo-LHVS were added to the respective samples and left to incubate for 30 min (at 
room temperature). Imaged at x100 
 
This is an interesting result in contrast to the previous autophagosome and viability 
assays. When the bradyzoite cyst is within the HFF cells, the dipeptide vinyl-sulfone 262943 
failed to reduce bradyzoite viability and does not result in the formation of dark puncta and 
autophagosomes. These competition results show that when treating these ex vivo cysts, 262943 
is capable of reaching TgCPL. This suggests the lack of efficacy previously seen is a result of 
HFF cells precluding the compound from reaching the bradyzoites, likely due to lowering the 
cLogP.  The BODIPY labeled triazine nitrile 263473 was previously unable to label TgCPL in 
intracellular cysts in HFF cells. It was unclear if the lack of labeling was due to poor 
permeability or lack of covalency. The competition assays are performed directly on ex vivo 
bradyzoite cysts, which eliminates permeability issues that could be imparted by the HFF cells. 
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This bradyzoite competition experiment was therefore attempted with the BODIPY triazine 
nitrile 263473 and unlabeled triazine inhibitor 262962 (Figure 36). 
 
 
Figure 36. Competition assay between BODIPY labeled (263473) and unlabeled (262962) TgCPL triazine 
nitrile inhibitors suggests they compete for the same target. 
Ex vivo T. gondii cysts were pre-incubated with 262962 (200 nM or 2 µM) for 30 min, then 200 nM 263473 was 
added to samples and samples left to incubate for a further 30 min (at room temperature). Cysts were also stained 
to show cathepsin L, using Rb α-TgCPL primary Ab. Cysts were imaged at x100 magnification. 
 
Interestingly, the competition assay between labeled and unlabeled triazine nitrile TgCPL 
inhibitors showed similar results as with the vinyl sulfone type inhibitors. This implies that the 
triazine nitrile inhibitor 262962 is competing for the same target as the BODIPY labeled 263473, 
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presumably TgCPL. Importantly, this suggests that the BODIPY-TRZ probe 263473 is capable 
of labeling TgCPL in extracellular bradyzoites but is impeded from accessing the cyst in 
intracellular cysts in some manner. Perhaps the lack of covalency prevents the BODIPY probe 
from accumulating in the VAC with sufficient levels for imaging. A similar intracellular 
competition assay between BO-LHVS (able to accumulate and label intracellular TgCPL) and 
unlabeled triazine nitrile inhibitor 262962 is currently underway. 
 
Bradyzoite Cyst Viability Assay 
 
In the competition assays in ex vivo cysts, it appears the triazine nitrile compounds can 
compete for the same target as the BODIPY labeled probes, indicating they are capable of 
inhibiting TgCPL. The lack of dark puncta and autophagosomes in our previous experiments 
may simply be due to the reversible nature of the nitrile warhead. We were pleased, therefore, to 
find that the triazine nitrile TgCPL inhibitors (262962 and 263392) exhibit strong efficacy in our 
plaque-forming, bradyzoite viability assay (Figure 37). They successfully reduced T. gondii 
bradyzoite viability with the same efficacy as the genetic knockout of TgCPL (ΔCPL) and 

































































































Figure 37. Bradyzoite viability assay results 
for triazine nitrile inhibitors of TgCPL 
 
To our knowledge, this is the first example of a CNS penetrant inhibitor of TgCPL 
showing efficacy against the chronic stage Toxoplasma. Newer triazine nitrile analogs 263683, 
264081, and 264239 showed variable efficacy when treating the bradyzoite. The reason for this 
observation is unclear but may be a result of the frequency of dosing (once per day), or duration 





Triazine nitrile and vinyl sulfone BODIPY fluorescent probes were synthesized in order 
to confirm that our compounds were able to reach and bind to our cathepsin target within the 
parasite vacuole. Genetic knockouts of TgCPL and treatment of intracellular bradyzoites in 
human fibroblast cells with the irreversibly covalent inhibitor LHVS each resulted in the 
development of dark granules and stain positive for autophagosome accumulation. Curiously, 
this response is not observed when TgCPL intracellular bradyzoites are treated with our 
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dipeptide nitrile, dipeptide vinyl sulfone, or triazine nitrile TgCPL inhibitors. Treatment of 
intracellular bradyzoites with the BODIPY-tagged dipeptide vinyl sulfone probe 263252 results 
in the fluorescent labeling of distinct areas within the parasite, presumably labeling TgCPL in the 
VAC organelle. This phenomenon was not observed when treating intracellular cysts with the 
triazine nitrile BODIPY probe 263473, potentially due to issues with solubility, permeability of 
HFF cells, or lack of covalency. Competition assays between BODIPY labeled versus unlabeled 
TgCPL inhibitors with both the vinyl sulfone and triazine nitrile compounds were performed on 
ex vivo bradyzoites. In this cell-free environment, we were able to demonstrate fluorescent 
labeling within the bradyzoite with our triazine nitrile probe, and that both vinyl sulfone and 
triazine nitrile inhibitors apparently compete for the same TgCPL target. Importantly, we then 
demonstrated for the first time that treatment of chronic stage T. gondii bradyzoite cysts with 
triazine nitrile inhibitors reduces parasite viability with efficacy equivalent to a TgCPL genetic 
knockout.  Although the BODIPY-tagged probe was unable to form fluorescent puncta in the 
intracellular cysts (potentially due to permeability or solubility issues), the untagged version 
(263392) was able reach the parasite VAC in sufficient concentration to cause parasite death. 
This is the first example of a CNS penetrant, reversible TgCPL inhibitor showing efficacy in an 
in vitro model of the chronic stage parasite. Current studies are underway to confirm these results 









Chemistry General Information: All reagents were used without further purification as 
received from commercial sources unless noted otherwise. 1H NMR spectra were taken in 
DMSO-d6, MeOD, or CDCl3 at room temperature on Varian Inova 400 MHz or Varian Inova 
500 MHz instruments. Reported chemical shifts for the 1H NMR spectra were recorded in parts 
per million (ppm) on the δ scale from an internal standard of residual tetramethylsilane (0 ppm). 
Mass spectrometry data were obtained on either a Micromass LCT or Agilent Q-TOF. An 
Agilent 1100 series HPLC with an Agilent Zorbax Eclipse Plus−C18 column was used to 
determine purity of biologically tested compounds. Unless otherwise noted, all tested compounds 
were determined to be >95% pure using a 6 minute gradient of 10-90% acetonitrile in water 
followed by a 2 minute hold at 90% acetonitrile with detection at 254 nm. Flash chromatographic 





In a dry round bottom flask containing 2 mL anhydrous THF was added diethyl 
((phenylsulfonyl)methyl)phosphonate (494 mg, 1.689 mmol). The solution was cooled to 0°C, 
sodium hydride (67.5 mg, 1.689 mmol) was added and reaction was stirred at this temperature 
for 30 min. Next, tert-butyl (S)-(1-oxopropan-2-yl)carbamate (225 mg, 1.299 mmol) in THF (1-
2mL) was added and the reaction was allowed to warm to room temperature and stirred for 1h. 
Reaction was poured into EtOAc and washed with 1N HCl, sat. NaHCO3, and brine. Organic 
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layer was dried over MgSO4 and concentrated. Crude was purified by FC (1-100% 
EtOAc:Hexanes gradient) to afford tert-butyl (S,E)-(4-(phenylsulfonyl)but-3-en-2-yl)carbamate 
(360 mg, 1.156 mmol, 89 % yield) as a colorless oil.; 1H NMR (500 MHz, MeOH-d4) δ 7.88 (d, 
J = 7.34 Hz, 2H), 7.68 (t, J = 7.34 Hz, 1H), 7.60 (t, J = 7.58 Hz, 2H), 6.90 (dd, J = 3.42, 15.20 




Tert-butyl (S,E)-(4-(phenylsulfonyl)but-3-en-2-yl)carbamate (360 mg, 1.156 mmol) was 
dissolved in 4N HCl in dioxane (~3mL) and stirred at rt for 1h. Solvent was removed in vacuo to 
afford (S,E)-4-(phenylsulfonyl)but-3-en-2-amine, HCl (286 mg, 1.154 mmol, 100 % yield). 
Product was used without further purification.; 1H NMR (500 MHz, MeOH-d4) δ 7.93 (d, J = 
7.34 Hz, 2H), 7.73 (t, J = 7.34 Hz, 1H), 7.65 (t, J = 7.34 Hz, 2H), 6.96 (br. d, J = 2.00 Hz, 2H), 




In a dry round bottom flask, (tert-butoxycarbonyl)-L-leucine (187 mg, 0.807 mmol) was 
dissolved with DMF (1 mL). HATU (460 mg, 1.211 mmol) and DIPEA (0.423 ml, 2.422 mmol) 
were then added and reaction was allowed to stir for 10-15min. (S,E)-4-(phenylsulfonyl)but-3-
en-2-amine, HCl (200 mg, 0.807 mmol) was added and the reaction was left to stir for 6 h. The 
solution was poured into water and extracted with DCM 3 times. Combined organic layer was 
washed with sat. NaHCO3 (aq) and brine, dried over MgSO4 and concentrated. Crude was purified 
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on FC (0-100% EtOAc:Hexanes gradient) to afford tert-butyl ((S)-4-methyl-1-oxo-1-(((S,E)-4-
(phenylsulfonyl)but-3-en-2-yl)amino)pentan-2-yl)carbamate (201 mg, 0.473 mmol, 58.6 % 
yield).; 1H NMR (CDCl3, 500 MHz) δ  7.78 (d, J = 7.34 Hz, 2H), 7.53 (t, J = 7.34 Hz, 1H), 7.45 
(t, J = 7.83 Hz, 2H), 6.85 (dd, J = 4.89, 15.16 Hz, 1H), 6.39 (d, J = 15.16 Hz, 1H), 5.49 (d, J = 
7.34 Hz, 1H), 4.59 - 4.74 (m, 1H), 4.09 (d, J = 6.85 Hz, 1H), 1.45 - 1.56 (m, 1H), 1.36 - 1.44 (m, 
2H), 1.30 (s, 9H), 1.14 (d, J = 6.85 Hz, 3H), 0.77 (dd, J = 6.85, 19.56 Hz, 6H) ;   13C NMR 
(CDCl3, 126 MHz) δ  172.4, 155.7, 146.9, 140.0, 133.2, 129.6, 129.1, 127.3, 79.6, 60.2, 52.8, 
44.7, 41.0, 28.1, 24.4, 22.6, 21.6, 19.2, 14.0   
 
(S)-2-Amino-4-methyl-N-((S,E)-4-(phenylsulfonyl)but-3-en-2-yl)pentanamide 
To a small vial charged with tert-butyl ((S)-4-methyl-1-oxo-1-(((S,E)-4-(phenylsulfonyl)but-3-
en-2-yl)amino)pentan-2-yl)carbamate (100 mg, 0.236 mmol) was added 4N HCl in Dioxane (1 
ml). Reaction was left to stir under nitrogen for 1h, at which time HPLC indicated reaction was 
complete. Solvent was removed in vacuo and product was used directly in next step without 
further purification.; 1H NMR (CDCl3, 500 MHz) δ 7.88 (d, J = 7.83 Hz, 2H), 7.70 (t, J = 7.34 
Hz, 1H), 7.62 (t, J = 7.83 Hz, 2H), 6.93 (dd, J = 5.87, 15.16 Hz, 1H), 6.62 (d, J = 15.16 Hz, 1H), 
4.70 (quin, J = 6.24 Hz, 1H), 3.88 (t, J = 6.85 Hz, 1H), 3.65 (s, 3H), 1.56 - 1.74 (m, 3H), 1.34 (d, 




In a dry round bottom flask, 3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)propanoic acid (24 mg, 0.082 mmol) was dissolved in DCM (2 mL) 
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and cooled to -10°C. HATU (34.4 mg, 0.090 mmol) and DIPEA (0.050 ml, 0.288 mmol) were 
added and reaction was stirred at -10°C for 10-15min. (S)-2-(3-(5,5-difluoro-7,9-dimethyl-5H-
5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)-4-methyl-N-((S,E)-4-
(phenylsulfonyl)but-3-en-2-yl)pentanamide was then added and reaction was slowly warmed to 
rt and left to stir overnight. The solution was poured into water and extracted with EtOAc 3 
times. Combined organic layer was washed with 1N HCl, sat. NaHCO3 (aq) and brine, dried over 
Na2SO4 and concentrated. Crude was purified on FC (20-100% EtOAc:Hexanes gradient) to 
afford (S)-2-(3-(5,5-difluoro-7,9-dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-
3-yl)propanamido)-4-methyl-N-((S,E)-4-(phenylsulfonyl)but-3-en-2-yl)pentanamide (15 mg, 
0.025 mmol, 30.5 % yield).; 1H NMR (CDCl3, 500 MHz) δ 7.86 (d, J = 7.83 Hz, 2H), 7.60 (t, J = 
7.34 Hz, 1H), 7.52 (t, J = 7.58 Hz, 2H), 7.10 (s, 1H), 6.87 (d, J = 3.91 Hz, 1H), 6.84 (d, J = 4.40 
Hz, 1H), 6.65 (d, J = 7.83 Hz, 1H), 6.40 (dd, J = 1.47, 15.16 Hz, 1H), 6.24 (d, J = 3.91 Hz, 1H), 
6.21 (d, J = 7.34 Hz, 1H), 6.12 (s, 1H), 4.67 (d, J = 6.36 Hz, 1H), 4.32 (d, J = 5.87 Hz, 1H), 3.22 
(t, J = 7.09 Hz, 2H), 2.60 - 2.72 (m, 2H), 2.54 (s, 3H), 2.25 (s, 3H), 1.50 - 1.61 (m, 1H), 1.35 - 
1.47 (m, 2H), 1.19 (d, J = 7.34 Hz, 3H), 0.82 (d, J = 6.36 Hz, 3H), 0.79 (d, J = 6.36 Hz, 3H); 13C 
NMR (CDCl3, 126 MHz) δ 172.3, 171.4, 160.8, 156.3, 146.7, 144.3, 140.1, 135.3, 133.4, 133.2, 
130.0, 129.3, 128.2, 127.6, 123.9, 120.6, 117.0, 60.4, 51.9, 45.1, 40.1, 35.3, 24.5, 24.5, 22.8, 






General procedure B1 from 2,4,6-trichloro-1,3,5-triazine (250 mg, 1.356 mmol), N-(1-(4-
fluorophenyl)ethyl)-3-methylbutan-1-amine (284 mg, 1.356 mmol), DIPEA (0.474 ml, 2.71 
mmol) and tert-butyl (2-aminoethyl)carbamate (0.215 ml, 1.356 mmol) gave tert-butyl (2-((4-
chloro-6-((1-(4-fluorophenyl)ethyl)(isopentyl)amino)-1,3,5-triazin-2-yl)amino)ethyl)carbamate 
(464 mg, 0.965 mmol, 71.2 % yield).;  1H NMR (CDCl3, 500 MHz) δ 7.16 - 7.40 (m, 2H), 6.90 - 
7.08 (m, 2H), 4.10 (dd, J = 6.60, 13.45 Hz, 1H), 3.51 (br. s., 2H), 3.19 - 3.41 (m, 2H), 2.03 (d, J 
= 12.72 Hz, 2H), 1.55 (dd, J = 6.36, 12.23 Hz, 3H), 1.33 - 1.49 (m, 9H), 1.24 (td, J = 6.79, 13.33 




General Procedure B2 from tert-butyl (2-((4-chloro-6-((1-(4-
fluorophenyl)ethyl)(isopentyl)amino)-1,3,5-triazin-2-yl)amino)ethyl)carbamate (200 mg, 0.416 
mmol), potassium cyanide (29.8 mg, 0.457 mmol), and DABCO (93 mg, 0.832 mmol) gave tert-
butyl (2-((4-cyano-6-((1-(4-fluorophenyl)ethyl)(isopentyl)amino)-1,3,5-triazin-2-
yl)amino)ethyl)carbamate (174 mg, 0.369 mmol, 89 % yield).; 1H NMR (CDCl3, 500 MHz) δ 
7.10 - 7.33 (m, 2H), 7.00 (t, J = 8.31 Hz, 2H), 6.13 (d, J = 6.85 Hz, 1H), 5.12 (br. s., 1H), 3.41 - 
3.57 (m, 2H), 3.21 - 3.39 (m, 3H), 3.12 (dd, J = 4.16, 12.47 Hz, 1H), 1.49 - 1.61 (m, 3H), 1.32 - 





In a dry round bottom flask, tert-butyl (2-((4-cyano-6-((1-(4-fluorophenyl)ethyl) 
(isopentyl)amino)-1,3,5-triazin-2-yl)amino)ethyl)carbamate (174 mg, 0.369 mmol) was 
dissolved with a 2:1 EtOAc:4N HCl in dioxane solution and allowed to stir for 30 min. Solvent 
was removed in vacuo to afford 4-((2-aminoethyl)amino)-6-((1-(4-fluorophenyl)ethyl) 
(isopentyl)amino)-1,3,5-triazine-2-carbonitrile (137 mg, 0.369 mmol, 100 % yield). Compound 
was carried directly to next step. 1H NMR (CDCl3, 500 MHz) δ 7.22 (s, 1H), 7.25 (s, 1H), 6.83 - 
7.06 (m, 2H), 5.88 - 6.11 (m, 1H), 5.29 (s, 1H), 3.76 (br. s., 2H), 3.14 - 3.44 (m, 2H), 3.09 (br. s., 






yl)propanoic acid (35.4 mg, 0.121 mmol) was dissolved into DMF (0.5 mL) and cooled to 0°C. 
HATU (46.1 mg, 0.121 mmol) and DIPEA (0.042 ml, 0.242 mmol) were then added and reaction 
was stirred at 0°C for 5 min. 4-((2-aminoethyl)amino)-6-((1-(4-fluorophenyl)ethyl) 
(isopentyl)amino)-1,3,5-triazine-2-carbonitrile (30 mg, 0.081 mmol) was dissolved into DMF 
(0.5 mL) and added dropwise to the stirring solution. Reaction was allowed to warm slowly to rt 
and left to stir over 6 h. Reaction was monitored by HPLC detecting at 502 nM. Reaction was 
poured into EtOAc and washed with brine, dried over NaSO4, and concentrated. Crude was 
purifies by FC (1-100% E:H gradient) to afford N-(2-((4-cyano-6-((1-(4-
fluorophenyl)ethyl)(isopentyl)amino)-1,3,5-triazin-2-yl)amino)ethyl)-3-(5,5-difluoro-7,9-
dimethyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamide (18.5 mg, 
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0.029 mmol, 35.5 % yield).; 1H NMR (CDCl3, 500 MHz) δ 7.26 (s, 1H), 7.22 - 7.25 (m, 1H), 
7.14 - 7.19 (m, 1H), 7.00 (t, J = 8.56 Hz, 2H), 6.87 - 6.92 (m, 1H), 3.42 (br. s., 1H), 3.30 - 3.40 
(m, 3H), 3.17 - 3.30 (m, 4H), 3.05 (dt, J = 4.89, 12.47 Hz, 1H), 2.67 (q, J = 7.34 Hz, 2H), 2.52 - 
2.62 (m, 3H), 2.27 - 2.33 (m, 2H), 2.24 (d, J = 15.16 Hz, 1H), 1.49 - 1.58 (m, 3H), 1.35 - 1.48 
(m, 1H), 1.28 - 1.35 (m, 1H), 1.17 - 1.23 (m, 2H), 1.07 - 1.16 (m, 1H), 0.77 - 0.84 (m, 5H), 0.75 
(d, J = 6.85 Hz, 1H).; HRMS–ESI (m/z): [M+Na]+ calcd for, C33H39BF3N9O; 668.3215; found, 
668.3220 
 
Bradyzoite Competition Assay: 
Mice were infected with T. gondii tachyzoites (Prugniaud strain) and left for 5 weeks to 
allow parasite cysts to form on the brain. Infected brains were then removed from euthanized 
mice and subsequently homogenized (by syringing) in 1ml of 1x PBS, to liberate cysts. 
Assuming a cyst diameter between 20-50 µm, samples of homogenized brain extract were passed 
over a 20um filter to separate cysts from brain material. Homogenized brain material passes 
through the filter, while cysts are retained on top of the filter. To gently remove cysts from the 
filter, the filter was placed into a non-pyrogenic falcon tube (50ml) with PBS and left to incubate 
for 1 hour at room temperature on a rotator. A 10ul aliquot of the PBS (now containing cysts) 
was placed on a haemocytometer and the number of cysts counted. This information was then 
used to estimate the number of cysts present in the whole sample. Cysts were aliquoted into the 
wells of a chamber slide that had been coated with Cel-Tak adhesive (Corning) and allowed to 
settle on the bottom. Wells were then washed with PBS before adding the inhibitors (LHVS or 
test compound, e.g. triazine). Cysts were left to incubate at room temperature with 200nM 
BODIPY LHVS (BO-LHVS) alone, or a 1:1 or 1:10 mixture of BO-LHVS and LHVS. This was 
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repeated for BODIPY-inhibitor (vinyl sulfone and triazine) versus the respective unlabeled 
inhibitor. After three washes with 1 x PBS, brain material was fixed with 4% paraformaldehyde 
and stained with rabbit anti-CPL antibodies at 1:200 dilution followed by Alexa 594- conjugated 
goat anti-rabbit antibodies. Slides were mounted with mowiol and images were captured with a 
Zeiss Axiovert Observer Z1 inverted fluorescence microscope and an AxioCAM MRm camera 
and processed using Zeiss Axiovision 4.3 software. If the un-tagged (normal) inhibitor binds to 
the target, the BODIPY version will not be able to bind as much, and thus BODIPY signal will 
be lower compared to the signal produced by the BODIPY inhibitor in the absence of a 
competitor.  
 
Bradyzoite Viability Assay: 
Split HFF cells and seed them into the wells of 6-well plates. Leave at 37°C until HFF cells are 
confluent. Meanwhile, once parasite stocks have egressed from the host cell culture in a T25 
flask, pass a large number of drops (e.g. 10 drops) of parasites into a new T25 flask containing 
confluent HFF cells. Leave for two days at 37°C. After two days, check cells are full of 
intracellular parasites. Proceed to harvest parasites as follows: 1)Pour off the D10 media and 
replace with 10 ml fresh D10 media. 2) Using a sterile cell scraper, lift the cells from the surface 
of the T25 flask by mechanically scraping them off. 3) Transfer the media containing scraped 
cells to a sterile conical tube. 4) Using a 20G syringe needle, syringe up and down to break open 
the cells release the parasites. Repeat three times with a 20G syringe needle, then once with a 
23G needle. 5) Pass the syringed media through a sterile 0.22uM filter (into a new sterile conical 
tube).;  Place 10 ul of the harvested parasites onto a haemocytometer and count the number of 
parasites within a 5x5 grid. This count determines the number of parasites in 0.1 ul. Multiply this 
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by 10 to determine the number of tachyzoites per ul of media. Resuspend the harvested 
tachyzoites so that there is 1000 tachyzoites per 2 ml of D10 media. Next, place 2 ml of media 
containing these parasites onto the well of the 6-well plate (that contains the confluent HFF cells, 
see the first step above). I.e. place 1000 tachyzoites into the well of a 6-well plate that already 
contains a confluent HFF cells monolayer. Leave the plate at 37°C overnight. The next day, 
check the HFF cells in the 6-well plate contain intracellular tachyzoites.  Aspirate the D10 media 
from the wells and replace with 2 ml conversion media per well. Place the plate at 37°C in an 
incubator that contains 0% CO2. Allow one week for conversion of parasites from tachyzoite to 
bradyzoite life stage. During this period, replace the conversion media every 24 hours for fresh 
conversion media.  Following the conversion phase, replace the conversion media for conversion 
media containing the inhibitor/compound-of-interest (e.g. LHVS). Continue to treat for the 
required amount of time (e.g. one week), replacing the conversion media containing the inhibitor 
every 24 hours (replacing with fresh conversion media containing fresh inhibitor). Towards the 
end of the treatment phase, split HFF cells into 6-well plates. Prepare three wells of HFF cells 
per treatment sample (i.e. for every well in the treatment phase, prepare three wells for the 
plaquing phase, to allow for three technical replicates).; After the treatment phase, harvest the 
parasites from the 6-well plate and set up the plaquing phase as follows: 1) Aspirate the media 
and replace with 1 ml HBSS. 2) Use a cell scraper to mechanically lift the cells containing the 
bradyzoites from the bottom of the well. 3) Using a 20G syringe needle, syringe up and down to 
break open the cells and release the parasites. Repeat three times with a 20G syringe needle, then 
once with a 25G needle. 4) Transfer the syringed media containing the released parasites to a 
sterile conical tube. 5) To maximize bradyzoite yield, rinse the scraped well with 1 ml HBSS and 
add this to the conical tube that already contains 1 ml of the syringed parasites (in HBSS). 6) 
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Add 2 ml of 2X pepsin solution and mix. (Note, pepsin treatment is to kill any tachyzoites). 7) 
Incubate samples in a water bath at 37°C for 30 min. 8) Stop the reaction by adding 4 ml of 2X 
neutralization buffer. 9) Centrifuge the samples for 10 minutes at room temperate at 1800g.10) 
Very carefully discard the supernatant from the samples, ensuring the pellet remains in the 
conical tube. 11) Suspend the pellet in 1 ml D10 media. 12) Count the number of parasites using 
a haemocytometer (as described above). 13) Infect the wells of the 6-well plate with 1000 
bradyzoites in 2.5 ml D10 media (seed triplicate wells with 1000 bradyzoites each, for each 
sample). Important: keep a record of the volume of parasites added to 2.5 ml of media. 14) Leave 
the plates at 37°C for 12 days without moving them and without any media change. 15) After 10 
days stain, pour off the media and stain wells with crystal violet. It is advisable to count the 
number of plaques under a microscope prior to crystal violet staining (in the event that plaques 
aren’t large enough to be identified following crystal violet staining). At step 11 (above) where 
parasites were resuspended in 1 ml D10 media, remove 500 ul of the resuspended parasites and 
transfer to a sterile microcentrifuge tube. Centrifuge samples for 10 min at room temperate at 
1000g. Carefully remove the supernatant and store the pellet at -80C until required. Extract 
genomic DNA using the Qiagen DNA extraction kit (following manufacturer protocol). Elute in 
100 ul sterile, nuclease-free distilled water. Determine the number of genomes in the sample by 
qPCR. Use genomic DNA standards in the qPCR assay to generate a standard curve. Use the 
TUB2 forward (5’-GCGTCTTCTTGGATTTGGAG-3’) and reverse (5’-
TGGAGACCAGTGCAGTTGTC-3’) primers. The software will generate a “Cq” value for each 
of the standards and use this to plot a standard curve. A Cq value will also be determined for 
each sample from the viability assay too. Based on the number of genomes stated for each of the 
standards, the software will then determine the number of genomes present in each qPCR 
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reaction. Since 10 ul of the extracted genomic DNA is used in the qPCR reaction, multiply the 
number of genomes by 10 to determine the number of genomes present in the entire genomic 
DNA extract (since genomic DNA was eulted into 100 ul of sterile, nuclease-free distilled 
water). Next, multiply the number of genomes by 2 to determine how many genomes were 
present in the pellet that was resuspended in 1 ml D10 media (since half of the sample was taken 
for genomic DNA extraction). Next, divide the number of genomes by 1000 to determine the 
number of genomes per 1 ul of media. Then, based on the volume of parasites added at step 13 
above, we can determine the precise number of genomes added into the well for the plaquing 
stage. After counting the number of plaques that form, then calculate the number of plaques per 
1000 genomes.  
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Chapter 5 Future Directions 
 
Overview of Objectives 
 
Over the course of this project, several inhibitors of TgCPL have been developed that 
achieve both potent inhibition and CNS penetrance (Figure 38). While these represent 
significant advancement towards a viable probe with which to validate TgCPL as a clinically 
relevant target for the treatment of toxoplasmosis, there is still a large body of work remaining to 
progress toward in vivo proof of concept. 
 
 
Figure 38. Select developed inhibitors of Toxoplasma gondii cathepsin L 
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One of the key remaining objectives is to achieve robust selectivity (>10-fold) for TgCPL 
over the human isoform. This has been a consistently difficult challenge to overcome, primarily 
due to the minimal differences in the active site binding pockets between human and parasite 
cathepsins. To date, analog 264683 has exhibited one of the better inhibitory and metabolic 
profiles (Figure 38), while also displaying the physicochemical properties that are predictive of 
CNS penetrance. However, several features of this compound preclude advancement toward in 
vivo studies. While the metabolic stability was acceptable (MLM t1/2 = 15 min), the solubility 
was too poor for further PK studies. Similar solubility issues were previously overcome by 
replacing the P1 morpholine with an oxetane, as seen in compound 263392. This change not only 
improved compound solubility, but also improved the exposure levels and BBB permeability in 
our PK studies (1:1 brain:plasma @ 2h). Additionally, it seems that there is potential for this 
scaffold to switch binding modes by rotation around the triazine-P2/3 pendant nitrogen bond 
(Figure 39), which may be a reason we see very little change in selectivity in favor of TgCPL 
over the human isoform. Furthermore, the triazine nitrile is known to react with the active site 
cysteine rapidly, which may obscure any selective effects due to the weakly bound P2-P3 
pendants. The modification of the core, conformationally restricting the P2-P3 exchange and 
improving solubility are all paramount in achieving a refined selectivity profile. 
 
Conformational Restriction 
-Variable Binding Modes and Conformational Restriction 
The scaffold hop to the triazine nitriles, significantly reduces the number of rotatable 
bonds versus the dipeptide nitriles. This serves to, further increase the rigidity of the scaffold and 
has resulted in improved binding, selectivity, and CNS penetrance. However, the triazine nitrile 
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scaffold  may still require further conformational restriction to improve selectivity and its CNS 
profile. Shown below in Figure 39, one of the docking poses suggests the possibility that the P2-
P3 vectors may flip, placing the intended P3 4-fluorobenzyl pendant in the S2 pocket.  
 
 
Figure 39. Potential flip of binding mode 
Alternative docking pose (right) of 262962 (gray) indicating a possible flip of 
P2/P3 binding poses. Derived from PDB: 3F75 
 
It is known that human cathepsin L favors a phenylalanine (mimicked closely by the 4-
fluorobenzyl) in S2 and is amenable to nearly any lipophilic amino acid. TgCPL prefers leucine 
as the P2 substrate, and given the slightly small pocket size, is somewhat less accepting of larger 
sidechains such as the 4-fluorobenzyl. This binding mode exchange would result in a 
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significantly less variable P2 SAR for HsCPL. Restricting the scaffold, e.g. by preventing 
rotation about the triazine-nitrogen bond, would force the P2 and P3 vectors to bind in their 
respective pockets, enabling a more reliable selectivity differentiation between parasite and 
human isoforms. Figure 40 shows proposed changes to the scaffold that could reduce or 
eliminate the rotational freedom and variable binding modes. 
 
-Example Conformationally Restricted Analogs: 
 
Figure 40. Possible conformational restrictions to keep the desired binding orientation 
of TgCPL inhibitors 
 
Proposed scaffolds 5.3a-d exemplify fused ring systems that are predicted to retain the 
P2-P3 binding motifs. While 5.3b-d increase overall TPSA, the reduction in rotational freedom 
would be beneficial for BBB permeability. Compound 5.3e does not restrict overall rotational 
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freedom, however it does orient the P2 and P3 vectors in a non-interchangeable manner. While 
this modification pushed the physiochemical properties toward the limit of CNS penetrance, 
there is literature precedent (compound 5.3f) demonstrating this chemotype can still access the 
CNS. 
 
-Benzylic modification for improved solubility and restriction of binding mode 
The docking model of 263251 shows this compound bound with the expected P2/P3 
orientation (Figure 41). The α-methyl of the P3 pendant docks near the backbone carbonyl of 
Leu165, with only a 3.95 Å distance between the features. The binding variability could 
potentially be reduced through either hydrogen bonding or steric interactions at this position. 
     
Figure 41. Docking of 263251 in TgCPL 




The formation of a meaningful hydrogen bond between the ligand and backbone residue 
would serve to improve binding as well as better orient the P3 vector. This idea could be 
explored through the incorporation of a hydroxyl, or other hydrogen bond donors as shown in 
Figure 42 (5.5a). As an added benefit, the additional steric bulk of a branched benzylic position 
would be unfavorable for binding in the S2 pocket further ensuring the desired binding mode 
pictured in Figure 41. If the addition of a hydrogen bond donor proves to be unsuitable for 
binding, or compromises BBB permeability, perhaps simple substitution of the benzylic methyl 
with a slightly larger lipophilic group, such as the cyclopropyl (5.5b), may be enough to orient 
the P3 vector in the desired pocket. This would maintain the low TPSA and H-bond donors 
required for CNS penetrance. 
 
Figure 42. Modifications of benzylic position to impede rotation and improve solubility 
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Modification in this benzylic position has additional potential to modulate solubility. 
With the analogs synthesized thus far, solubility is primarily imparted by the P1 morpholine 
group. As was demonstrated previously in analog 263392, this can be exchanged with an amino 
oxetane for improved solubility and still retain CNS penetrance. Given the proximity of this 
position to the Leu165 carbonyl, the migration of the solubilizing group to this position (5.5c) 
may simultaneously provide the necessary solubility, while restricting rotation via hydrogen 
bonding with the Leu165 backbone. Given that this location is mostly solvent exposed, much 
like the P1 morpholine position, we anticipate this will be a tolerated change. 
 
P3 Heterocyclic and Basic Vectors 
Work done previously in the Carruthers lab determined the peptide substrate preference 
for TgCPL and TgCPB.121 The proteolysis of small tripeptides was used to elucidate the P2/P3 
preferential residues in terms of catalytic turnover.164 In P2 they found that smaller lipophilic 
sidechains were preferred, namely Leucine, Valine, and Tryptophan. This data is in agreement 
with the SAR we have found for our TgCPL inhibitors. In P3, the preferential substrates tended 
to be polar and even charged. Examples include Aspartate, Glutamate, Arginine, Glutamine. A 
heterocyclic SAR campaign and a fluorine scan of P3 in HsCPL revealed significant variability 
in the inhibitor binding based on the ring system electronics.158, 160 Presumably, this is due to a 
heteroarene π-stack with the amide backbone of Gly64 in the S3 pocket. A similar backbone 
structure is seen in TgCPL and given that the optimal S3 vector we have found is a 4-
fluorophenyl, it is reasonable to believe that TgCPL will also exhibit a varying preference for 
certain heteroaromatic vectors that modulate this interaction. Once the appropriate 
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conformational restriction is found, the synthesis of new analogs can be approached through 
several potential routes analogous to those of the triazine nitriles shown in Chapter 4. 
5.3 Modified Heteroaryl Cores and Intramolecular Stabilization of Iminium Transition 
State  
It has been incredibly difficult to find anything that is selective for TgCPL over HsCPL. 
This could be a due to several possibilities. While very similar in topology, HsCPL has slightly 
larger S2 and S3 pockets. This feature seems to impart a higher tolerance for the P2/P3 residues, 
as compared to the parasite isoform. Additionally, the triazine nitrile warhead is one of the more 
reactive and potent of the known aryl-nitriles.  The triazine nitrile warhead may be too reactive 
to reliably illuminate the motifs necessary to achieve selectivity in favor of TgCPL. Highly 
reactive nitriles are less dependent on the proximity effects and are able to react with the cysteine 
even if the P2,P3 vectors are not tightly bound. A slightly less-reactive nitrile would require an 
initial pre-binding event in order to properly orient the warhead in close proximity to the 
catalytic cysteine. The greater dependence on the free energy contribution of the initial non-
covalent binding event results in a reduced dependence on the high reactivity of the nitrile 
warhead, and therefore serves to better differentiate the SAR due to P2/P3 binding. Furthermore, 
the potential off-target effects of a highly reactive nitrile could lead to unwanted off-target 
effects in later development.  Nevertheless, the electrophilic warhead is necessary for TgCPL 
inhibition, as its removal results in a drastic loss of potency. As an alternative, we may need to 
replace the strongly electron withdrawing triazine with some less reactive, heterocyclic cores. To 
date, we have only tested a small number of these (Figure 43) and found that despite the 
identical P2-P3 vectors, the electronics of the warhead and core significantly impact potency. 
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Figure 43. Synthesized alternative cores and TgCPL inhibition 
 
These modifications slightly reduce potency (e.g. 263392 and 263760) as compared to 
the lead 262962. The modulated reactivity may enable the development of a more sensitive SAR 
model for achieving selectivity between isoforms, as explained above. In the case of 263211, the 
values for potency are likely convoluted due to the very poor solubility of the compound when 
the morpholine group was removed. If the conformational restriction mentioned above enables 
the rearrangement of the solubilizing group to the benzylic position, the more lipophilic core can 
be revisited to more accurately assess the electronic effects on potency and selectivity. 
 
Throughout the literature, several similar cores have been employed. Figure 44 below 
shows a few proposed examples of heterocyclic-nitrile cores, derived from known human and 




Figure 44. Alternative core scaffolds 
 
Several variations of the pyrimidine nitrile cores (5.7a) have been assessed versus HsCPL 
and rhodesain, revealing significant variation in potency and selectivity. Replacement of the X 
groups with either Br, Cl, F, and CF3 can tune the electron withdrawing characteristics of the 
ring system. Electron donating groups (NH-R of O-R) in the Y-position, similarly modulate the 
warhead reactivity and provide improvements to solubility. The imizadopyridine nitrile (5.7b) 
and the purine nitrile (5.7c) cores have been precedented in literature as potent and selective 
inhibitors of various human cathepsins, T. brucei Cathepsin B, and P. falciparum rhodesain.159, 
165-166 It is postulated that while the electronics of these heterocycles will reduce the initial 
reactivity of the nitrile warhead when compared to the triazine nitrile, the transition state is 
stabilized via an intramolecular hydrogen bond between the heterocyclic N(3) and the 
thioimidate NH, leading to improved potency and selectivity (Figure 45).167 
 242 
 
Figure 45. Intramolecular stabilization of transition state 
Transition state stabilization by imidazopyridine (top) and 
difluoromethyl pyrimidine nitriles (Bottom). 
 
While the imidazopyridine and purine cores could improve potency and selectivity, this 
comes at the cost of increased TPSA, molecular weight and hydrogen bonding. These features 
make them less desirable for a CNS therapeutic. The (difluormethyl)pyrimidine nitrile core 5.7d 
is a proposed unique core that could preemptively avoid these concerns. There is precedent in 
literature that the di-fluoro methyl can serve as a ‘masked’ hydrogen bond donor.168-169 This and 
related fluorine-induced hydrogen bond donating motifs have been successfully employed in the 
development of several clinical candidates. This strategy would provide reduced molecular 
volume and TPSA, while ‘masking’ the hydrogen bond donor, thus favoring CNS penetrance. 
Importantly, the difluoromethyl is still capable of forming the intramolecular hydrogen bond 
with the thioimidate transition state, which may provide the same type of selectivity and potency 




One of the greatest challenges in the development of a TgCPL inhibitor has been obtaining a 
TgCPL crystal structure with a small molecule bound. To date, the only crystal structure resolved 
is of mature TgCPL with its cleaved propeptide bound in the active site. To date, all our 
structure-based design has been done generating a model via the superposition of TgCPL with 
HsCPL crystal structures bound to various inhibitors. The homology between isoform active site 
is high and provides a reasonable model to begin the development of small molecule inhibitors; 
however a true co-crystal of TgCPL with inhibitor is paramount in understanding the subtle 
differences that could lead to isoform selectivity. Given the shallow nature of the enzyme active 
site and conformational flexibility of the surface residues, it is unclear if our current model is 
providing an accurate representation. Acquiring a co-crystal of a small molecule inhibitor bound 
in the enzyme active site would significantly aid further structure-based design. Additionally, the 
presence of the propeptide tail in the enzymatic assay may influence the inhibitory activity of our 
compounds. It is unclear what level of effect this might have on the physiological relevance of 
the biochemical results.  
 
5.4.1 Advances Toward TgCPL Co-Crystal 
 
A significant number of approaches have been tried to obtain a crystal structure of 
TgCPL with a small molecule inhibitor bound, but several factors have impeded this goal. 
Primarily, the obstruction of the catalytic site by the enzyme’s pro-peptide tail has been the 
greatest obstacle. TgCPL is an auto-maturase that catalyzes the cleavage of its pro-peptide tail in 
order to become catalytically active. Once cleaved, the pro-peptide tail is able to re-associate 
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with the enzyme via strong hydrophobic interactions. This complex of mature enzyme and 
peptide tail tends to undergo crystallization (e.g. PDB: 3F75) more favorably than that of any 
enzyme inhibitor complex. Any attempts to form enzyme-ligand co-crystals, even with high 
affinity irreversible inhibitor LHVS, to date have failed due to the presence of the pro-peptide. 
Several attempts to optimize conditions for the maturation and inhibition of TgCPL, followed by 
the removal of the pro-peptide tail have been undertaken. While some significant advances were 
made, overall the attempts have to date been unsuccessful for a variety of reasons detailed below.  
 
TgCPL undergoes auto-maturation when introduced to an acidic environment (pH ~5.5). 
However, if the maturation is done at higher protein concentration (i.e. >1 mg/mL) the activated 
enzyme appears to digest itself. We found this can be avoided by maturing the enzyme in more 
dilute conditions (Figure 46) at 37°C for 1-3 h, followed by inhibition of the matured protein 
with a small molecule inhibitor such as LHVS. Once matured and inhibited, various strategies to 
separate the cleaved pro-peptide tail from the enzyme were attempted. Ion exchange 
chromatography, Ni columns, size exclusion, gel filtration, pH adjustment, buffer exchange, 
dialysis, chaotropic agents (urea), lipophilicity chromatography, and attempts to digest the pro-
peptide in situ with pepsin have all been unsuccessful in removing the tail completely. The pro-
peptide appears to have such a high affinity for the mature cathepsin that overcoming the 




Figure 46. Example purification of mature TgCPL 
10 mg of apo-TgCPL was diluted in activation buffer to 0.1mg/mL an incubated for 2-3h at 37°C. Protein was 
treated with 5 eq LHVS and incubated overnight. The protein was subjected to a Ni column, followed by 
purification via FPLC S-12 column. Activation Buffer: pH=5.5; NaAc= 60mM; NaCl= 900mM; DTT= 5mM; 
EDTA= 2.0mM; TgCPL = 0.1mg/mL 
 
In the most successful attempt to date, only a fraction of the sample was successfully 
purified away from the pro-peptide.  Conditions were optimized to fully mature the enzyme in a 
manner that minimizes auto-digestion. Beginning with 10 mg of mature TgCPL, we obtained 
only 200 µL at a final concentration of ~0.5 mg/mL of the mature TgCPL which is inadequate 
for any crystallization attempts. This sample was the only attempt that provided purified TgCPL 
free of its propeptide tail. Through efforts by the Center for Structural Biology at the University 
of Michigan, we are now able to produce the apo-TgCPL with good yields (>100 mg/L culture 
versus original prep yields of ~1 mg/mL culture). We hoped that we could simply upscale the 
preparation and do several FPLC purifications to afford enough for crystallization. 





5.5.2 Current Efforts in the Crystallization of TgCPL 
 
 So far, we have optimized the expression and maturation of apo-TgCPL. To avoid auto-
proteolysis, TgCPL was inhibited with LHVS. This is enabling current studies toward the 
removal of the pro-peptide tail. Efforts are being made using combinations of buffer exchange, 
denaturation and refolding, and lipophilicity columns to disrupt this tight binding interaction. If 
these prove unsuccessful, we envision mutagenesis of a few residues in the pro-peptide tail 
(primarily those that interface with the lipophilic pocket seen in the crystal structure PDB-3F75) 
may reduce the enzyme-tail affinity. This disruption of the lipophilic interaction could allow for 
further separation via size exclusion or ion exchange chromatography. Once a separation method 
is optimized, LHVS (irreversibly covalent) can be replaced with S-Methyl methanethiosulfonate 
(MMTS) as the inhibitor to block auto-proteolysis. This will allow for facile reductive re-
activation of the catalytic cysteine post-purification in the presence of reversible inhibitors such 




Throughout this project, significant advances have been made in developing small 
molecule inhibitors of TgCPL. We have elucidated key SAR for the inhibition of TgCPL, 
developed potent and CNS penetrant inhibitors across three chemotypes, and demonstrated 
efficacy against bradyzoite cysts in vitro. More work needs to be done to optimize selectivity for 
the T. gondii isoform and to improve upon the PK profile to advance to in vivo proof-of-concept 
 247 
studies. Given the rotational flexibility of the triazine nitrile scaffold, we envision 
conformational restriction, either though ring closure or steric restriction, will improve our 
ability to exploit key divergent features between the parasite and human isoforms. We may be 
able to also use the necessary solubilizing group toward this end, enabling further modification 
of the triazine core.  The triazine nitrile warhead may be too electrophilic (cysteine reactive), 
overwhelming subtle differences in on-rate between the isoforms that might be necessary for 
selectivity and increasing the potential for off-target reactivity. Modifications of this core to tune 
the electronics of the nitrile warhead could be used to achieve parasite cathepsin selectivity. 
Additionally, potency and CNS profile could be enhanced via the intramolecular stabilization of 
the thioimidate transition state. Finally, in order to fully enable a structure-based approach, 
efforts are being made to obtain a TgCPL co-crystal structure with a small molecule inhibitor. 
Success in these aims will provide improved selectivity, potency, and pharmacokinetic profile 
for these TgCPL inhibitors. These second-generation inhibitors can be advanced toward in vivo 
studies, providing proof-of-concept that TgCPL inhibition is a viable approach for treating the 
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